Tumor mutational load

ABSTRACT

The present invention encompasses the discovery that the likelihood of a favorable response to cancer immunotherapy for a wide range of different cancers can be predicted through definition of a tumor mutational load threshold for the tumor (and/or the relevant immunotherapy).

BACKGROUND

Cancer immunotherapy involves the attack of cancer cells by a patient's immune system. Regulation and activation of T lymphocytes depends on signaling by the T cell receptor and also cosignaling receptors that deliver positive or negative signals for activation. Immune responses by T cells are controlled by a balance of costimulatory and inhibitory signals, called immune checkpoints. It is predicted that worldwide cancer spending will exceed $150 billion by 2020, in significant part due to immunotherapy drug development.

SUMMARY

In recent years, immune checkpoint modulators have revolutionized treatment for patients with advanced stage solid tumors. These agents include antibodies that act as a CTLA-4 blockade or a PD-1/PD-L1 blockade, which can modulate immunoregulatory signals.¹

The present disclosure recognizes the source of a problem that can arise with respect to immunotherapy regimens. In particular, it has been observed that durable benefit is often achieved in only a subset of patients.

Recent work has discovered that likelihood of a favorable response to cancer immunotherapy can often be predicted.² See, International Patent Application WO2016/081947 to Chan et al of the Memorial Sloan Kettering Cancer Center, incorporated herein by reference. In particular, it has been demonstrated that, for certain cancers, tumor mutational load can correlate with likely responsiveness to a particular therapy (e.g., to immunotherapy, and in particular to immune checkpoint modulator therapy), and also that certain cancer cells may harbor somatic mutations that result in neoepitopes that are recognizable by a patient's immune system as non-self, and that presence and/or identity of such neoepitopes may correlate with responsiveness to particular therapy. Further, the ability to present neoepitopes to the immune system, particularly through diverse HLA molecules, may correlate with responsiveness to particular therapy. Certain characteristics and/or mutational “signatures” that can be detected to predict responsiveness to immunotherapy, were defined, including specifically for lung cancer (e.g., small cell or non-small-cell carcinoma) and melanoma.

The present invention encompasses a discovery that likelihood of a favorable response to cancer immunotherapy for a wide range of different cancers can be predicted through definition of a tumor mutational load threshold for the tumor (and/or the relevant immunotherapy); in some embodiments, the present disclosure defines such thresholds and/or provides technologies that achieve such definition.

Moreover, in some embodiments, the present invention establishes that likelihood of durable responsiveness to cancer immunotherapy (and/or to a specific immunotherapy agent and/or regimen) can be predicted for tumors that have already been treated with prior immunotherapy. In particular, the present disclosure demonstrates that tumor mutational load thresholds can be defined for tumors that have already received prior immunotherapy, and that predict likely responsiveness to continued (and/or additional, extended, or modified) immunotherapy.

The present invention encompasses a discovery that likelihood of a favorable response to cancer immunotherapy for a wide range of different cancers can be predicted through HLA heterozygosity. In some embodiments, HLA heterozygosity alone is sufficient to determine likelihood of a favorable response to cancer immunotherapy. In some embodiments, HLA heterozygosity and tumor mutational load can be used in combination to determine likelihood of a favorable response to cancer immunotherapy.

Among other things, in some embodiments, the present disclosure provides technologies for defining tumor mutational load thresholds (and/or other characteristics—e.g., nature, level and/or frequency of neoantigens mutations) that predict ongoing responsiveness and/or durability of response to cancer immunotherapy. In some embodiments, the present disclosure defines such thresholds. Moreover, in some embodiments, the present disclosure provides technologies for treating tumors that have been exposed to cancer immunotherapy, for example by administering (e.g., continuing, supplementing, and/or initiating new) cancer immunotherapy to those tumors that display a mutational load characteristic (i.e., tumor mutational load above a defined threshold and/or neoantigen nature, level, and/or frequency) as described herein. In many embodiments, tumors that display a tumor mutational load above a threshold that has been correlated with a statistically significant probability of responding to immunotherapy are treated with such immunotherapy; in some embodiments, the tumors had previously been exposed to (the same or different) immunotherapy.

In some embodiments, the present disclosure provides technologies for treating tumors in subjects with a particular HLA class I genotype or HLA class I heterozygosity. Additionally, in some embodiments, the present disclosure provides technologies for treating tumors that have been exposed to cancer immunotherapy, for example by administering (e.g., continuing, supplementing, and/or initiating new) cancer immunotherapy to those tumors that display a mutational load characteristic (i.e., tumor mutational load above a defined threshold and/or neoantigen nature, level, and/or frequency) as described herein and are in a subject with a particular HLA class I genotype or HLA class I heterozygosity.

In some embodiments, a tumor mutational load characteristic may comprise (e.g., in addition or as an alternative to tumor mutational load) nature (e.g., identity or type), level, and/or frequency of neoepitopes that are recognizable by a patient's immune system as non-self. The present disclosure defines certain characteristics of particular tumor cells (e.g., cells that have been previously treated with cancer immunotherapy) that can be detected to predict responsiveness (e.g., continued responsiveness and/or durability of responsiveness) to immunotherapy, and particularly to therapy with immune checkpoint modulators. Among other things, the present disclosure provides tools and technologies that can be practically applied to define, characterize, and/or detect one or more tumor mutational load characteristics (e.g., tumor mutational load thresholds, neoepitope identity, type, level, and/or frequency, etc).

In some embodiments, HLA class I heterozygosity may comprise heterozygosity at a single HLA class I locus, two HLA class I loci, or at three HLA class I loci. In some embodiments, maximal heterozygosity is heterozygosity at three HLA class I loci (i.e., A, B, and C).

Among other things, the present disclosure demonstrates that a relevant tumor mutational load can be determined and/or detected using targeted gene panel technologies (e.g., assessed with next-generation sequencing), and do not necessarily require whole exome sequencing. The present disclosure recognizes the source of a problem with certain prior technologies for assessing tumor mutational load to the extent that they relied on and/or required whole exome sequencing, which is typically not broadly performed as part of routine clinical care.

In some embodiments of the present invention, tumor mutational load is or was determined and/or detected by use of a targeted sequence panel. In some embodiments, tumor mutational load is measured using next-generation sequencing. In some embodiments, tumor mutational load is measured using an Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assay.^(8, 17)

In some embodiments, the step of determining comprises detecting at least one mutation characteristic by nucleic acid sequencing. In some embodiments, nucleic acid sequencing is or comprises whole exome sequencing. In some embodiments, nucleic acid sequencing does not involve whole exome sequencing. In some embodiments, nucleic acid sequencing is or comprises next generation sequencing.

In some embodiments, the present disclosure relates to administration of immunotherapy to a subject. In some embodiments, administration comprises steps of detecting a tumor mutational load characteristic (e.g., a tumor mutational load level relative to a threshold) in a cancer sample from a subject; and identifying the subject as a candidate for treatment (e.g. continued and/or extended or modified treatment) with an immunotherapy. In some embodiments, a tumor mutational load threshold is used to determine if a subject is a candidate for treatment (e.g., continued treatment and/or extended or modified treatment) with an immunotherapy. In some embodiments, the invention provides methods for detecting a low tumor mutational load, or a tumor mutational load below the defined tumor mutational load threshold, in a cancer sample from a subject; and identifying the subject as a poor candidate for treatment (e.g. continued treatment and/or extended or modified treatment) with an immune checkpoint modulator. In some embodiments, the step of detecting comprises sequencing one or more exomes from the cancer sample. In some embodiments, the step of detecting doesn't involve sequencing one or more exomes.

In some embodiments, the present disclosure relates to administration of immunotherapy to a subject. In some embodiments, such immunotherapy is or comprises immune checkpoint modulation therapy. In some embodiments, immunotherapy involves administration of one or more immunomodulatory agents; in some embodiments an immunomodulatory agent is or comprises an immune checkpoint modulator. In some embodiments, an immune checkpoint modulator is an agent (e.g., an antibody agent) that targets (i.e., specifically interacts with) an immune checkpoint target. In some embodiments, an immune checkpoint target is or comprises one or more of CTLA-4, PD-1, PD-L1, GITR, OX40, LAG-3, KIR, TIM-3, CD28, CD40, and CD137; in some embodiments, immune checkpoint modulator therapy is or comprises administration of an antibody agent that targets one or more such immune checkpoint targets. In some embodiments, the immune checkpoint modulator interacts with cytotoxic T-lymphocyte antigen 4 (CTLA4) or its ligands, and/or programmed death 1 (PD-1) or its ligands. In some embodiments, the antibody agent is or comprises a monoclonal antibody or antigen binding fragment thereof. In some embodiments, the antibody is selected from the group comprising of atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab, or tremelimumab, and combinations therein.

In some embodiments, a cancer is selected from the group consisting of bladder cancer, bone cancer, breast cancer, cancer of unknown primary, esophagogastric cancer, gastrointestinal cancer, glioma, head and neck cancer, hepatobiliary cancer, melanoma, mesothelioma, non-hodgkin lymphoma, non-small cell lung cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, skin cancer (non-melanoma), small cell lung cancer, soft tissue sarcoma, thyroid cancer, and combinations thereof.

In some embodiments, a cancer is selected from the group consisting of bladder cancer, breast cancer, esophagogastric cancer, glioma, head and neck cancer, melanoma, non-small cell lung cancer, renal cell carcinoma, and combinations thereof.

BRIEF DESCRIPTION OF THE DRAWING

The following figures are presented for the purpose of illustration only, and are not intended to be limiting.

FIG. 1 shows a Consolidated Standard of Reporting Trials (CONSORT) diagram demonstrating the flow of patient selection for analysis.

FIG. 2 shows the effect of tumor mutational load on overall survival after immune checkpoint modulator therapy. Kaplan-Meier curves are shown for the number of patients with the indicated number of mutations (1-15, 16-25, or greater than 25) identified from MSK-IMPACT testing. Overall survival is determined from the first dose of immune checkpoint modulator therapy. M, months. P<0.05 for all pairwise comparisons.

FIG. 3A-3B shows overall survival in relation to pan-cancer tumor mutational load threshold (A) with and (B) without immune checkpoint modulator (ICM) therapy. Kaplan-Meier curves are shown for patients who were treated with ICM or never treated with ICM with the indicated number of normalized mutations identified on MSK-IMPACT testing. Overall survival is determined starting from the first dose of ICM or first dose of any chemotherapy.

FIG. 4A-4B shows the effect of tumor mutational load on overall survival (A) after ICM therapy by cancer subtype and drug class. A Forest plot is shown for all patients in the identified cohort (“Pan Cancer”) or individual cancer subtypes. Indicated are the number of patients and hazard ratio. Horizontal lines represent the 95% confidence interval. The threshold used of normalized tumor mutational load from MSK-IMPACT for that particular subtype to select high tumor mutational load is shown, as well as the log-rank p value for the comparison of high and low tumor mutational load survival curves. All cancer types tested with a patient number of N>35 are displayed. (B) shows the effect of tumor mutational load on overall survival by cancer subtype without ICM therapy. A Forest plot is shown for all patients in the cohort of patients who did not receive ICM (“Pan Cancer”) or individual cancer subtypes. Indicated are the number of patients and hazard ratio. Horizontal lines represent the 95% confidence interval. The thresholds used are the optimal cutoff for that particular subtype in the ICM cohort. Log-rank p value are indicated for the comparison of high and low tumor mutational load survival curves. All cancer types tested with a patient number of N>35 are displayed. In both panels A and B, the term “cutoff' is used to denote a tumor mutational load threshold determined herein.

FIG. 5 shows selection of tumor mutational load threshold values used for analysis. (A) demonstrates the use of maximum chi-squared analysis for optimal threshold with individual cut points of normalized tumor mutational load on the x-axis and the p value. (B) demonstrates the hazard ratio at each cut point.

FIG. 6A-6H shows the effect of tumor mutational load on overall survival after ICM therapy organized by cancer subtype. The first column in panels A-H demonstrates the distribution of normalized tumor mutational load frequency over subsets of tumor mutational load. The second column in panels A-H demonstrates Kaplan-Meier curves for patients who were treated with ICM therapy, with the indicated number of normalized mutations identified on MSK-IMPACT testing. Each panel represents a cancer subtype, with (A) bladder cancer, (B) breast cancer, (C) esophagogastric cancer, (D) glioma, (E) head and neck cancer, (F) melanoma, (G) non-small cell lung cancer (NSCLC), and (H) renal cell carcinoma.

FIG. 7 shows a funnel plot of hazard ratio for all cancer subtypes. The funnel plot is of the reciprocal of the number of patients (y-axis) and hazard ratios for normalized tumor mutational load (x-axis) as a continuous variable for particular histologies.

FIG. 8A-8I shows the Effect of HLA class I homozygosity on survival in patients treated with immune check point modulator. (A) Association between homozygosity in at least one HLA class I locus and reduced overall survival in cohort 1, composed of 369 patients with melanoma or NSCLC treated with ICM therapy. (B) Association between homozygosity in at least one HLA class I locus and reduced survival in cohort 2, composed of 1,166 patients representing different cancer types treated with ICM therapy. (C) Association between homozygosity at one or more class I loci and for individual loci (HLA-A, HLA-B, and HLA-C) with decreased overall survival from all 1,535 patients. Indicated are the number of patients and hazard ratio (HR). Horizontal lines represent the 95% confidence interval. P value was calculated using the Log-rank test. Patients were divided into: individuals who were heterozygous at all three class I loci; individuals homozygous at one or more class I loci; individuals homozygous at the specified locus, but heterozygous at both of the other two loci; and individuals homozygous at the specified locus and also at one of the other two loci, but heterozygous at the other one. Homozygosity at HLA-A and HLA-B and homozygosity at HLA-A and HLA-C were rare in these patients, which limited the interpretability of analyses involving combinations of loci. (D) Improved survival in cohort 1 patients with heterozygosity at all HLA class I loci and a high tumor mutational load compared to patients that are homozygous for at least one HLA class I locus and have a low tumor mutational load. Mutational load was calculated from the total nonsynonymous mutational count from whole exome sequencing. High mutational load is defined here as tumors with >113 mutations. (E) Improved survival in cohort 2 patients with heterozygosity at all HLA class I loci and a high tumor mutational load compared to patients that are homozygous in at least one HLA class I locus and have a low tumor mutational load. Mutational load was calculated from the total nonsynonymous mutational count from MSK-IMPACT. High mutational load is defined here as tumors with >16.72 mutations. (F and G) Box plots illustrating the distribution of hazard ratios resulting from the survival analyses using a range of cutoffs to stratify patients based on their tumor mutational load. This analysis shows that the combined effect of HLA class I heterozygosity at all loci and mutation load on improved survival was greater compared to simply considering tumor mutational load alone in cohort 1 (F) and cohort 2 (G). For this analysis, we used a range of cutoffs across the quartiles of mutation load. P values were calculated using the Wilcoxon-rank sum test. (H) Survival analysis showing that LOH of heterozygous germline HLA class I is associated with decreased overall survival in patients treated with ICM immunotherapy. The number of patients who are of heterozygous germline at all HLA class I loci and without LOH is 199; the number of patients with heterozygous germline at all HLA class I loci and with LOH is 32. (I) Survival analysis showing that the effect of LOH of heterozygous germline HLA class I is enhanced in tumors with low mutation burden compared to tumors with high mutation load and without LOH. High mutation load is defined here as in (D). The number of patients who are of heterozygous germline at each HLA class I locus, without LOH, and with tumors containing high mutation load is 142; the number of patients with heterozygous germline at all HLA class I loci, with LOH, and with tumors having low mutation burden is 8.

FIGS. 9A-9J show the influence of HLA B44 supertype on survival in patients with advanced melanoma treated with ICM. (A) Prevalence of the different HLA supertypes in patients with melanoma from cohort 1. (B) Prevalence of the different HLA supertypes in the patients with melanoma from cohort 2. (C and D) Survival analysis showing the overall survival of advanced melanoma patients treated with ICM therapy possessing the B44 supertype [B44 (+)] compared with patients without the B44 supertype [B44 (−)] from cohort 1 (C) and cohort 2 (D). (E and F) Survival analysis of patients with the B44 supertype and high mutation burden versus patients without B44 and with low mutation burden, from cohort 1 (E) and cohort 2 (F). (G and H) Box plots illustrating the distribution of hazard ratios resulting from the survival analyses using different cutoffs to stratify patients based on their tumor mutational burden. This analysis shows that the combined effect of B44 and mutation load on increased survival was greater compared to simply considering tumor mutational load alone in patients with melanoma treated with ICM therapy from cohort 1 (G) and cohort 2 (H). For this analysis, we used a range of cutoffs across the quartiles of mutation load. P values were calculated using the Wilcoxon-rank sum test. (I) Survival analysis of melanoma patients with and without the B44 supertype from the TCGA cohort. (J) Left: Example of peptide motif common among B44 HLA alleles, docked in complex with HLA-B*44:02 based on an available crystal structure (PDB: 1M60). The five common residues (E2, I3, P4, V6, and Y9) of the motif were reported in (45). Peptide residues are colored according to their properties as basic, acidic, polar, or hydrophobic. Center: Close up view of example peptide conforming to the B44 motif reported in the literature. Residues at positions 2 and 9 are particularly important for anchoring the peptide in the HLA peptide-binding groove. Right: Alignment between B44 peptide motif and known immunogenic neoantigens (table 8) within the B44 supertype expressed by melanomas. All neoepitopes feature a glutamate at position 2; neoantigens are also either identical or similar to the motif at one or two additional positions. The second neoantigen (FAM3C: TESPFEQHI) was identified in a melanoma patient with a long-term response to anti-CTLA-4 from cohort 1. Sequence similarity was determined using standard residue classes (GAVLI, FYW, CM, ST, KRH, DENQ, and P).

FIG. 10A-10E shows the effect of the HLA-B*15:01 allele on overall survival in patients with melanoma treated with ICM therapy. (A) Survival analysis showing reduced survival in ICM-treated melanoma patients from cohort 1 with and without the HLA-B*15:01 allele. (B) Overview of the three-dimensional structure of the peptide-binding groove of HLA-B*15:01, light purple; bound peptide, yellow; bridging residues, light pink. (C) Side view of the bridge-sequestration effect over bound-peptide residue positions P2 and P3 (light blue and red, respectively). (D) MD simulation snapshots of both the isolated HLA B*15:01 molecule and its complex with a 9-mer peptide; each trajectory was run over the course of 500 ns of simulation time. (E) Observables from the MD simulations described in (D). The mean bridge distances in the HLA-B*15:01 molecule and in the HLA-B*15:01-peptide complex are comparable. The residue-position root mean square fluctuations (RMSFs) indicate that each of the bridging residues becomes more rigid in the presence of the peptide.

FIGS. 11A-11B show the number of somatic coding mutations in the tumors between patients who were homozygous for at least one HLA class I locus and patients who are heterozygous at each class I locus in cohort 1 and cohort 2, respectively. The P value was calculated by Wilcoxon-rank sum test.

FIGS. 12A-12D show molecular dynamics simulations for HLA-B*07:02 and HLA-B*53:01. (A and C) MD simulation snapshots of both the isolated HLA B*07:02 and HLA B*53:01 molecules, respectively, and their complexes with a 9-mer peptide; each trajectory was run over the course of 300 ns of simulation time. (B and D) Observables from the MD simulations described in (A and C). Both mean bridge distances and bridging residues RMSFs in the HLA B*07:02 and HLA B*53:01 molecules and in their corresponding HLA-peptide complexes are shown.

FIG. 13 shows a Consolidated Standard of Reporting Trials (CONSORT) diagram demonstrating the flow of patient selection for analysis for a confirmatory cohort.

FIGS. 14A and 14B show effect of mutational load on overall survival after ICI treatment. A. Kaplan-Meier curves for patients with tumors falling into the depicted deciles of tumor mutational burden (TMB) within each histology. TMB is defined as normalized somatic mutations per MB identified on MSK-IMPACT testing. Overall survival is from the first dose of ICI. Log-rank p value indicated for all patients, with univariate Cox regression hazard ratio of 0.76 (95% CI 0.62-0.94) and 0.52 (95% CI 0.42-0.64) for the 10-20% and Top 10% groups, respectively, compared to Bottom 80% group. m, months B. Cox regression hazard ratios for overall survival, at depicted cutoffs of tumor mutational burden (TMB) measured in mutations per MB across all cancer subtypes. Solid black circles represent hazard ratios with p-values <0.05.

FIG. 15 demonstrates he distribution of cancer types within the groups demonstrated in FIG. 14A.

FIGS. 16A-16D demonstrates overall survival of high TMB patients by quantiles across cancer types. Kaplan Meier survival analysis of high vs. low TMB defined by the top indicated percentage of patients from each cancer type. P values indicate log rank test.

FIG. 17 demonstrates effect of non-synonymous mutational load on overall survival after ICI Treatment by cancer subtype and drug class. Forest plot for all patients in the identified cohort or individual cancer subtypes. Indicated are the number of patients and hazard ratio comparing overall survival after ICI in patients in the highest 20th percentile TMB within each histology. Horizontal lines represent the 95% confidence interval. The cutoff defining top 20% of normalized mutational burden from MSK-IMPACT for each cancer type is shown, as well as the log-rank p value for the comparison of high and low mutational burden survival curves. All cancer types in analysis are displayed.

FIGS. 18A and 18B show forest plot for all patients in the cohort and individual cancer histologies. Indicated are the number of patients and hazard ratio comparing overall survival after ICI in patients with 10% highest TMB (A) or 30% (B) for each histology. Horizontal lines represent the 95% confidence interval. The cutoff used of normalized mutational burden from MSK-IMPACT for that particular subtype to select high mutational burden is shown, as well as the log-rank p value for the comparison of high and low mutational burden survival curves.

FIG. 19 shows effect of non-synonymous mutational load on overall survival after ICI Treatment, or in non-ICI treated patients, by cancer subtype. Individual plots for all patients in the identified cohort (“All cancer types”) or individual cancer subtypes. The first column demonstrates the distribution of normalized mutational load frequency. The second column demonstrates Kaplan-Meier curves for patients who were treated with ICI with the top 20% TMB within each histology identified on MSK-IMPACT testing. The third column represents OS comparing the top 20% of tumors in the cohort of patients never treated with ICI from date of diagnosis.

FIG. 20 shows forest plot depicting the Cox proportional hazards model across all cancer types and individual histologies demonstrating the hazard ratio for TMB as a continuous variable.

FIGS. 21A-21C show TMB as a predictor of clinical response to ICI. Pie charts demonstrating the relative proportion of patients with a clinical benefit (defined as radiographic response or stable disease for ≥6 months) with low or high TMB in A. NSCLC, B. Head and Neck, and C. Esophagogastric cancer. Fisher's exact test p values indicated. Similar data for the association between TMB and tumor response in MSK-IMPACT sequenced NSCLC patients have also been separately published.

FIGS. 22A-22D show TMB predicts for progression free survival progression free survival (A,B,C) or time to next treatment (D) in patients with high and low TMB (Top20%) tumors in the indicated cancer types. Log-rank p values indicated.

FIG. 23 shows effect of non-synonymous mutational load on OS by cancer Subtype in Patients Not Treated with ICI. Forest plot for all metastatic patients in the cohort of patients who did not receive ICI (”All cancer types“) or individual cancer subtypes. Indicated are the number of patients and hazard ratio. Horizontal lines represent the 95% confidence interval. The cutoffs used are the top 20% in this cohort. Log-rank p value are indicated for the comparison of high and low mutational burden survival curves.

FIG. 24 shows modified versions of FIG. 17 and FIG. 23, with the TMB cutoff instead defined as the top 20% among all patients in both ICI-treated and non-ICI treated cohorts.

FIG. 25 shows a modified version of FIG. 19, with TMB cutoff instead defined as the top 20% from all patients in both the ICI-treated and non-ICI treated cohorts. The first column demonstrates the distribution of normalized mutational load frequency across the combined ICI treated and non-ICI treated cohorts in that histology. The second column demonstrates Kaplan-Meier curves for patients who were treated with ICI with the top 20% TMB (across the combined cohorts) within each histology identified on MSK-IMPACT testing. The third column represents OS comparing the top 20% TMB (across the combined cohorts) in the cohort of patients never treated with ICI from date of diagnosis.

DEFINITIONS

In order for the present invention to be more readily understood, certain terms are defined below. Those skilled in the art will appreciate that definitions for certain terms may be provided elsewhere in the specification, and/or will be clear from context.

Administration: As used herein, the term “administration” refers to the administration of a composition to a subject. Administration may be by any appropriate route. For example, in some embodiments, administration may be bronchial (including by bronchial instillation), buccal, enteral, interdermal, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, vaginal and vitreal.

Affinity: As is known in the art, “affinity” is a measure of the tightness with a particular ligand binds to its partner. Affinities can be measured in different ways. In some embodiments, affinity is measured by a quantitative assay. In some such embodiments, binding partner concentration may be fixed to be in excess of ligand concentration so as to mimic physiological conditions. Alternatively or additionally, in some embodiments, binding partner concentration and/or ligand concentration may be varied. In some such embodiments, affinity may be compared to a reference under comparable conditions (e.g., concentrations).

Amino acid: As used herein, term “amino acid,” in its broadest sense, refers to any compound and/or substance that can be incorporated into a polypeptide chain. In some embodiments, an amino acid has the general structure H2N—C(H)(R)—COOH. In some embodiments, an amino acid is a naturally occurring amino acid. In some embodiments, an amino acid is a synthetic amino acid; in some embodiments, an amino acid is a d-amino acid; in some embodiments, an amino acid is an 1-amino acid. “Standard amino acid” refers to any of the twenty standard 1-amino acids commonly found in naturally occurring peptides. “Nonstandard amino acid” refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source. As used herein, “synthetic amino acid” encompasses chemically modified amino acids, including but not limited to salts, amino acid derivatives (such as amides), and/or substitutions. Amino acids, including carboxy- and/or amino-terminal amino acids in peptides, can be modified by methylation, amidation, acetylation, protecting groups, and/or substitution with other chemical groups that can change the peptide's circulating half-life without adversely affecting their activity. Amino acids may participate in a disulfide bond. Amino acids may comprise one or posttranslational modifications, such as association with one or more chemical entities (e.g., methyl groups, acetate groups, acetyl groups, phosphate groups, formyl moieties, isoprenoid groups, sulfate groups, polyethylene glycol moieties, lipid moieties, carbohydrate moieties, biotin moieties, etc.). The term “amino acid” is used interchangeably with “amino acid residue,” and may refer to a free amino acid and/or to an amino acid residue of a peptide. It will be apparent from the context in which the term is used whether it refers to a free amino acid or a residue of a peptide.

Antibody agent: As used herein, the term “antibody agent” refers to an agent that specifically binds to a particular antigen. In some embodiments, the term encompasses any polypeptide with immunoglobulin structural elements sufficient to confer specific binding. Suitable antibody agents include, but are not limited to, human antibodies, primatized antibodies, chimeric antibodies, bi-specific antibodies, humanized antibodies, conjugated antibodies (i.e., antibodies conjugated or fused to other proteins, radiolabels, cytotoxins), Small Modular Immuno Pharmaceuticals (“SMIPs™”), single chain antibodies, cameloid antibodies, and antibody fragments. As used herein, the term “antibody agent” also includes intact monoclonal antibodies, polyclonal antibodies, single domain antibodies (e.g., shark single domain antibodies (e.g., IgNAR or fragments thereof)), multispecific antibodies (e.g. bi-specific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity. In some embodiments, the term encompasses stapled peptides. In some embodiments, the term encompasses one or more antibody-like binding peptidomimetics. In some embodiments, the term encompasses one or more antibody-like binding scaffold proteins. In some embodiments, the term encompasses monobodies or adnectins. In many embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes one or more structural elements recognized by those skilled in the art as a complementarity determining region (CDR); in some embodiments an antibody agent is or comprises a polypeptide whose amino acid sequence includes at least one CDR (e.g., at least one heavy chain CDR and/or at least one light chain CDR) that is substantially identical to one found in a reference antibody. In some embodiments an included CDR is substantially identical to a reference CDR in that it is either identical in sequence or contains between 1-5 amino acid substitutions as compared with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that it shows at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that it shows at least 96%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that 1-5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that 1-5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR. In some embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes structural elements recognized by those skilled in the art as an immunoglobulin variable domain. In some embodiments, an antibody agent is a polypeptide protein having a binding domain which is homologous or largely homologous to an immunoglobulin-binding domain.

Antibody polypeptide: As used herein, the terms “antibody polypeptide” or “antibody”, or “antigen-binding fragment thereof”, which may be used interchangeably, refer to polypeptide(s) capable of binding to an epitope. In some embodiments, an antibody polypeptide is a full-length antibody, and in some embodiments, is less than full length but includes at least one binding site (comprising at least one, and preferably at least two sequences with structure of antibody “variable regions”). In some embodiments, the term “antibody polypeptide” encompasses any protein having a binding domain which is homologous or largely homologous to an immunoglobulin-binding domain. In particular embodiments, “antibody polypeptides” encompasses polypeptides having a binding domain that shows at least 99% identity with an immunoglobulin binding domain. In some embodiments, “antibody polypeptide” is any protein having a binding domain that shows at least 70%, 80%, 85%, 90%, or 95% identity with an immuglobulin binding domain, for example a reference immunoglobulin binding domain. An included “antibody polypeptide” may have an amino acid sequence identical to that of an antibody that is found in a natural source. Antibody polypeptides in accordance with the present invention may be prepared by any available means including, for example, isolation from a natural source or antibody library, recombinant production in or with a host system, chemical synthesis, etc., or combinations thereof. An antibody polypeptide may be monoclonal or polyclonal. An antibody polypeptide may be a member of any immunoglobulin class, including any of the human classes: IgG, IgM, IgA, IgD, and IgE. In certain embodiments, an antibody may be a member of the IgG immunoglobulin class. As used herein, the terms “antibody polypeptide” or “characteristic portion of an antibody” are used interchangeably and refer to any derivative of an antibody that possesses the ability to bind to an epitope of interest. In certain embodiments, the “antibody polypeptide” is an antibody fragment that retains at least a significant portion of the full-length antibody's specific binding ability. Examples of antibody fragments include, but are not limited to, Fab, Fab′, F(ab′)₂, scFv, Fv, dsFv diabody, and Fd fragments. Alternatively or additionally, an antibody fragment may comprise multiple chains that are linked together, for example, by disulfide linkages. In some embodiments, an antibody polypeptide may be a human antibody. In some embodiments, the antibody polypeptides may be a humanized. Humanized antibody polypeptides include may be chimeric immunoglobulins, immunoglobulin chains or antibody polypeptides (such as Fv, Fab, Fab′, F(ab′)2 or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin. In general, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity. In particular embodiments, antibody polyeptides for use in accordance with the present invention bind to particular epitopes of on immune checkpoint molecules.

Antigen: An “antigen” is a molecule or entity to which an antibody binds. In some embodiments, an antigen is or comprises a polypeptide or portion thereof. In some embodiments, an antigen is a portion of an infectious agent that is recognized by antibodies. In some embodiments, an antigen is an agent that elicits an immune response; and/or (ii) an agent that is bound by a T cell receptor (e.g., when presented by an MHC molecule) or to an antibody (e.g., produced by a B cell) when exposed or administered to an organism. In some embodiments, an antigen elicits a humoral response (e.g., including production of antigen-specific antibodies) in an organism; alternatively or additionally, in some embodiments, an antigen elicits a cellular response (e.g., involving T-cells whose receptors specifically interact with the antigen) in an organism. It will be appreciated by those skilled in the art that a particular antigen may elicit an immune response in one or several members of a target organism (e.g., mice, rabbits, primates, humans), but not in all members of the target organism species. In some embodiments, an antigen elicits an immune response in at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% of the members of a target organism species. In some embodiments, an antigen binds to an antibody and/or T cell receptor, and may or may not induce a particular physiological response in an organism. In some embodiments, for example, an antigen may bind to an antibody and/or to a T cell receptor in vitro, whether or not such an interaction occurs in vivo. In general, an antigen may be or include any chemical entity such as, for example, a small molecule, a nucleic acid, a polypeptide, a carbohydrate, a lipid, a polymer [in some embodiments other than a biologic polymer (e.g., other than a nucleic acid or amino acid polymer)] etc. In some embodiments, an antigen is or comprises a polypeptide. In some embodiments, an antigen is or comprises a glycan. Those of ordinary skill in the art will appreciate that, in general, an antigen may be provided in isolated or pure form, or alternatively may be provided in crude form (e.g., together with other materials, for example in an extract such as a cellular extract or other relatively crude preparation of an antigen-containing source). In some embodiments, antigens utilized in accordance with the present invention are provided in a crude form. In some embodiments, an antigen is or comprises a recombinant antigen.

Approximately: As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

“Blockade”: The term “blockade” as used herein, refers to an entity or event whose presence or level correlates with a reduction in level and/or activity of an indicated target. Thus, for example, “a PD-1 blockade” is an agent or event whose presence correlates with reduction in level and/or activity of PD-1. In some such embodiments, a relevant activity of PD-1 may be or comprise interaction with one of more of its ligands (e.g., PD-L1 and/or PD-L2) and/or a downstream effect thereof. In some embodiments, a PD-1 blockade may be achieved by administration of an agent, such as an antibody agent, that targets PD-1 and/or a PD-1 ligand (e.g., PD-L1 and/or PD-L2) and/or a complex thereof. In some particular embodiments, a PD-1 blockade may be achieved through administration of an antibody agent that binds to PD-1. In some embodiments, a PD-1 blockade may be achieved through administration of one or more of nivolumab, pembrolizumab, atezolizumab, avelumab, and/or durvalumab. Analogously, a “CTL4-blockade is an agent or event whose presence correlates with reduction in level and/or activity of CTLA-4. In some such embodiments, a relevant activity of CTLA-4 may be or comprise interaction with one of more of its ligands (e.g., CD80 and/or CD86) and/or a downstream effect thereof. In some embodiments, a CTLA-4 blockade may be achieved by administration of an agent, such as an antibody agent, that targets CTLA-4 ligand (e.g., CD80 and/or CD86) and/or a complex thereof. In some particular embodiments, a CTLA-4 blockade may be achieved through administration of an antibody agent that binds to CTLA-4. In some embodiments, a CTLA-4 blockade may be achieved through administration of one or more of ipilimumab and/or tremelimumab.

Combination therapy: The term “combination therapy”, as used herein, refers to those situations in which two or more different pharmaceutical agents are administered in overlapping regimens so that the subject is simultaneously exposed to both agents. When used in combination therapy, two or more different agents may be administered simultaneously or separately. This administration in combination can include simultaneous administration of the two or more agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. That is, two or more agents can be formulated together in the same dosage form and administered simultaneously. Alternatively, two or more agents can be simultaneously administered, wherein the agents are present in separate formulations. In another alternative, a first agent can be administered just followed by one or more additional agents. In the separate administration protocol, two or more agents may be administered a few minutes apart, or a few hours apart, or a few days apart.

Comparable: The term “comparable” is used herein to describe two (or more) sets of conditions, circumstances, individuals, or populations that are sufficiently similar to one another to permit comparison of results obtained or phenomena observed. In some embodiments, comparable sets of conditions, circumstances, individuals, or populations are characterized by a plurality of substantially identical features and one or a small number of varied features. Those of ordinary skill in the art will appreciate that sets of circumstances, individuals, or populations are comparable to one another when characterized by a sufficient number and type of substantially identical features to warrant a reasonable conclusion that differences in results obtained or phenomena observed under or with different sets of circumstances, individuals, or populations are caused by or indicative of the variation in those features that are varied. Those skilled in the art will appreciate that relative language used herein (e.g., enhanced, activated, reduced, inhibited, etc) will typically refer to comparisons made under comparable conditions.

Consensus sequence: As used herein, the term “consensus sequence” refers to a core sequence that elicits or drives a physiological phenomenon (e.g., an immune response). It is to be understood by those of skill in the art that a a cancer cell that shares a “consensus sequence” with an antigen of an infectious agent shares a portion of amino acid sequence that affects the binding affinity of the antigen to an MHC molecule (either directly or allosterically), and/or facilitates recognition by T cell receptors. In some embodiments, a consensus sequence is a tetrapeptide. In some embodiments, a consensus sequence is a nonapeptide. In some embodiments, a consensus sequence is between four and nine amino acids in length. In some embodiments, a consensus sequence is greater than nine amino acids in length.

Diagnostic information: As used herein, diagnostic information or information for use in diagnosis is any information that is useful in determining whether a patient has a disease or condition and/or in classifying the disease or condition into a phenotypic category or any category having significance with regard to prognosis of the disease or condition, or likely response to treatment (either treatment in general or any particular treatment) of the disease or condition. Similarly, diagnosis refers to providing any type of diagnostic information, including, but not limited to, whether a subject is likely to have a disease or condition (such as cancer), state, staging or characteristic of the disease or condition as manifested in the subject, information related to the nature or classification of a tumor, information related to prognosis and/or information useful in selecting an appropriate treatment. Selection of treatment may include the choice of a particular therapeutic (e.g., chemotherapeutic) agent or other treatment modality such as surgery, radiation, etc., a choice about whether to withhold or deliver therapy, a choice relating to dosing regimen (e.g., frequency or level of one or more doses of a particular therapeutic agent or combination of therapeutic agents), etc.

Dosing regimen: A “dosing regimen” (or “therapeutic regimen”), as that term is used herein, is a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by periods of time. In some embodiments, a given therapeutic agent has a recommended dosing regimen, which may involve one or more doses. In some embodiments, a dosing regimen comprises a plurality of doses each of which are separated from one another by a time period of the same length; in some embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses. In some embodiments, a dosing regimen is or has been correlated with a desired therapeutic outcome, when administered across a population of patients.

Durable clinical benefit: As used herein, the term “durable clinical benefit” (DCB), has its art-understood meaning, referring to a clinical benefit that lasts for a relevant period of time. In some embodiments, such a clinical benefit is or comprises reduction in tumor size, increase in progression free survival, increase in overall survival, decrease in overall tumor burden, decrease in the symptoms caused by tumor growth such as pain, organ failure, bleeding, damage to the skeletal system, and other related sequelae of metastatic cancer and combinations thereof. In some embodiments, the relevant period of time is at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, or longer. In some particular embodiments, the relevant period of time is 6 months.

Exome: As used herein, the term “exome” is used in accordance with its art-understood meaning referring to the set of exon sequences that are found in a particular genome.

Favorable response: As used herein, the term “favorable response” refers to a reduction in frequency and/or intensity of one or more symptoms, reduction in tumor burden, full or partial remission, or other improvement in disease pathophysiology. Symptoms are reduced when one or more symptoms of a particular disease, disorder or condition is reduced in magnitude (e.g., intensity, severity, etc.) and/or frequency. For purposes of clarity, a delay in the onset of a particular symptom is considered one form of reducing the frequency of that symptom. Many cancer patients with smaller tumors have no symptoms. It is not intended that the present invention be limited only to cases where the symptoms are eliminated. The present invention specifically contemplates treatment such that one or more symptoms is/are reduced (and the condition of the subject is thereby “improved”), albeit not completely eliminated. In some embodiments, a favorable response is established when a particular therapeutic regimen shows a statistically significant effect when administered across a relevant population; demonstration of a particular result in a specific individual may not be required. Thus, in some embodiments, a particular therapeutic regimen is determined to have a favorable response when its administration is correlated with a relevant desired effect.

Homology: As used herein, the term “homology” refers to the overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% similar.

Identity: As used herein, the term “identity” refers to the overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Calculation of the percent identity of two nucleic acid sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4: 11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleotide sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.

Immune checkpoint modulator: As used herein, the term “immune checkpoint modulator” refers to an agent that interacts directly or indirectly with an immune checkpoint. In some embodiments, an immune checkpoint modulator increases an immune effector response (e.g., cytotoxic T cell response), for example by stimulating a positive signal for T cell activation. In some embodiments, an immune checkpoint modulator increases an immune effector response (e.g., cytotoxic T cell response), for example by inhibiting a negative signal for T cell activation (e.g. disinhibition). In some embodiments, an immune checkpoint modulator interferes with a signal for T cell anergy. In some embodiments, an immune checkpoint modulator reduces, removes, or prevents immune tolerance to one or more antigens.

Long Term Benefit: In general, the term “long term benefit” refers to a desirable clinical outcome, e.g., observed after administration of a particular treatment or therapy of interest, that is maintained for a clinically relevant period of time. To give but one example, in some embodiments, a long term benefit of cancer therapy is or comprises (1) no evidence of disease (“NED”, for example upon radiographic assessment) and/or (2) stable or decreased volume of diseases. In some embodiments, a clinically relevant period of time is at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months or more. In some embodiments, a clinically relevant period of time is at least six months. In some embodiments, a clinically relevant period of time is at least 1 year.

Marker: A marker, as used herein, refers to an agent whose presence or level is a characteristic of a particular tumor or metastatic disease thereof. For example, in some embodiments, the term refers to a gene expression product that is characteristic of a particular tumor, tumor subclass, stage of tumor, etc. Alternatively or additionally, in some embodiments, a presence or level of a particular marker correlates with activity (or activity level) of a particular signaling pathway, for example that may be characteristic of a particular class of tumors. The statistical significance of the presence or absence of a marker may vary depending upon the particular marker. In some embodiments, detection of a marker is highly specific in that it reflects a high probability that the tumor is of a particular subclass. Such specificity may come at the cost of sensitivity (i.e., a negative result may occur even if the tumor is a tumor that would be expected to express the marker). Conversely, markers with a high degree of sensitivity may be less specific that those with lower sensitivity. According to the present invention a useful marker need not distinguish tumors of a particular subclass with 100% accuracy.

Modulator: The term “modulator” is used to refer to an entity whose presence in a system in which an activity of interest is observed correlates with a change in level and/or nature of that activity as compared with that observed under otherwise comparable conditions when the modulator is absent. In some embodiments, a modulator is an activator, in that activity is increased in its presence as compared with that observed under otherwise comparable conditions when the modulator is absent. In some embodiments, a modulator is an inhibitor, in that activity is reduced in its presence as compared with otherwise comparable conditions when the modulator is absent. In some embodiments, a modulator interacts directly with a target entity whose activity is of interest. In some embodiments, a modulator interacts indirectly (i.e., directly with an intermediate agent that interacts with the target entity) with a target entity whose activity is of interest. In some embodiments, a modulator affects level of a target entity of interest; alternatively or additionally, in some embodiments, a modulator affects activity of a target entity of interest without affecting level of the target entity. In some embodiments, a modulator affects both level and activity of a target entity of interest, so that an observed difference in activity is not entirely explained by or commensurate with an observed difference in level.

Mutation: As used herein, the term “mutation” refers to permanent change in the DNA sequence that makes up a gene. In some embodiments, mutations range in size from a single DNA building block (DNA base) to a large segment of a chromosome. In some embodiments, mutations can include missense mutations, frameshift mutations, duplications, insertions, nonsense mutation, deletions and repeat expansions. In some embodiments, a missense mutation is a change in one DNA base pair that results in the substitution of one amino acid for another in the protein made by a gene. In some embodiments, a nonsense mutation is also a change in one DNA base pair. Instead of substituting one amino acid for another, however, the altered DNA sequence prematurely signals the cell to stop building a protein. In some embodiments, an insertion changes the number of DNA bases in a gene by adding a piece of DNA. In some embodiments, a deletion changes the number of DNA bases by removing a piece of DNA. In some embodiments, small deletions may remove one or a few base pairs within a gene, while larger deletions can remove an entire gene or several neighboring genes. In some embodiments, a duplication consists of a piece of DNA that is abnormally copied one or more times. In some embodiments, frameshift mutations occur when the addition or loss of DNA bases changes a gene's reading frame. A reading frame consists of groups of 3 bases that each code for one amino acid. In some embodiments, a frameshift mutation shifts the grouping of these bases and changes the code for amino acids. In some embodiments, insertions, deletions, and duplications can all be frameshift mutations. In some embodiments, a repeat expansion is another type of mutation. In some embodiments, nucleotide repeats are short DNA sequences that are repeated a number of times in a row. For example, a trinucleotide repeat is made up of 3-base-pair sequences, and a tetranucleotide repeat is made up of 4-base-pair sequences. In some embodiments, a repeat expansion is a mutation that increases the number of times that the short DNA sequence is repeated.

“Mutational Load”: The term “mutational load” is used herein to refer to the number of mutations detected in a sample (e.g., a tumor sample) at a given point in time. Those skilled in the art will appreciate that “mutational load” may also be referred to as “mutational burden”. In some embodiments, mutations included in an assessment of mutational load may be neoantigen mutations (i.e., mutations that give rise to neoantigens). In some embodiments, a sample in which mutational load is assessed is from a single tumor. In some embodiments, a sample is pooled from multiple tumors, either from a single individual subject, or from a plurality of subjects.

Neoepitope: A “neoepitope” is understood in the art to refer to an epitope that emerges or develops in a subject after exposure to or occurrence of a particular event (e.g., development or progression of a particular disease, disorder or condition, e.g., infection, cancer, stage of cancer, etc). As used herein, a neoepitope is one whose presence and/or level is correlated with exposure to or occurrence of the event. In some embodiments, a neoepitope is one that triggers an immune response against cells that express it (e.g., at a relevant level). In some embodiments, a neopepitope is one that triggers an immune response that kills or otherwise destroys cells that express it (e.g., at a relevant level). In some embodiments, a relevant event that triggers a neoepitope is or comprises somatic mutation in a cell. In some embodiments, a neoepitope is not expressed in non-cancer cells to a level and/or in a manner that triggers and/or supports an immune response (e.g., an immune response sufficient to target cancer cells expressing the neoepitope). In some embodiments, a neoepitope is a neoantigen.

No Benefit: As used herein, the phrase “no benefit” is used to refer to absence of detectable clinical benefit (e.g., in response to administration of a particular therapy or treatment of interest). In some embodiments, absence of clinical benefit refers to absence of statistically significant change in any particular symptom or characteristic of a particular disease, disorder, or condition. In some embodiments, absence of clinical benefit refers to a change in one or more symptoms or characteristics of a disease, disorder, or condition, that lasts for only a short period of time such as, for example, less than about 6 months, less than about 5 months, less than about 4 months, less than about 3 months, less than about 2 months, less than about 1 month, or less. In some embodiments, no benefit refers to no durable benefit.

Objective Response: As used herein, the phrase “objective response” refers to size reduction of a cancerous mass by a defined amount. In some embodiments, the cancerous mass is a tumor. In some embodiments, confirmed objective response is response confirmed at least four (4) weeks after treatment.

Objective Response Rate: As used herein, the term “objective response rate” (“ORR”) has its art-understood meaning referring to the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period. In some embodiments, response duration usually measured from the time of initial response until documented tumor progression. In some embodiments, ORR involves the sum of partial responses plus complete responses.

Patient: As used herein, the term “patient” or “subject” refers to any organism to which a provided composition is or may be administered, e.g., for experimental, diagnostic, prophylactic, cosmetic, and/or therapeutic purposes. Typical patients include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and/or humans). In some embodiments, a patient is a human. In some embodiments, a patient is suffering from or susceptible to one or more disorders or conditions. In some embodiments, a patient displays one or more symptoms of a disorder or condition. In some embodiments, a patient has been diagnosed with one or more disorders or conditions. In some embodiments, the disorder or condition is or includes cancer, or presence of one or more tumors. In some embodiments, the disorder or condition is metastatic cancer.

Polypeptide: As used herein, a “polypeptide”, generally speaking, is a string of at least two amino acids attached to one another by a peptide bond. In some embodiments, a polypeptide may include at least 3-5 amino acids, each of which is attached to others by way of at least one peptide bond. Those of ordinary skill in the art will appreciate that polypeptides sometimes include “non-natural” amino acids or other entities that nonetheless are capable of integrating into a polypeptide chain, optionally.

Prognostic and predictive information: As used herein, the terms prognostic and predictive information are used interchangeably to refer to any information that may be used to indicate any aspect of the course of a disease or condition either in the absence or presence of treatment. Such information may include, but is not limited to, the average life expectancy of a patient, the likelihood that a patient will survive for a given amount of time (e.g., 6 months, 1 year, 5 years, etc.), the likelihood that a patient will be cured of a disease, the likelihood that a patient's disease will respond to a particular therapy (wherein response may be defined in any of a variety of ways). Prognostic and predictive information are included within the broad category of diagnostic information.

Progression Free Survival: As used herein, the term “progression free survival” (PFS) has its art-understood meaning relating to the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In some embodiments, measuring the progression-free survival is utilized as an assessment of how well a new treatment works. In some embodiments, PFS is determined in a randomized clinical trial; in some such embodiments, PFS refers to time from randomization until objective tumor progression and/or death.

Protein: As used herein, the term “protein” refers to a polypeptide (i.e., a string of at least two amino acids linked to one another by peptide bonds). Proteins may include moieties other than amino acids (e.g., may be glycoproteins, proteoglycans, etc.) and/or may be otherwise processed or modified. Those of ordinary skill in the art will appreciate that a “protein” can be a complete polypeptide chain as produced by a cell (with or without a signal sequence), or can be a characteristic portion thereof. Those of ordinary skill will appreciate that a protein can sometimes include more than one polypeptide chain, for example linked by one or more disulfide bonds or associated by other means. Polypeptides may contain L-amino acids, D-amino acids, or both and may contain any of a variety of amino acid modifications or analogs known in the art. Useful modifications include, e.g., terminal acetylation, amidation, methylation, etc. In some embodiments, proteins may comprise natural amino acids, non-natural amino acids, synthetic amino acids, and combinations thereof. The term “peptide” is generally used to refer to a polypeptide having a length of less than about 100 amino acids, less than about 50 amino acids, less than 20 amino acids, or less than 10 amino acids.

Reference: Those of skill in the art will appreciate that, in many embodiments described herein, a determined value or characteristic of interest is compared with an appropriate reference. In some embodiments, a reference value or characteristic is one determined for a comparable cohort, individual, population, or sample. In some embodiments, a reference value or characteristic is tested and/or determined substantially simultaneously with the testing or determination of the characteristic or value of interest. In some embodiments, a reference characteristic or value is or comprises a historical reference, optionally embodied in a tangible medium. Typically, as would be understood by those skilled in the art, a reference value or characteristic is determined under conditions comparable to those utilized to determine or analyze the characteristic or value of interest.

Response: As used herein, the term “response” may refer to an alteration in a subject's condition that occurs as a result of or correlates with treatment. In some embodiments, a response is or comprises a beneficial response. In some embodiments, a beneficial response may include stabilization of the condition (e.g., prevention or delay of deterioration expected or typically observed to occur absent the treatment), amelioration (e.g., reduction in frequency and/or intensity) of one or more symptoms of the condition, and/or improvement in the prospects for cure of the condition, etc. In some embodiments, “response” may refer to response of an organism, an organ, a tissue, a cell, or a cell component or in vitro system. In some embodiments, a response is or comprises a clinical response. In some embodiments, presence, extent, and/or nature of response may be measured and/or characterized according to particular criteria; in some embodiments, such criteria may include clinical criteria and/or objective criteria. In some embodiments, techniques for assessing response may include, but are not limited to, clinical examination, positron emission tomography, chest X-ray CT scan, Mill, ultrasound, endoscopy, laparoscopy, presence or level of a particular marker in a sample, cytology, and/or histology. Where a response of interest is or comprises response of a tumor to therapy, those of ordinary skill will be aware of a variety of established techniques for assessing such response, including, for example, for determining tumor burden, tumor size, tumor stage, etc. For example, certain technologies for assessing response of solid tumors to treatment are discussed in Therasse et. al., “New guidelines to evaluate the response to treatment in solid tumors”, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J. Natl. Cancer Inst., 2000, 92(3):205-216. Those of ordinary skill in the art will be aware of, and/or will appreciate in light of the present disclosure, strategies for determining particular response criteria for individual tumors, tumor types, patient populations or cohorts, etc, as well as for determining appropriate references therefor.

Sample: As used herein, the term “sample” typically refers to a biological sample obtained or derived from a source of interest, as described herein. In some embodiments, a source of interest comprises an organism, such as an animal or human. In some embodiments, a biological sample is or comprises biological tissue or fluid. In some embodiments, a biological sample may be or comprise bone marrow; blood; blood cells; ascites; tissue or fine needle biopsy samples; cell-containing body fluids; free floating nucleic acids; sputum; saliva; urine; cerebrospinal fluid, peritoneal fluid; pleural fluid; feces; lymph; gynecological fluids; skin swabs; vaginal swabs; oral swabs; nasal swabs; washings or lavages such as a ductal lavages or broncheoalveolar lavages; aspirates; scrapings; bone marrow specimens; tissue biopsy specimens; surgical specimens; feces, other body fluids, secretions, and/or excretions; and/or cells therefrom, etc. In some embodiments, a biological sample is or comprises cells obtained from an individual. In some embodiments, obtained cells are or include cells from an individual from whom the sample is obtained. In some embodiments, a sample is a “primary sample” obtained directly from a source of interest by any appropriate means. For example, in some embodiments, a primary biological sample is obtained by methods selected from the group consisting of biopsy (e.g., fine needle aspiration or tissue biopsy), surgery, collection of body fluid (e.g., blood, lymph, feces etc.), etc. In some embodiments, as will be clear from context, the term “sample” refers to a preparation that is obtained by processing (e.g., by removing one or more components of and/or by adding one or more agents to) a primary sample. For example, filtering using a semi-permeable membrane. Such a “processed sample” may comprise, for example nucleic acids or proteins extracted from a sample or obtained by subjecting a primary sample to techniques such as amplification or reverse transcription of mRNA, isolation and/or purification of certain components, etc.

Specific: The term “specific”, when used herein with reference to an agent having an activity, is understood by those skilled in the art to mean that the agent discriminates between potential target entities or states. For example, an in some embodiments, an agent is said to bind “specifically” to its target if it binds preferentially with that target in the presence of one or more competing alternative targets. In many embodiments, specific interaction is dependent upon the presence of a particular structural feature of the target entity (e.g., an epitope, a cleft, a binding site). It is to be understood that specificity need not be absolute. In some embodiments, specificity may be evaluated relative to that of the binding agent for one or more other potential target entities (e.g., competitors). In some embodiments, specificity is evaluated relative to that of a reference specific binding agent. In some embodiments specificity is evaluated relative to that of a reference non-specific binding agent. In some embodiments, the agent or entity does not detectably bind to the competing alternative target under conditions of binding to its target entity. In some embodiments, binding agent binds with higher on-rate, lower off-rate, increased affinity, decreased dissociation, and/or increased stability to its target entity as compared with the competing alternative target(s).

Specific binding: As used herein, the terms “specific binding” or “specific for” or “specific to” refer to an interaction (typically non-covalent) between a target entity (e.g., a target protein or polypeptide) and a binding agent (e.g., an antibody, such as a provided antibody). As will be understood by those of ordinary skill, an interaction is considered to be “specific” if it is favored in the presence of alternative interactions. In many embodiments, an interaction is typically dependent upon the presence of a particular structural feature of the target molecule such as an antigenic determinant or epitope recognized by the binding molecule. For example, if an antibody is specific for epitope A, the presence of a polypeptide containing epitope A or the presence of free unlabeled A in a reaction containing both free labeled A and the antibody thereto, will reduce the amount of labeled A that binds to the antibody. It is to be understood that specificity need not be absolute. For example, it is well known in the art that numerous antibodies cross-react with other epitopes in addition to those present in the target molecule. Such cross-reactivity may be acceptable depending upon the application for which the antibody is to be used. In particular embodiments, an antibody specific for receptor tyrosine kinases has less than 10% cross-reactivity with receptor tyrosine kinase bound to protease inhibitors (e.g., ACT). One of ordinary skill in the art will be able to select antibodies having a sufficient degree of specificity to perform appropriately in any given application (e.g., for detection of a target molecule, for therapeutic purposes, etc.). Specificity may be evaluated in the context of additional factors such as the affinity of the binding molecule for the target molecule versus the affinity of the binding molecule for other targets (e.g., competitors). If a binding molecule exhibits a high affinity for a target molecule that it is desired to detect and low affinity for non-

Stage of cancer: As used herein, the term “stage of cancer” refers to a qualitative or quantitative assessment of the level of advancement of a cancer. Criteria used to determine the stage of a cancer include, but are not limited to, the size of the tumor and the extent of metastases (e.g., localized or distant).

Subject: As used herein, the term “subject” or “patient” refers to any organism upon which embodiments of the invention may be used or administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans; insects; worms; etc.).

Substantially: As used herein, the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.

Suffering from: An individual who is “suffering from” a disease, disorder, or condition (e.g., a cancer) has been diagnosed with and/or exhibits one or more symptoms of the disease, disorder, or condition. In some embodiments, an individual who is suffering from cancer has cancer, but does not display any symptoms of cancer and/or has not been diagnosed with a cancer.

Susceptible to: An individual who is “susceptible to” a disease, disorder, or condition (e.g., cancer) is at risk for developing the disease, disorder, or condition. In some embodiments, an individual who is susceptible to a disease, disorder, or condition does not display any symptoms of the disease, disorder, or condition. In some embodiments, an individual who is susceptible to a disease, disorder, or condition has not been diagnosed with the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, or condition is an individual who displays conditions associated with development of the disease, disorder, or condition. In some embodiments, a risk of developing a disease, disorder, and/or condition is a population-based risk.

Target cell or target tissue: As used herein, the terms “target cell” or “target tissue” refer to any cell, tissue, or organism that is affected by a condition described herein and to be treated, or any cell, tissue, or organism in which a protein involved in a condition described herein is expressed. In some embodiments, target cells, target tissues, or target organisms include those cells, tissues, or organisms in which there is a detectable amount of immune checkpoint signaling and/or activity. In some embodiments, target cells, target tissues, or target organisms include those cells, tissues or organisms that display a disease-associated pathology, symptom, or feature.

Therapeutic regimen: As used herein, the term “therapeutic regimen” refers to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of and/or reduce incidence of one or more symptoms or features of a particular disease, disorder, and/or condition. It may include a treatment or series of treatments designed to achieve a particular effect, e.g., reduction or elimination of a detrimental condition or disease such as cancer. The treatment may include administration of one or more compounds either simultaneously, sequentially or at different times, for the same or different amounts of time. Alternatively, or additionally, the treatment may include exposure to radiation, chemotherapeutic agents, hormone therapy, or surgery. In addition, a “treatment regimen” may include genetic methods such as gene therapy, gene ablation or other methods known to reduce expression of a particular gene or translation of a gene-derived mRNA.

Therapeutic agent: As used herein, the phrase “therapeutic agent” refers to any agent that, when administered to a subject, has a therapeutic effect and/or elicits a desired biological and/or pharmacological effect.

Therapeutically effective amount: As used herein, the term “therapeutically effective amount” refers to an amount of an agent (e.g., an immune checkpoint modulator) that confers a therapeutic effect on the treated subject, at a reasonable benefit/risk ratio applicable to any medical treatment. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect). In particular, the “therapeutically effective amount” refers to an amount of a therapeutic agent or composition effective to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect, such as by ameliorating symptoms associated with the disease, preventing or delaying the onset of the disease, and/or also lessening the severity or frequency of symptoms of the disease. A therapeutically effective amount is commonly administered in a dosing regimen that may comprise multiple unit doses. For any particular therapeutic agent, a therapeutically effective amount (and/or an appropriate unit dose within an effective dosing regimen) may vary, for example, depending on route of administration, on combination with other pharmaceutical agents. Also, the specific therapeutically effective amount (and/or unit dose) for any particular patient may depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific pharmaceutical agent employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and/or rate of excretion or metabolism of the specific fusion protein employed; the duration of the treatment; and like factors as is well known in the medical arts.

Treatment: As used herein, the term “treatment” (also “treat” or “treating”) refers to any administration of a substance (e.g., provided compositions) that partially or completely alleviates, ameliorates, relieves, inhibits, delays onset of, reduces severity of, and/or reduces incidence of one or more symptoms, features, and/or causes of a particular disease, disorder, and/or condition (e.g., cancer). Such treatment may be of a subject who does not exhibit signs of the relevant disease, disorder and/or condition and/or of a subject who exhibits only early signs of the disease, disorder, and/or condition. Alternatively or additionally, such treatment may be of a subject who exhibits one or more established signs of the relevant disease, disorder and/or condition. In some embodiments, treatment may be of a subject who has been diagnosed as suffering from the relevant disease, disorder, and/or condition. In some embodiments, treatment may be of a subject known to have one or more susceptibility factors that are statistically correlated with increased risk of development of the relevant disease, disorder, and/or condition.

Wild-type: As used herein, the term “wild-type” has its art-understood meaning that refers to an entity having a structure and/or activity as found in nature in a “normal” (as contrasted with mutant, diseased, altered, etc.) state or context. Those of ordinary skill in the art will appreciate that wild-type genes and polypeptides often exist in multiple different forms (e.g., alleles).

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS Cancers

In some embodiments, the present disclosure relates to treatment of cancer. Certain exemplary cancers that may, in some embodiments, be treated in accordance with the present disclosure include, for example, adrenocortical carcinoma, astrocytoma, basal cell carcinoma, carcinoid, cardiac, cholangiocarcinoma, chordoma, chronic myeloproliferative neoplasms, craniopharyngioma, ductal carcinoma in situ, ependymoma, intraocular melanoma, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gestational trophoblastic disease, glioma, histiocytosis, leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), hairy cell leukemia, myelogenous leukemia, and myeloid leukemia), lymphoma (e.g., Burkitt lymphoma (non-Hodgkin lymphoma), cutaneous T-cell lymphoma, Hodgkin lymphoma, mycosis fungoides, Sezary syndrome, AIDS-related lymphoma, follicular lymphoma, diffuse large B-cell lymphoma), melanoma, merkel cell carcinoma, mesothelioma, myeloma (e.g., multiple myeloma), myelodysplastic syndrome, papillomatosis, paraganglioma, pheochromacytoma, pleuropulmonary blastoma, retinoblastoma, sarcoma (e.g., Ewing sarcoma, Kaposi sarcoma, osteosarcoma, rhabdomyosarcoma, uterine sarcoma, vascular sarcoma), Wilms' tumor, and/or cancer of the adrenal cortex, anus, appendix, bile duct, bladder, bone, brain, breast, bronchus, central nervous system, cervix, colon, endometrium, esophagus, eye, fallopian tube, gall bladder, gastrointestinal tract, germ cell, head and neck, heart, intestine, kidney (e.g., Wilms' tumor), larynx, liver, lung (e.g., non-small cell lung cancer, small cell lung cancer), mouth, nasal cavity, oral cavity, ovary, pancreas, rectum, skin, stomach, testes, throat, thyroid, penis, pharynx, peritoneum, pituitary, prostate, rectum, salivary gland, ureter, urethra, uterus, vagina, or vulva.

In some embodiments, a cancer may involve one or more tumors. In some embodiments, a tumor comprises a solid tumor. In some embodiments, solid tumors include but are not limited to tumors of the bladder, breast, central nervous system, cervix, colon, esophagus, endometrium, head and neck, kidney, liver, lung, ovary, pancreas, skin, stomach, uterus, or upper respiratory tract.

In some embodiments, a cancer is selected from the group consisting of bladder cancer, bone cancer, breast cancer, cancer of unknown primary, esophagogastric cancer, gastrointestinal cancer, glioma, head and neck cancer, hepatobiliary cancer, melanoma, mesothelioma, non-hodgkin lymphoma, non-small cell lung cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, skin cancer (non-melanoma), small cell lung cancer, soft tissue sarcoma, thyroid cancer, and combinations thereof.

In some embodiments, a cancer is selected from the group consisting of bladder cancer, breast cancer, esophagogastric cancer, glioma, head and neck cancer, melanoma, non-small cell lung cancer, renal cell carcinoma, and combinations thereof.

In some embodiments, a cancer that may be treated in accordance with the present disclosure is one that has been exposed to immunotherapy as described herein.

In some embodiments, a cancer that may be treated in accordance with the present disclosure is one that has been exposed to immunotherapy, which in some embodiments may be or include therapy with one or more immune checkpoint inhibitor modulators.

In some embodiments, a cancer that may be treated in accordance with the present disclosure is one characterized by high tumor mutational load (i.e., tumor mutational load above a relevant threshold) as described herein. Alternatively or additionally, a cancer that may be treated in accordance with the present disclosure is one characterized by neoantigens.

In some embodiments, a cancer that may be treated in accordance with the present disclosure is characterized by both prior exposure to immunotherapy comprising immune checkpoint modulators and high tumor mutational load; in some such embodiments, the cancer shows higher tumor mutational load than was present prior to its exposure to the immunotherapy.

Immunotherapy

In some embodiments, the present disclosure relates to administration of immunotherapy to a subject. In some embodiments, immunotherapy is or comprises immune checkpoint modulation therapy. In some embodiments, immunotherapy involves administration of one or more immunomodulatory agents; in some embodiments an immunomodulatory agent is or comprises an immune checkpoint modulator. In some embodiments, an immune checkpoint modulator is an agent (e.g., an antibody agent) that targets (i.e., specifically interacts with) an immune checkpoint target. In some embodiments, an immune checkpoint target is or comprises one or more of CTLA-4, PD-1, PD-L1, GITR, OX40, LAG-3, KIR, TIM-3, CD28, CD40, and CD137; in some embodiments, immune checkpoint modulator therapy is or comprises administration of an antibody agent that targets one or more such immune checkpoint targets.

In some embodiments, immune checkpoint refers to inhibitory pathways of an immune system that are responsible for maintaining self-tolerance and modulating duration and amplitude of physiological immune responses. Certain cancer cells thrive by taking advantage of immune checkpoint pathways as a major mechanism of immune resistance, particularly with respect to T cells that are specific for tumor antigens. For example, certain cancer cells may overexpress one or more immune checkpoint proteins responsible for inhibiting a cytotoxic T cell response. Thus, among other things, immune checkpoint modulators may be administered to overcome inhibitory signals and permit and/or augment an immune attack against cancer cells. Immune checkpoint modulators may facilitate immune cell responses against cancer cells by decreasing, inhibiting, or abrogating signaling by negative immune response regulators (e.g. CTLA-4), or may stimulate or enhance signaling of positive regulators of immune response (e.g. CD28).

Advances in understanding of molecular mechanisms of T cell activation and inhibition and immune homeostasis have allowed for rational development of immunologically targeted therapies for cancer. The best known of these are immune checkpoint modulator monoclonal antibodies that block CTLA-4 and PD-1 pathways, representing critical inhibitory checkpoints that restrain T cells from full and persistent activation and proliferation under normal physiologic conditions. Blockade of CTLA-4 and/or PD-1 pathways can result in durable regressions for patients with a widening spectrum of malignancies. In some embodiments, an immunotherapy is or comprises administration of one or more of PD-1 or PD-L1 blockade therapies. In some embodiments, an immunotherapy is or comprises administration of one or more of CTLA-4 blockade therapies. In some embodiments, an immunotherapy can include any of ipilumimab and tremelimumab which target CTLA-4; pembrolizumab, nivolumab, avelumab, durvalumab, and atezoluzumab, which target PD-1; or combinations thereof.

Teachings of the present disclosure, among other things, predict responsiveness to immune checkpoint modulators, and particularly to therapeutic modalities or regimens targeting immune checkpoint regulators. The present disclosure, among other things, demonstrates that tumor mutational load threshold correlates with responsiveness to immune checkpoint modulators. In some embodiments, the present disclosure demonstrates that tumor mutational load threshold correlates with an increased likelihood of clinical efficacy from immune checkpoint regulators for those cancers responsive to immunotherapy (e.g., to PD-1 blockade and/or to CTLA-4 blockade). In some embodiments, immunotherapy (e.g. immune checkpoint modulator therapy) involves administration of an agent that acts as a blockade of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). In certain embodiments, immunotherapy involves treatment with an agent that interferes with an interaction involving CTLA-4 (e.g., with CD80 or CD86). In some embodiments, immunotherapy involves administration of one or more of tremelimumab and/or ipilimumab. In some embodiments, immunotherapy (e.g. immune checkpoint modulator therapy) involves administration of an agent (e.g. antibody agent) that acts as a blockade of programmed cell death 1 (PD-1). In certain embodiments, immunotherapy involves treatment with an agent that interferes with an interaction involving PD-1 (e.g., with PD-L1). In some embodiments, immunotherapy involves administration of an agent (e.g. antibody agent) that specifically interacts with PD-1 or with PD-L1. In some embodiments, immunotherapy (e.g. immune checkpoint modulator therapy) involves administration of one or more of nivolumab, pembrolizumab, atezolizumab, avelumab, and/or durvalumab.

CTLA-4

CTLA-4 is a member of the immunoglobulin superfamily that is expressed by activated T cells and transmits an inhibitory signal to T cells. CTLA-4 is structurally similar to T cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86 on antigen-presenting cells.¹⁸ CTLA-4 binds CD80 and CD86 with greater affinity than CD28, thus enabling it to outcompete CD28 for its ligands.¹⁸ CTLA-4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. T cell activation through T cell receptor and CD28 leads to increased expression of CTLA-4.

The mechanism by which CTLA-4 acts in T cells remains somewhat elusive. Biochemical evidence suggests that CTLA-4 recruits a phosphatase to a T cell receptor, thus attenuating the signal. It has also been suggested that CTLA-4 may function in vivo by capturing and removing CD80 and CD86 from membranes of antigen-presenting cells, thus making these antigens unavailable for triggering of CD28.

CTLA-4 protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. CTLA-4 has an intracellular domain that is similar to that of CD28, in that it has no intrinsic catalytic activity and contains one YVKM motif able to bind PI3K, PP2A and SHP-2, as well as one proline-rich motif able to bind SH3-containing proteins. One role of CTLA-4 in inhibiting T cell responses seems to directly involve SHP-2 and PP2A dephosphorylation of T cell receptor-proximal signaling proteins, such as CD3 and LAT. CTLA-4 can also affect signaling indirectly, via competition with CD28 for CD80 and/or CD86 binding.

The first clinical evidence that modulation of T cell activation could result in effective anti-cancer therapy came from development of CTLA-4 blockade antibody ipilimumab.¹⁸ In some embodiments, ipilimumab is a human IgG1 antibody with specificity for CTLA-4. In some embodiments, another CTLA-4 blockade therapy, tremelimumab, is a human IgG2 antibody.

PD-1

PD-1 is expressed on T cells, B cells, and certain myeloid cells; however, its role is best characterized in T cells. PD-1 expression on T cells is induced by antigen stimulation. Unlike CTLA-4, which limits early T-cell activation, PD-1 mainly exerts its inhibitory effect on T cells in the periphery where T cells encounter PD-1 ligands. Two ligands of PD-1 have been identified so far, PD-L1 and PD-L2, which are expressed by a large range of cell types, including tumor cells, monocyte-derived myeloid dendritic cells, epithelial cells, T cells, and B cells.¹⁸ In cancer, tumor cells and myeloid cells are thought to be main cell types mediating T-cell suppression through PD-1 ligation. It is still unclear whether effects of PD-L1 and PD-L2 on PD-1 downstream signaling are dependent on cell type that expresses a given ligand. Moreover, there are differences between PD-L1- versus PD-L2-induced effects, which remain to be fully elucidated.

Several mechanisms of PD-1-mediated T cell suppression have been proposed.¹⁸ One mechanism suggests that PD-1 ligation inhibits T cell activation only upon T cell receptor engagement. PD-1 has an intracellular “immunoreceptor tyrosine-based inhibition motif” or (ITIM) and an immunoreceptor tyrosine-based switch motif. It has been shown that PD-1 ligation leads to recruitment of phosphatases called “src homology 2 domain-containing tyrosine phosphatases,” or SHP-1 and SHP-2, to immunoreceptor tyrosine-based switch motif. Moreover, PD-1 ligation has been shown to interfere with signaling molecules, such as phosphatidylinositol-4,5-bisphosphate 3-kinase and Ras, which are important for T-cell proliferation, cytokine secretion, and metabolism. Analysis of human immunodeficiency virus (HIV)-specific T cells has also demonstrated PD-1-dependent basic leucine zipper transcription factor upregulation, which inhibits T cell function. Ligation of PD-1 has also been shown to induce metabolic alterations in T cells. Metabolic reprogramming of T cells from glycolysis to lipolysis is a consequence of PD-1-mediated impairment of T-cell effector function. Furthermore, PD-1-induced defects in mitochondrial respiration and glycolysis leads to impaired T-cell effector function that could be reversed by a mammalian target of rapamycin inhibition. Since most of the identified mechanisms of PD-1-mediated T-cell suppression are based on in vitro or ex vivo experiments, it remains to be demonstrated that these same mechanisms are responsible for T-cell exhaustion in vivo.

PD-1 is a type I membrane protein of 288 amino acids and is a member of the extended CD28/CTLA-4 family of T cell regulators.¹⁹ PD-1 protein structure includes an extracellular IgV domain followed by a transmembrane region and an intracellular tail, which contains two phosphorylation sites located in an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif, which suggests that PD-1 negatively regulates T cell receptor signals. This is consistent with binding of SHP-1 and SHP-2 phosphatases to PD-1 cytoplasmic tail upon ligand binding. In addition, PD-1 ligation up-regulates E3-ubiquitin ligases CBL-b and c-CBL that trigger T cell receptor down-modulation. PD-1 is expressed on the surface of activated T cells, B cells, and macrophages, suggesting that compared to CTLA-4, PD-1 more broadly negatively regulates immune responses.

CTLA-4 and PD-1 in Combination

Although monotherapies with CTLA-4- or PD-1-blocking antibodies have significantly prolonged survival of some patients with certain cancers, there are cases where some patients do not respond to therapy. A previous study has shown that combined treatment with ipilimumab (CTLA-4 blockade) and nivolumab (PD-1 blockade) induced better responses than either treatment alone.'⁸′²⁰ In some embodiments, immunotherapy, in accordance with the present disclosure, comprises both PD-1 blockade therapy and CTLA-4 blockade therapy. In certain embodiments, immunotherapy (e.g. immune checkpoint modulator therapy) involves treatment with an agent (e.g. antibody agent) that interferes with an interaction involving CTLA-4 and/or PD-1. In some embodiments, immunotherapy (e.g. immune checkpoint modulator therapy) involves administration of an agent (e.g. antibody agent) that specifically interacts with one or more of CTLA-4, CD80, CD86, PD-1 or PD-L1. In some embodiments, such therapy involves administration of one or more of atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab, and/or tremelimumab.

Tumor Mutational Load

Among other things, the present disclosure demonstrates a that tumor mutational load can predict clinical efficacy of immunotherapy treatment for certain cancers. The present disclosure establishes, among other things, that in certain cases, individuals with higher tumor mutational loads are more likely to respond positively to immunotherapy than individuals with significantly lower tumor mutational loads. The present disclosure, among other things, establishes that, in certain cases, individuals with higher tumor mutational loads and who have already received immunotherapy, are more likely to respond positively to immunotherapy, than individuals with significantly lower tumor mutational loads.

In some embodiments, tumor mutational load comprises a number of somatic mutations within a region of a tumor genome. In some embodiments, somatic mutations comprise DNA alterations in non-germline cells and commonly occur in cancer cells. In some embodiments, a somatic mutation results in a neoantigen or neoepitope. It has been discovered that certain somatic mutations in cancer cells result in expression of neoepitopes, that in some embodiments transition a stretch of amino acids from being recognized as “self” to “non-self”. A cancer cell harboring a “non-self” antigen is typically more likely to elicit an immune response against a cancer cell. The identification of multiple mutations in a cancer sample as described herein can be useful for determining which cancer patients are likely to respond favorably to immunotherapy (e.g. continued and/or extended or modified immunotherapy); in some embodiments, such identification can be useful for determining which cancer patients are likely to respond, in particular, to treatment with an immune checkpoint modulator and/or otherwise to PD-1 and/or CTLA-4 blockade.

The present disclosure, among other things, demonstrates that, for certain cancers, patients with high numbers of somatic mutations, or a high tumor mutational load, are more likely to benefit from treatment with immune checkpoint modulators than those patients with lower tumor mutational loads. In some embodiments, patients with a high tumor mutational load respond better to PD-1 (programmed cell death 1) blockade than those patients with a significantly lower tumor mutational load. In some embodiments, individuals with a high tumor mutational load respond better to treatment with anti-PD-1 antibodies than those individuals with a low tumor mutational load. In some embodiments, individuals with a high tumor mutational load respond better to treatment with CTLA-4 blockade than those individuals with a low tumor mutational load. In some embodiments, individuals with a high tumor mutational load respond better to treatment with CTLA-4 antibodies than those individuals with a low tumor mutational load.

Tumor Mutational Load Threshold

The present disclosure, among other things, encompasses an insight that meaningful limits can be imposed on mutational analysis of cancer cells and, moreover, that use of such limits surprisingly defines and/or provides tumor mutational load thresholds that effectively predict responsiveness to treatment (e.g., continued and/or extended or modified immunotherapy). In some embodiments, a tumor mutational load threshold as described herein correlates with and/or predicts response to immunotherapy (e.g., immune checkpoint modulator therapy, e.g. PD-1 blockade or CTLA-4 blockade).

Moreover, the present disclosure, among other things, encompasses the discovery that a tumor mutational load threshold that predicts likelihood of responsiveness to cancer immunotherapy (and/or to a specific immunomodulatory agent and/or regimen) can be defined for tumors that have already received prior immunotherapy. In some embodiments, the number of mutations in a given tumor correlates with and/or is predictive of positive response to immunotherapy. Moreover, the present disclosure demonstrates that tumor mutational load level relative to a threshold, can be detected and effectively utilized to predict tumor responsiveness for a wide variety of cancers.

In some embodiments, as described herein, the present disclosure provides technologies for defining tumor mutational load thresholds that predict responsiveness to immunotherapy (e.g. continued and/or extended or modified), and particularly to immune checkpoint modulator therapy. In some embodiments, the present disclosure describes and/or establishes effective use of such thresholds in predicting therapeutic responsiveness.

The present disclosure demonstrates that a mutational landscape and/or tumor mutational load threshold of a particular tumor can predict the likelihood of clinical benefit from immunotherapy (e.g., PD-1 blockade or CTLA-4 blockade). The disclosure also teaches that a tumor mutational load threshold can predict likelihood of positive response to immunotherapy with immune checkpoint modulators. Furthermore, the nature of the somatic mutations present can predict response to immunotherapy with immune checkpoint modulators.

In some embodiments, tumor mutational load level relative to a threshold, can be determined and/or detected using targeted gene panel technologies (e.g., assessed with next-generation sequencing), and do not necessarily require whole exome sequencing.

Thus, among other things, the present disclosure establishes that relevant thresholds for these cancers may be, for example:

Cancer Type Threshold Bladder Cancer Within a range of about 7 to about 27; in some embodiments about 17. Breast Cancer Within a range of about 1 to about 14; in some embodiments about 4. Esophagogastric Cancer Within a range of about 1 to about 21; in some embodiments about 11. Glioma Within a range of about 1 to about 15; in some embodiments about 5. Head and Neck Cancer Within a range of about 1 to about 18; in some embodiments about 8. Melanoma Within a range of about 1 to about 21; in some embodiments about 11. Non-Small Cell Within a range of Lung Cancer about 1 to about 29; in some embodiments about 18. Renal Cell Carcinoma Within a range of about 1 to about 12; in some embodiments about 2. Detection of Tumor Mutational Load and/or Neoepitopes

Cancers may be screened to detect mutations and/or neoepitopes (e.g., to detect tumor mutational load and/or neoepitope load and/or neoantigen identity, and/or neopitope nature, level, and/or frequency) as described herein using any of a variety of known technologies. In some embodiments, particular mutations or neoepitopes, or expression thereof, is/are detected at the nucleic acid level (e.g., in DNA or RNA). One of skill in the art would recognize that mutations or neoepitopes, or expression thereof, can be detected in a sample comprising DNA or RNA from cancer cells. Further, one of skill in the art would understand that a sample comprising DNA or RNA from cancer cells can include but is not limited to circulating tumor DNA (ctDNA), cell free DNA (cfDNA), cells, tissues, or organs. In some embodiments, mutations or neopeitopes, or expression thereof, is detected at the protein level (e.g., in a sample comprising polypeptides from cancer cells, which sample may be or comprise polypeptide complexes or other higher order structures including but not limited to cells, tissues, or organs).

In some particular embodiments, detection involves nucleic acid sequencing. In some embodiments, detection involves whole exome sequencing. In some embodiments, detection involves an immunoassay. In some embodiments, detection involves use of a microarray. In some embodiments, detection involves massively parallel exome sequencing. In some embodiments, detection involves genome sequencing. In some embodiments, detection involves RNA sequencing. In some embodiments, detection involves standard DNA or RNA sequencing. In some embodiments, detection involves mass spectrometry.

In some embodiments, detection involves next generation sequencing (DNA and/or RNA). In some embodiments, detection involves genome sequencing, genome resequencing, targeted sequencing panels, transcriptome profiling (RNA-Seq), DNA-protein interactions (ChIP-sequencing), and/or epigenome characterization. In some embodiments, re-sequencing of a patient's genome may be utilized, for example to detect genomic variations.

In some embodiments, detection involves using a technique such as ELISA, Western Transfer, immunoassay, mass spectrometry, microarray analysis, etc.

In some embodiments, detection involves next generation sequencing (DNA and/or RNA). In some embodiments, detection involves next generation sequencing of targeted gene panels (e.g. MSK-IMPACT or FoundationOne®). In some embodiments, detection involves genomic profiling. In some embodiments, detection involves genomic profiling using Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT).^(8,17) MSK-IMPACT is a comprehensive molecular profiling assay that involves hybridization capture and deep sequencing of all exons and selected introns of multiple oncogenes and tumor-suppressor genes, allowing for detection of point mutations, small and large insertions or deletions, and rearrangements. MSK-IMPACT also captures intergenic and intronic single-nucleotide polymorphisms (e.g., tiling probes), interspersed across a genome, aiding in accurate assessment of genome-wide copy number. In some embodiments, probes may target a megabase.

In some embodiments, detection may involve sequencing of exon and/or intron sequences from at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000 or more genes (e.g., oncogenes and/or tumor-suppressor genes). For example, literature reports indicate that MSK-IMPACT has been used to achieve deep sequencing of all exons and selected introns of 468 oncogenes and tumor-suppressor genes.

Alternatively or additionally, in some embodiments, detection may involve sequencing of intergenic and/or intronic single-nucleotide polymorphisms. For example, literature reports indicate that MSK-IMPACT has been used to achieve deep sequencing of >1000 intergenic and intronic single-nucleotide polymorphisms.

In some embodiments, administering immunotherapy to a subject who has received prior immunotherapy displays a tumor mutational load above a threshold that has been correlated with a statistically significant probability of responding to immunotherapy.

In some embodiments, a method of administering immunotherapy to a subject comprises a further step of measuring tumor mutational load level relative to a threshold in the subject, which measuring step is performed at a time selected from the group consisting of prior to the administering, during the administering, after the administering, and combinations thereof.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described herein.

Human Leukocyte Antigen

Prior to the present disclosure, there has been little understanding of how host genetics impact response to cancer immunotherapy. One factor that has been repeatedly associated with modulating the immune response during bacterial or viral infection, inflammatory conditions, and autoimmune diseases, is HLA class I genotype (21-29). The human leukocyte antigen (HLA) complex is a gene complex encoding the major histocompatibility complex (MHC) proteins. The major histocompatibility complex (MHC) class I coding region in humans is central to the immune response. Each HLA class I molecule binds specific peptides derived from intracellular proteins that have been processed and transported into the endoplasmic reticulum by the TAP proteins, where they are bound to the MHC class I molecules for presentation on the cell surface (30).

MHC molecules are extremely polymorphic, and over a thousand allelic variants have already been described at the class I A and B loci. Most of the polymorphism is located in the peptide-binding region, and as a result each variant is believed to bind a unique repertoire of peptide ligands. Despite this polymorphism, HLA class I molecules can be clustered into groups, designated as supertypes (a.k.a. superfamilies), representing sets of molecules that share largely overlapping peptide binding specificity. Exemplary supertypes include but are not limited to A02, A24, A03, B07, B27, B44, Each supertype can be described by a supermotif that reflects the broad main anchor motif recognized by molecules within the corresponding supertype. For example, molecules of the A02-supertype share specificity for peptides with aliphatic hydrophobic residues in position 2 and at the C-terminus, while A03-supertype molecules recognize peptides with small or aliphatic residues in position 2 and basic residues at the C-terminus.

Typically, in the case of human leukocyte antigen (HLA) class I, the main binding energy is provided by the interaction of residues in position 2 and the C-terminus of the peptide with the B and F binding pockets of the MHC molecule, respectively although side chains throughout the ligand can have a positive or negative influence on binding capacity. Once pathogen or tumor-derived epitopes are presented on the cell surface, CD8+ T-cells must be able to recognize them to subsequently elicit an immune response and eliminate cells bearing those same epitopes (31, 32). Some tumor cells have reduced ability to present epitopes on the surface due to genetic alterations resulting in loss of heterozygosity (LOH) in the HLA locus. LOH is a gross chromosomal event that results in loss of an entire gene and surrounding chromosomal region. The anti-tumor activity of immune checkpoint treatment has been shown to depend on CD8+ T cell, MHC class I-dependent immune activity (33-35).

Among other things, the present disclosure demonstrates that HLA class I genotype can influence clinical efficacy of immunotherapy treatment for certain cancers. The present disclosure establishes, among other things, that heterozygosity at one or more HLA class I loci (e.g., A, B, or C) can influence clinical efficacy of immunotherapy treatment. In some embodiments, heterozygosity at all three HLA class I loci (i.e., maximum heterozygosity) can influence clinical efficacy of immunotherapy treatment.

The present disclosure establishes, among other things, that in certain cases, individuals with heterozygosity at one or more HLA class I loci (e.g., A, B, or C) are more likely to respond positively to immunotherapy. In some embodiments, individuals with heterozygosity at all three HLA class I loci (i.e., maximum heterozygosity) are more likely to respond positively to immunotherapy.

In some embodiments, the present disclosure establishes that individuals with particular HLA class I superfamily alleles are more likely to respond positively to immunotherapy. In some embodiments, individuals with HLA class I B44 allele are more likely to respond positively to immunotherapy. In some embodiments, individuals with HLA class I B62 allele are more likely to respond positively to immunotherapy.

Further, the present disclosure establishes, among other things, that in certain cases, individuals with heterozygosity at one or more HLA class I loci (e.g., A, B, or C) and higher tumor mutational loads as described herein are more likely to respond positively to immunotherapy than individuals with significantly lower tumor mutational loads and/or no or less heterozygosity at HLA class I loci. In some embodiments, individuals with heterozygosity at all three HLA class I loci and higher tumor mutational loads as described herein are more likely to respond positively to immunotherapy than individuals with significantly lower tumor mutational loads and/or no or less heterozygosity at HLA class I loci.

In some embodiments, a subject's HLA class I genotype can be determined sequencing. Sequencing can be performed by methods known in the art. In some embodiments, for example, HLA class I genotype can be determined by exome sequencing. In some embodiments, a subject's HLA class I genotype can be determined using a clinically validated HLA typing assay.

Treatment

In some embodiments, the invention relates to treatment of tumors that display a tumor mutational load above a relevant threshold. In some embodiments, such tumors have previously received immunotherapy. In some embodiments, such immunotherapy is an immune checkpoint modulator.

Administration of Immune Checkpoint Modulators

In accordance with certain methods of the invention, an immunomodulatory agent (e.g. immune checkpoint modulator) is and/or has been administered to an individual. In some embodiments, treatment with an immunomodulatory agent (e.g. immune checkpoint modulator) is utilized as a sole therapy. In some embodiments, treatment with an immunomodulatory agent (e.g. immune checkpoint modulator) is used in combination with one or more other therapies.

Those of ordinary skill in the art will appreciate that appropriate formulations, indications, and dosing regimens are typically analyzed and approved by government regulatory authorities such as the Food and Drug Administration in the United States. For example, Examples 4 and 5 present certain FDA-approved dosing information for PD-1 and CTLA-4 blockade regimens, respectively. In some embodiments, an immunomodulatory agent (e.g. immune checkpoint modulator) is administered in accordance with the present invention according to such an approved protocol. However, the present disclosure, among other things, provides certain technologies for identifying, characterizing, and/or selecting particular patients to whom an immunomodulatory agent (e.g. immune checkpoint modulator) may be desirably administered. In some embodiments, insights provided by the present disclosure permit dosing of a given an immunomodulatory agent (e.g. immune checkpoint modulator) with greater frequency and/or greater individual doses (e.g., due to reduced susceptibility to and/or incidence or intensity of undesirable effects) relative to that recommended or approved based on population studies that include both individuals identified as described herein (e.g., expressing neoepitopes or having a tumor mutational load above the threshold) and other individuals. In some embodiments, insights provided by the present disclosure permit dosing of a given an immunomodulatory agent (e.g. immune checkpoint modulator) with reduced frequency and/or reduced individual doses (e.g., due to increased responsiveness) relative to that recommended or approved based on population studies that include both individuals identified as described herein (e.g., expressing neoepitopes or having a tumor mutational load above the threshold) and other individuals.

In some embodiments, an immunomodulatory agent (e.g. immune checkpoint modulator) is administered in a pharmaceutical composition that also comprises a physiologically acceptable carrier or excipient. In some embodiments, a pharmaceutical composition is sterile. In many embodiments, a pharmaceutical composition is formulated for a particular mode of administration.

In some embodiments, suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions (e.g., NaCl), saline, buffered saline, alcohols, glycerol, ethanol, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose, amylose or starch, sugars such as mannitol, sucrose, or others, dextrose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrrolidone, etc., as well as combinations thereof. In some embodiments, a pharmaceutical preparation can, if desired, comprise one or more auxiliary agents (e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances and the like) which do not deleteriously react with the active compounds or interference with their activity. In some embodiments, a water-soluble carrier suitable for intravenous administration is used.

In some embodiments, a pharmaceutical composition or medicament, if desired, can contain an amount (typically a minor amount) of wetting or emulsifying agents, and/or of pH buffering agents. In some embodiments, a pharmaceutical composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. In some embodiments, a pharmaceutical composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. In some embodiments, oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, polyvinyl pyrrolidone, sodium saccharine, cellulose, magnesium carbonate, etc.

In some embodiments, a pharmaceutical composition can be formulated in accordance with routine procedures as a pharmaceutical composition adapted for administration to human beings. For example, in some embodiments, a composition for intravenous administration typically is a solution in sterile isotonic aqueous buffer. In some embodiments, where necessary, a composition may also include a solubilizing agent and a local anesthetic to ease pain at the site of the injection. In some embodiments, generally, ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampule or sachet indicating the quantity of active agent. In some embodiments, where a composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water, saline or dextrose/water. In some embodiments, where a composition is administered by injection, an ampule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

In some embodiments, an immunomodulatory agent (e.g. immune checkpoint modulator) can be formulated in a neutral form; in some embodiments it may be formulated in a salt form. In some embodiments, pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

Pharmaceutical compositions for use in accordance with the present invention may be administered by any appropriate route. In some embodiments, a pharmaceutical composition is administered intravenously. In some embodiments, a pharmaceutical composition is administered subcutaneously. In some embodiments, a pharmaceutical composition is administered by direct administration to a target tissue, such as heart or muscle (e.g., intramuscular), or nervous system (e.g., direct injection into the brain; intraventricularly; intrathecally). Alternatively or additionally, in some embodiments, a pharmaceutical composition is administered parenterally, transdermally, or transmucosally (e.g., orally or nasally). More than one route can be used concurrently, if desired.

In some embodiments, an immunomodulatory agent (e.g. immune checkpoint modulator (or a composition or medicament containing an immune checkpoint modulator)), can be administered alone, or in conjunction with other immunomodulatory agents. The term, “in conjunction with,” indicates that a first immune checkpoint modulator is administered prior to, at about the same time as, or following another immune checkpoint modulator. In some embodiments, a first immunomodulatory agent (e.g. immune checkpoint modulator) can be mixed into a composition containing one or more different immunomodulatory agents (e.g. immune checkpoint modulators), and thereby administered contemporaneously; alternatively, in some embodiments, the agent can be administered contemporaneously, without mixing (e.g., by “piggybacking” delivery of the agent on the intravenous line by which the immunomodulatory agent (e.g. immune checkpoint modulator) is also administered, or vice versa). In some embodiments, an immunomodulatory agent (e.g. immune checkpoint modulator) can be administered separately (e.g., not admixed), but within a short time frame (e.g., within 24 hours) of administration of another immunomodulatory agent (e.g. immune checkpoint modulator).

In some embodiments, subjects treated with an immunomodulatory agent (e.g. immune checkpoint modulator) are administered one or more immunosuppressants. In some embodiments, one or more immunosuppressants are administered to decrease, inhibit, or prevent an undesired autoimmune response (e.g., enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and/or endocrinopathy), for example, hypothyroidism. In some embodiments, exemplary immunosuppressants include steroids, antibodies, immunoglobulin fusion proteins, and the like. In some embodiments, an immunosuppressant inhibits B cell activity (e.g. rituximab). In some embodiments, an immunosuppressant is a decoy polypeptide antigen.

In some embodiments, an immunomodulatory agent (e.g. immune checkpoint modulators (or a composition or medicament containing immune checkpoint modulators)) are administered in a therapeutically effective amount (e.g., a dosage amount and/or according to a dosage regimen that has been shown, when administered to a relevant population, to be sufficient to treat cancer, such as by ameliorating symptoms associated with the cancer, preventing or delaying the onset of the cancer, and/or also lessening the severity or frequency of symptoms of cancer). In some embodiments, long term clinical benefit is observed after treatment with an immunomodulatory agent (e.g. immune checkpoint modulators), including, for example, PD-1 blockade such as pembrolizumab, CTLA-4 blockade such as ipilimumab, and/or other agents. Those of ordinary skill in the art will appreciate that a dose which will be therapeutically effective for the treatment of cancer in a given patient may depend, at least to some extent, on the nature and extent of cancer, and can be determined by standard clinical techniques. In some embodiments, one or more in vitro or in vivo assays may optionally be employed to help identify optimal dosage ranges. In some embodiments, a particular dose to be employed in the treatment of a given individual may depend on the route of administration, the extent of cancer, and/or one or more other factors deemed relevant in the judgment of a practitioner in light of patient's circumstances. In some embodiments, effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems (e.g., as described by the U.S. Department of Health and Human Services, Food and Drug Administration, and Center for Drug Evaluation and Research in “Guidance for Industry: Estimating Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers”, Pharmacology and Toxicology, July 2005).

In some embodiments, a therapeutically effective amount of an immunomodulatory agent (e.g. immune checkpoint modulator) can be, for example, more than about 0.01 mg/kg, more than about 0.05 mg/kg, more than about 0.1 mg/kg, more than about 0.5 mg/kg, more than about 1.0 mg/kg, more than about 1.5 mg/kg, more than about 2.0 mg/kg, more than about 2.5 mg/kg, more than about 5.0 mg/kg, more than about 7.5 mg/kg, more than about 10 mg/kg, more than about 12.5 mg/kg, more than about 15 mg/kg, more than about 17.5 mg/kg, more than about 20 mg/kg, more than about 22.5 mg/kg, or more than about 25 mg/kg body weight. In some embodiments, a therapeutically effective amount can be about 0.01-25 mg/kg, about 0.01-20 mg/kg, about 0.01-15 mg/kg, about 0.01-10 mg/kg, about 0.01-7.5 mg/kg, about 0.01-5 mg/kg, about 0.01-4 mg/kg, about 0.01-3 mg/kg, about 0.01-2 mg/kg, about 0.01-1.5 mg/kg, about 0.01-1.0 mg/kg, about 0.01-0.5 mg/kg, about 0.01-0.1 mg/kg, about 1-20 mg/kg, about 4-20 mg/kg, about 5-15 mg/kg, about 5-10 mg/kg body weight. In some embodiments, a therapeutically effective amount is about 0.01 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, about 0.2 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1.0 mg/kg, about 1.1 mg/kg, about 1.2 mg/kg, about 1.3 mg/kg about 1.4 mg/kg, about 1.5 mg/kg, about 1.6 mg/kg, about 1.7 mg/kg, about 1.8 mg/kg, about 1.9 mg/kg, about 2.0 mg/kg, about 2.5 mg/kg, about 3.0 mg/kg, about 4.0 mg/kg, about 5.0 mg/kg, about 6.0 mg/kg, about 7.0 mg/kg, about 8.0 mg/kg, about 9.0 mg/kg, about 10.0 mg/kg, about 11.0 mg/kg, about 12.0 mg/kg, about 13.0 mg/kg, about 14.0 mg/kg, about 15.0 mg/kg, about 16.0 mg/kg, about 17.0 mg/kg, about 18.0 mg/kg, about 19.0 mg/kg, about 20.0 mg/kg, body weight, or more. In some embodiments, the therapeutically effective amount is no greater than about 30 mg/kg, no greater than about 20 mg/kg, no greater than about 15 mg/kg, no greater than about 10 mg/kg, no greater than about 7.5 mg/kg, no greater than about 5 mg/kg, no greater than about 4 mg/kg, no greater than about 3 mg/kg, no greater than about 2 mg/kg, or no greater than about 1 mg/kg body weight or less.

In some embodiments, the administered dose for a particular individual is varied (e.g., increased or decreased) over time, depending on the needs of the individual.

In some embodiments, a loading dose (e.g., an initial higher dose) of a therapeutic composition may be given at the beginning of a course of treatment, followed by administration of a decreased maintenance dose (e.g., a subsequent lower dose) of the therapeutic composition. Without wishing to be bound by any theories, it is contemplated that a loading dose may clear out an initial and, in some cases massive, accumulation of undesirable materials (e.g., fatty materials and/or tumor cells, etc) in tissues (e.g., in the liver), and maintenance dosing may delay, reduce, or prevent buildup of fatty materials after initial clearance.

In some embodiments, it will be appreciated that a loading dose and maintenance dose amounts, intervals, and duration of treatment may be determined by any available method, such as those exemplified herein and those known in the art. In some embodiments, a loading dose amount is about 0.01-1 mg/kg, about 0.01-5 mg/kg, about 0.01-10 mg/kg, about 0.1-10 mg/kg, about 0.1-20 mg/kg, about 0.1-25 mg/kg, about 0.1-30 mg/kg, about 0.1-5 mg/kg, about 0.1-2 mg/kg, about 0.1-1 mg/kg, or about 0.1-0.5 mg/kg body weight. In some embodiments, a maintenance dose amount is about 0-10 mg/kg, about 0-5 mg/kg, about 0-2 mg/kg, about 0-1 mg/kg, about 0-0.5 mg/kg, about 0-0.4 mg/kg, about 0-0.3 mg/kg, about 0-0.2 mg/kg, about 0-0.1 mg/kg body weight. In some embodiments, a loading dose is administered to an individual at regular intervals for a given period of time (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more months) and/or a given number of doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30 or more doses), followed by maintenance dosing. In some embodiments, a maintenance dose ranges from 0-2 mg/kg, about 0-1.5 mg/kg, about 0-1.0 mg/kg, about 0-0.75 mg/kg, about 0-0.5 mg/kg, about 0-0.4 mg/kg, about 0-0.3 mg/kg, about 0-0.2 mg/kg, or about 0-0.1 mg/kg body weight. In some embodiments, a maintenance dose is about 0.01, 0.02, 0.04, 0.06, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, or 2.0 mg/kg body weight. In some embodiments, maintenance dosing is administered for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more months. In some embodiments, maintenance dosing is administered for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more years. In some embodiments, maintenance dosing is administered indefinitely (e.g., for life time).

In some embodiments, a therapeutically effective amount of an immunomodulatory agent (e.g. an immune checkpoint modulator) may be administered as a one-time dose or administered at intervals, depending on the nature and extent of the cancer, and on an ongoing basis. Administration at an “interval,” as used herein indicates that the therapeutically effective amount is administered periodically (as distinguished from a one-time dose). In some embodiments, an interval can be determined by standard clinical techniques. In some embodiments, an immunomodulatory agent (e.g. immune checkpoint modulator) is administered bimonthly, monthly, twice monthly, triweekly, biweekly, weekly, twice weekly, thrice weekly, or daily. In some embodiments, the administration interval for a single individual need not be a fixed interval, but can be varied over time, depending on the needs and rate of recovery of the individual.

As used herein, those of skill in the art are familiar with certain terms commonly used to describe dosing regimens. For example, the term “bimonthly” has its art understood meaning, referring to administration once per two months (i.e., once every two months); the term “monthly” means administration once per month; the term “triweekly” means administration once per three weeks (i.e., once every three weeks); the term “biweekly” means administration once per two weeks (i.e., once every two weeks); the term “weekly” means administration once per week; and the term “daily” means administration once per day.

The invention, among other things, additionally pertains to a pharmaceutical composition comprising an immunomodulatory agent (e.g. immune checkpoint modulator), as described herein; in some embodiments in a container (e.g., a vial, bottle, bag for intravenous administration, syringe, etc.) with a label containing instructions for administration of the composition for treatment of cancer.

Combination Therapy

In some embodiments, an immunomodulatory agent can be used in combination with another therapeutic agent to treat diseases such as cancer. In some embodiments, an immunomodulatory agent, or a pharmaceutical composition comprising immunotherapy as described herein can optionally contain, and/or be administered in combination with, one or more additional therapeutic agents, such as a cancer therapeutic agent, e.g., a chemotherapeutic agent or a biological agent. An additional agent can be, for example, a therapeutic agent that is art-recognized as being useful to treat the disease or condition being treated by the immunomodulatory agent, e.g., an anti-cancer agent, or an agent that ameliorates a symptom associated with the disease or condition being treated. The additional agent also can be an agent that imparts a beneficial attribute to the therapeutic composition (e.g., an agent that affects the viscosity of the composition). For example, in some embodiments, immunotherapy is administered to a subject who has received, is receiving, and/or will receive therapy with another therapeutic agent or modality (e.g., with a chemotherapeutic agent, surgery, radiation, or a combination thereof).

Some embodiments of combination therapy modalities provided by the present disclosure provide, for example, administration of an immunomodulatory agent and additional agent(s) in a single pharmaceutical formulation. Some embodiments provide administration of an immunomodulatory agent and administration of an additional therapeutic agent in separate pharmaceutical formulations.

Examples of chemotherapeutic agents that can be used in combination with an immunomodulatory agent described herein include platinum compounds (e.g., cisplatin, carboplatin, and oxaliplatin), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, nitrogen mustard, thiotepa, melphalan, busulfan, procarbazine, streptozocin, temozolomide, dacarbazine, and bendamustine), antitumor antibiotics (e.g., daunorubicin, doxorubicin, idarubicin, epirubicin, mitoxantrone, bleomycin, mytomycin C, plicamycin, and dactinomycin), taxanes (e.g., paclitaxel and docetaxel), antimetabolites (e.g., 5-fluorouracil, cytarabine, premetrexed, thioguanine, floxuridine, capecitabine, and methotrexate), nucleoside analogues (e.g., fludarabine, clofarabine, cladribine, pentostatin, and nelarabine), topoisomerase inhibitors (e.g., topotecan and irinotecan), hypomethylating agents (e.g., azacitidine and decitabine), proteosome inhibitors (e.g., bortezomib), epipodophyllotoxins (e.g., etoposide and teniposide), DNA synthesis inhibitors (e.g., hydroxyurea), vinca alkaloids (e.g., vicristine, vindesine, vinorelbine, and vinblastine), tyrosine kinase inhibitors (e.g., imatinib, dasatinib, nilotinib, sorafenib, and sunitinib), nitrosoureas (e.g., carmustine, fotemustine, and lomustine), hexamethylmelamine, mitotane, angiogenesis inhibitors (e.g., thalidomide and lenalidomide), steroids (e.g., prednisone, dexamethasone, and prednisolone), hormonal agents (e.g., tamoxifen, raloxifene, leuprolide, bicaluatmide, granisetron, and flutamide), aromatase inhibitors (e.g., letrozole and anastrozole), arsenic trioxide, tretinoin, nonselective cyclooxygenase inhibitors (e.g., nonsteroidal anti-inflammatory agents, salicylates, aspirin, piroxicam, ibuprofen, indomethacin, naprosyn, diclofenac, tolmetin, ketoprofen, nabumetone, and oxaprozin), selective cyclooxygenase-2 (COX-2) inhibitors, or any combination thereof.

Examples of biological agents that can be used in the compositions and methods described herein include monoclonal antibodies (e.g., rituximab, cetuximab, panetumumab, tositumomab, trastuzumab, alemtuzumab, gemtuzumab ozogamicin, bevacizumab, catumaxomab, denosumab, obinutuzumab, ofatumumab, ramucirumab, pertuzumab, ipilimumab, nivolumab, nimotuzumab, lambrolizumab, pidilizumab, siltuximab, BMS-936559, RG7446/MPDL3280A, MEDI4736, tremelimumab, or others known in the art), enzymes (e.g., L-asparaginase), cytokines (e.g., interferons and interleukins), growth factors (e.g., colony stimulating factors and erythropoietin), cancer vaccines, gene therapy vectors, or any combination thereof.

In some embodiments, an immunomodulatory agent is administered to a subject in need thereof in combination with another agent for the treatment of cancer, either in the same or in different pharmaceutical compositions. In some embodiments, the additional agent is an anticancer agent. In some embodiments, the additional agent affects (e.g., inhibits) histone modifications, such as histone acetylation or histone methylation. In certain embodiments, an additional anticancer agent is selected from the group consisting of chemotherapeutics (such as 2CdA, 5-FU, 6-Mercaptopurine, 6-TG, Abraxane™, Accutane®, Actinomycin-D, Adriamycin®, Alimta®, all-trans retinoic acid, amethopterin, Ara-C, Azacitadine, BCNU, Blenoxane®, Camptosar®, CeeNU®, Clofarabine, Clolar™, Cytoxan®, daunorubicin hydrochloride, DaunoXome®, Dacogen®, DIC, Doxil®, Ellence®, Eloxatin®, Emcyt®, etoposide phosphate, Fludara®, FUDR®, Gemzar®, Gleevec®, hexamethylmelamine, Hycamtin®, Hydrea®, Idamycin®, Ifex®, ixabepilone, Ixempra®, L-asparaginase, Leukeran®, liposomal Ara-C, L-PAM, Lysodren, Matulane®, mithracin, Mitomycin-C, Myleran®, Navelbine®, Neutrexin®, nilotinib, Nipent®, Nitrogen Mustard, Novantrone®, Oncaspar®, Panretin®, Paraplatin®, Platinol®, prolifeprospan 20 with carmustine implant, Sandostatin®, Targretin®, Tasigna®, Taxotere®, Temodar®, TESPA, Trisenox®, Valstar®, Velban®, Vidaza™, vincristine sulfate, VM 26, Xeloda® and Zanosar®); biologics (such as Alpha Interferon, Bacillus Calmette-Guerin, Bexxar®, Campath®, Ergamisol®, Erlotinib, Herceptin®, Interleukin-2, Iressa®, lenalidomide, Mylotarg®, Ontak®, Pegasys®, Revlimid®, Rituxan®, Tarceva™, Thalomid®, Velcade® and Zevalin™); small molecules (such as Tykerb®); corticosteroids (such as dexamethasone sodium phosphate, DeltaSone® and Delta-Cortef®); hormonal therapies (such as Arimidex®, Aromasin®, Casodex®, Cytadren®, Eligard®, Eulexin®, Evista®, Faslodex®, Femara®, Halotestin®, Megace®, Nilandron®, Nolvadex®, Plenaxis™ and Zoladex®); and radiopharmaceuticals (such as Iodotope®, Metastron®, Phosphocol® and Samarium SM-153).

The additional agents that can be used in combination with immunotherapy as set forth above are for illustrative purposes and not intended to be limiting. The combinations embraced by this disclosure, include, without limitation, one or more immunomodulatory agent(s) as provided herein or otherwise known in the art, and at least one additional agent selected from the lists above or otherwise provided herein. Immunomodulatory agents can also be used in combination with one or with more than one additional agent, e.g., with two, three, four, five, or six, or more, additional agents.

In some embodiments, treatment methods described herein are performed on subjects for which other treatments of the medical condition have failed or have had less success in treatment through other means, e.g., in subjects having a cancer refractory to standard-of-care treatment. Additionally, the treatment methods described herein can be performed in conjunction with one or more additional treatments of the medical condition, e.g., in addition to or in combination with standard-of-care treatment. For instance, the method can comprise administering a cancer regimen, e.g., nonmyeloablative chemotherapy, surgery, hormone therapy, and/or radiation, prior to, substantially simultaneously with, or after the administration of an immunomodulatory agent described herein, or composition thereof. In certain embodiments, a subject to which an immunomodulatory agent described herein is administered can also be treated with antibiotics and/or one or more additional pharmaceutical agents.

EXEMPLIFICATION Example 1 Pan-Cancer Analysis of Tumor Mutational Load Threshold and Survival After Immunotherapy with Immune Checkpoint Modulators

This example illustrates the association between tumor mutational load, as measured by a targeted sequencing panel, and overall survival after treatment with immune checkpoint modulators (ICM).

In prior studies, the data on tumor mutational load were primarily based on whole exome sequencing, which is typically not broadly performed as part of routine clinical care. Currently, the most widely used precision oncology platforms utilize next-generation sequencing of targeted gene panels. An association between higher tumor mutational load and clinical benefit from ICM were observed in melanoma patients treated with CTLA4 blockade,^(3,4) as well as non-small cell lung cancer (NSCLC), melanoma, and bladder cancer patients treated with PD-1/PD-L1 inhibitors.⁵⁻⁷ Importantly, it remains unknown how broadly tumor mutational load predicts clinical benefit across different human cancers.

At Memorial Sloan Kettering Cancer Center, over 15,000 patients have undergone genomic profiling using an assay termed “Integrated Mutation Profiling of Actionable Cancer Targets” (MSK-IMPACT), which identifies somatic exonic mutations in a pre-defined subset of 341, 410 or in its most updated version, 468 cancer-related genes, using both tumor-derived and matched germline normal DNA.^(8,17)

Specifically, MSK-IMPACT was used to analyze a cohort of 1534 patients treated at Memorial Sloan Kettering Cancer Center (MSKCC) who previously received at least one dose of an ICM (FIG. 1). Patients who previously received atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab pembrolizumab, or tremelimumab as monotherapy or in combination were included in the study. In total, 130 patients received anti-CTLA-4 immunotherapy, 1166 anti-PD-1 or PD-L1 immunotherapy, and 228 received both anti-CTLA-4 and anti-PD-1 or PD-L1 immunotherapy. The total number of somatic mutations was calculated for all patient samples in the cohort and normalized to the total number of megabases in the exons sequenced. Tumor mutational load, as measured by targeted next-generation sequencing (NGS) panels, including MSK-IMPACT, has been previously validated as a means to estimate total tumor mutational load of tumors by multiple investigators.^(9,10,11) Overall survival (OS) was measured from the date of first ICM treatment to time of death or last follow-up. Median followup was 11 months with 984 (64%) patients alive at last followup.

The largest number of patients had tumors with histologies for which use of an ICM is FDA approved: 351 patients with non-small cell lung cancer (NSCLC), 323 with melanoma, 155 with renal cell carcinoma (RCC), 127 with bladder cancer and 78 with head and neck squamous cell cancer (Table 1). Patients with other tumor types such as breast cancer, glioma and gastrointestinal cancers were also included in the study. Multivariable analysis of all patients using Cox proportional-hazards regression demonstrated that the normalized number of somatic, exonic non-synonymous mutations discovered using MSK-IMPACT, or tumor mutational load relative to a threshold, was significantly associated with overall survival (as a continuous variable: HR=0.987, p=0.001; binary cutoff: HR 0.524, p=5.0×10⁻⁵), adjusting for cancer type, age, and drug class of ICM (Table 2). In the table, the term “cutoff” is used to signify tumor mutational load threshold, as used herein. As one of skill in the art will appreciate, a hazard ratio (HR) in survival analysis is the ratio of the hazard rates corresponding to conditions described by two levels of an explanatory variable. For example, in a drug study, if a treated population survives at twice the rate per unit time as a control population, the hazard ratio would be 0.5, indicating higher hazard of death from no treatment.

TABLE 1 Hazard ratios of OS for normalized tumor mutational load threshold across histologies tested Histology HR Cllo Clhi pvalue N Threshold Med OS< Med OS> Pan Cancer 0.44 0.32 0.60 3.00 × 10⁻⁸ 1551 17.55 20 NA Bladder Cancer 0.48 0.23 0.98 0.038 127 16.73 10 NA Breast Cancer 0.35 0.13 0.91 0.025 46 3.51 4 NA Cancer of Unknown 4.71 0.42 52.75 0.166 29 25.58 9  1 Primary Esophagogastric Cancer 0.34 0.1 1.13 0.065 53 10.82 4 NA Glioma 1.93 1.01 3.71 0.043 117 4.46 NA 12 Head and Neck Cancer 0.36 0.14 0.93 0.028 78 7.87 8 NA Hepatobiliary Cancer 0.43 0.07 2.65 0.352 23 1.12 5 NA Melanoma 0.35 0.21 0.57 1.11 × 10⁻⁵ 323 11.15 29 NA Non-Small Cell Lung 0.23 0.10 0.57 4.69 × 10⁻⁴ 351 17.84 12 NA Cancer Pancreatic Cancer 0 0.084 23 9.84 3 NA Prostate Cancer 4.55 0.75 27.44 0.07 23 32.34 NA 20 Renal Cell Carcinoma 0.43 0.19 0.98 0.038 155 1.76 32 NA Skin Cancer, Non- 1.86 0.57 6.1 0.3 30 4.46 NA 15 Melanoma Drug Class Combination 0.54 0.25 1.18 0.115 238 17.55 32 NA CTLA4 0.29 0.12 0.68 0.003 130 17.55 34 NA PD-1/PD-L1 0.49 0.35 0.70 6.89 × 10⁻⁵ 1166 17.55 13 NA *Other rare and miscellaneous cancers are included in the overall analysis but limited numbers (<20) did not allow analysis individually.

TABLE 2 Multivariate analysis of factors associated with overall survival. HR 95% CI P value Normalized Mutation Count Continuous 0.987 0.979-0.995 .001 Binary (>17.55) 0.524 0.384-0.716 5.0 × 10⁻⁵ Cancer Type Melanoma (reference) NSCLC 1.803 1.329-2.444 1.5 × 10⁻⁴ Not Melanoma/NSCLC 1.445 1.101-1.898 .008 Age 1.003 0.997-1.010 0.340 Drug Class PD-1/PD-L1 (reference) CTLA4 0.619 0.441-0.866 .005 Combo 0.701 0.541-0.908 .007

In pan-cancer analysis, a higher number of somatic mutations, or high tumor mutational load, was associated with proportionally improved overall survival (FIG. 2). As expected, distribution of tumor mutational load varied across diverse histologies.¹² More importantly, optimal tumor mutational load thresholds were identified that predict overall survival after ICM therapy for each cancer subtype using maximum chi-squared analysis (FIGS. 4A and 5A-B).¹³ A significant association or strong trend was observed with increased tumor mutational load and improved overall survival from immunotherapy treatment across many histologies, concordant with the number of patients in the subgroup (FIGS. 6A-H and 7). Importantly, in patients who did not receive ICM therapy (n=9196), there was no association between higher tumor mutational load and improved overall survival (FIGS. 3B and 4B).

A significant association with improved overall survival and higher tumor mutational load was observed with CTLA-4 and PD-1/PD-L1 blockade targeted therapy while a similar non-significant trend was observed with combination therapy. It is intriguing that combination therapy appears to lessen the significance of tumor mutational load on outcome. This relationship suggests that abrogating multiple immune checkpoints may enable the immune system to target a broader set of potential neoantigens more effectively, increasing the likelihood of establishing an effective anti-tumor response.

Glioma was an outlier in the study (FIG. 4A), as increased tumor mutational load, or a high tumor mutational load threshold was associated with a trend towards poorer overall survival. This is in contrast to reports of dramatic responses to immune checkpoint modulators in patients with glioblastoma associated with childhood biallelic mismatch repair deficiency.¹⁴ This discrepancy may reflect the fact that mismatch repair is very rare in GBM and tumor mutational load in these patients may reflect prior exposure to the alkylating agent temozolomide, which has been shown to promote the expansion of subclonal mutations that have been suggested to be less immunogenic.¹⁵ It should be noted, as anticipated from a large pan-cancer analysis, that the patients included were heterogeneous, with some having been heavily pre-treated whereas others were treated with a variety of combination therapies.

These findings are confirmed by additional analysis of a larger cohort in the MSK-IMPACT study. The cohort included 1662 patients whose tumors were profiled by next generation sequencing and who received at least one dose of ICI therapy, representing a variety of cancer types with sufficient number of patients for analysis (FIG. 13). Patients who received atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab, or tremelimumab as monotherapy or in combination were included in the study. The vast majority of patients (1446, 94% of tumors excluding glioma) had stage IV or metastatic disease. A small number of patients had locally recurrent disease (n=10), or were melanoma patients with regionally advanced unresectable disease (stage III, n=89 (Table 3). In total, 146 received anti-CTLA4, 1447 received anti-PD1 or PD-L1, and 189 received both. A large number of patients had cancers for which ICI is FDA-approved, including 350 NSCLCs, 321 melanomas, 151 renal cell carcinomas (RCC), 214 bladder cancers and 138 head and neck squamous cell cancers (Table 4). To calculate tumor mutational burden (TMB), the total number of somatic non-synonymous mutations was normalized to the total number of megabases sequenced. OS was measured from the date of first ICI treatment to time of death or last follow-up. The median followup was 19 months (range 0-80, with 830 [50%] patients alive and censored at last followup.

TABLE 3 Patient Clinical Characteristics N (%) Gender Male 1034 (62) Female 628 (38) Cancer Type See FIG. 1 Cancer Disease State Metastatic 1446 (87) Unresectable locally recurrent 10 (0.7) Melanoma stage III 89 (6) Glioma 117 (7) Drug Class CTLA4 targeted 146 (9) PD-1/PD-L1 targeted 1256 (76) Combination of above 260 (16) Year of ICI start 2011-2012 26 (2) 2013-2014 189 (11) 2015-2017 1447 (87) Median (range) Age 62 (4-93) Tumor Mutational Burden 5.9 (0-210)

TABLE 4 Multivariable analysis of TMB association with removal of Melanoma and NSCLC patients HR 95% CI P value Normalized Mutation Count Continuous 0.982 0.974-0.990 1.7 × 10⁻⁵ Cancer Type Bladder Cancer (reference) Glioma 1.25 0.91-1.72 0.17 Esophagogastric Cancer 1.28 0.91-1.79 0.16 Renal Cell Carcinoma 0.41 0.29-0.58 5.1 × 10⁻⁷ Head and Neck Cancer 1.20 0.88-1.64 0.24 Other 1.17 0.87-1.57 0.30 Age 0.993 0.986-1.00  0.05 Drug Class PD-1/PD-L1 (reference) CTLA4 1.41 0.85-2.34 0.18 Combo 0.78 0.57-1.06 0.11 Year of ICI start 0.02

TMB subgroups were defined by percentiles within each histology. This approach was used because the median and range of mutational load has been shown to vary across tumor types¹³; therefore, a universal cutoff for “high TMB” would be enriched for tumor types with higher mutation load. Across the entire cohort, stratifying tumors by TMB decile within histology revealed that a higher number of mutations was associated with improved OS. This significant association, stratified by histology, was seen across a variety of cutpoints chosen to define the high TMB group (ranging from top 10-50%; FIGS. 14A, 15, 16). A clear trend toward decreasing hazard ratio (HR) of death with increasing TMB cutoff was observed across cancer types demonstrating increasing benefit from ICI with higher TMB (FIGS. 14B, 16).¹³

To confirm that these results were present across multiple cancer types, two additional analyses were performed. First, a multivariable analysis across the entire cohort using Cox proportional-hazards regression demonstrated that the tumor mutation burden was significantly associated with OS both as a continuous variable (HR=0.985, p=3.4×10⁻⁷) and with a binary cutoff (top 20% of each histology, HR 0.61 p=1.3×10⁻⁷), adjusting for cancer type, age, drug class of ICI, and year of ICI start (Table 5). Furthermore, this association remained significant with removal of melanoma and NSCLC patients from the cohort (Table 4), indicating that this effect was not solely driven by these histologies.

TABLE 5 Multivariable analysis of factors associated with overall survival. HR 95% CI P value Normalized Mutation Count Continuous 0.985 0.979-0.991 3.4 × 10⁻⁷ Binary (Top 20% of each histology) 0.61 0.508-0.733 1.3 × 10⁻⁷ Cancer Type Melanoma (reference) NSCLC 2.08 1.61-2.68 1.9 × 10⁻⁸ Not Melanoma/NSCLC 1.52 1.21-1.92 3.7 × 10⁻⁴ Age 0.995 0.990-1.004 0.07 Drug Class PD-1/PD-L1 (reference) CTLA4 1.18 0.846-1.66  0.32 Combo 0.67 0.534-0.844 6.6 × 10⁻⁴ Year of ICI start 2.3 × 10⁻⁸

A stratified analysis within each cancer type was also performed, by selecting the higher mutation load quintile (top 20%) in each histology as the TMB-high group. Using this approach, a similar association of longer OS with higher TMB (top 20% within each histology) across multiple cancer types was observed (FIGS. 17, 18). Although the effect for some individual cancers did not reach statistical significance, possibly due to smaller sample size, the numerical trend of better OS (HR<1) was observed in nearly all cancer types, with glioma the clearest exception. Taken together, these data indicate that the association between TMB and improved survival after ICI is likely to be present in the majority of cancer histologies.

Consistent with varying distributions of TMB across histologies, the TMB cutoff associated with the top 20% of each cancer type varied markedly (FIGS. 17, 19). Importantly, this suggests that there is not likely to be a universal number defining high TMB that is predictive of clinical benefit to ICI across all cancer types, and that the optimal cutpoint is likely to vary for different cancers.

A similar numerical trend was observed for longer OS with TMB measured as a continuous variable, across many histologies, concordant with the number of patients in the subgroup (FIG. 20). Consistent with the differences in OS, similar associations between TMB and rates of clinical benefit to ICI, or progression free survival, was observed in patients with cancer types for which response data was available—NSCLC, melanoma, esophagogastric, head and neck, and renal cell cancer (FIGS. 21-22).⁷²⁻⁷⁴

To investigate the possibility that the observed survival differences among patients with higher TMB tumors could simply be attributable to a general prognostic benefit of high mutational load, unrelated to ICI, the outcomes of 5371 patients with metastatic cancers who did not receive ICI, and whose tumors were sequenced with MSK-IMPACT was measured. In these patients, there was no association between higher TMB and improved OS (HR 1.12, p=0.11). This lack of prognostic benefit was also observed within each histology (FIGS. 17, 23).

Of note, the TMB cutpoint for the top 20% of colorectal cancer patients was high (52.2/MB), potentially consistent with many MSI-high colorectal tumors receiving ICI treatment. To evaluate the possibility that the ICI-treated cohort of patients might be enriched for patients with higher TMB—if, for example, clinicians were more likely to triage higher TMB patients to ICI therapy—the survival analyses was repeated, instead calculating the top 20% of TMB among all (both ICI and non-ICI treated) patients. The TMB cutpoints in other cancer types were not changed with this calculation, and the associations with survival in each cancer type remained very similar, in both the ICI and non-ICI treated cohorts (FIGS. 24, 25).

Distinct from the other cancer types, there was no association between higher TMB and improved survival in patients with glioma; in fact, the trend was toward poorer survival. Although there have been case reports of dramatic responses to ICI in patients with glioblastoma associated with childhood biallelic mismatch repair deficiency¹⁴, mismatch repair is very rare in GBM, and higher TMB in many glioma patients may reflect prior exposure to the alkylating agent temozolomide, which can promote the expansion of less immunogenic subclonal mutations.¹⁵ Alternatively, anti-tumor immune responses in the CNS may be distinct and less dependent on TMB.

As would be expected in a large multi-cancer analysis of tumors sequenced as part of clinical care, the patients included were heterogeneous, with some having been heavily pre-treated whereas others were treated with a variety of combination therapies. The timing of MSK-IMPACT testing relative to ICI start was also variable. Nevertheless, the finding of a significant association with OS in a heterogeneous cohort underscores the robustness of TMB as a predictive biomarker, suggesting it is likely to be clinically meaningful.

The variable threshold of TMB across histologies can likely be attributed to distinct tumor microenvironments as well as the numerous other factors shows to independently predict response to ICI including clonality, immune infiltration, immune cell exclusion, HLA genotype and alterations, expression levels of checkpoint molecules, as well as others.^(15,75-78) Our data overall suggest that TMB is associated with increasing OS in a dose-dependent fashion. The pan-cancer nature of this biomarker likely reflects fundamental mechanisms by which ICI functions. Our data are also consistent with the hypothesis that higher mutation load is associated with a higher number of tumor neoantigens presented on MEW molecules that facilitate immune recognition as foreign and the development of an anti-tumor immune response.^(79,80)

This finding is in line with the observation that patients with hypermutated tumors as a result of defective mismatch repair have high response rates to pembrolizumab, a finding that had led to the FDA's tissue/site-agnostic approval of this agent for microsatellite instability-high or mismatch repair deficient tumors⁶⁵. Mutational load can predict survival across diverse types of human cancers and is relevant in patients treated with either anti-CTLA4 or anti-PD1 therapies. Second, previous studies on the association between mutational load and survival after ICI had examined small cohorts and therefore, the effects of TMB on clinical benefit could not be quantified in a precise manner. This study presents genomic data from the largest cohort of patients treated with ICI to date and demonstrates the continuous association between higher TMB and superior OS. Capturing as little as 3% of the coding exome using targeted panels such as MSK IMPACT appears to provide a sufficient estimation of total tumor mutational load to confer predictive value for patients in whom ICI treatment is being considered. Finally, the mutational number defining TMB high appears to vary across cancer types, and there is unlikely to be a universal number that defines the likelihood of benefit from ICI across all histologies.

Example 2 Patient Population Selection Criteria for Example 1

The present example describes the criteria in which a patient was selected for analysis in predicting overall survival based on tumor mutational load threshold.

After receiving institutional review board approval from the Memorial Sloan Kettering Cancer Center, institutional pharmacy records were used to identify patients who received at least one dose of an immune checkpoint modulator (e.g. tezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab, or tremelimumab) and then cross-referenced with patients who had MSK-IMPACT testing done in the context of routine clinical care. Importantly, concurrent sequencing of germline DNA from peripheral blood is performed for all samples to identify somatic tumor mutations. Patients enrolled in ongoing clinical trials for which publication of outcomes data was prohibited were removed. Other preceding or concurrent non-ICM treatments were not recorded or accounted for in the analysis. The timing of tissue pathology on which MSK-IMPACT was performed relative to ICM administration is also heterogeneous with a small portion of patients with testing after ICM administration.

For analysis of patients who did not receive ICM, all patients for whom MSK-IMPACT data was available across all histologies were included. Overall survival analysis was performed from the start of first chemotherapy.

This study addresses several fundamentally important questions in immune-oncology. First, it had previously been unclear how broadly tumor mutational load thresholds predicted for clinical benefit from immune checkpoint modulators across human cancers. Our study suggests that tumor mutational load threshold can predict survival across many diverse types of human cancers, in patients treated with both CTLA-4 blockade or PD-1 blockade therapies. Second, previous studies on the association between tumor mutational load and survival after ICM therapy had examined smaller cohorts and therefore, the effects of tumor mutational load on clinical benefit could not be quantified in a precise manner. This study presents genomic data from the largest cohort of patients treated with ICM to date (over 1500 patients) and also expands upon and validates earlier data from smaller studies. Lastly, the MSK-IMPACT targeted panel captures approximately 3% of the coding exome and our data indicate that this profiling strategy provides sufficient representation of total tumor mutational load to have predictive value in patients treated with ICM. Taken together, these data collectively indicate that tumor mutational load and tumor mutational load threshold is a predictive biomarker for ICM response across multiple human cancer types and could potentially have value in concert with PD-L1 immunohistochemistry.¹⁶ The pan-cancer nature of this biomarker likely reflects fundamental mechanisms by which ICM functions. Our data is thus consistent with the theory that higher tumor mutation load is presumed to be associated with a higher number of tumor neoantigens presented on MHC molecules that facilitate immune recognition as foreign and development of an anti-tumor immune response.

Example 3 Calculation of Tumor Mutational Load Threshold for Example 1

The present example describes how tumor mutational load is calculated from collected patient data.

The total number of somatic mutations, or tumor mutational load, identified was normalized to the exonic coverage of the respective MSK-IMPACT panel in megabases. Overall survival analysis on ICM therapy patients was performed from the date of first infusion of any ICM. For patients who received multiple courses of ICM, the first treatment was used for analysis. Patients were censored at the date of last attended appointment. For non-ICM patients, the date of first dose of any chemotherapy was used for overall survival analysis.

Survival analysis was performed using Kaplan Meier with log-rank p values reported. Multivariable analysis was performed using Cox proportional hazard regression. These data analysis methods are known to one of skill in the art. Optimal tumor mutational load cutoffs, or tumor mutational load thresholds as used herein, were determined by maximum chi-squared analysis as known to one of skill in the art, as the distribution of tumor mutational load varied significantly by histology. Statistical analysis was performed in R using the survival package.

Example 4 HLA Class I Genotype Influences Survival with Immune Checkpoint Modulators Materials and Methods

Study Design and Description of Patient Sets

For the analyses presented in this study, we used two different sets of cancer patients who were treated with immune checkpoint inhibitors. For cohort 1, we obtained exome sequencing data and clinical data from 371 patients who were treated with anti-CTLA-4 or anti-PD-1 therapy. Two patients did not have overall survival data and they were not included in the analyses. Out of the 369 patients with complete clinical data, 269 patients had advanced melanoma and 100 patients had advanced non-small cell lung cancer (NSCLC). The melanoma data are from four previously reported studies (3, 4, 7, 36). The NSCLC data are from patients with metastatic disease treated mainly with anti-PD-1 monotherapy. The patients are from a prospective trial that we reported previously (5) and from New York-Presbyterian/Columbia University Medical Center. Exome sequencing data were not available for 67 patients with NSCLC. All patients were treated under institutional review approved prospective protocols. For cohort 2, we obtained independent next-generation sequencing data using a targeted gene panel (MSK-IMPACT) and clinical data from 1,166 patients representing different cancer types on an institutional IRB-approved research protocol (NCT01775072). These patients were treated with anti-CTLA-4, or PD-1/PD-L1 blockade, or a combination of both drugs at the Memorial Sloan Kettering Cancer Center (32). Clinical characteristics of patient cohorts are provided in Appendix 1. For analysis of germline variants, original sequencing files and relevant clinical data were anonymized by a third party without investigator access to the original patient identification according the protocol design. Additional details regarding these tumors can be found in the original publications (3-5, 7,11, 36). The results published here are in part based on data generated by TCGA pilot project established by the National Cancer Institute and National Human Genome Research Institute. Information about TCGA and the investigators and institutions that constitute the TCGA research network can be found at cancergenome.nih.gov/. The TCGA exome data for the patients with melanoma was obtained from the Cancer Genome Atlas (TCGA) (N=378).

Overall Survival and Clinical Response Data

The clinical endpoint used in these analyses was overall survival, defined as the length of time from treatment start to time to event (survival or censor). All clinical data were obtained from the original studies (3-5, 7,11, 36). Clinical data for the TCGA patients with melanoma were accessed through the TCGA data portal.

HLA Class I Genotyping Data

We performed high-resolution HLA class I genotyping from germline normal DNA exome sequencing data directly or using a clinically validated HLA typing assay (LabCorp). Patient exome data or targeted gene panels were obtained and the well-validated tool Polysolver was used to identify HLA class I alleles with default parameter settings (38). It has previously been shown that Polysolver is highly accurate compared to serology or PCR-based methods (37, 38). For quality assurance, a subset of these patients (N=22) was molecularly HLA typed at a CLIA-certified center (New York Blood Center) and typed using Polysolver. The overall concordance between Polysolver and the molecular typing was 96%. Concordance is defined as [(6−number of allele mismatches between Polysolver and molecular typing)/6]×100. Furthermore, HLA class I homozygosity detected by Polysolver was confirmed by two additional computational tools, OptiType and HLA-SOAP (39,40). For the 67 patients with NSCLC with no available exome sequencing data, HLA class I molecular typing was done at LabCorp. For quality assurance of MSK-IMPACT (CLIA-certified hybridization-capture based assay) captures HLA class I (8,11,41), we compared HLA class I typing by Polysolver between 37 samples that we sequenced with MSK-IMPACT and whole exome. The MSK-IMPACT panel successfully captured HLA-A, -B, and -C. To make sure that HLA class I genes have adequate coverage in MSK-IMPACT bam files, we also applied bedtools multicov tool (//bedtools.readthedocs.io/en/latest/content/tools/multicov.html), which reports the count of alignments from multiple position-sorted and indexed BAM files that overlap with targets intervals in a BED format. Only high quality reads were counted and only samples with sufficient coverage were used. The overall concordance of class I typing between the MSK-IMPACT samples and their matched WES samples was 96%.

Statistical Analysis

We performed survival analyses using the Kaplan-Meier estimator. The log-rank test was used to determine statistical significance of the survival distributions between patients with a specific genotyping and patients without it. We computed hazard ratios using univariate or multivariable Cox regression. To stratify patients into two groups, with high and low tumor mutational load, we used cutoffs calculated by the R function maxstat.test (//cran.r-project.org/web/packages/maxstat/vignettes/maxstat.pdf). In FIG. 8F, FIG. 8G, FIG. 9G, and FIG. 9H we used a range of cutoffs across the quartiles of the distribution of the number of somatic mutations of the specific cohort analyzed. The cutoffs were used to stratify patients into two groups, high or low tumor mutational load, and to generate the box plot showing the distribution of hazard ratios resulting from the survival analyses using the multiple cutoffs. In FIG. 8F, we used the range [80, 542]. For FIG. 8G, we used [5, 65]. For FIG. 9G, we used the range [108, 569]. And for FIG. 9H, we used [5, 25]. Comparison of number of somatic mutations between HLA class I homozygotes and heterozygotes groups was performed with the Wilcoxon-rank sum test. All statistical analysis was performed in the R Statistical Computing environment version 3.3.1 (www.r-project.org).

Mutational Analysis Pipeline

For cohort 1, whole-exome sequencing for all data sets was previously completed (3-5, 36). Analysis was performed as described by DePristo et al. (42, 43) As previously described (42), paired-end reads in FASTQ format were aligned to the reference human genome GRCh37 using the Burrows-Wheeler aligner (BWA; v0.7.10) (44). Local realignment was performed using the Genome Analysis Toolkit (GATK 3.2.2) (45). Duplicate reads were removed using Picard version 1.119. To identify somatic single nucleotide variants (SNVs), we used a pipeline that integrates mutation calls from four different mutation callers: MuTect 1.1.4, Strelka 1.0.3, SomaticSniper 1.0.4, and Varscan 2.3.7 (46-49). Insertions and deletions were determined using Strelka 1.0.3 with default settings (42,43). SNVs with an allele read count of less than 4 or with corresponding normal coverage of less than 7 reads were filtered out. For cohort 2, relative mutational load was determined using MSK-IMPACT consistent with targeted panels as a validated method to determine relative mutational load (8, 11, 41, 50).

Loss of Heterozygosity of HLA Class I Analysis

Copy number variation analysis was performed using FACETS 0.5.6 (51) to determine allele specific copy number. Segments within the chromosome 6p locus were identified containing the HLA-A, HLA-B and HLA-C loci. Loss of heterozygosity (LOH) was defined as a minor allele copy number estimate of 0 for any of the HLA loci using the expectation-maximization model.

HLA Class I Structural Analysis and Molecular Dynamics Simulations

The neoantigen structure within the pHLA complex presented in PDB 1M6O was mutated to conform to the desired B44 motif (F3I, P4G, A6V, F9Y) using the VMD Mutator plugin. All images were rendered using the VMD 1.9.2 software package (52).

Molecular dynamics (MD) simulations of isolated HLA class I alleles and HLA-peptide complexes were initiated from configurations drawn from crystal structures at the highest available resolutions: HLA-B*15:01 (PDB ID: 1XR9); HLA-B*07:02 (PDB ID: 5EO0); and HLA-B*53:01 (PDB ID: 1A1M). To generate isolated HLA configurations, atoms corresponding to bound peptides were removed. After the addition of hydrogen atom and disulfide bond patches, each system was solvated in TIP3P water molecules and brought to a physiological concentration (150 mM) of Na⁺ and Cl⁻ ions. Following similar protocols used in our previous studies (53-55), the resulting protein-water systems were minimized for 25000 steps by steepest descent, and then equilibrated with and without harmonic protein restraints in separate 5 ns simulations. Configurations taken from the ends of equilibration runs were used to seed production simulations, which were extended to 500 ns in duration for HLA-B*15:01 and 300 ns in length for HLA-B*07:02 and HLA-B*53:01. In all equilibration and production runs, temperature and pressure were constrained at 310 K and 1 atm using a Langevin thermostat and Parrinello-Rahman barostat, respectively. All MD simulations were conducted with the NAMD 2.11 simulation package (56). Inter-residue separations and residue-position root mean square fluctuations (RMSFs) were computed using standard utilities included in the GROMACS 5.1 software suite (57). Simulation snapshots were generated with VMD (52).

Results

We performed survival and genetic association analyses to address two hypotheses: (i) heterozygosity at HLA class I genes confers a selective advantage on survival with the administration of immune checkpoint inhibitors in cancer patients, and (ii) individual HLA class I germline alleles vary in their influence on survival after ICM therapy.

To examine these hypotheses, we scrutinized two sets of cancer patients (henceforth called cohort 1 and cohort 2) who were treated with ICM therapy. Cohort 1 was comprised of 369 patients who were treated with anti-CTLA-4 or anti-PD-1 drugs, for which exome sequencing data and clinical data were obtained. Out of these 369 patients, 269 patients had advanced melanoma, previously reported by Snyder et al. (3), Van Allen et al. (4), Hugo et al. (7), and Riaz et al. (36), and 100 patients had advanced non-small cell lung cancer (NSCLC) (5) (Appendix 1). The patients with NSCLC were treated mainly with anti-PD-1 monotherapy. Cohort 2 was comprised of 1,166 patients representing different cancer types including melanoma and NSCLC (Appendix 1), whose tumors were subjected to targeted next-generation sequencing (MSK-IMPACT) (11). These patients were treated with drugs targeting CTLA-4, PD-1/PD-L1, or a combination of both, at the Memorial Sloan Kettering Cancer Center (11). For all patients in both cohorts, we performed high-resolution HLA class I genotyping from normal DNA using DNA sequencing data or a clinically validated HLA typing assay (LabCorp). HLA typing from sequencing data was done using Polysolver, which has been extensively validated (33, 34). For quality assurance, a subset of these patients (N=22) were HLA typed using a CLIA-certified assay (at the New York Blood Center) and typed using Polysolver (38). As expected and previously shown, the overall concordance between Polysolver and the HLA-typing assay was very high (96%).

MHC class I molecules are extremely polymorphic with most of the polymorphism located in the peptide-binding region; each variant binds a select repertoire of peptide ligands. As such, a person who is homozygous in at least one HLA class I locus would be predicted to present a smaller, less diverse repertoire of tumor-derived peptides that are recognized by cytotoxic T lymphocytes (CTLs) compared to a person who is heterozygous at each class I locus (32). We thus reasoned that, greater diversity (heterozygosity) in the repertoire of antigen-presenting HLA class I molecules would be associated with better survival following ICM treatment. Conversely, less diversity (homozygosity) at these class I genes would be associated with poorer survival. We tested this hypothesis by examining HLA zygosity at each of the HLA class I genes (HLA-A, -B, and -C) in cohort 1 and cohort 2, independently. For this analysis, we employed a Cox proportional hazard regression model to examine the probability of overall survival. The results showed a statistically significant association between HLA class I homozygosity and reduced survival in the 369 patients from cohort 1 treated with ICM therapy (FIG. 8A). The association was apparent when at least one HLA class I locus was homozygous (cohort 1; P=0.036, HR=1.40, 95% CI 1.02-1.9; FIG. 8A). We validated this finding in the independent cohort of 1,166 patients treated with ICM therapy (cohort 2; P=0.028, HR=1.31, 95% CI 1.03-1.70; FIG. 8B). The number of somatic mutations in tumors was not statistically different between homozygotes and heterozygotes patients in either cohort 1 (Wilcoxon rank-sum test P=0.09; FIG. 11A) or cohort 2 (Wilcoxon rank-sum test P=0.7; FIG. 11B). Furthermore, the association of homozygosity with reduced survival remained significant in multivariable Cox regression modeling when including mutation load, tumor stage, age, and drug class in cohort 1 (P=0.02, HR=1.50, 95% CI 1.07-2.10) (Table 4) and in cohort 2 (P=0.028, HR=1.31, 95% CI 1.03-1.67) (table 5).

TABLE 4 Multivariable survival analysis incorporating homozygosity for at least one HLA class locus, mutation burden (as a continuous variable), age, tumor stage, and drug class from cohort Covariate HR 95% CI P value Homozygosity for 1.50 1.07-2.10 0.02 at least one HLA-I locus Mutation load 1.00 0.98-0.99 0.004 (Continuous) Age 1.00 0.99-1.01 0.96 Stage M0 (reference) Stage M1a 2.30 0.75-6.70 0.15 Stage M1b 2.70 0.91-7.77 0.08 Stage M1c 4.06  1.49-11.08 0.006 Drug class: CTLA-4 (reference) Drug class: PD-1 0.64 0.47-0.87 0.004

TABLE 5 Multivariable survival analysis incorporating homozygosity for at least one HLA class I locus, mutation burden (as a continuous variable), age, tumor stage, and drug class from cohort 2 Covariate HR 95% CI P value Homozygosity for 1.31 1.03-1.67 0.028 at least one HLA-I locus Mutation load 0.99 0.98-0.99 0.003 (Continuous) Age group <30 (reference) Age group >71 0.94 0.44-2.02 0.88 Age group 31-50 0.90 0.44-1.84 0.78 Age group 50-60 0.77 0.37-1.59 0.47 Age group 61-70 0.76 0.36-1.61 0.48 Drug class: Combo (reference) Drug class: 0.52 0.28-0.96 0.036 CTLA-4 Drug class: 1.53 1.12-2.08 0.007 PD-1/PDL-1

The generation of HLA class I-restricted T-cell responses has been shown to be important in the clinical response of cancer patients treated with immunotherapies (3, 5, 34, 35). These results suggest that by limiting the number of HLA class I-restricted tumor-derived epitopes that can be presented to T cells, HLA homozygosity may impair a patient's survival after ICM therapy perhaps by decreasing the chance that antigens needed for anti-tumor immunity will be presented. Interestingly, these data are consistent with the association of rapid progression to AIDS of HIV-infected patients having HLA class I homozygosity (22, 25), and with the association of HLA class II with persistent hepatitis B virus infection (58).

We next examined all 1,535 patients from cohort 1 and 2 together, to determine whether the effect of homozygosity may be due to a single class I locus, or a combination of different loci. This analysis revealed that homozygosity at one HLA class I locus (A, or B, or C) was associated with significant reduction of overall survival (P=0.003, HR=1.38, 95% CI 1.11-1.70; FIG. 8C). Interestingly, the effect of homozygosity on survival due to specific HLA class I locus seemed mostly associated with HLA-B (P=0.052, HR=1.66, 95% CI 0.93-2.94; FIG. 8C) and HLA-C (P=0.004, HR=1.60, 95% CI 1.16-2.21; FIG. 8C). Of note, the number of patients available likely limited the interpretability of analyses involving combinations of loci (HLA-A and -B, etc.).

Without wishing to be bound by any particular theory, there are two possible explanations for the significant association of homozygosity at the HLA-B locus with decreased survival. First, HLA-B is expressed at higher levels on the cell surface than HLA-A and HLA-C, and HLA-B alleles bind to greater diversity of peptides (59,60). Amino acids that bind to the B pocket of HLA-A alleles are broadly hydrophobic residues. In contrast, the B pocket of HLA-B alleles can accommodate a greater variety of residues (proline, positively and negatively charged residues, and histidine and glutamine) (60). The principal source of HLA-B diversity arises from intralocus recombination events within exon 3, primarily affecting the F, C, and D pockets (60) and the HLA-B locus is dominant in determining clinical outcomes in infectious diseases such as HIV and malaria (21-28). Similarly, heterozygosity at HLA-C loci may enable greater peptide ligand diversity. Although HLA-C also has the ability to present peptides to cytotoxic CD8⁺ T cells, antigen-presenting cells (APCs) express higher levels of HLA-C on the cell surface than other cell types (61). Because HLA-C molecules bind to inhibitory killer cell immunoglobulin-like receptors (KIRs) that are up regulated upon acquisition of effector functions (62), heterozygous HLA-C locus may more effectively limit CTL lysis of cross-presenting APCs. This may, therefore, facilitate continuous priming of naïve CTLs during treatment with ICM therapy (63).

Previous reports have shown that the total number of somatic coding mutations in a cancer genome correlates with response to ICM therapy (6, 3-5, 65). An explanation for this observation is that the number of neopeptides presented by the tumor increases with the number of somatic mutations, which in turn also increases the probability that CD8⁺ T cells recognize a neoepitope following ICM therapy (64). Therefore, we assessed the effect of zygosity at the HLA class I loci in combination with mutation burden. This analysis revealed that HLA class I homozygosity and low mutation burden were strongly associated with decreased survival compared to patients who were heterozygous at each class I locus and whose tumors had high mutation burden. This effect was seen in both in cohort 1 (P=0.003, HR=2.03, 95% CI 1.27-3.30; FIG. 8D) and in cohort 2 (P<0.0001, HR=2.98, 95% CI 1.84-4.82; FIG. 8E). Notably, the combined effect of HLA class I heterozygosity and mutation load on survival was greater compared with mutation load alone in both cohort 1 and cohort 2 (FIG. 8, F and G).

Previous work has reported the presence of loss of heterozygosity (LOH) of HLA class I genes in cancer (66). We therefore examined whether LOH of HLA class I in the tumor may have a similar effect on survival outcome after ICM therapy as in the case of germline HLA class I homozygosity. We analyzed all tumor exomes from cohort 1 and identified 32 patients who were heterozygous at all HLA class I loci, but had LOH in at least one HLA class I locus in their tumors (Appendix 1). We found that patients with LOH of HLA class I were associated with reduced survival compared to patients who were heterozygous at each HLA class I locus and without LOH (P=0.05, HR=1.60, 95% CI 1.03-2.43; FIG. 8H). Consistent with the above results, the effect of LOH of HLA class I on survival was enhanced in patients whose tumors contained low mutation load compared to patients who were heterozygous at all HLA class I loci, without LOH, and whose tumors had high mutation burden (P=0.0006, HR=3.68, 95% CI 1.64-8.23; FIG. 8I). Taken together, these results indicate that patient-specific diversity of antigen-presenting HLA class I molecules and mutation burden in the tumor may both impact the number of immunogenic neoantigens that are presented on the cell surface, which in turn, influences response to ICM therapy. Furthermore, the demonstration of a significant survival advantage to HLA class I heterozygosity in patients treated with ICM therapy both at the germline and somatic level highlights its importance in the dynamic anti-tumor immune response and its evasion.

To investigate the clinical relevance of individual HLA class I alleles after anti-PD-1 or anti-CTLA-4 therapy, we examined the effects of HLA class I supertypes on overall survival after ICM treatment. Individual HLA class I alleles are classified into twelve discrete supertypes (or superfamilies) (67,68). HLA alleles within the same supertype are expected to present similar peptides and this classification is supported by strong evidence for shared-presentation of peptide-binding motifs by different HLA class I molecules (25, 67, 68). Importantly, these supertypes together cover most HLA-A and HLA-B alleles found in distinct populations (67, 68).

To assess the effect of HLA supertype on survival, we focused on melanoma patients, as we had enough patients in the two patient sets for meaningful analysis given HLA allelic diversity. Based on the biological definition of supertypes, we classified the 27 HLA-A alleles present in the patients with melanoma into six A supertypes, and the 50 HLA-B alleles into six B supertypes (Appendix 1 and FIG. 9A). We determined whether each HLA superfamily was associated with survival following ICM treatment. Strikingly, this analysis identified two supertypes, both B supertypes, associated with survival outcome in patients with advanced melanoma treated with anti-CTLA-4. Patients with B44 superfamily alleles had significantly better overall survival (P=0.01, HR=0.61, 95% CI 0.42-0.89) (Table 3) and patients with B62 alleles had significantly decreased survival (P=0.0007, HR=2.29, 95% CI 1.40-3.7) (Table 3). In these patients, the B44 supertype was present at a prevalence of 45%; the B62 supertype, 15% (FIG. 9A). We did not find any supertype significantly associated with overall survival in patients with NSCLC, likely due to the limited sample size.

TABLE 3 HLA supertype association with overall survival in patients with melanoma from cohort 1 treated with ICM and influence of specific alleles on the associations HLA class I supertype Frequency HR P value A24 0.29 0.67 (0.44-1.03) 0.07 A01 0.59 0.87 (0.60-1.27) 0.47 A03 0.52 1.39 (0.96-2.03) 0.08 A02 0.5 1.13 (0.76-1.63) 0.53 B58 0.09 0.98 (0.51-1.88) 0.96 B62 0.15 2.29 (1.40-3.74) 0.0007 B27 0.29 1.09 (0.73-1.63) 0.67 B44 0.45 0.61 (0.42-0.89) 0.009 B07 0.54 1.35 (0.92-1.97) 0.12 B08 0.2 0.85 (0.52-1.39) 0.51 A01A03 0.04 1.20 (0.49-2.94) 0.69 A01A24 0.09 0.89 (0.43-1.83) 0.76 Alleles influencing the significant associations B44s, B*18:01, B*44:02, B*44:03, B*44:05, 0.34  0.5 (0.32-0.76) 0.001 B*50:01 B62s, B*15:01 0.13 2.21 (1.33-3.7) 0.002

We then examined whether these supertype associations were influenced by the presence of specific component HLA class I alleles. The B44 association was influenced by HLA-B*18:01, HLA-B*44:02, HLA-B*44:03, HLA-B*44:05, and HLA-B*50:01 (P=0.001, HR=0.49, 95% CI 0.32-0.76; FIG. 9C) (Table 3). And, the B62 association was significantly driven by HLA-B*15:01 (P=0.002, HR=2.21, 95% CI 1.33-3.7; FIG. 10A) (Table 3). Both of these B44 and B62 supertype allele associations remained statistically significant (P=0.01 and P=0.02, respectively) after a conservative Bonferroni correction for multiple comparisons.

In the independent set of patients, cohort 2, melanoma patients treated with anti-PD-1 or anti-CTLA-4 who had the B44 supertype alleles had significantly better overall survival (P=0.05, HR=0.32, 95% CI 0.09-1.1; FIG. 9, B and D). The association of the B44s with increased survival remained significant in multivariable analysis when including mutation load, tumor stage, age, and drug class (anti-CTLA-4 or anti-PD-1) in both cohort 1 (table 6) and in cohort 2 (table 7). Furthermore, the effect of B44s on extended survival was enhanced when somatic mutational load in the tumor was also considered. Patients with melanoma possessing B44s and whose tumors also contained high mutation burden had significantly prolonged survival compared to patients who did not carry B44s and having tumors that contained low mutation load in cohort 1 (P<0.0001, HR=0.23, 95% CI 0.13-0.41; FIG. 9E) and in cohort 2 (P=0.023, HR=0.13, 95% CI 0.02-1.07; FIG. 9F). The combined effect of the B44s and mutation load was greater than simply considering mutation burden alone in both cohort 1 and cohort 2 (FIG. 9, G and H). We note that, in general, outcomes of melanoma patients in cohort 2 tended to be better than in cohort 1 because patients who received ICM therapy and were accrued to our protocol for MSK-IMPACT testing tended to have lived longer. Yet, despite this trend, we still observed a significant effect from the B44 superfamily alleles. Notably, the B44 supertype did not associate with overall survival in patients with melanoma from The Cancer Genome Atlas (TCGA), suggesting that the presence of B44 is predictive of response to ICM therapy and is not prognostic (FIG. 9I).

TABLE 6 Multivariable survival analysis incorporating presence of B44s, mutation burden (as a continuous variable), age, tumor stage, and drug class from patients with melanoma from cohort 1 Covariate HR 95% CI P value HLA-B44(+) 0.54 0.34-0.84 0.013 Mutation load 1.00 0.98-0.99 0.007 (Continuous) Age 1.00 0.99-1.01 0.5 Stage M0 (reference) Stage M1a 1.91 0.62-5.87 0.26 Stage M1b 2.14 0.73-6.25 0.16 Stage M1c 3.53 1.30-9.64 0.01 Drug class: CTLA-4 (reference) Drug class: PD-1 0.73 0.52-1.02 0.07

TABLE 7 Multivariable survival analysis incorporating presence of B44s, mutation burden (as a continuous variable), age, and drug class from patients with melanoma from cohort 2 Covariate HR 95% CI P value HLA-B44(+) 0.27 0.07-0.95 0.04 Mutation load 0.99 0.97-1.01 0.4 (continuous variable) Age group <30 (reference) Age group >71 0 0- 1.00 Age group 31-50 0.25 0.06-1.01 0.05 Age group 50-60 0.7 0.17-2.97 0.63 Age group 61-70 0.64 0.12-3.46 0.60 Drug class: CTLA-4 (reference) Drug class: 4.36  1.35-14.10 0.01 PD-1/PDL-1

Members of the B44 supertype share a preference for peptides with negatively charged residues at anchor position P2 (Glu) near the N-terminus and polar residues at the C-terminus (69) (FIG. 9J). A number of previously identified immunogenic antigens expressed by melanomas are HLA-B44 restricted (FIG. 9J and table 8), including the testis antigen MAGEA3 epitope, which has been shown to be restricted to HLA-B*44:03 and HLA-B*18:01 (both members of B44), and an immunogenic clonal neoantigen (FAM3C: TESPFEQHI) identified in a melanoma patient who derived a long-term response to CTLA-4 blockade from cohort 1 (table 8) (3, 15). Additionally, an association of B44 with spontaneous immune response in NY-ESO-1 expressing tumors has been recently reported (70). Taken together, these data suggest that the B44s may facilitate presentation of tumor-derived antigens that are recognized by CD8+ T cells, which in turn contribute to the improved survival outcome following ICM therapy.

TABLE 8 Some experimentally identified immunogenic HLA-B44 restricted neoantigens expressed by melanomas reported in the literature Neoantigen HLA-B44 WT Neo- Gene WT Peptide allele score score antigen Reference MAGE3 — MEVDPIGHLY B*44:03 — 0.01 (67, 68) MAGE3 — MEVDPIGHLY B*18:01 — 0.10 (67, 68) TYR — SEIWRDIDF B*44:03 — 0.25 (69) FAM3C TKSPFEQHI TESPFEQHI B*44:02 16 0.6 (10) MUM1 EEKLSVVLF EEKLIVVLF B*44:02  0.09 0.1 (70) MUM2 SELFRSRLDSY SELFRSGLDSY B*44:02  0.7 2.5 (71) OS9 KELEGILLP KELEGILLL B*44:03  2.5 0.6 (72) The WT score and the neoantigen score refer to the binding strengths of the wild type peptide and its mutated peptide, respectively, predicted by NetMHC version 4.0 (73).

In contrast, the B62 association with poor survival driven by the HLA-B*15:01 allele was intriguing (FIG. 10A) (Table 3). In an exploratory analysis, we sought to determine whether any molecular features in the HLA-B*15:01 allele are associated with its effect on survival following immunotherapy. Out of all the HLA-B alleles that were available for three-dimensional structural analysis (N=119; Appendix 2), we identified three alleles at their highest resolutions, HLA-B*15:01 (PDB ID: 1XR9); HLA-B*07:02 (PDB ID: 5EO0); and HLA-B*53:01 (PDB ID: 1A1M), as possessing a structural bridge in the peptide-binding grooves at positions 62, 66, and 163. The bridge in HLA-B*15:01 apparently sequesters bound-peptide residue positions P2 and P3 (FIG. 10, B and C).

The poor survival associated with the HLA-B*15:01 allele may not reflect simple failure to present peptides, because significant peptide presentation has been reported for this allele (71). We thus postulated that this specific structural feature may modulate the effective T cell recognition of neoepitopes presented on the HLA-B*15:01 molecule. To evaluate the validity of this hypothesis, we conducted molecular dynamics (MD) simulations on these three HLA class I molecules following similar protocols used in previous studies (53-55).

In the case of HLA-B*07:02 and HLA-B*53:01, molecular dynamics simulations demonstrated that the bound peptide expands the respective HLA binding cleft, effectively breaking the bridge (FIG. 12, A to D). Conversely, in the HLA-B*15:01 molecule, the bridge was largely maintained with the peptide present, and the bridging residues were also made much less flexible (FIG. 10, D and E). FIG. 10D shows MD simulation snapshots of both the isolated HLA B*15:01 and its complex with a 9-mer UBCH6 peptide, each over the course of 500 ns of dynamics. In both cases, the bridging residues (Arg62, Ile66, and Leu163) separated somewhat when their crystal coordinates were relaxed, and bridging residue positions fluctuated as the trajectories proceeded. However, the general bridge configuration seen in the crystal structure was conserved in our simulated conformational ensembles (FIG. 10, D and E). As FIG. 10E illustrates, the occupation of the peptide-binding groove in HLA-B*15:01 had the effect of arresting bridging residue dynamics. While the mean bridge separation remained nearly constant (˜6 Å) in both systems of HLA B*15:01 (FIG. 10E), the fluctuations in this distance were less dramatic in the peptide-bound complex. The residue-position root mean square fluctuations (RMSFs) indicate that each of the bridging residues was more rigid with the presence of peptide (FIG. 10E). Altogether, these unique structural and dynamical elements of the HLA-B*15:01 molecule may impair the total strength of the interaction for effective antigen recognition between the HLA-B*15:01-neoepitope complex and T-cell receptor. However, further experimental work will be necessary to test this hypothesis.

Thus, results presented here show that HLA class I genes influence survival outcome with ICM therapy. Our data indicate that patient-specific HLA class I genotype and somatic alterations, in combination or in the alternative, in tumors impact clinical outcomes following ICM therapy. Both can be considered during the design of future clinical trials and/or recommended therapeutic dosing. The observation that the B44 superfamily is associated with extended overall survival may provide an opportunity for the development of therapeutic vaccines that potentially target immunodominant HLA-B44-restricted neoantigens expressed by melanomas. Additionally, our findings suggest that HLA class I homozygosity and LOH of HLA class I represent a genetic barrier that can be considered to enhance immunotherapeutic efficacy.

Example 5 Exemplary Dosing Regimens for Approved PD-1 Immune Checkpoint Modulators

The present Example sets forth certain dosing regimens that have been approved by the United States Food and Drug Administration for the indicated immune checkpoint modulator agents. Atezolizumab (TECENTRIQ™)

—Indications and Usage—

TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:

Have disease progression during or following platinum-containing chemotherapy;

Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

—Dosage and Administration—

Administer 1200 mg as an intravenous infusion over 60 minutes every 3 weeks.

Dilute prior to intravenous infusion.

—Dosage Forms and Strengths—

Injection: 1200 mg/20 mL (60 mg/mL) solution in a single-dose vial.

—Contraindications—

None.

—Warnings and Precautions—

Immune-Related Pneumonitis: Withhold for moderate and permanently discontinue for severe or life-threatening pneumonitis. (5.1)

Immune-Related Hepatitis: Monitor for changes in liver function. Withhold for moderate and permanently discontinue for severe or life-threatening transaminase or total bilirubin elevation.

Immune-Related Colitis: Withhold for moderate or severe, and permanently discontinue for life-threatening colitis.

Immune-Related Endocrinopathies:

Hypophysitis: Withhold for moderate or severe and permanently discontinue for life-threatening hypophysitis.

Thyroid Disorders: Monitor for changes in thyroid function. Withhold for symptomatic thyroid disease.

Adrenal Insufficiency: Withhold for symptomatic adrenal insufficiency.

Type 1 Diabetes Mellitus: Withhold for ≥Grade 3 hyperglycemia.

Immune-Related Myasthenic Syndrome/Myasthenia Gravis, Guillain-Barré or Meningoencephalitis: Permanently discontinue for any grade.

Ocular Inflammatory Toxicity: Withhold for moderate and permanently discontinue for severe ocular inflammatory toxicity.

Immune-Related Pancreatitis: Withhold for moderate or severe, and permanently discontinue for life-threatening pancreatitis, or any grade of recurring pancreatitis.

Infection: Withhold for severe or life-threatening infection.

Infusion Reaction: Interrupt or slow the rate of infusion for mild or moderate infusion reactions and discontinue for severe or life-threatening infusion reactions.

Embryo-Fetal Toxicity: TECENTRIQ can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and use of effective contraception.

Avelumab (BAVENCIO®)

—Indications and Usage—

BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).

This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

—Dosage and Administration—

Administer 10 mg/kg as an intravenous infusion over 60 minutes every 2 weeks.

Premedicate with acetaminophen and an antihistamine for the first 4 infusions and subsequently as needed.

—Dosage Forms and Strengths—

Injection: 200 mg/10 mL (20 mg/mL) solution in single-dose vial.

Contraindications

None. (4)

—Warnings and Precautions—

Immune-mediated pneumonitis: Withhold for moderate pneumonitis; permanently discontinue for severe, life-threatening or recurrent moderate pneumonitis.

Immune-mediated hepatitis: Monitor for changes in liver function. Withhold for moderate hepatitis; permanently discontinue for severe or life-threatening hepatitis.

Immune-mediated colitis: Withhold for moderate or severe colitis; permanently discontinue for life-threatening or recurrent severe colitis.

Immune-mediated endocrinopathies: Withhold for severe or life-threatening endocrinopathies.

Immune-mediated nephritis and renal dysfunction: Withhold for moderate or severe nephritis and renal dysfunction; permanently discontinue for life-threatening nephritis or renal dysfunction.

Infusion-related reactions: Interrupt or slow the rate of infusion for mild or moderate infusion-related reactions. Stop the infusion and permanently discontinue BAVENCIO for severe or life-threatening infusion-related reactions.

Embryo-fetal toxicity: BAVENCIO can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception.

Durvalumab (IMFINZI™)

—Indications and Usage—

IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with:

Locally advanced or metastatic urothelial carcinoma who:

have disease progression during or following platinum-containing chemotherapy.

have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

—Dosage and Administration—

Administer 10 mg/kg as an intravenous infusion over 60 minutes every 2 weeks.

Premedicate with acetaminophen and an antihistamine for the first 4 infusions and subsequently as needed.

—Dosage Forms and Strengths—

Administer 10 mg/kg as an intravenous infusion over 60 minutes every 2 weeks and dilute prior to intravenous infusion.

—Contraindications—

None.

—Warnings and Precautions—

Immune-Mediated Pneumonitis: Withhold for moderate and permanently discontinue for severe or life-threatening pneumonitis.

Immune-Mediated Hepatitis: Monitor for changes in liver function.

Withhold for moderate and permanently discontinue for severe or life-threatening transaminase or total bilirubin elevation.

Immune-Mediated Colitis: Withhold for moderate and permanently discontinue for severe or life-threatening colitis.

Immune-Mediated Endocrinopathies: Adrenal Insufficiency, Hypophysitis, or Type 1 Diabetes Mellitus: Withhold for moderate, severe or life-threatening.

Immune-Mediated Nephritis: Monitor for changes in renal function. Withhold for moderate and permanently discontinue for severe or life-threatening nephritis.

Infection: Withhold for severe or life-threatening infection.

Infusion-Related Reactions: Interrupt infusion or slow the rate of infusion for mild or moderate and permanently discontinue for severe or life-threatening infusion-related reactions.

Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and use of effective contraception.

Nivolumab (OPDIVO®)

—Indications and Usage—

OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. (1, 14)

—Dosage and Administration—

Administer 3 mg/kg as an intravenous infusion over 60 minutes every 2 weeks.

—Dosage Forms and Strengths—

Injection: 40 mg/4 mL and 100 mg/10 mL solution in a single-use vial.

—Contraindications—

None.

—Warnings and Precautions—

Immune-mediated adverse reactions: Administer corticosteroids based on the severity of the reaction

Immune-mediated pneumonitis: Withhold for moderate and permanently discontinue for severe or life-threatening pneumonitis.

Immune-mediated colitis: Withhold for moderate or severe and permanently discontinue for life-threatening colitis.

Immune-mediated hepatitis: Monitor for changes in liver function. Withhold for moderate and permanently discontinue for severe or life-threatening transaminase or total bilirubin elevation.

Immune-mediated nephritis and renal dysfunction: Monitor for changes in renal function. Withhold for moderate and permanently discontinue for severe or life-threatening serum creatinine elevation.

Immune-mediated hypothyroidism and hyperthyroidism: Monitor for changes in thyroid function. Initiate thyroid hormone replacement as needed.

Embryofetal toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception.

Pembrolizumab (KEYTRUDA®)

—Indications and Usage—

KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.

This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

—Dosage and Administration—

Administer 2 mg/kg as an intravenous infusion over 30 minutes every 3 weeks.

Reconstitute and dilute prior to intravenous infusion.

—Dosage Forms and Strengths—

For injection: 50 mg, lyophilized powder in single-use vial for reconstitution.

—Contraindications—

None.

—Warnings and Precautions—

Immune-mediated adverse reactions: Administer corticosteroids based on the severity of the reaction.

Immune-mediated pneumonitis: Withhold for moderate, and permanently discontinue for severe or life-threatening pneumonitis.

Immune-mediated colitis: Withhold for moderate or severe, and permanently discontinue for life-threatening colitis.

Immune-mediated hepatitis: Monitor for changes in hepatic function. Based on severity of liver enzyme elevations, withhold or discontinue.

Immune-mediated hypophysitis: Withhold for moderate, withhold or discontinue for severe, and permanently discontinue for life-threatening hypophysitis.

Immune-mediated nephritis: Monitor for changes in renal function. Withhold for moderate, and permanently discontinue for severe or life-threatening nephritis.

Immune-mediated hyperthyroidism and hypothyroidism: Monitor for changes in thyroid function. Withhold for severe and permanently discontinue for life-threatening hyperthyroidism.

Embryofetal Toxicity: KEYTRUDA may cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus.

Example 6 Exemplary Dosing Regimens for Approved CTLA-4 Immune Checkpoint Modulators

The present Example sets forth certain dosing regimens that have been approved by the United States Food and Drug Administration for the indicated immune checkpoint modulator agents.

Ipilimumab (YERVOY™)

—Indications and Usage—

YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for:

Treatment of unresectable or metastatic melanoma.

Adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.

—Dosage and Administration—

Unresectable or metastatic melanoma: 3 mg/kg administered intravenously over 90 minutes every 3 weeks for a total of 4 doses.

Adjuvant melanoma: 10 mg/kg administered intravenously over 90 minutes every 3 weeks for 4 does, followed by 10 mg/kg every 12 weeks for up to 3 years or until documented disease recurrence or unacceptable toxicity.

Permanently discontinue for severe adverse reactions.

—Dosage Forms and Strengths—

Injection: 50 mg/10 mL (5 mg/mL)

Injection: 200 mg/40 mL (5 mg/mL)

—Contraindications—

None.

—Warnings and Precautions—

Immune-mediated adverse reactions: Permanently discontinue for severe reactions. Withhold dose for moderate immune-mediated adverse reactions until return to baseline, improvement to mild severity, or complete resolution, and patient is receiving less than 7.5 mg prednisone or equivalent per day. Administer systemic high-dose corticosteroids for severe, persistent, or recurring immune-mediated reactions.

Immune-mediated hepatitis: Evaluate liver function tests before each dose of YERVOY.

Immune-mediated endocrinopathies: Monitor clinical chemistries, ACTH level, and thyroid function tests prior to each dose. Evaluate at each visit for signs and symptoms of endocrinopathy. Institute hormone replacement therapy as needed.

Embryo-fetal toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception.

Tremelimumab

—Indications and Usage—

Tremelimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody, still in clinical trials for the following:

Treatment of Head and Neck Cancer, HR+/HER2 Breast Cancer, Malignant Mesothelioma, Melanoma, Metastatic Renal Cell Carcinoma, Unresectable Malignant Melanoma, Urothelial Cancer, NSCLC, etc.

—Dosage and Administration—

In combination with one or more other drugs, Tremelimumab is given via IV over one hour on day 29 of the dosing cycle, which repeats once a month three of the treatment regimen. Doses range from 6 mg/kg to 15 mg/kg. Alternatively, in combination with one or more other drugs or given alone, Tremelimumab is given via IV every 90 days for four cycles at a concentration of 15 mg/kg; or IV infusions every 3 weeks for 12 weeks for four cycles with an additional dose administered at week 16.

APPENDIX 1 Cohort 1 OS_ OS_ Drug Stage Cancer HLA Class Homozygous LOH (1 = Sample Months Event Class M Stage Age Gender MutCnt Type Reference HLA Class I Alleles I Supertypes (1 = Yes; 0 = No) Yes; 0 = No) CR0095 67.93688479 0 CTLA-4 M1b Stage 4 74 M 282 Melanoma Snyder et al. 2014 A0201,A3101,B3502, A02,A03,B07, 0 0 B3906,C0702,C0401 B27,UNK,UNK CR04885 25.61752464 0 CTLA-4 M0 Stage 3 49 F 2102 Melanoma Snyder et al. 2014 A0201,A3201,B0702, A02,A01,B07, 0 0 B1801,C0701,C0702 B44,UNK,UNK CR06670 44.4303943 1 CTLA-4 M0 Stage 3 79 F 590 Melanoma Snyder et al. 2014 A2402,A2601,B1801, A24,A01,B44, 0 0 B4403,C1601,C1203 B44,UNK,UNK CR1509 53.88891476 0 CTLA-4 M1c Stage 4 54 F 539 Melanoma Snyder et al. 2014 A3301,A2601,B3801, A03,A01,B27, 0 0 B3501,C1203,C0401 B07,UNK,UNK CR22640 51.23504928 0 CTLA-4 M1c Stage 4 71 M 334 Melanoma Snyder et al. 2014 A0301,A0201,B4101, A03,A02,B44, 0 0 B5001,C1701,C0602 B44,UNK,UNK CR3665 31.87933827 0 CTLA-4 M1b Stage 4 70 M 141 Melanoma Snyder et al. 2014 A0205,A6801,B1402, A02,A03,B27, 0 0 B1801,C0701,C0802 B44,UNK,UNK CR4880 64.35087166 0 CTLA-4 M1b Stage 4 63 M 2570 Melanoma Snyder et al. 2014 A0101,A0201,B4001, A01,A02,B44, 0 0 B0801,C0701,C0304 B08,UNK,UNK CR6126 22.81560788 0 CTLA-4 M1b Stage 4 66 F 562 Melanoma Snyder et al. 2014 A0301,A3201,B5101, A03,A01,B07, 0 0 B4402,C0501,C1502 B44,UNK,UNK CR6161 31.32142661 1 CTLA-4 M1b Stage 4 81 M 930 Melanoma Snyder et al. 2014 A0201,A0201,B1801, A02,A02,B44, 1 0 B5701,C0602,C1203 B58,UNK,UNK CR7623 64.84435925 0 CTLA-4 M1c Stage 4 62 M 503 Melanoma Snyder et al. 2014 A0201,A6801,B3501, A02,A03,B07, 0 0 B5101,C0602,C0401 B07,UNK,UNK CR9306 63.56129152 0 CTLA-4 M1c Stage 4 65 M 1389 Melanoma Snyder et al. 2014 A2402,A2402,B3502, A24,A24,B07, 1 0 B4402,C1604,C0401 B44,UNK,UNK CR9699 52.83614457 0 CTLA-4 M1c Stage 4 70 M 1226 Melanoma Snyder et al. 2014 A2301,A2601,B4403, A24,A01,B44, 0 1 B2705,C0102,C0401 B27,UNK,UNK CRNR0244 25.21725082 0 CTLA-4 M1c Stage 4 49 M 543 Melanoma Snyder et al. 2014 A0101,A0301,B0702, A01,A03,B07, 0 0 B4402,C0702,C0501 B44,UNK,UNK CRNR2472 20.41396495 0 CTLA-4 M1c Stage 4 71 M 627 Melanoma Snyder et al. 2014 A3002,A3201,B1801, A01,A01,B44, 0 0 B1501,C0501,C0303 B62,UNK,UNK CRNR4941 86.45914566 0 CTLA-4 M1c Stage 4 40 F 117 Melanoma Snyder et al. 2014 A6802,A0206,B4801, A02,A02,B27, 0 0 B1801,C0501,C0803 B44,UNK,UNK LSD0167 32.42217962 0 CTLA-4 M1c Stage 4 33 M 399 Melanoma Snyder et al. 2014 A0301,A0101,B0801, A03,A01,B08, 0 0 B0702,C0701,C0702 B07,UNK,UNK LSD2057 40.12745071 0 CTLA-4 M1c Stage 4 36 F 171 Melanoma Snyder et al. 2014 A1101,A2402,B3501, A03,A24,B07, 0 0 B5101,C0102,C0401 B07,UNK,UNK LSD3484 34.82382256 0 CTLA-4 M1c Stage 4 74 M 531 Melanoma Snyder et al. 2014 A0201,A1101,B4402, A02,A03,B07, 0 0 B3501,C0501,C0401 B44,UNK,UNK LSD4691 87.65996713 0 CTLA-4 M1c Stage 4 62 M 393 Melanoma Snyder et al. 2014 A0101,A2402,B3508, A01,A24,B07, 0 0 B4402,C0501,C0401 B44,UNK,UNK LSD4744 25.21725082 0 CTLA-4 M1c Stage 4 52 M 1124 Melanoma Snyder et al. 2014 A2402,A0201,B0702, A24,A02,B07, 0 0 B3901,C0702,C1203 B27,UNK,UNK LSD6819 40.8279299 0 CTLA-4 M1c Stage 4 55 M 216 Melanoma Snyder et al. 2014 A0101,A2902,B0801, A01,A01A24,B08, 0 0 B4403,C0701,C1601 B44,UNK,UNK LSDNR1120 55.23778751 0 CTLA-4 M1a Stage 4 68 M 537 Melanoma Snyder et al. 2014 A0301,A0201,B0801, A03,A02,B08, 1 0 B0801,C0702,C0701 B08,UNK,UNK LSDNR1650 32.42217962 1 CTLA-4 M1c Stage 4 71 F 25 Melanoma Snyder et al. 2014 A0301,A3201,B4101, A03,A01,B44, 0 0 B3501,C1701,C0401 B07,UNK,UNK LSDNR3086 31.22135816 1 CTLA-4 M1c Stage 4 43 M 54 Melanoma Snyder et al. 2014 A3001,A0201,B4001, A01A03,A02,B44, 0 0 B1302,C0602,C0304 UNK,UNK,UNK LSDNR9298 50.03422781 0 CTLA-4 M1c Stage 4 82 F 1277 Melanoma Snyder et al. 2014 A3201,A2902,B4501, A01,A01A24,B44, 0 0 B4402,C0602,C0501 B44,UNK,UNK NR1867 18.52226085 1 CTLA-4 M1c Stage 4 68 M 80 Melanoma Snyder et al. 2014 A6801,A3402,B1503, A03,A03,B27, 1 1 B1503,C0210,C0210 B27,UNK,UNK NR2137 9.806708651 0 CTLA-4 M1c Stage 4 18 M 635 Melanoma Snyder et al. 2014 A0101,A0201,B0702, A01,A02,B07, 0 0 B3901,C0702,C1203 B27,UNK,UNK NR3156 12.63330229 1 CTLA-4 M1b Stage 4 68 F 6 Melanoma Snyder et al. 2014 A6801,A3201,B4402, A03,A01,B44, 0 0 B1401,C0704,C0802 B27,UNK,UNK NR3549 6.18505312 1 CTLA-4 M1c Stage 4 50 M 365 Melanoma Snyder et al. 2014 A1101,A0301,B0702, A03,A03,B07, 1 0 B0702,C0702,C0702 B07,UNK,UNK NR4018 3.302258036 0 CTLA-4 M1c Stage 4 55 M 146 Melanoma Snyder et al. 2014 A0201,A2601,B3501, A02,A01,B07, 0 0 B1801,C1203,C0401 B44,UNK,UNK NR4045 20.41396495 1 CTLA-4 M1c Stage 4 42 M 451 Melanoma Snyder et al. 2014 A0201,A2601,B0702, A02,A01,B07, 0 0 B1801,C0702,C1203 B44,UNK,UNK NR4083 2.701848302 1 CTLA-4 M1c Stage 4 54 M 444 Melanoma Snyder et al. 2014 A0101,A3101,B2705, A01,A03,B27, 0 0 B3701,C0602,C0202 B44,UNK,UNK NR4631 6.004107338 1 CTLA-4 M1c Stage 4 59 M 1165 Melanoma Snyder et al. 2014 A0101,A0301,B4201, A01,A03,B07, 0 0 B0702,C0702,C0701 B07,UNK,UNK NR4810 4.80328587 1 CTLA-4 M1c Stage 4 48 F 358 Melanoma Snyder et al. 2014 A0201,A3301,B1402, A02,A03,B27, 0 0 B1501,C0202,C0802 B62,UNK,UNK NR4949 8.356401514 1 CTLA-4 M1c Stage 4 79 F 513 Melanoma Snyder et al. 2014 A0301,A0201,B4402, A03,A02,B44, 0 1 B2705,C0501,C0102 B27,UNK,UNK NR5784 5.494169495 1 CTLA-4 M1c Stage 4 58 F 39 Melanoma Snyder et al. 2014 A2403,A0201,B0702, A24,A02,B07, 0 NA B5107,C0702,C1402 UNK,UNK,UNK NR6689 15.01026834 1 CTLA-4 M1c Stage 4 46 F 6 Melanoma Snyder et al. 2014 A0301,A1101,B0801, A03,A03,B08, 0 0 B3501,C0701,C0401 B07,UNK,UNK NR6721 9.60657174 1 CTLA-4 M1a Stage 4 64 M 128 Melanoma Snyder et al. 2014 A0301,A1101,B5501, A03,A03,B07, 0 0 B5101,C0102,C0303 B07,UNK,UNK NR6842 9.806708651 1 CTLA-4 M1c Stage 4 64 M 3 Melanoma Snyder et al. 2014 A2402,A0201,B1502, A24,A02,B62, 0 0 B3503,C0303,C0401 B07,UNK,UNK NR8727 5.198076941 1 CTLA-4 M1c Stage 4 69 M 2 Melanoma Snyder et al. 2014 A6802,A2901,B3502, A02,A01A24,B07, 0 0 B1402,C0401,C0802 B27,UNK,UNK NR8815 14.91019989 1 CTLA-4 M1b Stage 4 67 F 1699 Melanoma Snyder et al. 2014 A0301,A0201,B2702, A03,A02,B27, 0 0 B5101,C0102,C0202 B07,UNK,UNK NR9341 12.1398147 1 CTLA-4 M1a Stage 4 77 M 323 Melanoma Snyder et al. 2014 A0301,A0301,B1402, A03,A03,B27, 1 0 B0702,C0702,C0802 B07,UNK,UNK NR9445 2.501711391 1 CTLA-4 M1c Stage 4 50 M 267 Melanoma Snyder et al. 2014 A0201,A2601,B5701, A02,A01,B58, 0 0 B2705,C0102,C0602 B27,UNK,UNK NR9449 7.204928805 1 CTLA-4 M1c Stage 4 64 F 295 Melanoma Snyder et al. 2014 A0301,A0201,B4402, A03,A02,B44, 0 0 B5701,C0602,C0501 B58,UNK,UNK NR9521 32.42217962 1 CTLA-4 M1b Stage 4 74 M 1061 Melanoma Snyder et al. 2014 A2402,A0201,B5101, A24,A02,B07, 0 0 B4402,C0102,C0501 B44,UNK,UNK NR9705 14.40985761 1 CTLA-4 M1c Stage 4 63 F 37 Melanoma Snyder et al. 2014 A0101,A2402,B0801, A01,A24,B08, 0 0 B1501,C0701,C0303 B62,UNK,UNK NR9765 25.01711391 1 CTLA-4 M1b Stage 4 38 F 1148 Melanoma Snyder et al. 2014 A0101,A0301,B0702, A01,A03,B07, 0 0 B1517,C0702,C0701 B58,UNK,UNK PR03803 94.66475902 1 CTLA-4 M0 Stage 3 90 M 269 Melanoma Snyder et al. 2014 A2301,A0201,B5001, A24,A02,B44, 0 0 B4002,C0701,C0202 B44,UNK,UNK PR12117 18.7128012 1 CTLA-4 M1c Stage 4 66 M 1081 Melanoma Snyder et al. 2014 A0301,A0201,B4001, A03,A02,B44, 0 0 B3501,C0304,C0401 B07,UNK,UNK PR4035 50.23436472 0 CTLA-4 M1c Stage 4 78 M 525 Melanoma Snyder et al. 2014 A0101,A0201,B3901, A01,A02,B27, 0 0 B3906,C1203,C0602 B27,UNK,UNK PR4046 25.31731927 0 CTLA-4 M1a Stage 4 44 M 139 Melanoma Snyder et al. 2014 A0201,A0205,B1501, A02,A02,B62, 0 0 B4901,C0701,C0303 UNK,UNK,UNK PR4077 72.74976724 0 CTLA-4 M1c Stage 4 75 M 1741 Melanoma Snyder et al. 2014 A0101,A0101,B0801, A01,A01,B08, 1 0 B5701,C0701,C0602 B58,UNK,UNK PR4081 72.44956187 0 CTLA-4 M1a Stage 4 65 F 277 Melanoma Snyder et al. 2014 A0101,A0201,B3701, A01,A02,B44, 0 0 B4402,C0602,C0501 B44,UNK,UNK PR4092 72.8498357 0 CTLA-4 M1a Stage 4 57 F 3267 Melanoma Snyder et al. 2014 A0402,A2601,B3801, A24,A01,B27, 0 0 B4901,C0701,C1203 UNK,UNK,UNK SD0346 34.77446881 1 CTLA-4 M1b Stage 4 43 F 537 Melanoma Snyder et al. 2014 A0301,A201,B0702, A03,A02,B07, 0 0 B1402,C0702,C0802 B27,UNK,UNK SD1494 23.7203368 0 CTLA-4 M1c Stage 4 70 M 915 Melanoma Snyder et al. 2014 A0101,A2902,B4403, A01,A01A24,B44, 0 0 B0801,C0701,C1601 B08,UNK,UNK SD2051 10.16585434 1 CTLA-4 M1c Stage 4 61 F 38 Melanoma Snyder et al. 2014 A3601,A2301,B5301, A01,A24,B07, 1 0 B5301,C0401,C0401 B07,UNK,UNK SD2056 47.27618107 0 CTLA-4 M1b Stage 4 39 F 136 Melanoma Snyder et al. 2014 A0301,A2402,B2705, A03,A24,B27, 0 0 B3906,C0702,C0401 B27,UNK,UNK SD5038 13.98216503 1 CTLA-4 M1c Stage 4 55 M 256 Melanoma Snyder et al. 2014 A0201,A3301,B1402, A02,A03,B27, 0 0 B3901,C0802,C1203 B27,UNK,UNK SD5118 32.86632346 1 CTLA-4 M1c Stage 4 55 F 74 Melanoma Snyder et al. 2014 A0101,A0101,B0702, A01,A01,B07, 1 0 B0702,C0702,C0702 B07,UNK,UNK SD5934 19.80532859 1 CTLA-4 M1c Stage 4 52 M 156 Melanoma Snyder et al. 2014 A2402,A2402,B3502, A24,A24,B07, 1 0 B3502,C0401,C0401 B07,UNK,UNK SD6336 83.4324151 0 CTLA-4 M1c Stage 4 53 M 338 Melanoma Snyder et al. 2014 A3001,A3301,B1302, A01,A03,A03,UNK 0 0 B1402,C0602,C0802 B27,UNK,UNK SD6494 8.718293078 1 CTLA-4 M1c Stage 4 63 F 594 Melanoma Snyder et al. 2014 A6802,A2402,B3501, A02,A24,B07, 0 0 B1402,C0802,C0401 B27,UNK,UNK SD7357 24.50991694 1 CTLA-4 M1c Stage 4 50 F 1148 Melanoma Snyder et al. 2014 A2402,A0201,B5501, A24,A02,B07, 0 0 B1801,C1203,C0303 B44,UNK,UNK Pat02 53.6547744 0 CTLA-4 M1c Stage 4 42 F 233 Melanoma Van Allen et al. 2015 A0201,A2601,B0702, A02,A01,B08, 0 0 B0801,C0702,C0701 B07,UNK,UNK Pat03 3.28767 1 CTLA-4 M1c Stage 4 61 F 372 Melanoma Van Allen et al. 2015 A0301,A2901,B0705, A03,A01A24,B07, 0 1 B3501,C1505,C0401 B07,UNK,UNK Pat04 32.4493029 0 CTLA-4 M1b Stage 4 71 M 336 Melanoma Van Allen et al. 2015 A0101,A0201,B1501, A01,A02,B62, 0 0 B4405,C0202,C0303 B44,UNK,UNK Pat06 5.2931487 1 CTLA-4 M1c Stage 4 33 M 174 Melanoma Van Allen et al. 2015 A1101,A0201,B2702, A03,A02,B27, 0 0 B5501,C0303,C0202 B07,UNK,UNK Pat07 34.520535 0 CTLA-4 M0 Stage 3 36 M 148 Melanoma Van Allen et al. 2015 A0101,A0101,B0702, A01,A01,B07, 1 0 B0801,C0702,C0701 B08,UNK,UNK Pat08 4.602738 1 CTLA-4 M1c Stage 4 73 M 265 Melanoma Van Allen et al. 2015 A8801,A2601,B3501, A03,A01,B07, 0 0 B3801,C1203,C0401 B27,UNK,UNK Pat100 11.835612 1 CTLA-4 M1c Stage 4 70 M 519 Melanoma Van Allen et al. 2015 A0301,A0201,B4001, A03,A02,B44, 0 0 B4403,C1601,C0304 B44,UNK,UNK Pat101 9.4684896 1 CTLA-4 M1c Stage 4 75 M 50 Melanoma Van Allen et al. 2015 A0301,A2902,B0702, A03,A01A24,B07, 0 1 B4403,C0702,C1601 B44,UNK,UNK Pat103 34.4547816 1 CTLA-4 M1c Stage 4 70 M 630 Melanoma Van Allen et al. 2015 A0101,A2301,B0801, A01,A24,B08, 0 0 B5001,C0701,C0602 B44,UNK,UNK Pat104 7.7917779 1 CTLA-4 M1c Stage 4 45 F 35 Melanoma Van Allen et al. 2015 A0301,A0201,B0702, A03,A02,B07, 0 1 B1501,C0702,C0304 B62,UNK,UNK Pat105 34.4219049 0 CTLA-4 M0 Stage 3 41 M 125 Melanoma Van Allen et al. 2015 A0101,A201,B0801, A01,A02,B08, 0 0 B4402,C0701,C0501 B44,UNK,UNK Pat106 8.239175 1 CTLA-4 M1b Stage 4 43 F 30 Melanoma Van Allen et al. 2015 A1101,A0201,B1501, A03,A02,B62, 0 0 B1302,C0602,C0304 UNK,UNK,UNK Pat109 2.7287661 1 CTLA-4 M1b Stage 4 69 M 286 Melanoma Van Allen et al. 2015 A0301,A0201,B4001, A03,A02,B44, 0 0 B1501,C0102,C0304 B62,UNK,UNK Pat110 10.520544 1 CTLA-4 M1b Stage 4 76 M 6301 Melanoma Van Allen et al. 2015 A0201,A3201,B4002, A02,A01,B44, 1 0 B4405,C0202,C0202 B44,UNK,UNK Pat113 9.8958667 1 CTLA-4 M1c Stage 4 68 M 317 Melanoma Van Allen et al. 2015 A0101,A2301,B0801, A01,A24,B08, 0 0 B1402,C0701,C0802 B27,UNK,UNK Pat115 4.7671215 1 CTLA-4 M1c Stage 4 45 M 76 Melanoma Van Allen et al. 2015 A0201,A0201,B0702, A02,A02,B07, 1 0 B1501,C0702,C0303 B62,UNK,UNK Pat117 30.0493038 0 CTLA-4 M1c Stage 4 73 M 689 Melanoma Van Allen et al. 2015 A1101,A0201,B0801, A03,A02,B08, 0 0 B2702,C0701,C0202 B27,UNK,UNK Pat118 10.2904071 1 CTLA-4 M1c Stage 4 43 F 113 Melanoma Van Allen et al. 2015 A0301,A0201,B3501, A03,A02,B07, 0 0 B5101,C0102,C0401 B07,UNK,UNK Pat121 4.0109574 1 CTLA-4 M1c Stage 4 46 M 63 Melanoma Van Allen et al. 2015 A0201,A2601,B1509, A02,A01,B27, 0 0 B4402,C0704,C0501 B44,UNK,UNK Pat123 28.0438251 1 CTLA-4 M1c Stage 4 50 F 482 Melanoma Van Allen et al. 2015 A0101,A3101,B5101, A01,A03,B07, 0 0 B3501,C0202,C0401 B07,UNK,UNK Pat124 4.7999982 1 CTLA-4 M1b Stage 4 78 M 441 Melanoma Van Allen et al. 2015 A3201,A0201,B1302, A01,A02,UNK, 0 0 B5101,C1502,C0602 B07,UNK,UNK Pat126 21.0739647 0 CTLA-4 M1b Stage 4 77 M 397 Melanoma Van Allen et al. 2015 A0101,A0201,B4001, A01,A02,B44, 0 0 B0801,C0701,C0304 B08,UNK,UNK Pat127 10.9150644 1 CTLA-4 M1c Stage 4 25 F 109 Melanoma Van Allen et al. 2015 A2402,A3101,B0702, A24,A03,B07, 0 0 B0702,C0702,C0202 B27,UNK,UNK Pat128 3.7150671 1 CTLA-4 M1c Stage 4 29 M 76 Melanoma Van Allen et al. 2015 A2601,A2601,B5501, A01,A01,B07, 1 0 B5501,C0303,C0303 B07,UNK,UNK Pat129 17.7205413 0 CTLA-4 M1b Stage 4 18 M 107 Melanoma Van Allen et al. 2015 A1101,A2902,B5101, A03,A01A24,B07, 0 0 B4403,C1502,C1602 B44,UNK,UNK Pat130 1.4794515 1 CTLA-4 M1c Stage 4 76 M 197 Melanoma Van Allen et al. 2015 A0201,A0201,B4002, A02,A02,B44, 1 0 B1501,C0202,C0304 B62,UNK,UNK Pat131 8.4493119 1 CTLA-4 M1c Stage 4 32 M 102 Melanoma Van Allen et al. 2015 A0101,A6601,B0801, A01,A03,B08, 1 0 B1801,C0701,C0701 B44,UNK,UNK Pat132 22.2246492 0 CTLA-4 M1c Stage 4 81 M 1862 Melanoma Van Allen et al. 2015 A0101,A2301,B4403, A01,A24,B44, 0 1 B0801,C0701,C0401 B08,UNK,UNK Pat133 17.8191714 1 CTLA-4 M1b Stage 4 76 M 228 Melanoma Van Allen et al. 2015 A1101,A2402,B0702, A03,A24,B07, 0 1 B4402,C0702,C0202 B44,UNK,UNK Pat135 2.6630127 1 CTLA-4 M1c Stage 4 29 F 238 Melanoma Van Allen et al. 2015 A0301,A0201,B0801, A03,A02,B08, 0 0 B0702,C0702,C0701 B07,UNK,UNK Pat138 48.5917626 1 CTLA-4 M1c Stage 4 39 F 5120 Melanoma Van Allen et al. 2015 A6801,A3201,B1402, A03,A01,B27, 0 0 B4402,C0501,C0802 B44,UNK,UNK Pat139 3.2547933 1 CTLA-4 M1c Stage 4 58 M 1429 Melanoma Van Allen et al. 2015 A0201,A3201,B3901, A02,A01,B27, 0 1 B1501,C0304,C1203 B62,UNK,UNK Pat14 5.3589021 1 CTLA-4 M1c Stage 4 48 F 46 Melanoma Van Allen et al. 2015 A3001,A6602,B5701, A01A03,A02,B58, 0 0 B5301,C0602,C0401 B07,UNK,UNK Pat140 16.1753364 1 CTLA-4 M1c Stage 4 62 M 326 Melanoma Van Allen et al. 2015 A0301,A0201,B1302, A03,A02,UNK, 0 0 B4002,C0202,C0602 B44,UNK,UNK Pat143 5.0301351 1 CTLA-4 M1c Stage 4 71 M 878 Melanoma Van Allen et al. 2015 A6801,A0201,B1501, A03,A02,B62, 1 0 B1501,C0304,C0303 B62,UNK,UNK Pat147 7.3643808 1 CTLA-4 M1a Stage 4 63 M 542 Melanoma Van Allen et al. 2015 A0101,A2402,B0801, A01,A24,B08, 0 1 B5502,C0701,C0102 B07,UNK,UNK Pat148 2.7616428 1 CTLA-4 M1c Stage 4 35 F 227 Melanoma Van Allen et al. 2015 A0101,A0101,B0801, A01,A01,B08, 1 1 B1501,C0701,C0304 B62,UNK,UNK Pat15 1.643835 1 CTLA-4 M1c Stage 4 32 M 242 Melanoma Van Allen et al. 2015 A2902,A3201,B1501, A01A24,A01,B62, 0 0 B4001,C0303,C0304 B44,UNK,UNK Pat151 6.7068468 1 CTLA-4 M1c Stage 4 68 M 1754 Melanoma Van Allen et al. 2015 A6801,A0201,B5101, A03,A02,B07, 0 0 B4403,C1601,C1502 B44,UNK,UNK Pat157 2.8273962 1 CTLA-4 M1c Stage 4 69 F 132 Melanoma Van Allen et al. 2015 A0101,A0201,B0704, A01,A02,B07, 1 0 B0702,C0702,C0702 B07,UNK,UNK Pat160 4.9972584 1 CTLA-4 M1c Stage 4 79 M 54 Melanoma Van Allen et al. 2015 A0201,A0201,B5101, A02,A02,B07, 1 0 B1501,C0401,C0303 B62,UNK,UNK Pat162 6.9369837 1 CTLA-4 M1c Stage 4 55 F 54 Melanoma Van Allen et al. 2015 A0101,A0101,B0801, A01,A01,B08, 1 0 B0702,C0701,C0702 B07,UNK,UNK Pat165 3.7808205 1 CTLA-4 M1c Stage 4 50 F 69 Melanoma Van Allen et al. 2015 A6801,A0201,B1501, A03,A02,B62, 0 0 B4402,C0303,C0501 B44,UNK,UNK Pat166 2.5315059 1 CTLA-4 M1c Stage 4 31 M 57 Melanoma Van Allen et al. 2015 A0301,A0201,B0702, A03,A02,B07, 0 0 B4001,C0702,C0304 B44,UNK,UNK Pat167 13.4136936 1 CTLA-4 M1c Stage 4 50 M 33 Melanoma Van Allen et al. 2015 A3001,A0201,B5801, A01A03,A02,B58, 0 1 B1302,C0302,C0602 UNK,UNK,UNK Pat168 2.02027389 1 CTLA-4 M1c Stage 4 68 M 245 Melanoma Van Allen et al. 2015 A0101,A0201,B0801, A01,A02,B08, 0 1 B1501,C0701,C0303 B62,UNK,UNK Pat117 6.7397235 1 CTLA-4 M1c Stage 4 44 M 219 Melanoma Van Allen et al. 2015 A3303,A2601,B5801, A03,A01,B56, 0 0 B4402,C0704,C0302 B44,UNK,UNK Pat170 3.5506836 1 CTLA-4 M1c Stage 4 48 M 234 Melanoma Van Allen et al. 2015 A1101,A0201,B5301, A03,A02,B07, 0 0 B4402,C0501,C0401 B44,UNK,UNK Pat171 15.3205422 1 CTLA-4 M1a Stage 4 66 M 99 Melanoma Van Allen et al. 2015 A0301,A0101,B3501, A03,A01,B07, 1 0 B3508,C0401,C0401 B07,UNK,UNK Pat174 22.6191696 0 CTLA-4 M1a Stage 4 57 F 668 Melanoma Van Allen et al. 2015 A0201,A2902,B5101, A02,A01A24,B07, 0 0 B4402,C0704,C0202 B44,UNK,UNK Pat175 2.958903 1 CTLA-4 M1a Stage 4 67 F 89 Melanoma Van Allen et al. 2015 A0101,A0201,B0801, A01,A02,B08, 0 1 B4002,C0701,C0202 B44,UNK,UNK Pat19 5.7534225 1 CTLA-4 M1c Stage 4 59 M 470 Melanoma Van Allen et al. 2015 A0101,A2402,B5701, A01,A24,B58, 0 0 B1501,C0602,C0303 B62,UNK,UNK Pat21 22.2246492 1 CTLA-4 M1c Stage 4 81 M 1375 Melanoma Van Allen et al. 2015 A0301,A0101,B0801, A03,A01,B08, 1 0 B0801,C0701,C0701 B08,UNK,UNK Pat24 31.9232757 0 CTLA-4 M1b Stage 4 74 F 33 Melanoma Van Allen et al. 2015 A0101,A0201,B4201, A01,A02,B07, 0 0 B0702,C0702,C0701 B07,UNK,UNK Pat25 10.6849275 1 CTLA-4 M1c Stage 4 69 M 51 Melanoma Van Allen et al. 2015 A2902,A6601,B4002, A01A24,A03,B44, 0 0 B4403,C1601,C0202 B44,UNK,UNK Pat29 43.5945042 0 CTLA-4 M1c Stage 4 82 M 37 Melanoma Van Allen et al. 2015 A0301,A0201,B0702, A03,A02,B07, 0 0 B1801,C0702,C1203 B44,UNK,UNK Pat32 4.8328749 1 CTLA-4 M1c Stage 4 72 M 714 Melanoma Van Allen et al. 2015 A0301,A0301,B3801, A03,A03,B27, 1 0 B3501,C1203,C0401 B07,UNK,UNK Pat33 6.9369837 1 CTLA-4 M1c Stage 4 65 M 15 Melanoma Van Allen et al. 2015 A1101,A3004,B0702, A03,A01,B07, 1 0 B4201,C0702,C0702 B07,UNK,UNK Pat36 1.7753418 1 CTLA-4 M1c Stage 4 52 F 12 Melanoma Van Allen et al. 2015 A0101,A0101,B2705, A01,A01,B27, 1 0 B4402,C0501,C0303 B44,UNK,UNK Pat37 2.301369 1 CTLA-4 M1c Stage 4 47 F 108 Melanoma Van Allen et al. 2015 A0101,A6601,B0801, A01,A03,B08, 0 0 B1402,C0701,C0802 B27,UNK,UNK Pat38 50.5972413 0 CTLA-4 M1c Stage 4 45 M 2398 Melanoma Van Allen et al. 2015 A0301,A0201,B4002, A03,A02,B44, 0 1 B1517,C0701,C0202 B58,UNK,UNK Pat39 48.8876529 0 CTLA-4 M1b Stage 4 67 M 75 Melanoma Van Allen et al. 2015 A0101,A0201,B0801, A01,A02,B08, 0 0 B5101,C0701,C1502 B07,UNK,UNK Pat40 1.1178078 1 CTLA-4 M1c Stage 4 74 M 108 Melanoma Van Allen et al. 2015 A0101,A0201,B0801, A01,A02,B08, 0 0 B4402,C0701,C0501 B44,UNK,UNK Pat41 4.2082176 1 CTLA-4 M1c Stage 4 64 M 345 Melanoma Van Allen et al. 2015 A2301,A0201,B2705, A24,A02,B27, 0 0 B4901,C0701,C0102 UNK,UNK,UNK Pat43 1.2164379 1 CTLA-4 M1b Stage 4 75 F 168 Melanoma Van Allen et al. 2015 A0101,A2902,B2705, A01,A01A24,B27, 0 0 B4403,C0220,C1601 B44,UNK,UNK Pat44 8.9095857 1 CTLA-4 M1c Stage 4 57 F 32 Melanoma Van Allen et al. 2015 A1101,A2601,B3501, A03,A01,B07, 0 0 B5201,C1202,C0401 B62,UNK,UNK Pat45 2.9260263 1 CTLA-4 M1c Stage 4 68 M 937 Melanoma Van Allen et al. 2015 A2402,A0201,B5101, A24,A02,B07, 0 0 B4402,C0501,C1502 B44,UNK,UNK Pat46 5.260272 1 CTLA-4 M1b Stage 4 36 F 244 Melanoma Van Allen et al. 2015 A0101,A2601,B3701, A01,A01,B44, 0 0 B2705,C0202,C0602 B27,UNK,UNK Pat47 36.3616302 0 CTLA-4 M1c Stage 4 78 M 137 Melanoma Van Allen et al. 2015 A2301,A3201,B1501, A24,A01,B62, 0 0 B4403,C0401,C0303 B44,UNK,UNK Pat49 33.9945078 0 CTLA-4 M1c Stage 4 36 M 669 Melanoma Van Allen et al. 2015 A0101,A1101,B3701, A01,A03,B44, 1 0 B5701,C0602,C0602 B58,UNK,UNK Pat50 2.1369855 1 CTLA-4 M1c Stage 4 77 M 444 Melanoma Van Allen et al. 2015 A1101,A0201,B1801, A03,A02,B44, 0 0 B2703,C0704,C1203 B27,UNK,UNK Pat54 6.8383536 1 CTLA-4 M1c Stage 4 73 M 866 Melanoma Van Allen et al. 2015 A0301,A0201,B4001, A03,A02,B44, 0 0 B3501,C0304,C0401 B07,UNK,UNK Pat55 6.3452031 1 CTLA-4 M1c Stage 4 71 F 484 Melanoma Van Allen et al. 2015 A0301,A0201,B0702, A03,A02,B07, 0 0 B1501,C0702,C0401 B62,UNK,UNK Pat56 7.7260245 1 CTLA-4 M1c Stage 4 68 M 44 Melanoma Van Allen et al. 2015 A2402,A0201,B0702, A24,A02,B07, 0 0 B5501,C0702,C0303 B07,UNK,UNK Pat57 8.219175 1 CTLA-4 M0 Stage 3 69 M 56 Melanoma Van Allen et al. 2015 A0301,A0101,B0702, A03,A01,B07, 0 0 B5701,C0702,C0701 B58,UNK,UNK Pat58 21.4356084 1 CTLA-4 M0 Stage 3 59 F 1921 Melanoma Van Allen et al. 2015 A0201,A2902,B3901, A02,A01A24,B27, 0 0 B4403,C1601,C1203 B44,UNK,UNK Pat59 7.3643808 1 CTLA-4 M1b Stage 4 36 M 273 Melanoma Van Allen et al. 2015 A0201,A0201,B5101, A02,A02,B07, 1 0 B1501,C1502,C0303 B62,UNK,UNK Pat60 8.9424624 1 CTLA-4 M1c Stage 4 86 M 738 Melanoma Van Allen et al. 2015 A0101,A1101,B0801, A01,A03,B08, 0 0 B5502,C0701,C0102 B07,UNK,UNK Pat62 19.7917734 1 CTLA-4 M1c Stage 4 76 M 1379 Melanoma Van Allen et al. 2015 A2402,A0201,B5101, A24,A02,B07, 0 1 B2705,C0102,C1402 B27,UNK,UNK Pat63 34.1588913 0 CTLA-4 M0 Stage 3 65 M 209 Melanoma Van Allen et al. 2015 A0301,A0301,B4402, A03,A03,B44, 1 0 B4405,C0704,C0202 B44,UNK,UNK Pat64 3.4849302 1 CTLA-4 M1c Stage 4 83 M 659 Melanoma Van Allen et al. 2015 A0101,A1101,B0801, A01,A03,B08, 0 0 B5101,C0701,C1502 B07,UNK,UNK Pat66 21.4684851 0 CTLA-4 M0 Stage 3 44 F 327 Melanoma Van Allen et al. 2015 A0101,A2402,B5501, A01,A24,B07, 1 1 B5801,C0303,C0303 B58,UNK,UNK Pat67 2.5972593 1 CTLA-4 M1c Stage 4 39 M 27 Melanoma Van Allen et al. 2015 A1101,A2601,B0702, A03,A01,B07, 0 0 B3503,C1602,C0401 B07,UNK,UNK Pat70 17.4904044 1 CTLA-4 M1c Stage 4 38 M 77 Melanoma Van Allen et al. 2015 A0301,A2402,B0702, A03,A24,B07, 0 0 B2702,C0702,C0202 B27,UNK,UNK Pat71 4.5041079 1 CTLA-4 M1c Stage 4 63 M 722 Melanoma Van Allen et al. 2015 A2601,A0201,B0702, A01,A02,B07, 0 0 B3801,C0702,C1203 B27,UNK,UNK Pat73 14.5315014 1 CTLA-4 M1c Stage 4 71 M 243 Melanoma Van Allen et al. 2015 A2601,A3101,B3801, A01,A03,B27, 0 0 B5101,C1203,C1502 B07,UNK,UNK Pat74 6.3452031 1 CTLA-4 M1c Stage 4 73 M 509 Melanoma Van Allen et al. 2015 A3001,A1101,B5201, A01A03,A03,B62, 0 0 B1302,C1203,C0602 UNK,UNK,UNK Pat76 4.5698613 1 CTLA-4 M1c Stage 4 74 M 188 Melanoma Van Allen et al. 2015 A0101,A0101,B0801, A01,A01,B08, 1 0 B3501,C0701,C0404 B07,UNK,UNK Pat77 33.8301243 0 CTLA-4 M0 Stage 3 21 M 375 Melanoma Van Allen et al. 2015 A2402,A2601,B5502, A24,A01,B07, 0 1 B3801,C0102,C1203 B27,UNK,UNK Pat78 1.2493146 1 CTLA-4 M1c Stage 4 71 F 154 Melanoma Van Allen et al. 2015 A0301,A0101,B1402, A03,A01,B27, 0 1 B0801,C0701,C0802 B08,UNK,UNK Pat79 26.3342367 1 CTLA-4 M1b Stage 4 69 M 321 Melanoma Van Allen et al. 2015 A2301,A0201,B1402, A24,A02,B27, 0 1 B2705,C0202,C0802 B27,UNK,UNK Pat80 23.8027308 1 CTLA-4 M1c Stage 4 48 M 193 Melanoma Van Allen et al. 2015 A0301,A0201,B0702, A03,A02,B07, 0 0 B4001,C0702,C0304 B44,UNK,UNK Pat81 20.6465676 1 CTLA-4 M1a Stage 4 54 F 111 Melanoma Van Allen et al. 2015 A0201,A2601,B5101, A02,A01,B07, 0 0 B5801,C0706,C1402 B58,UNK,UNK Pat82 3.4191768 1 CTLA-4 M1c Stage 4 54 F 408 Melanoma Van Allen et al. 2015 A2602,A2902,B0702, A01,A01A24,B07, 0 0 B4403,C0702,C1601 B44,UNK,UNK Pat85 15.0575286 1 CTLA-4 M1c Stage 4 83 M 408 Melanoma Van Allen et al. 2015 A1101,A0201,B2705, A03,A02,B27, 1 1 B2702,C0202,C0202 B27,UNK,UNK Pat86 9.6328731 1 CTLA-4 M1a Stage 4 55 M 82 Melanoma Van Allen et al. 2015 A3001,A6801,B1302, A01A03,A03,UNK, 0 1 B3503,C0602,C0401 B07,UNK,UNK Pat88 32.5150563 0 CTLA-4 M1c Stage 4 60 F 1597 Melanoma Van Allen et al. 2015 A0301,A2902,B1402, A03,A01A24,B27, 0 0 B4403,C1601,C0802 B44,UNK,UNK Pat90 33.0410835 0 CTLA-4 M1c Stage 4 59 M 207 Melanoma Van Allen et al. 2015 A2402,A2601,B4002, A24,A01,B44, 0 0 B1801,C0701,C0202 B44,UNK,UNK Pat92 4.0438341 1 CTLA-4 M1c Stage 4 49 M 39 Melanoma Van Allen et al. 2015 A0301,A0101,B3701, A03,A01,B44, 0 0 B3501,C0602,C0401 B07,UNK,UNK Pat98 4.602738 1 CTLA-4 M1c Stage 4 57 F 33 Melanoma Van Allen et al. 2015 A0301,A0101,B0801, A03,A01,B08, 0 0 B3503,C0701,C0401 B07,UNK,UNK Pt10 8.4164362 1 PD-1 M1a Stage 4 81 F 75 Melanoma Riaz et al. 2017 A3002,A0201,B4402, A01,A02,B44, 1 0 B1801,C0501,C0501 B44,UNK,UNK Pt100 27.616428 1 PD-1 M1c Stage 4 64 M 6 Melanoma Riaz et al. 2017 A2601,A6802,B1402, A01,A02,B27, 0 0 B2705,C0202,C0802 B27,UNK,UNK Pt101 27.4191678 0 PD-1 M1a Stage 4 47 F 10 Melanoma Riaz et al. 2017 A0301,A0301,B0702, A03,A03,B07, 1 0 B0702,C0702,C0702 B07,UNK,UNK Pt102 20.9095812 0 PD-1 NA NA 62 F 393 Melanoma Riaz et al. 2017 A3001,A0201,B1302, A01A03,A02,UNK, 0 0 B1801,C0701,C0602 B44,UNK,UNK Pt103 15.9123228 0 PD-1 M1b Stage 4 52 F 21 Melanoma Riaz et al. 2017 A1101,A1101,B4001, A03,A03,B44, 1 0 B1301,C0304,C0304 UNK,UNK,UNK Pt104 26.8931406 0 PD-1 NA NA 64 M 5 Melanoma Riaz et al. 2017 A1101,A3101,B4001, A03,A03,B44, 0 0 B4901,C0304,C1701 UNK,UNK,UNK Pt106 2.9917797 1 PD-1 M1c Stage 4 53 M 700 Melanoma Riaz et al. 2017 A6801,A6801,B4402, A03,A03,B44 1 0 B4402,C0704,C0704 B44,UNK,UNK Pt108 30.0164271 0 PD-1 M1b Stage 4 37 F 19 Melanoma Riaz et al. 2017 A2601,A2902,B0801, A01,A01A24,B08, 0 0 B1302,C0701,C0602 UNK,UNK,UNK Pt11 27.5177979 1 PD-1 NA NA 61 F 106 Melanoma Riaz et al. 2017 A0301,A0101,B0801, A03,A01,B08, 0 0 B0702,C0702,C0701 B07,UNK,UNK Pt13 9.205476 1 PD-1 NA NA 67 M 171 Melanoma Riaz et al. 2017 A0301,A0201,B5501, A03,A02,B07, 0 1 B3701,C0602,C0303 B44,UNK,UNK Pt17 1.8739719 1 PD-1 M1c Stage 4 48 F 20 Melanoma Riaz et al. 2017 A0301,A2902,B0702, A03,A01A24,B07, 0 0 B4403,C0702,C1601 B44,UNK,UNK Pt18 35.2766991 0 PD-1 M1a Stage 4 53 M 217 Melanoma Riaz et al. 2017 A0101,A3101,B0801, A01,A03,B08, 0 0 B4001,C0701,C0304 B44,UNK,UNK Pt23 1.7095884 1 PD-1 M1c Stage 4 53 F 646 Melanoma Riaz et al. 2017 A0301,A0201,B1501, A03,A02,B62, 0 1 B1801,C0701,C0304 B44,UNK,UNK Pt24 4.8986283 0 PD-1 M1c Stage 4 63 M 1 Melanoma Riaz et al. 2017 A3001,A1101,B3501, A01A03,A03,B07, 1 0 B5101,C0401,C0401 B07,UNK,UNK Pt25 3.3205467 1 PD-1 M1c Stage 4 52 M 96 Melanoma Riaz et al. 2017 A3002,A0201,B0702, A01,A02,B07, 0 0 B4001,C0702,C0501 B44,UNK,UNK Pt26 31.2986184 0 PD-1 M1b Stage 4 22 F 125 Melanoma Riaz et al. 2017 A0101,A6802,B0801, A01,A02,B08, 0 0 B1402,C0701,C0802 B27,UNK,UNK Pt27 15.6164325 1 PD-1 M1c Stage 4 65 M 183 Melanoma Riaz et al. 2017 A2402,A6801,B4001, A24,A03,B44, 0 1 B3501,C0401,C0304 B07,UNK,UNK Pt28 24.328758 1 PD-1 NA NA 79 F 42 Melanoma Riaz et al. 2017 A2301,A6801,B4001, A24,A03,B44, 0 0 B4102,C1701,C0304 B44,UNK,UNK Pt29 8.9753391 1 PD-1 M1c Stage 4 57 F 412 Melanoma Riaz et al. 2017 A0201,A2902,B0702, A02,A01A24,B07, 0 0 B4403,C0702,C1601 B44,UNK,UNK Pt3 37.6109448 0 PD-1 NA NA 52 M 182 Melanoma Riaz et al. 2017 A0101,A2301,B3901, A01,A24,B27, 0 0 B4403,C1203,C0401 B44,UNK,UNK Pt30 34.6191651 0 PD-1 M1a Stage 4 89 F 66 Melanoma Riaz et al. 2017 A0101,A2402,B0801, A01,A24,B08, 1 1 B0801,C0701,C0702 B08,UNK,UNK Pt31 31.5945087 0 PD-1 M1a Stage 4 56 F 450 Melanoma Riaz et al. 2017 A0201,A0201,B0702, A02,A02,B07, 1 0 B1402,C0702,C0802 B27,UNK,UNK Pt32 3.7479438 0 PD-1 M1c Stage 4 34 M 112 Melanoma Riaz et al. 2017 A1101,A2301,B3701, A03,A24,B44, 0 1 B4403,C0602,C0401 B44,UNK,UNK Pt34 27.4191678 0 PD-1 M1b Stage 4 71 M 212 Melanoma Riaz et al. 2017 A1101,A3201,B5501, A03,A01,B07, 0 0 B3501,C0401,C0303 B07,UNK,UNK Pt36 35.5397127 0 PD-1 M1c Stage 4 58 M 2 Melanoma Riaz et al. 2017 A3001,A0101,B1302, A01A03,A01,UNK, 0 0 B1801,C0701,C0602 B44,UNK,UNK Pt37 21.2383482 1 PD-1 M1a Stage 4 63 M 29 Melanoma Riaz et al. 2017 A0101,A2402,B0801, A01,A24,B08, 0 0 B4402,C0701,C0501 B44,UNK,UNK Pt38 5.4904089 1 PD-1 M1c Stage 4 54 F 449 Melanoma Riaz et al. 2017 A0301,A2402,B3503, A03,A24,B07, 0 0 B5701,C0602,C0401 B58,UNK,UNK Pt4 20.8109511 1 PD-1 M1b Stage 4 62 F 285 Melanoma Riaz et al. 2017 A2301,A2402,B4501, A24,A24,B44, 1 0 B4501,C0602,C0602 B44,UNK,UNK Pt44 35.9342331 0 PD-1 NA NA 61 M 365 Melanoma Riaz et al. 2017 A0201,A0201,B4402, A02,A02,B44, 1 0 B5701,C0501,C0602 B58,UNK,UNK Pt46 7.4630109 1 PD-1 M1a Stage 4 79 M 180 Melanoma Riaz et al. 2017 A0101,A0101,B0702 A01,A01,B07, 1 0 B0702,C0102,C0102 B07,UNK,UNK Pt47 23.6054706 1 PD-1 M1b Stage 4 52 M 1005 Melanoma Riaz et al. 2017 A1101,A2402,B4402, A03,A24,B44, 0 0 B5108,C0102,C0501 B07,UNK,UNK Pt48 34.3890282 0 PD-1 M1c Stage 4 44 M 99 Melanoma Riaz et al. 2017 A0301,A0301,B0702, A03,A03,B07, 1 0 B3501,C0702,C0401 B07,UNK,UNK Pt49 27.1890309 0 PD-1 NA NA 52 F 852 Melanoma Riaz et al. 2017 A0101,A2402,B3503, A01,A24,B07, 0 0 B5101,C1402,C0401 B07,UNK,UNK Pt5 7.2986274 1 PD-1 M1c Stage 4 58 F 52 Melanoma Riaz et al. 2017 A0201,A0201,B4403, A02,A02,B44, 1 0 B5101,C0202,C1601 B07,UNK,UNK Pt51 1.8739719 0 PD-1 M1a Stage 4 43 M 204 Melanoma Riaz et al. 2017 A0301,A0301,B0702, A03,A03,B07, 1 0 B0702,C0702,C0702 B07,UNK,UNK Pt52 15.6493092 1 PD-1 M1c Stage 4 45 F 353 Melanoma Riaz et al. 2017 A0101,A0201,B3901, A01,A02,B27, 0 0 B4402,C1203,C0501 B44,UNK,UNK Pt53 14.2356111 1 PD-1 M1c Stage 4 82 M 81 Melanoma Riaz et al. 2017 A3301,A2402,B1402, A03,A24,B27, 1 1 B1402,C0802,C0802 B27,UNK,UNK Pt54 28.4383455 0 PD-1 NA NA 59 M 7360 Melanoma Riaz et al. 2017 A6801,A0201,B0801, A03,A02,B08, 0 0 B2705,C0701,C0304 B27,UNK,UNK Pt58 16.4054733 1 PD-1 M1c Stage 4 53 F 862 Melanoma Riaz et al. 2017 A0301,A0301,B0702, A03,A03,B07, 1 0 B0801,C0702,C0701 B08,UNK,UNK Pt59 23.2767036 1 PD-1 M1a Stage 4 49 F 432 Melanoma Riaz et al. 2017 A2402,A2601,B0702, A24,A01,B07, 0 1 B5201,C0702,C1202 B62,UNK,UNK Pt60 24.2630046 0 PD-1 M1a Stage 4 50 M 829 Melanoma Riaz et al. 2017 A0201,A2601,B3801, A02,A01,B27, 0 1 B4402,C1203,C0501 B44,UNK,UNK Pt65 22.7506764 0 PD-1 M1b Stage 4 63 F 2619 Melanoma Riaz et al. 2017 A0101,A0201,B0702, A01,A02,B07, 1 0 B0702,C0702,C0501 B07,UNK,UNK Pt66 17.8191714 1 PD-1 NA NA 49 F 153 Melanoma Riaz et al. 2017 A2301,A0205,B5001, A24,A02,B44, 0 0 B4403,C0602,C0401 B44,UNK,UNK Pt67 33.9287544 0 PD-1 M1c Stage 4 33 F 16 Melanoma Riaz et al. 2017 A0101,A0201,B0702, A01,A02,B07, 0 0 B4001,C0702,C0304 B44,UNK,UNK Pt68 27.6821814 0 PD-1 M1b Stage 4 69 M 1012 Melanoma Riaz et al. 2017 A0301,A0101,B0702, A03,A01,B07, 0 0 B0801,C0701,C0702 B08,UNK,UNK Pt7 37.7753283 0 PD-1 M1c Stage 4 55 M 1517 Melanoma Riaz et al. 2017 A1101,A2604,B1401, A03,A01,B27, 0 0 B5101,C0501,C0802 B07,UNK,UNK Pt70 10.2246537 1 PD-1 M1c Stage 4 72 M 428 Melanoma Riaz et al. 2017 A6801,A3101,B0801, A03,A03,B08, 0 0 B4001,C0701,C0304 B44,UNK,UNK Pt71 8.0876682 0 PD-1 M1c Stage 4 50 F 5 Melanoma Riaz et al. 2017 A0101,A0201,B0801, A01,A02,B08, 0 0 B2705,C0701,C0102 B27,UNK,UNK Pt72 25.315059 1 PD-1 M1b Stage 4 43 F 437 Melanoma Riaz et al. 2017 A0301,A0201,B0702, A03,A02,B07, 0 0 B4402,C0702,C0501 B44,UNK,UNK Pt73 9.2383527 0 PD-1 M1c Stage 4 60 M 14 Melanoma Riaz et al. 2017 A0301,A3201,B0702, A03,A01,B07, 0 0 B3501,C0702,C0401 B07,UNK,UNK Pt74 0.657534 1 PD-1 M1c Stage 4 27 M 44 Melanoma Riaz et al. 2017 A0101,A2402,B0801, A01,A24,B08, 0 0 B1501,C0701,C0303 B62,UNK,UNK Pt76 0.328767 1 PD-1 M1c Stage 4 60 M 224 Melanoma Riaz et al. 2017 A0301,A2902,B0702, A03,A01A24,B07, 1 0 B0702,C0702,C1601 B07,UNK,UNK Pt77 15.4849257 1 PD-1 M1a Stage 4 56 F 49 Melanoma Riaz et al. 2017 A6801,A2402,B0702, A03,A24,B07, 1 1 B0702,C0702,C0704 B07,UNK,UNK Pt79 7.1671206 1 PD-1 NA NA 64 M 544 Melanoma Riaz et al. 2017 A0301,A2902,B0702, A03,A01A24,B07, 1 0 B0702,C0702,C1601 B07,UNK,UNK Pt8 8.5150653 1 PD-1 M0 Stage 3 40 M 87 Melanoma Riaz et al. 2017 A0201,A0201,B4001, A02,A02,B44, 1 0 B4402,C0501,C0304 B44,UNK,UNK Pt82 14.1041043 1 PD-1 M1c Stage 4 60 F 33 Melanoma Riaz et al. 2017 A0201,A0201,B0702, A02,A02,B07, 1 0 B1501,C0702,C0304 B62,UNK,UNK Pt83 15.1890354 0 PD-1 M1c Stage 4 39 F 339 Melanoma Riaz et al. 2017 A1101,A0201,B0801, A03,A02,B08, 0 0 B3501,C0701,C0401 B07,UNK,UNK Pt84 4.9643817 1 PD-1 M1c Stage 4 48 F 11 Melanoma Riaz et al. 2017 A0301,A0101,B0801, A03,A01,B06, 0 0 B3501,C0701,C0401 B07,UNK,UNK Pt85 29.7205368 0 PD-1 M1a Stage 4 66 M 129 Melanoma Riaz et al. 2017 A3201,A0201,B2705, A01,A02,B27, 0 0 B4402,C0202,C0501 B44,UNK,UNK Pt86 8.9424624 1 PD-1 M1c Stage 4 50 F 562 Melanoma Riaz et al. 2017 A0101,A1101,B0801, A01,A03,B08, 0 0 B3501,C0701,C0401 B07,UNK,UNK Pt87 32.0219058 0 PD-1 NA NA 68 M 677 Melanoma Riaz et al. 2017 A0101,A0201,B5701, A01,A02,B56, 0 0 B1501,C0602,C0303 B62,UNK,UNK Pt89 27.7479348 1 PD-1 M1a Stage 4 56 M 214 Melanoma Riaz et al. 2017 A3401,A0201,B4001, UNK,A02,B44, 0 0 B1502,C0702,C0403 B62,UNK,UNK Pt9 3.0246564 1 PD-1 M1c Stage 4 46 M 409 Melanoma Riaz et al. 2017 A0101,A3201,B0801, A01,A01,B08, 0 0 B1801,C0701,C0202 B44,UNK,UNK Pt90 5.7205458 1 PD-1 M1c Stage 4 60 F 283 Melanoma Riaz et al. 2017 A6601,A0201,B4102, A03,A02,B44, 0 0 B4402,C1701,C0501 B44,UNK,UNK Pt92 10.9479411 1 PD-1 NA NA 58 M 642 Melanoma Riaz et al. 2017 A0101,A2402,B3801, A01,A24,B27, 0 0 B4901,C0701,C1203 UNK,UNK,UNK Pt93 27.9123183 0 PD-1 M1c Stage 4 52 M 7 Melanoma Riaz et al. 2017 A0301,A0101,B2705, A03,A01,B27, 0 0 B5201,C1202,C0102 B62,UNK,UNK Pt94 32.2520427 0 PD-1 M1c Stage 4 41 M 405 Melanoma Riaz et al. 2017 A0301,A2402,B1401, A03,A24,B27, 0 0 B1501,C0303,C0802 B62,UNK,UNK Pt98 24.5588949 1 PD-1 M1c Stage 4 74 M 20 Melanoma Riaz et al. 2017 A1101,A2601,B3801, A03,A01,B27, 0 0 B5201,C1202,C1203 B62,UNK,UNK LAPT1 19.9561569 1 PD-1 M1b Stage 4 66 F 1638 Melanoma Hugo et al. 2016 A0101,A0201,B4001, A01,A02,B44, 0 0 B4402,C0304,C0501 B44,UNK,UNK LAPT10 12.7232829 0 PD-1 M1a Stage 4 60 M 225 Melanoma Hugo et al. 2016 A0201,A0201,B4001, A02,A02,B44, 1 0 B4001,C0304,C0304 B44,UNK,UNK LAPT11 15.3534189 1 PD-1 M1c Stage 4 37 M 259 Melanoma Hugo et al. 2016 A0101,A0301,B1601, A01,A03,B44, 0 0 B5701,C0602,C0501 B58,UNK,UNK LAPT12 10.7506809 1 PD-1 M1c Stage 4 59 M 50 Melanoma Hugo et al. 2016 A0101,A2402,B5201, A01,A24,B62, 0 1 B3508,C0401,C1202 B07,UNK,UNK LAPT13 30.1479339 0 PD-1 M1c Stage 4 53 F 528 Melanoma Hugo et al. 2016 A2501,A3101,B4001, A01,A03,B44, 0 0 B3901,C1203,C0304 B27,UNK,UNK LAPT14 1.7753418 0 PD-1 M1c Stage 4 27 F 1457 Melanoma Hugo et al. 2016 A0301,A0101,B3501, A03,A01,B07, 0 0 B0801,C0701,C0401 B08,UNK,UNK LAPT15 32.219166 1 PD-1 M1b Stage 4 70 M 514 Melanoma Hugo et al. 2016 A0201,A2402,B5101, A02,A24,B07, 0 0 B5801,C0102,C0302 B58,UNK,UNK LAPT16 6.1150662 1 PD-1 M1b Stage 4 19 M 519 Melanoma Hugo et al. 2016 A0201,A0201,B4901, A02,A02,UNK, 1 0 B5101,C1504,C1502 B07,UNK,UNK LAPT17 31.3314951 1 PD-1 M1a Stage 4 67 M 846 Melanoma Hugo et al. 2016 A0101,A2402,B0801, A01,A24,B08, 0 0 B4405,C0202,C0701 B44,UNK,UNK LAPT18 35.5397127 0 PD-1 M1c Stage 4 64 M 297 Melanoma Hugo et al. 2016 A2402,A0201,B4001, A24,A02,B44, 0 0 B4402,C0304,C0501 B44,UNK,UNK LAPT19 34.849302 0 PD-1 M1c Stage 4 45 M 618 Melanoma Hugo et al. 2016 A0201,A0301,B0702, A02,A03,B07, 0 0 B5101,C0702,C0202 B07,UNK,UNK LAPT2 30.4767009 0 PD-1 M1c Stage 4 55 M 1868 Melanoma Hugo et al. 2016 A3101,A0301,B0702, A03,A03,B07, 0 0 B1801,C0701,C0702 B44,UNK,UNK LAPT20 11.0794479 1 PD-1 M1c Stage 4 63 F 542 Melanoma Hugo et al. 2016 A2501,A0301,B801, A01,A03,B06, 0 0 B1302,C0701,C0602 UNK,UNK,UNK LAPT21 31.0684815 1 PD-1 M1b Stage 4 60 M 237 Melanoma Hugo et al. 2016 A2902,A0301,B3503, A01A24,A03,B07, 0 0 B1801,C0701,C0401 B44,UNK,UNK LAPT22 5.9835594 1 PD-1 M1c Stage 4 55 M 68 Melanoma Hugo et al. 2016 A0101,A0201,B3701, A01,A02,B44, 0 0 B2705,C0202,C0602 B27,UNK,UNK LAPT23 3.3863001 1 PD-1 M1c Stage 4 63 M 233 Melanoma Hugo et al. 2016 A1101,A0201,B4402, A03,A02,B44, 1 0 B4402,C0501,C0501 B44,UNK,UNK LAPT24 32.0219058 1 PD-1 M1c Stage 4 70 M 385 Melanoma Hugo et al. 2016 A2902,A2601,B4001, A01A24,A01,B44, 0 0 B2704,C0304,C1502 B27,UNK,UNK LAPT25 8.6136954 1 PD-1 M1c Stage 4 74 M 110 Melanoma Hugo et al. 2016 A2501,A2601,B3801, A01,A01,B27, 1 0 B1801,C1203,C1203 B44,UNK,UNK LAPT26 43.9232712 0 PD-1 M1c Stage 4 71 M 1079 Melanoma Hugo et al. 2016 A0301,A3201,B3501, A03,A01,B07, 0 0 B3801,C1203,C0401 B27,UNK,UNK LAPT27 18.0164316 0 PD-1 M1c Stage 4 83 M 2297 Melanoma Hugo et al. 2016 A1101,A0301,B5601, A03,A03,B07, 0 0 B4402,C0102,C0501 B44,UNK,UNK LAPT28 14.4328713 1 PD-1 M1c Stage 4 82 M 465 Melanoma Hugo et al. 2016 A3301,A0101,B1402, A03,A01,B27, 0 0 B5701,C0802,C0602 B58,UNK,UNK LAPT29 8.8438323 1 PD-1 M1c Stage 4 84 M 225 Melanoma Hugo et al. 2016 A0201,A0201,B5701, A02,A02,B56, 1 0 B4402,C0501,C0602 B44,UNK,UNK LAPT3 22.7177997 1 PD-1 M1c Stage 4 58 M 1144 Melanoma Hugo et al. 2016 A2901,A6801,B0705, A01A24,A03,B07, 0 1 B2705,C0202,C1505 B27,UNK,UNK LAPT30 3.28767 1 PD-1 M1c Stage 4 80 F 559 Melanoma Hugo et al. 2016 A0301,A0301,B0702, A03,A03,B07, 1 0 B3501,C0702,C0401 B07,UNK,UNK LAPT31 23.451968 0 PD-1 M1c Stage 4 47 M 594 Melanoma Hugo et al. 2016 A0301,A0101,B0801, A03,A01,B06, 0 0 B4402,C0701,C0501 B44,UNK,UNK LAPT32 5.6219157 1 PD-1 M1c Stage 4 47 M 259 Melanoma Hugo et al. 2016 A1101,A6801,B3501, A03,A03,B07, 0 0 B1803,C0701,C0401 B44,UNK,UNK LAPT33 71.5725759 0 PD-1 M1a Stage 4 60 F 663 Melanoma Hugo et al. 2016 A6802,A2301,B4901, A02,A24,UNK, 0 1 B1402,C0701,C0802 B27,UNK,UNK LAPT34 13.7424606 0 PD-1 M1c Stage 4 42 M 89 Melanoma Hugo et al. 2016 A3004,A0301,B3503, A01,A03,B07, 0 0 B4403,C0706,C0401 B44,UNK,UNK LAPT35 14.0383509 0 PD-1 M1c Stage 4 65 F 313 Melanoma Hugo et al. 2016 A0301,A0201,B0702, A03,A02,B07, 0 1 B4402,C0702,C0501 B44,UNK,UNK LAPT36 27.5177979 1 PD-1 M1a Stage 4 61 F 72 Melanoma Hugo et al. 2016 A0301,A0101,B0702, A03,A01,B07, 0 0 B0801,C0702,C0701 B08,UNK,UNK LAPT37 11.9671188 0 PD-1 M1c Stage 4 70 F 553 Melanoma Hugo et al. 2016 A0201,A2403,B3503, A02,A24,B07, 1 0 B3501,C0401,C0401 B07,UNK,UNK LAPT38 14.7287616 0 PD-1 M1c Stage 4 57 F 78 Melanoma Hugo et al. 2016 A0201,A0201,B5101, A02,A02,B07, 1 0 B5101,C1402,C1502 B07,UNK,UNK LAPT4 31.1671116 0 PD-1 M1c Stage 4 62 M 3727 Melanoma Hugo et al. 2016 A2301,A0201,B4002, A24,A02,B44, 0 0 B4402,C0202,C0501 B44,UNK,UNK LAPT5 14.4326713 0 PD-1 M1c Stage 4 61 M 312 Melanoma Hugo et al. 2016 A0201,A6801,B1507, A02,A03,B62, 0 0 B4402,C0303,C0704 B44,UNK,UNK LAPT6 28.9972494 0 PD-1 M1c Stage 4 51 M 207 Melanoma Hugo et al. 2016 A2402,A3201,B3501, A24,A01,B07, 1 1 B3501,C0401,C0401 B07,UNK,UNK LAPT7 21.7643754 1 PD-1 M1c Stage 4 55 F 1184 Melanoma Hugo et al. 2016 A0201,A0201,B3503, A02,A02,B07, 1 1 B3801,C0401,C1203 B27,UNK,UNK LAPT8 NA NA PD-1 M1a Stage 4 69 M 805 Melanoma Hugo et al. 2016 A1101,A0201,B5501, A03,A02,B07, 0 NA B4402,C0303,C0501 B44,UNK,UNK LAPT9 34.6520418 0 PD-1 M0 Stage 3 68 M 474 Melanoma Hugo et al. 2016 A0302,A0301,B5301, A03,A03,B07, 0 0 B5101,C0401,C1502 B07,UNK,UNK AL4602 40.3 0 PD-1 M1c Stage 4 59 M 146 Non-Small Rizvi et al. 2015 A0301,A3201,B0801, A03,A01,B08, 0 0 Cell Lu B5101,C0702,C1502 B07,UNK,UNK AU5884 2.4 1 PD-1 M1c Stage 4 64 M 68 Non-Small Rizvi et al. 2015 A2402,A0201,B5101, A24,A02,B07, 0 0 Cell Lu B1302,C0602,C1502 UNK,UNK,UNK BL3403 13.36666667 1 PD-1 M1c Stage 4 73 F 36 Non-Small Rizvi et al. 2015 A0201,A2601,B3501, A02,A01,B07, 0 1 Cell Lu B4402,C0501,C0401 B44,UNK,UNK CA9903 49.53333333 0 PD-1 M1c Stage 4 57 M 329 Non-Small Rizvi et al. 2015 A1101,A0201,B1801, A03,A02,B44, 0 0 Cell Lu B5108,C0701,C1602 B07,UNK,UNK CU9061 15.56666667 1 PD-1 M1c Stage 4 57 M 324 Non-Small Rizvi et al. 2015 A0101,A2902,B3801, A01,A01A24,B27, 0 1 Cell Lu B4403,C1601,C1203 B44,UNK,UNK DI6359 29.1 1 PD-1 M1c Stage 4 61 F 237 Non-Small Rizvi et al. 2015 A0301,A1101,B5101, A03,A03,B07, 0 0 Cell Lu B1801,C1203,C1504 B44,UNK,UNK DM123062 2.9 1 PD-1 M1c Stage 4 50 M 85 Non-Small Rizvi et al. 2015 A0301,A0201,B1801, A03,A02,B44, 0 0 Cell Lu B4002,C0501,C0202 B44,UNK,UNK FR9547 25.9 1 PD-1 M1c Stage 4 65 F 265 Non-Small Rizvi et al. 2015 A2402,A0201,B0801, A24,A02,B08, 1 1 Cell Lu B1801,C0701,C0701 B44,UNK,UNK GR0134 34.16666667 0 PD-1 M1c Stage 4 80 M 32 Non-Small Rizvi et al. 2015 A0201,A3301,B1402, A02,A03,B27, 0 0 Cell Lu B1302,C0602,C0802 UNK,UNK,UNK GR4788 2.766666667 1 PD-1 M1c Stage 4 59 M 75 Non-Small Rizvi et al. 2015 A0101,A2601,B3501, A01,A01,B07, 0 0 Cell Lu B3701,C0602,C0401 B44,UNK,UNK HE3202 46.4 0 PD-1 M1c Stage 4 63 F 681 Non-Small Rizvi et al. 2015 A2403,A3201,B3801, A24,A01,B27, 0 0 Cell Lu B4101,C1203,C1701 B44,UNK,UNK JB112852 15.86666667 0 PD-1 M1c Stage 4 60 M 60 Non-Small Rizvi et al. 2015 A1101,A1101,B4402, A03,A03,B44, 1 0 Cell Lu B3502,C0704,C0401 B07,UNK,UNK KA3947 25.66666667 1 PD-1 M1c Stage 4 64 F 302 Non-Small Rizvi et al. 2015 A2301,A2402,B4101, A24,A24,B44, 0 0 Cell Lu B4901,C0701,C1701 UNK,UNK,UNK LO3793 11.46666667 0 PD-1 M1c Stage 4 62 F 75 Non-Small Rizvi et al. 2015 A0301,A0201,B2705, A03,A02,B27, 0 0 Cell Lu B4901,C0701,C0102 UNK,UNK,UNK LO5004 22.73333333 1 PD-1 M1c Stage 4 56 F 31 Non-Small Rizvi et al. 2015 A2601,A0201,B5501, A01,A02,B07, 0 0 Cell Lu B3801,C1203,C0303 B27,UNK,UNK M4945 46.6 0 PD-1 M1c Stage 4 66 M 250 Non-Small Rizvi et al. 2015 A3001,A0201,B1302, A01A03,A02,UNK, 0 0 Cell Lu B4403,C1602,C0602 B44,UNK,UNK MA7027 2.766666667 1 PD-1 M1c Stage 4 56 M 204 Non-Small Rizvi et al. 2015 A2402,A2402,B0702, A24,A24,B07, 1 0 Cell Lu B5108,C0702,C1602 B07,UNK,UNK NI9507 32.56666667 1 PD-1 M1c Stage 4 41 F 62 Non-Small Rizvi et al. 2015 A0301,A0201,B0702, A03,A02,B07, 1 1 Cell Lu B0702,C0702,C0702 B07,UNK,UNK R7495 2.1 1 PD-1 M1c Stage 4 63 M 80 Non-Small Rizvi et al. 2015 A1101,A1101,B3801, A03,A03,B27, 1 0 Cell Lu B3501,C1203,C0401 B07,UNK,UNK RH090935 11.13333333 0 PD-1 M1c Stage 4 78 F 114 Non-Small Rizvi et al. 2015 A2601,A3201,B3501, A01,A01,B07, 0 0 Cell Lu B3801,C1203,C0401 B27,UNK,UNK RI1933 46.7 0 PD-1 M1c Stage 4 60 F 441 Non-Small Rizvi et al. 2015 A3101,A2601,B5701, A03,A01,B58, 1 0 Cell Lu B1302,C0602,C0602 UNK,UNK,UNK RO3338 3.866666667 1 PD-1 M1c Stage 4 71 M 54 Non-Small Rizvi et al. 2015 A3002,A0201,B3801, A01,A02,B27, 0 0 Cell Lu B0801,C0701,C1203 B08,UNK,UNK SA9755 40.1 0 PD-1 M1c Stage 4 63 F 1109 Non-Small Rizvi et al. 2015 A1101,A0101,B0801, A03,A01,B08, 0 0 Cell Lu B3501,C0701,C0401 B07,UNK,UNK SB010944 27.56666667 0 PD-1 M1c Stage 4 68 M 190 Non-Small Rizvi et al. 2015 A0301,A0101,B0702, A03,A01,B07, 0 1 Cell Lu B0801,C0702,C0701 B08,UNK,UNK SC0899 44.33333333 0 PD-1 M1c Stage 4 64 F 364 Non-Small Rizvi et al. 2015 A2402,A2601,B3801, A24,A01,B27, 0 0 Cell Lu B3502,C1203,C0401 B07,UNK,UNK SC6470 36.83333333 0 PD-1 M1c Stage 4 59 M 194 Non-Small Rizvi et al. 2015 A3002,A3101,B3502, A01,A03,B07, 0 0 Cell Lu B1801,C0501,C0401 B44,UNK,UNK SR070761 15.13333333 1 PD-1 M1c Stage 4 51 F 138 Non-Small Rizvi et al. 2015 A0101,A6801,B3502, A01,A03,B07, 0 1 Cell Lu B5502,C0102,C0401 B07,UNK,UNK TU0428 3.666666667 1 PD-1 M1c Stage 4 66 M 1167 Non-Small Rizvi et al. 2015 A0301,A0101,B0702, A03,A01,B07, 0 0 Cell Lu B3501,C0702,C0401 B07,UNK,UNK VA1330 23.36666667 1 PD-1 M1c Stage 4 71 F 7 Non-Small Rizvi et al. 2015 A0301,A2601,B3502, A03,A01,B07, 1 0 Cell Lu B4403,C0401,C0401 B44,UNK,UNK VA7859 17.23333333 1 PD-1 M1c Stage 4 57 F 3 Non-Small Rizvi et al. 2015 A2301,A2902,B4901, A24,A01A24,UNK, 0 0 Cell Lu B4403,C0701,C1601 B44,UNK,UNK WA7899 18.73333333 1 PD-1 M1c Stage 4 49 M 70 Non-Small Rizvi et al. 2015 A0301,A2402,B3502, A03,A24,B07, 1 0 Cell Lu B3501,C0401,C0401 B07,UNK,UNK Y2087 14.86666667 1 PD-1 M1c Stage 4 68 F 170 Non-Small Rizvi et al. 2015 A1101,A3101,B1302, A03,A03,UNK, 0 0 Cell Lu B3501,C0602,C0401 B07,UNK,UNK ZA6505 25.76666667 1 PD-1 M1c Stage 4 76 F 711 Non-Small Rizvi et al. 2015 A2901,A2601,B0705, A01A24,A01,B07, 0 0 Cell Lu B1801,C1505,C1203 B44,UNK,UNK ZA6965 21.43333333 0 PD-1 M1c Stage 4 57 F 60 Non-Small Rizvi et al. 2015 A0201,A3201,B4001, A02,A01,B44, 0 0 Cell Lu B4501,C0602,C0304 B44,UNK,UNK PT300 2.9260263 1 PD-L1 + M1c Stage 4 52.3 M NA Non-Small Rizvi_CUMC A3101,A6801,B4001, A03,A03,B44, 1 NA CTLA Cell Lu B4004,C0304,C0304 B44,UNK,UNK PT301 14.3342412 0 PD-1 M1c Stage 4 53.4 M NA Non-Small Rizvi_CUMC A1101,A2301,B0702, A03,A24,B07, 0 NA Cell Lu B4403,C0401,C1502 B44,UNK,UNK PT302 13.2164334 0 PD-1 M1c Stage 4 62.8 M NA Non-Small Rizvi_CUMC A0101,A2901,B0705, A01,A01A24,B07, 0 NA Cell Lu B0801,C0701,C1505 B08,UNK,UNK PT303 6.6739701 1 PD-1 M1c Stage 4 64.4 F NA Non-Small Rizvi_CUMC A0101,A0201,B5101, A01,A02,B07, 0 NA Cell Lu B5801,C0701,C1402 B58,UNK,UNK PT304 15.2547888 0 PD-1 M1c Stage 4 76.4 F NA Non-Small Rizvi_CUMC A0301,A3201,B0702, A03,A01,B07, 0 NA Cell Lu B5301,C0401,C0702 B07,UNK,UNK PT305 5.5561623 1 PD-1 M1c Stage 4 61.9 M NA Non-Small Rizvi_CUMC A3002,A6602,B1503, A01,A03,B27, 0 NA Cell Lu B5801,C0210,C1701 B58,UNK,UNK PT306 10.3561605 0 PD-1 M1c Stage 4 74.7 M NA Non-Small Rizvi_CUMC A0201,A2402,B0702, A02,A24,B07, 0 NA Cell Lu B2705,C0102,C0702 B27,UNK,UNK PT307 7.1342439 0 PD-1 M1c Stage 4 71.6 M NA Non-Small Rizvi_CUMC A0101,A0101,B2705, A01,B27,B58, 1 NA Cell Lu B5701,C0202,C0602 UNK,UNK PT308 17.0301306 0 PD-1 M1c Stage 4 63.6 F NA Non-Small Rizvi_CUMC A0201,A2301,B0702, A02,A24,B07, 0 NA Cell Lu B3924,C0701,C0702 B27,UNK,UNK PT309 12.493146 0 PD-1 M1c Stage 4 54.6 F NA Non-Small Rizvi_CUMC A0101,A0201,B5101, A01,A02,B07, 0 NA Cell Lu B5701,C0602,C1402 B58,UNK,UNK PT310 7.5945177 0 PD-1 M1c Stage 4 77.1 F NA Non-Small Rizvi_CUMC A0201,A0301,B5001, A02,A03,B44, 1 NA Cell Lu B5701,C0602,C0602 B58,UNK,UNK PT311 7.232874 1 PD-1 M1c Stage 4 80.8 M NA Non-Small Rizvi_CUMC A0305,A3002,B0702, A03,A01,B07, 1 NA Cell Lu B0801,C0702,C0702 B08,UNK,UNK PT312 13.3479402 0 PD-1 M1c Stage 4 63.7 M NA Non-Small Rizvi_CUMC A2402,A3010,B4101, A24,UNK,B44, 0 NA Cell Lu B4403,C0401,C0602 B44,UNK,UNK PT313 10.8164343 1 PD-1 M1c Stage 4 69.2 F NA Non-Small Rizvi_CUMC A1101,A2421,B5101, A03,A24,B07, 1 NA Cell Lu B5101,C0702,C1502 UNK,UNK PT314 3.945204 1 PD-1 M1c Stage 4 78.6 F NA Non-Small Rizvi_CUMC A6802,A6810,B5301, A02,A03,B07, 0 NA Cell Lu B5702,C0401,C1801 B58,UNK,UNK PT315 21.5342385 0 PD-1 M1c Stage 4 69.6 M NA Non-Small Rizvi_CUMC A0201,A0201,B1508, A02,B07,B07, 1 NA Cell Lu B5101,C0102,C1402 UNK,UNK PT316 11.9999955 0 PD-1 M1c Stage 4 70.3 F NA Non-Small Rizvi_CUMC A0201,A0201,B1503, A02,B27,B44, 1 NA Cell Lu B4501,C0210,C1601 UNK,UNK PT317 10.3890372 0 PD-1 M1c Stage 4 51.3 F NA Non-Small Rizvi_CUMC A0301,A3303,B0702, A03,A03,B07, 0 NA Cell Lu B3502,C0401,C0702 B07,UNK,UNK PT318 11.0465712 0 PD-1 M1c Stage 4 76.1 M NA Non-Small Rizvi_CUMC A0101,A6801,B3501, A01,A03,B07, 0 NA Cell Lu B5701,C0401,C0602 B58,UNK,UNK PT319 6.246573 1 PD-1 M1c Stage 4 70.1 F NA Non-Small Rizvi_CUMC A0101,A0301,B0702, A01,A03,B07, 0 NA Cell Lu B5701,C0602,C0702 B58,UNK,UNK PT320 2.6958894 1 CTLA-4 + M1c Stage 4 75.6 F NA Non-Small Rizvi_CUMC A0201,A6801,B4001, A02,A03,B44, 0 NA PD-1 Cell Lu B5701,C0304,C0602 B58,UNK,UNK PT321 17.424651 0 PD-1 M1c Stage 4 70.4 F NA Non-Small Rizvi_CUMC A2402,A6802,B1402, A24,A02,B27, 0 NA Cell Lu B1517,C0701,C0802 B58,UNK,UNK PT322 2.2684923 1 PD-1 M1c Stage 4 67.2 M NA Non-Small Rizvi_CUMC A0101,A1101,B3501, A01,A03,B07, 0 NA Cell Lu B5701,C0401,C0602 B58,UNK,UNK PT323 14.2027344 0 PD-L1 + M1c Stage 4 63.9 F NA Non-Small Rizvi_CUMC A2426,A2601,B1801, A24,A01,B44, 1 NA CTLA Cell Lu B3801,C1203,C1203 B27,UNK,UNK PT324 16.2082131 0 PD-1 M1c Stage 4 75.7 M NA Non-Small Rizvi_CUMC A3002,A6601,B4201, A01,A03,B07, 0 NA Cell Lu B5301,C0401,C1701 B07,UNK,UNK PT325 27.7808115 1 PD-1 M1c Stage 4 52.3 M NA Non-Small Rizvi_CUMC A0101,A3002,B1510, A01,A01,B27, 0 NA Cell Lu B4402,C0304,C0501 B44,UNK,UNK PT326 12.7232829 0 PD-1 M1c Stage 4 69.6 F NA Non-Small Rizvi_CUMC A0201,A2601,B0801, A02,A01,B08, 0 NA Cell Lu B1401,C0701,C0802 B27,UNK,UNK PT327 21.0082113 0 PD-1 M1c Stage 4 51.4 F NA Non-Small Rizvi_CUMC A0101,A2601,B0801, A01,A01,B08, 0 NA Cell Lu B3801,C0701,C1203 B27,UNK,UNK PT328 10.3561605 0 PD-1 M1c Stage 4 70.7 F NA Non-Small Rizvi_CUMC A0101,A2402,B1302, A01,A24,UNK, 0 NA Cell Lu B3502,C0401,C0602 B07,UNK,UNK PT329 17.2273908 1 PD-1 M1c Stage 4 62.2 M NA Non-Small Rizvi_CUMC A0101,A0207,B3701, A01,A02,B44, 0 NA Cell Lu B4601,C0102,C0602 B62,UNK,UNK PT330 8.7123255 0 PD-1 M1c Stage 4 70.2 M NA Non-Small Rizvi_CUMC A1101,A6802,B5201, A03,A02,B62, 0 NA Cell Lu B5301,C0401,C1202 B07,UNK,UNK PT331 6.6410934 1 PD-L1 + M1c Stage 4 73.3 F NA Non-Small Rizvi_CUMC A0301,A2902,B0702, A03,A01A24,B07, 0 NA CTLA Cell Lu B1402,C0702,C0802 B27,UNK,UNK PT332 6.1150662 1 PD-1 M1c Stage 4 59 F NA Non-Small Rizvi_CUMC A2301,A2301,B0702, A24,B07,B58, 1 NA Cell Lu B5703,C0702,C1801 UNK,UNK PT333 9.3041061 1 PD-1 M1c Stage 4 43.8 M NA Non-Small Rizvi_CUMC A0205,A2601,B3801, A02,A01,B27, 0 NA Cell Lu B5801,C0701,C1203 B58,UNK,UNK PT334 1.0520544 1 PD-1 M1c Stage 4 70.8 M NA Non-Small Rizvi_CUMC A0301,A3001,B0702, A03,A01A03,B07, 0 NA Cell Lu B1302,C0602,C0702 UNK,UNK,UNK PT335 2.2684923 1 PD-1 M1c Stage 4 78.1 M NA Non-Small Rizvi_CUMC A0201,A1101,B0702, A02,A03,B07, 0 NA Cell Lu B4002,C0202,C0702 B44,UNK,UNK PT336 38.136972 0 PD-1 M1c Stage 4 80.5 M NA Non-Small Rizvi_CUMC A0201,A3301,B1402, A02,A03,B27, 0 NA Cell Lu B1302,C0602,C0802 UNK,UNK,UNK PT337 16.2082131 1 PD-1 M1c Stage 4 58.8 F NA Non-Small Rizvi_CUMC A6802,A7401,B0702, A02,A03,B07, 0 NA Cell Lu B1503,C0210,C1505 B27,UNK,UNK PT338 8.4621886 1 PD-1 M1c Stage 4 64.8 F NA Non-Small Rizvi_CUMC A0201,A2601,B0702, A02,A01,B07, 0 NA Cell Lu B1501,C1203,C0401 B62,UNK,UNK PT339 7.1013672 0 PD-1 M1c Stage 4 47.8 M NA Non-Small Rizvi_CUMC A0207,A2601,B4001, A02,A01,B44, 0 NA Cell Lu B4601,C0102,C0304 B62,UNK,UNK PT340 6.2136963 0 PD-1 M1c Stage 4 76 M NA Non-Small Rizvi_CUMC A0201,A0301,B0702, A02,A03,B07, 0 NA Cell Lu B4402,C0501,C0702 B44,UNK,UNK PT341 5.4904089 0 PD-1 M1c Stage 4 58.3 F NA Non-Small Rizvi_CUMC A2601,A3301,B1401, A01,A03,B27, 0 NA Cell Lu B4403,C0202,C0802 B44,UNK,UNK PT342 4.3068477 0 PD-1 M1c Stage 4 53.1 F NA Non-Small Rizvi_CUMC A2902,A3101,B0702, A01A24,A03,B07, 0 NA Cell Lu B4002,C0305,C0702 B44,UNK,UNK PT343 6.4438332 0 PD-L1 + M1c Stage 4 50.6 F NA Non-Small Rizvi_CUMC A2902,A3201,B4402, A01A24,A01,B44, 0 NA CTLA Cell Lu B4403,C0501,C1601 B44,UNK,UNK PT344 1.3808214 0 PD-1 M1c Stage 4 60.8 F NA Non-Small Rizvi_CUMC A0301,A0301,B1801, A03,B44,B44, 1 NA Cell Lu B4402,C0501,C0701 UNK,UNK PT345 8.9753391 0 PD-1 M1c Stage 4 70.6 M NA Non-Small Rizvi_CUMC A0201,A0301,B1801, A02,A03,B44, 0 NA Cell Lu B4403,C0401,C0501 B44,UNK,UNK PT346 17.6219112 0 PD-1 M1c Stage 4 66.2 F NA Non-Small Rizvi_CUMC A0201,A3001,B0702, A02,A01A03,B07, 0 NA Cell Lu B1503,C0210,C1203 B27,UNK,UNK PT347 5.917806 0 PD-1 M1c Stage 4 85.6 M NA Non-Small Rizvi_CUMC A0201,A2501,B1302, A02,A01,UNK, 0 NA Cell Lu B4402,C0501,C0602 B44,UNK,UNK PT348 5.589039 0 PD-1 M1c Stage 4 64.9 M NA Non-Small Rizvi_CUMC A0101,A0101,B1801, A01,B44,B07, 1 NA Cell Lu B5101,C0501,C1203 UNK,UNK PT349 0.7232874 1 PD-1 M1c Stage 4 86.8 F NA Non-Small Rizvi_CUMC A0301,A3001,B1302, A03,A01A03, 1 NA Cell Lu B4701,C0602,C0602 UNK,UNK,UNK PT350 10.0931469 0 PD-1 M1c Stage 4 66.1 F NA Non-Small Rizvi_CUMC A3201,A6801,B1801, A01,A03,B44, 0 NA Cell Lu B4001,C0304,C0701 B44,UNK,UNK PT351 1.8410952 0 PD-1 M1c Stage 4 81.9 M NA Non-Small Rizvi_CUMC A0201,A2902,B0702, A02,A01A24,B07, 0 NA Cell Lu B4402,C0501,C0702 B44,UNK,UNK PT352 16.5041034 0 PD-1 M1c Stage 4 64.4 F NA Non-Small Rizvi_CUMC A0203,A1101,B4601, A02,A03,B62, 1 NA Cell Lu B4601,C0102,C0102 UNK PT353 5.0630118 0 PD-1 M1c Stage 4 64.7 F NA Non-Small Rizvi_CUMC A1101,A2403,B0702, A03,A24,B07, 0 NA Cell Lu B3501,C0401,C0702 B07,UNK,UNK PT354 3.3863001 0 PD-1 M1c Stage 4 76.2 F NA Non-Small Rizvi_CUMC A0101,A2403,B1517, A01,A24,B58, 1 NA Cell Lu B5801,C0701,C0701 B58,UNK,UNK PT355 2.2356156 0 PD-1 M1c Stage 4 55.5 F NA Non-Small Rizvi_CUMC A0201,A6802,B4403, A02,A02,B44, 0 NA Cell Lu B5101,C0401,C1601 B07,UNK,UNK PT356 4.7671215 0 PD-1 M1c Stage 4 70.9 M NA Non-Small Rizvi_CUMC A0101,A3001,B0801, A01,A01A03,B08, 0 NA Cell Lu B1302,C0602,C0701 UNK,UNK,UNK PT357 17.9506782 0 PD-1 M1c Stage 4 78.6 F NA Non-Small Rizvi_CUMC A0301,A6801,B1402, A03,A03,B27, 0 NA Cell Lu B5701,C0701,C0802 B58,UNK,UNK PT358 2.6958894 0 PD-1 M1c Stage 4 76.5 M NA Non-Small Rizvi_CUMC A2402,A3402,B3501, A24,A03,B07, 0 NA Cell Lu B5201,C0401,C1502 B62,UNK,UNK PT359 2.301369 0 PD-1 M1c Stage 4 60.6 M NA Non-Small Rizvi_CUMC A0301,A3301,B3501, A03,A03,B07, 1 NA Cell Lu B3501,C0401,C0401 UNK PT360 1.972602 0 PD-1 M1c Stage 4 49.6 M NA Non-Small Rizvi_CUMC A0202,A0202,B5001, A02,B44,B58, 1 NA Cell Lu B5703,C0602,C0701 UNK,UNK PT361 2.2027389 0 CTLA-4 + M1c Stage 4 76.6 M NA Non-Small Rizvi_CUMC A0302,A2601,B1501, A03,A01,B62, 0 NA PD-1 Cell Lu B3501,C0401,C0704 B07,UNK,UNK PT362 8.1862983 0 PD-1 M1c Stage 4 74.1 M NA Non-Small Rizvi_CUMC A1101,A2902,B3501, A03,A01A24,B07, 0 NA Cell Lu B5801,C0401,C0701 B58,UNK,UNK PT363 5.5232856 0 PD-1 M1c Stage 4 79.3 M NA Non-Small Rizvi_CUMC A0201,A2901,B3503, A02,A01A24,B07, 0 NA Cell Lu B5801,C0401,C0701 B58,UNK,UNK PT364 2.9917797 0 PD-1 M1c Stage 4 88 F NA Non-Small Rizvi_CUMC A0205,A0301,B4101, A02,A03,B44, 0 NA Cell Lu B5001,C0602,C1701 B44,UNK,UNK PT365 4.8986283 0 CTLA-4 + M1c Stage 4 75.1 M NA Non-Small Rizvi_CUMC A0201,A1101,B1301, A02,A03,UNK, 0 NA PD-1 Cell Lu B4001,C0304,C0702 B44,UNK,UNK PT366 NA 1 PD-1 M1c Stage 4 60.9 F NA Non-Small Rizvi_CUMC NA UNK NA NA Cell Lu

APPENDIX 1 Cohort 2 Homo- zygous Age OS_ OS_ IMPACT- Drug Refer- HLA Class I (1 = Yes; Sample Group Months Event MutCnt Class Cancer Type ence HLA Class I Alleles Super-types 0 = No) OB042257 31-50 1 0 7.9 PD-1/ Non-Small Cell MSK- A3001,A3301,B1402, A01A03,A03,B27, 0 PDL-1 Lung Cancer IMPACT B1302,C0802,C0602 UNK,UNK,UNK EB372668 <30 0 0 4.39 PD-1/ Melanoma MSK- A3201,A0201,B0702, A01,A02,B07, 0 PDL-1 IMPACT B1517,C0701,C0702 B58,UNK,UNK BV379195 >71 3 1 1.76 PD-1/ Bladder Cancer MSK- A1101,A3303,B5201, A03,A03,B62, 0 PDL-1 IMPACT B5801,C0302,C1202 B58,UNK,UNK NB536456 31-50 2 0 20.19 PD-1/ Non-Small Cell MSK- A3401,A3303,B1525, UNK,A03,B62, 0 PDL-1 Lung Cancer IMPACT B5801,C0302,C0403 B58,UNK,UNK RX904694 31-50 2 0 60.56 PD-1/ Melanoma MSK- A2402,A0201,B5501, A24,A02,B07, 0 PDL-1 IMPACT B3501,C0102,C0401 B07,UNK,UNK AN293177 61-70 1 0 1.76 PD-1/ Glioma MSK- A0101,A3101,B0702, A01,A03,B07, 0 PDL-1 IMPACT B3901,C1203,C0702 B27,UNK,UNK NA303088 31-50 4 0 7.02 PD-1/ Renal Cell MSK- A3101,A2601,B4001, A03,A01,B44, 0 PDL-1 Carcinoma IMPACT B5801,C0304,C0706 B58,UNK,UNK NC668467 50-60 1 0 10.53 PD-1/ Head and Neck MSK- A2402,A0201,B0702, A24,A02,B07, 1 PDL-1 Cancer IMPACT B3906,C0702,C0702 B27,UNK,UNK KW787528 >71 2 0 2.63 PD-1/ Glioma MSK- A2601,A6901,B6701, A01,A02,B07, 0 PDL-1 IMPACT B5501,C0102,C1203 B07,UNK,UNK AW882070 <30 2 0 2.63 PD-1/ Non-Small Cell MSK- A0206,A0205,B4801, A02,A02,B27, 0 PDL-1 Lung Cancer IMPACT B5001,C0803,C0602 B44,UNK,UNK NE179096 61-70 2 0 4.39 PD-1/ Glioma MSK- A2402,A2402,B3801, A24,A24,B27, 1 PDL-1 IMPACT B1517,C1203,C0701 B58,UNK,UNK HK537369 50-60 6 1 8.78 Combo Esophago- MSK- A1101,A0101,B0801, A03,A01,B08, 0 gastric Cancer IMPACT B5501,C0303,C0701 B07,UNK,UNK WL084588 50-60 5 0 2.63 PD-1/ Renal Cell MSK- A3002,A6801,B1001, A01,A03,B44, 0 PDL-1 Carcinoma IMPACT B4402,C0304,C0704 B44,UNK,UNK WV248294 31-50 6 0 0.88 PD-1/ Non-Small Cell MSK- A0301,A2902,B0702, A03,A01A24,B07, 0 PDL-1 Lung Cancer IMPACT B4403,C1501,C0702 B44,UNK,UNK QT721351 31-50 0 0 44.76 PD-1/ Soft Tissue MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 Sarcoma IMPACT B5601,C0102,C0702 B07,UNK,UNK WE615011 61-70 2 0 7.02 PD-1/ Non-Small Cell MSK- A1101,A0201,B0702, A03,A02,B07, 1 PDL-1 Lung Cancer IMPACT B0702,C0702,C0702 B07,UNK,UNK RL562554 50-60 9 0 8.78 PD-1/ Gastrointestinal MSK- A1101,A2402,B3501, A03,A24,B07, 0 PDL-1 Neuroendocrine IMPACT B5101,C1502,C0401 B07,UNK,UNK Tumor GL866200 >71 5 0 4.39 PD-1/ Glioma MSK- A0205,A3301,B1402, A02,A03,B27, 0 PDL-1 IMPACT B5801,C0802,C0706 B58,UNK,UNK DC990051 31-50 6 0 2.63 PD-1/ Mesothelioma MSK- A0301,A2601,B0702, A03,A01,B07, 0 PDL-1 IMPACT B6701,C1203,C0702 B07,UNK,UNK AO750281 31-50 2 0 7.9 PD-1/ Non-Small Cell MSK- A3201,A0201,B3901, A01,A02,B27, 0 PDL-1 Lung Cancer IMPACT B1401,C0802,C1203 B27,UNK,UNK RU065936 31-50 7 0 35.99 PD-1/ Melanoma MSK- A0301,A0201,B3501, A03,A02,B07, 0 PDL-1 IMPACT B4901,C0401,C0701 UNK,UNK,UNK PW329375 31-50 5 0 0 PD-1/ Skin Cancer; MSK- A0101,A3303,B0801, A01,A03,B08, 0 PDL-1 Non-Melanoma IMPACT B1801,C1203,C0701 B44,UNK,UNK BP983860 50-60 46 0 7.9 PD-1/ Melanoma MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 IMPACT B1501,C0401,C0702 B62,UNK,UNK ZK434939 >71 6 0 7.02 PD-1/ Melanoma MSK- A6801,A0201,B1501, A03,A02,B62, 0 PDL-1 IMPACT B4402,C0303,C0501 B44,UNK,UNK RJ401736 31-50 3 0 3.51 PD-1/ Melanoma MSK- A2403,A2402,B3502, A24,A24,B07, 0 PDL-1 IMPACT B1801,C1203,C0401 B44,UNK,UNK ZL338926 61-70 3 1 0 PD-1/ Skin Cancer; MSK- A3201,A0201,B0702, A01,A02,B07, 1 PDL-1 Non-Melanoma IMPACT B3501,C0401,C0401 B07,UNK,UNK PT088136 50-60 0 0 3.51 PD-1/ Cancer of MSK- A2402,A0201,B1501, A24,A02,B62, 0 PDL-1 Unknown IMPACT B4102,C0304,C1701 B44,UNK,UNK Primary VI665293 31-50 3 0 0.88 PD-1/ Melanoma MSK- A2402,A6801,B1501, A24,A03,B62, 0 PDL-1 IMPACT B3503,C0303,C0401 B07,UNK,UNK PZ793599 31-50 53 0 66.71 PD-1/ Colorectal MSK- A0101,A0201,B0702, A01,A02,B07, 0 PDL-1 Cancer IMPACT B5701,C0602,C0702 B58,UNK,UNK OS197548 31-50 2 0 10.53 PD-1/ Non-Small Cell MSK- A3002,A6901,B5501, A01,A02,B07, 0 PDL-1 Lung Cancer IMPACT B1801,C0102,C0501 B44,UNK,UNK LR136554 61-70 3 0 2.63 PD-1/ Glioma MSK- A1101,A0207,B4601, A03,A02,B62, 0 PDL-1 IMPACT B1527,C0102,C0401 UNK,UNK,UNK WH928128 31-50 2 0 7.02 PD-1/ Non-Small Cell MSK- A0101,A0201,B0702, A01,A02,B07, 0 PDL-1 Lung Cancer IMPACT B0801,C0701,C0702 B08,UNK,UNK KB960411 50-60 1 0 52.66 PD-1/ Glioma MSK- A0101,A2902,B3701, A01,A01A24,B44, 0 PDL-1 IMPACT B5801,C0602,C0706 B58,UNK,UNK IH002321 50-60 2 0 10.53 PD-1/ Non-Small Cell MSK- A7401,A2301,B1503, A03,A24,B27, 0 PDL-1 Lung Cancer IMPACT B4501,C0210,C0602 B44,UNK,UNK HT275463 50-60 5 0 2.63 PD-1/ Renal Cell MSK- A2402,A2402,B0702, A24,A24,B07, 1 PDL-1 Carcinoma IMPACT B5701,C0602,C0702 B58,UNK,UNK AQ286794 31-50 1 0 7.02 PD-1/ Non-Small Cell MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 Lung Cancer IMPACT B3501,C0401,C0702 B07,UNK,UNK VK425379 31-50 0 0 1.76 PD-1/ Melanoma MSK- A1101,A0201,B0702, A03,A02,B07, 0 PDL-1 IMPACT B4402,C0501,C0702 B44,UNK,UNK FH814563 31-50 2 0 69.34 Combo Melanoma MSK- A0101,A2402,B5501, A01,A24,B07, 0 IMPACT B5801,C0102,C0706 B58,UNK,UNK DS020834 31-50 0 0 12.29 PD-1/ Cancer of MSK- A2301,A6901,B3502, A24,A02,B07, 0 PDL-1 Unknown IMPACT B5801,C0401,C0706 B58,UNK,UNK Primary QI713515 50-60 4 0 5.27 PD-1/ Glioma MSK- A3201,A0201,B4402, A01,A02,B44, 0 PDL-1 IMPACT B5201,C1202,C0501 B62,UNK,UNK IK662613 >71 4 0 0 PD-1/ Melanoma MSK- A0101,A0201,B0702, A01,A02,B07, 0 PDL-1 IMPACT B1302,C0602,C0702 UNK,UNK,UNK CD689551 50-60 1 0 20.19 PD-1/ Non-Small Cell MSK- A0101,A3303,B0702, A01,A03,B07, 0 PDL-1 Lung Cancer IMPACT B1801,C1505,C1203 B44,UNK,UNK OD111817 50-60 0 0 11.41 PD-1/ Bladder Cancer MSK- A1101,A0101,B5701, A03,A01,B58, 1 PDL-1 IMPACT B3701,C0602,C0602 B44,UNK,UNK LS167399 >71 1 0 8.78 PD-1/ Head and Neck MSK- A0301,A2601,B0702, A03,A01,B07, 1 PDL-1 Cancer IMPACT B0702,C0702,C0702 B07,UNK,UNK EL499261 50-60 0 1 4.39 Combo Non-Small Cell MSK- A1101,A1101,B5502, A03,A03,B07, 1 Lung Cancer IMPACT B3503,C0102,C1203 B07,UNK,UNK BD241560 31-50 1 0 36.86 Combo Cancer of MSK- A2301,A6801,B5501, A24,A03,B07, 0 Unknown IMPACT B4403,C0303,C0401 B44,UNK,UNK Primary WJ952117 31-50 1 0 8.78 PD-1/ Bladder Cancer MSK- A2902,A6802,B1402, A01A24,A02,B27, 1 PDL-1 IMPACT B1402,C0802,C0802 B27,UNK,UNK YR990519 50-60 0 0 21.94 PD-1/ Non-Small Cell MSK- A0201,A0205,B1501, A02,A02,B62, 0 PDL-1 Lung Cancer IMPACT B4901,C0303,C0701 UNK,UNK,UNK JL090305 >71 4 0 2.63 Combo Melanoma MSK- A0101,A0201,B4001, A01,A02,B44, 0 IMPACT B3701,C0304,C0602 B44,UNK,UNK VK851705 50-60 13 0 3.51 Combo Bladder Cancer MSK- A1101,A0201,B1509, A03,A02,B27, 0 IMPACT B3501,C0401,C0704 B07,UNK,UNK WE602111 31-50 2 0 28.09 PD-1/ Melanoma MSK- A0101,A6802,B0801, A01,A02,B08, 0 PDL-1 IMPACT B1402,C0802,C0701 B27,UNK,UNK DL240387 50-60 2 0 57.93 PD-1/ Bladder Cancer MSK- A0101,A2402,B0801, A01,A24,B08, 0 PDL-1 IMPACT B3501,C0401,C0701 B07,UNK,UNK SE949393 50-60 3 0 22.82 PD-1/ Non-Small Cell MSK- A0201,A0201,B1501, A02,A02,B62, 1 PDL-1 Lung Cancer IMPACT B4402,C0304,C0501 B44,UNK,UNK VK102917 31-50 1 1 8.78 PD-1/ Non-Small Cell MSK- A0101,A2902,B0801, A01,A01A24,B08, 0 PDL-1 Lung Cancer IMPACT B4403,C1601,C0701 B44,UNK,UNK EX315834 31-50 9 0 0 PD-1/ Skin Cancer; MSK- A2301,A6802,B1402, A24,A02,B27, 0 PDL-1 Non-Melanoma IMPACT B4901,C0701,C0802 UNK,UNK,UNK GD961875 31-50 7 0 6.14 PD-1/ Bladder Cancer MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 IMPACT B3501,C0401,C0701 B07,UNK,UNK GJ549646 31-50 22 0 5.27 Combo Bladder Cancer MSK- A6601,A2601,B3801, A03,A01,B27, 0 IMPACT B3508,C0401,C1203 B07,UNK,UNK YL846622 61-70 0 0 1.76 PD-1/ Hepatobiliary MSK- A2402,A0201,B3501, A24,A02,B07, 0 PDL-1 Cancer IMPACT B1302,C1402,C0602 UNK,UNK,UNK TJ956009 31-50 0 0 9.65 PD-1/ Non-Small Cell MSK- A1101,A0101,B3801, A03,A01,B27, 1 PDL-1 Lung Cancer IMPACT B3801,C1203,C1203 B27,UNK,UNK PL020321 31-50 1 0 17.55 PD-1/ Bladder Cancer MSK- A0201,A0201,B1501, A02,A02,B62, 1 PDL-1 IMPACT B5801,C0303,C0706 B58,UNK,UNK OP960829 61-70 5 0 1.76 Combo Melanoma MSK- A1101,A3101,B3801, A03,A03,B27, 0 IMPACT B3501,C1203,C0401 B07,UNK,UNK IN807029 31-50 1 0 6.14 PD-1/ Melanoma MSK- A2901,A2601,B0705, A01A24,A01,B07, 0 PDL-1 IMPACT B3801,C1505,C1203 B27,UNK,UNK ZV102948 31-50 3 0 1.76 CTLA4 Melanoma MSK- A0103,A6501,B7301, A01,A03,B27, 0 IMPACT B3501,C1505,C0401 B07,UNK,UNK HV623240 31-50 4 0 6.14 PD-1/ Melanoma MSK- A2402,A2301,B1501, A24,A24,B62, 0 PDL-1 IMPACT B4901,C0303,C0701 UNK,UNK,UNK IB174035 50-60 10 0 5.27 PD-1/ Renal Cell MSK- A2402,A2601,B1801, A24,A01,B44, 0 PDL-1 Carcinoma IMPACT B4102,C1203,C1701 B44,UNK,UNK NA945383 31-50 16 0 4.39 PD-1/ Non-Small Cell MSK- A2601,A2601,B3801, A01,A01,B27, 1 PDL-1 Lung Cancer IMPACT B3801,C1203,C1203 B27,UNK,UNK AE200159 >71 5 0 2.63 PD-1/ Glioma MSK- A0301,A3002,B4101, A03,A01,B44, 0 PDL-1 IMPACT B5101,C0202,C0602 B07,UNK,UNK HG070027 31-50 3 0 14.92 PD-1/ Non-Small Cell MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 Lung Cancer IMPACT B4402,C0501,C0702 B44,UNK,UNK PH640297 50-60 4 0 14.92 PD-1/ Non-Small Cell MSK- A3303,A3402,B1510, A03,A03,B27, 0 PDL-1 Lung Cancer IMPACT B5101,C0804,C1601 B07,UNK,UNK FD411530 31-50 12 0 7.9 PD-1/ Non-Small Cell MSK- A0301,A2901,B0705, A03,A01A24,B07, 0 PDL-1 Lung Cancer IMPACT B5601,C0102,C1505 B07,UNK,UNK RI929197 50-60 5 0 2.63 PD-1/ Renal Cell MSK- A1101,A2902,B5001, A03,A01A24,B44, 0 PDL-1 Carcinoma IMPACT B5201,C1202,C0602 B62,UNK,UNK GS234640 31-50 0 0 14.04 PD-1/ Non-Small Cell MSK- A1101,A3303,B4601, A03,A03,B62, 0 PDL-1 Lung Cancer IMPACT B4403,C0103,C0706 B44,UNK,UNK TZ388736 61-70 3 0 11.41 PD-1/ Melanoma MSK- A0101,A0201,B3906, A01,A02,B27, 0 PDL-1 IMPACT B5701,C0602,C0702 B58,UNK,UNK HR904519 31-50 3 0 17.55 PD-1/ Melanoma MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 IMPACT B5201,C1202,C0702 B62,UNK,UNK MQ748114 61-70 3 0 1.76 PD-1/ Melanoma MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 IMPACT B4402,C0501,C0702 B44,UNK,UNK YD623028 31-50 6 0 2.63 PD-1/ Bladder Cancer MSK- A3002,A0201,B1801, A01,A02,B44, 0 PDL-1 IMPACT B4901,C0501,C0701 UNK,UNK,UNK QV517854 61-70 4 0 1.76 PD-1/ Renal Cell MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 Carcinoma IMPACT B4402,C0501,C1202 B44,UNK,UNK OM156383 31-50 14 0 9.65 Combo Bladder Cancer MSK- A0201,A3301,B1402, A02,A03,B07, 0 IMPACT B1801,C0802,C1203 B44,UNK,UNK DO395401 31-50 2 0 1.76 Combo Melanoma MSK- A6601,A2601,B3801, A03,A01,B27, 1 IMPACT B3801,C1203,C1203 B27,UNK,UNK ED236873 31-50 1 1 14.92 PD-1/ Non-Small Cell MSK- A0301,A0101,B0801, A03,A01,B08, 0 PDL-1 Lung Cancer IMPACT B1402,C0802,C0701 B27,UNK,UNK LQ491699 31-50 3 0 10.53 Combo Small Cell MSK- A2601,A0201,B0801, A01,A02,B08, 0 Lung Cancer IMPACT B1801,C0702,C0701 B44,UNK,UNK RH138187 31-50 0 0 24.58 PD-1/ Non-Small Cell MSK- A2403,A0201,B3801, A24,A02,B27, 0 PDL-1 Lung Cancer IMPACT B1518,C1203,C0704 B27,UNK,UNK JE984424 50-60 4 0 5.27 PD-1/ Renal Cell MSK- A0101,A2301,B3801, A01,A24,B27, 0 PDL-1 Carcinoma IMPACT B5301,C0602,C0401 B07,UNK,UNK HN039410 61-70 1 0 4.39 PD-1/ Breast Cancer MSK- A1101,A0201,B0702, A03,A02,B07, 0 PDL-1 IMPACT B0801,C0701,C0702 B08,UNK,UNK LR229562 31-50 3 0 7.02 Combo Cancer of MSK- A2402,A3301,B1402, A24,A03,B27, 0 Unknown IMPACT B3502,C0802,C0401 B07,UNK,UNK Primary WA186194 31-50 6 0 2.63 PD-1/ Adrenocortical MSK- A2301,A2901,B0705, A24,A01A24,B07, 0 PDL-1 Carcinoma IMPACT B4403,C1505,C0401 B44,UNK,UNK ES387661 31-50 1 0 29.84 PD-1/ Non-Small Cell MSK- A2601,A0205,B5101, A01,A02,B07, 0 PDL-1 Lung Cancer IMPACT B5801,C0102,C0706 B58,UNK,UNK AE162231 >71 4 0 30.72 PD-1/ Melanoma MSK- A0301,A0101,B0702, A03,A01,B07, 0 PDL-1 IMPACT B1501,C0304,C0702 B62,UNK,UNK AH329297 31-50 1 0 23.7 PD-1/ Bladder Cancer MSK- A2402,A2402,B3901, A24,A24,B27, 1 PDL-1 IMPACT B1801,C0501,C1203 B44,UNK,UNK VB175191 31-50 3 0 12.29 PD-1/ Non-Small Cell MSK- A3001,A0101,B0801, A01A24,A01,B08, 0 PDL-1 Lung Cancer IMPACT B1302,C0602,C0701 UNK,UNK,UNK YX309246 <30 0 0 3.51 PD-1/ Cancer of MSK- A0101,A0101,B4002, A01,A01,B44, 1 PDL-1 Unknown IMPACT B5701,C0202,C0602 B58,UNK,UNK Primary RC276819 >71 4 0 30.72 Combo Melanoma MSK- A3201,A3201,B1501, A01,A01,B62, 1 IMPACT B3501,C0303,C0401 B07,UNK,UNK DT499956 61-70 4 0 6.14 PD-1/ Melanoma MSK- A0301,A0301,B0702, A03,A03,B07, 1 PDL-1 IMPACT B3501,C0401,C0702 B07,UNK,UNK GS256044 50-60 0 1 23.7 PD-1/ Adrenocortical MSK- A0201,A0201,B5701, A02,A02,B58, 1 PDL-1 Carcinoma IMPACT B3501,C0602,C0401 B07,UNK,UNK TO930220 31-50 3 0 6.14 PD-1/ Bladder Cancer MSK- A0301,A3301,B1402, A03,A03,B27, 0 PDL-1 IMPACT B2702,C0802,C0202 B27,UNK,UNK YF920516 31-50 4 1 8.78 PD-1/ Non-Small Cell MSK- A0301,A3001,B5701, A03,A01A03,B58, 0 PDL-1 Lung Cancer IMPACT B1801,C0602,C0701 B44,UNK,UNK IN573123 31-50 4 0 28.96 PD-1/ Non-Small Cell MSK- A0101,A2601,B3801, A01,A01,B27, 0 PDL-1 Lung Cancer IMPACT B5801,C1203,C0706 B58,UNK,UNK TG765862 31-50 3 0 0.88 PD-1/ Adrenocortical MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 Carcinoma IMPACT B0702,C0303,C0701 B07,UNK,UNK OV436909 61-70 0 0 8.78 PD-1/ Cancer of MSK- A6602,A3303,B5801, A03,A03,B58, 0 PDL-1 Unknown IMPACT B5301,C0404,C0706 B07,UNK,UNK Primary UA206372 61-70 3 0 24.58 Combo Melanoma MSK- A0301,A0201,B0801, A03,A02,B08, 0 IMPACT B4402,C0501,C0701 B44,UNK,UNK OX953757 31-50 0 0 5.27 PD-1/ Renal Cell MSK- A3201,A0201,B5501, A01,A02,B07, 0 PDL-1 Carcinoma IMPACT B5101,C0102,C1402 B07,UNK,UNK PJ953909 50-60 0 0 11.41 PD-1/ Non-Small Cell MSK- A0301,A1101,B3501, A03,A03,B07, 0 PDL-1 Lung Cancer IMPACT B5101,C1502,C0401 B07,UNK,UNK XA307833 50-60 0 0 2.63 PD-1/ Adrenocortical MSK- A0205,A2601,B3501, A02,A01,B07, 0 PDL-1 Carcinoma IMPACT B5001,C0602,C0401 B44,UNK,UNK JX834810 >71 1 0 0.88 PD-1/ Breast Cancer MSK- A0301,A0201,B5703, A03,A02,B58, 0 PDL-1 IMPACT B5801,C0706,C1801 B58,UNK,UNK YQ490591 31-50 2 0 5.27 PD-1/ Melanoma MSK- A0301,A3201,B3801, A03,A01,B27, 0 PDL-1 IMPACT B3501,C1203,C0401 B07,UNK,UNK QZ553792 31-50 0 0 19.31 PD-1/ Non-Small Cell MSK- A3001,A2402,B3501, A01A03,A24,B07, 0 PDL-1 Lung Cancer IMPACT B1302,C0602,C0401 UNK,UNK,UNK MF150507 31-50 2 0 10.53 PD-1/ Melanoma MSK- A0301,A0101,B0702, A03,A01,B07, 1 PDL-1 IMPACT B0702,C0702,C0702 B07,UNK,UNK PG599368 31-50 6 0 4.39 PD-1/ Non-Small Cell MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 Lung Cancer IMPACT B1516,C1402,C0701 B58,UNK,UNK LE993613 61-70 9 0 3.51 CTLA4 Breast Cancer MSK- A1101,A0201,B1803, A03,A02,B44, 0 IMPACT B3503,C0401,C0701 B07,UNK,UNK LS244934 31-50 0 0 6.14 PD-1/ Non-Small Cell MSK- A0201,A0201,B4402, A02,A02,B44, 1 PDL-1 Lung Cancer IMPACT B1501,C0401,C0501 B62,UNK,UNK EW664244 31-50 9 0 14.04 PD-1/ Non-Small Cell MSK- A0201,A3101,B0702, A02,A03,B07, 0 PDL-1 Lung Cancer IMPACT B1801,C0701,C0702 B44,UNK,UNK NK732633 50-60 2 0 21.07 Combo Melanoma MSK- A0301,A3002,B5604, A03,A01,B07, 0 IMPACT B3501,C0102,C0401 B07,UNK,UNK HP971166 31-50 0 0 2.63 PD-1/ Melanoma MSK- A0301,A2402,B4002, A03,A24,B44, 0 PDL-1 IMPACT B3501,C0202,C0401 B07,UNK,UNK WD007754 31-50 9 0 3.51 PD-1/ Bladder Cancer MSK- A1101,A0201,B4402, A03,A02,B44, 0 PDL-1 IMPACT B5101,C1502,C0501 B07,UNK,UNK OE782061 31-50 1 0 13.17 PD-1/ Non-Small Cell MSK- A0101,A2601,B0801, A01,A01,B08, 0 PDL-1 Lung Cancer IMPACT B2705,C0202,C0701 B27,UNK,UNK DD060789 61-70 9 0 13.17 PD-1/ Colorectal MSK- A2402,A3101,B0702, A24,A03,B07, 0 PDL-1 Cancer IMPACT B3501,C0401,C0702 B07,UNK,UNK RA911363 50-60 0 0 1.76 PD-1/ Cancer of MSK- A0301,A1101,B5701, A03,A03,B58, 0 PDL-1 Unknown IMPACT B5301,C0401,C0602 B07,UNK,UNK Primary CV324207 >71 1 0 0.88 PD-1/ Breast Cancer MSK- A0301,A0101,B0702, A03,A01,B07, 0 PDL-1 IMPACT B5701,C0602,C0702 B58,UNK,UNK RV653854 31-50 2 0 51.79 PD-1/ Melanoma MSK- A0101,A2402,B0801, A01,A24,B08, 0 PDL-1 IMPACT B1801,C1203,C0701 B44,UNK,UNK MM502191 50-60 2 1 2.63 PD-1/ Breast Cancer MSK- A0101,A0101,B0801, A01,A01,B08, 1 PDL-1 IMPACT B0801,C0701,C0701 B08,UNK,UNK TY080273 61-70 0 0 6.14 PD-1/ Colorectal MSK- A2301,A3301,B4201, A24,A03,B07, 0 PDL-1 Cancer IMPACT B7801,C1601,C1701 B07,UNK,UNK CF668249 >71 0 0 3.51 PD-1/ Melanoma MSK- A0301,A1101,B0702, A03,A03,B07, 0 PDL-1 IMPACT B3501,C0401,C0702 B07,UNK,UNK HI514659 31-50 3 0 1.76 Combo Melanoma MSK- A2402,A3201,B5701, A24,A01,B58, 0 IMPACT B5101,C1402,C0602 B07,UNK,UNK RY826164 31-50 1 0 2.63 PD-1/ Non-Small Cell MSK- A0201,A0201,B1801, A02,A02,B44, 1 PDL-1 Lung Cancer IMPACT B5502,C0102,C1203 B07,UNK,UNK GK989158 31-50 5 1 24.58 PD-1/ Non-Small Cell MSK- A0301,A0101,B0801, A03,A01,B08, 0 PDL-1 Lung Cancer IMPACT B1501,C0303,C0701 B62,UNK,UNK RF088631 61-70 4 0 4.39 PD-1/ Glioma MSK- A0301,A0101,B0702, A03,A01,B07, 0 PDL-1 IMPACT B0801,C0701,C0702 B08,UNK,UNK BX552244 31-50 2 0 23.7 PD-1/ Bladder Cancer MSK- A2402,A0201,B4002, A24,A02,B44, 0 PDL-1 IMPACT B1501,C0303,C0202 B62,UNK,UNK HT859944 31-50 4 0 5.27 PD-1/ Non-Small Cell MSK- A0201,A6901,B4402, A02,A02,B44, 0 PDL-1 Lung Cancer IMPACT B5101,C1502,C0501 B07,UNK,UNK OF320000 31-50 0 0 8.78 PD-1/ Bladder Cancer MSK- A2301,A2402,B4101, A24,A24,B44, 0 PDL-1 IMPACT B4901,C0701,C1701 UNK,UNK,UNK UC505968 >71 3 0 7.9 PD-1/ Head and Neck MSK- A3001,A0201,B4201, A01A03,A02,B07, 0 PDL-1 Cancer IMPACT B3501,C1601,C1701 B07,UNK,UNK SV274110 31-50 7 0 0.88 PD-1/ Non-Small Cell MSK- A0301,A2402,B2705, A03,A24,B27, 0 PDL-1 Lung Cancer IMPACT B5101,C0102,C0202 B07,UNK,UNK XE015183 >71 0 0 16.68 Combo Cancer of MSK- A2402,A0201,B4001, A24,A02,B44, 1 Unknown IMPACT B4001,C0304,C0304 B44,UNK,UNK Primary IY101457 50-60 5 0 0 PD-1/ Head and Neck MSK- A0205,A3301,B1402, A02,A03,B27, 0 PDL-1 Cancer IMPACT B5001,C0802,C0602 B44,UNK,UNK OA243943 31-50 14 0 46.52 Combo Breast Cancer MSK- A0301,A0101,B0801, A03,A01,B08, 1 IMPACT B0801,C0701,C0701 B08,UNK,UNK GV237003 31-50 1 0 23.7 PD-1/ Head and Neck MSK- A0101,A2601,B0801, A01,A01,B08, 0 PDL-1 Cancer IMPACT B1503,C1203,C0701 B27,UNK,UNK QM933384 31-50 2 0 18.43 PD-1/ Melanoma MSK- A2402,A3301,B1401, A24,A03,B27, 0 PDL-1 IMPACT B1517,C0802,C0701 B58,UNK,UNK BF819843 31-50 1 0 5.27 PD-1/ Head and Neck MSK- A6807,A3201,B2702, A02,A01,B27, 0 PDL-1 Cancer IMPACT B4402,C0202,C0501 B44,UNK,UNK KV679102 50-60 6 0 35.11 Combo Melanoma MSK- A0302,A0201,B0801, A03,A02,B08, 1 IMPACT B0801,C0701,C0701 B08,UNK,UNK WW331877 31-50 7 0 14.04 PD-1/ Bladder Cancer MSK- A1101,A0201,B1801, A03,A02,B44, 0 PDL-1 IMPACT B3501,C0401,C0701 B07,UNK,UNK HI004568 31-50 4 0 42.13 PD-1/ Bladder Cancer MSK- A0201,A0201,B4403, A02,A02,B44, 1 PDL-1 IMPACT B3503,C1601,C0401 B07,UNK,UNK OW961409 <30 0 0 1.76 PD-1/ Melanoma MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 IMPACT B4402,C0501,C0701 B44,UNK,UNK UB602657 50-60 0 1 7.9 PD-1/ Non-Small Cell MSK- A0205,A0201,B4006, A02,A02,B44, 0 PDL-1 Lung Cancer IMPACT B5001,C1502,C0602 B44,UNK,UNK ND701493 50-60 4 0 26.33 Combo Melanoma MSK- A0301,A0101,B5501, A03,A01,B07, 0 IMPACT B1402,C0303,C0802 B27,UNK,UNK ND919429 61-70 5 0 6.14 PD-1/ Non-Small Cell MSK- A0101,A0201,B4002, A01,A02,B44, 0 PDL-1 Lung Cancer IMPACT B4402,C0202,C0704 B44,UNK,UNK LH998687 50-60 2 0 79.87 Combo Melanoma MSK- A3201,A0201,B4402, A01,A02,B44, 1 IMPACT B4402,C0501,C0704 B44,UNK,UNK MX747377 50-60 3 0 21.07 PD-1/ Non-Small Cell MSK- A0301,A2402,B3801, A03,A24,B27, 0 PDL-1 Lung Cancer IMPACT B3502,C1203,C0401 B07,UNK,UNK EJ342170 31-50 1 0 4.39 PD-1/ Head and Neck MSK- A1101,A2402,B3501, A03,A24,B07, 0 PDL-1 Cancer IMPACT B4402,C0401,C0501 B44,UNK,UNK RR251424 50-60 1 1 5.27 PD-1/ Non-Small Cell MSK- A7401,A0201,B1801, A03,A02,B44, 1 PDL-1 Lung Cancer IMPACT B1801,C0202,C0701 B44,UNK,UNK AY135758 50-60 2 0 8.78 PD-1/ Cancer of MSK- A0201,A0201,B0702 A02,A02,B07, 1 PDL-1 Unknown IMPACT B0702,C0304,C0702 B07,UNK,UNK Primary YD425234 61-70 1 0 4.39 PD-1/ Non-Small Cell MSK- A6802,A3201,B1503, A02,A01,B27, 0 PDL-1 Lung Cancer IMPACT B7801,C0304,C1601 B07,UNK,UNK TO095715 <30 2 0 5.27 PD-1/ Non-Small Cell MSK- A0101,A2402,B0801, A01,A24,B08, 0 PDL-1 Lung Cancer IMPACT B2702,C0202,C0701 B27,UNK,UNK NE782263 61-70 2 0 19.31 PD-1/ Melanoma MSK- A0301,A2902,B1402, A03,A01A24,B27, 0 PDL-1 IMPACT B1501,C0304,C0802 B62,UNK,UNK KN798898 50-60 3 0 0.88 PD-1/ Mesothelioma MSK- A2901,A2601,B3801, A01A24,A01,B27, 0 PDL-1 IMPACT B5701,C1203,C0701 B58,UNK,UNK IR692253 50-60 3 0 9.65 PD-1/ Non-Small Cell MSK- A0101,A0101,B3502, A01,A01,B07, 1 PDL-1 Lung Cancer IMPACT B5703,C0401,C0602 B58,UNK,UNK YH996041 31-50 24 0 31.6 PD-1/ Bladder Cancer MSK- A1101,A2601,B0702, A03,A01,B07, 0 PDL-1 IMPACT B4402,C0501,C0702 B44,UNK,UNK VT397227 31-50 3 1 6.14 PD-1/ Bladder Cancer MSK- A0301,A6801,B0801, A03,A03,B08, 0 PDL-1 IMPACT B4402,C0501,C0701 B44,UNK,UNK JI889906 31-50 6 0 15.8 PD-1/ Bladder Cancer MSK- A2601,A6801,B3801, A01,A03,B27, 0 PDL-1 IMPACT B5701,C1203,C0701 B58,UNK,UNK OR646732 31-50 3 0 15.8 PD-1/ Non-Hodgkin MSK- A2601,A2601,B2705, A01,A01,B27, 1 PDL-1 Lymphoma IMPACT B1801,C0202,C1203 B44,UNK,UNK UD537460 61-70 2 0 5.27 PD-1/ Non-Small Cell MSK- A0301,A0101,B1501, A03,A01,B62, 0 PDL-1 Lung Cancer IMPACT B3501,C0303,C0401 B07,UNK,UNK LM227756 50-60 0 0 4.39 PD-1/ Glioma MSK- A0201,A0205,B4101, A02,A02,B44, 0 PDL-1 IMPACT B1501,C0304,C0701 B62,UNK,UNK VW330608 <30 1 0 5.27 PD-1/ Non-Small Cell MSK- A0101,A2601,B0801, A01,A01,B08, 0 PDL-1 Lung Cancer IMPACT B3801,C1203,C0701 B27,UNK,UNK MC345007 61-70 4 0 5.27 Combo Melanoma MSK- A2901,A2601,B0705, A01A24,A01,B07, 0 IMPACT B3801,C1505,C1203 B27,UNK,UNK BC681957 50-60 4 0 2.63 PD-1/ Renal Cell MSK- A0201,A0201,B0702, A02,A02,B07, 1 PDL-1 Carcinoma IMPACT B4402,C0501,C0702 B44,UNK,UNK MS303882 61-70 9 0 3.51 PD-1/ Esophago- MSK- A0201,A0201,B0702, A02,A02,B07, 1 PDL-1 gastric Cancer IMPACT B4402,C0501,C0501 B44,UNK,UNK ZY851796 50-60 7 1 5.27 PD-1/ Bladder Cancer MSK- A2601,A0201,B2705, A01,A02,B27, 0 PDL-1 IMPACT B4403,C0102,C0401 B44,UNK,UNK DE743683 31-50 0 0 2.63 PD-1/ Non-Small Cell MSK- A1101,A0207,B2705, A03,A02,B27, 0 PDL-1 Lung Cancer IMPACT B5801,C0102,C0302 B58,UNK,UNK XC690073 50-60 1 0 7.9 PD-1/ Non-Small Cell MSK- A1101,A0201,B5501, A03,A02,B07, 0 PDL-1 Lung Cancer IMPACT B4405,C0303,C0202 B44,UNK,UNK LI926221 31-50 1 0 5.27 PD-1/ Bladder Cancer MSK- A0201,A0201,B4102, A02,A02,B44, 1 PDL-1 IMPACT B4405,C0202,C1701 B44,UNK,UNK SK041077 31-50 2 0 4.39 PD-1/ Non-Small Cell MSK- A0201,A0201,B4101, A02,A02,B44, 1 PDL-1 Lung Cancer IMPACT B1801,C0701,C1701 B44,UNK,UNK BU012611 31-50 3 0 3.51 PD-1/ Bladder Cancer MSK- A3201,A0201,B1401, A01,A02,B27, 0 PDL-1 IMPACT B5201,C1202,C0802 B62,UNK,UNK JK338812 50-60 10 0 2.63 PD-1/ Glioma MSK- A3001,A3201,B3502, A01A03,A01,B07, 0 PDL-1 IMPACT B1302,C0602,C0401 UNK,UNK,UNK LM615085 31-50 3 0 21.07 PD-1/ Bladder Cancer MSK- A0301,A0201,B4403, A03,A02,B44, 0 PDL-1 IMPACT B5108,C0501,C0706 B07,UNK,UNK GG838274 31-50 0 0 6.14 PD-1/ Head and Neck MSK- A0101,A0201,B5701, A01,A02,B58, 0 PDL-1 Cancer IMPACT B3503,C0602,C0401 B07,UNK,UNK CK759649 >71 1 0 13.17 Combo Melanoma MSK- A0201,A3303,B3501, A02,A03,B07, 0 IMPACT B5101,C1502,C0401 B07,UNK,UNK PR346356 61-70 5 1 14.04 PD-1/ Bladder Cancer MSK- A0302,A0201,B2705, A03,A02,B27, 0 PDL-1 IMPACT B4402,C1604,C0202 B44,UNK,UNK TG872084 31-50 0 0 1.76 PD-1/ Melanoma MSK- A0301,A0201,B1801, A03,A02,B44, 0 PDL-1 IMPACT B4501,C0501,C1701 B44,UNK,UNK WB544363 31-50 1 0 0.87 PD-1/ Melanoma MSK- A0101,A0101,B0801, A01,A01,B08, 1 PDL-1 IMPACT B0801,C0701,C0701 B08,UNK,UNK HU011383 31-50 0 0 0.88 PD-1/ Renal Cell MSK- A0101,A0201,B1501, A01,A02,B62, 0 PDL-1 Carcinoma IMPACT B5201,C1202,C0202 B62,UNK,UNK OZ964185 50-60 0 0 1.76 PD-1/ Glioma MSK- A0201,A0201,B4001, A02,A02,B44, 1 PDL-1 IMPACT B1501,C0304,C0401 B62,UNK,UNK BX967817 31-50 2 0 100.06 PD-1/ Melanoma MSK- A3004,A0201,B1501, A01,A02,B62, 0 PDL-1 IMPACT B3502,C0303,C0401 B07,UNK,UNK KZ583833 61-70 11 1 1.97 Combo Bladder Cancer MSK- A0206,A3303,B4801, A02,A03,B27, 0 IMPACT B4801,C0302,C0401 B58,UNK,UNK GB398563 31-50 12 0 26.56 PD-1/ Melanoma MSK- A2402,A2601,B3502, A24,A01,B07, 0 PDL-1 IMPACT B3801,C0401,C1203 B27,UNK,UNK WW668436 61-70 6 1 1.97 PD-1/ Cancer of MSK- A2402,A2601,B0702, A24,A01,B07, 0 PDL-1 Unknown IMPACT B3801,C1203,C0702 B27,UNK,UNK Primary VK845635 50-60 2 1 1.97 PD-1/ Pancreatic MSK- A3004,A2301,B3701, A01,A24,B44, 0 PDL-1 Cancer IMPACT B4101,C0602,C1701 B44,UNK,UNK KS136792 50-60 18 0 2.95 CTLA4 Melanoma MSK- A2402,A3303,B5701, A24,A03,B58, 0 IMPACT B3503,C0302,C0701 B07,UNK,UNK RT578755 50-60 9 0 3.94 CTLA4 Breast Cancer MSK- A2402,A6802,B0702, A24,A02,B07, 0 IMPACT B5201,C1202,C0702 B62,UNK,UNK AI716687 50-60 34 1 0 PD-1/ Head and Neck MSK- A1101,A3201,B4001, A03,A01,B44, 0 PDL-1 Cancer IMPACT B5201,C0304,C1202 B62,UNK,UNK EP826889 31-50 7 0 25.58 PD-1/ Melanoma MSK- A0301,A1101,B0702, A03,A03,B07, 0 PDL-1 IMPACT B4403,C0401,C0702 B44,UNK,UNK DE217723 31-50 9 0 1.97 PD-1/ Bladder Cancer MSK- A0101,A6801,B5701, A01,A03,B58, 0 PDL-1 IMPACT B4001,C0304,C0602 B44,UNK,UNK EM140795 61-70 13 1 4.92 PD-1/ Colorectal MSK- A2601,A0201,B3801, A01,A02,B27, 1 PDL-1 Cancer IMPACT B5001,C1203,C1203 B44,UNK,UNK FE593501 >71 9 0 3.94 Combo Colorectal MSK- A0301,A0101,B0702, A03,A01,B07, 0 Cancer IMPACT B5701,C0602,C0702 B58,UNK,UNK FJ722993 31-50 10 0 5.9 PD-1/ Small Cell MSK- A3002,A0201,B3501, A01,A02,B07, 1 PDL-1 Lung Cancer IMPACT B5301,C0401,C0401 B07,UNK,UNK FL700026 31-50 5 0 9.84 PD-1/ Head and Neck MSK- A2902,A3101,B5703, A01A24,A03,B58, 0 PDL-1 Cancer IMPACT B4403,C1601,C0706 B44,UNK,UNK NT293292 50-60 2 1 2.95 Combo Pancreatic MSK- A0301,A2601,B3801, A03,A01,B27, 1 Cancer IMPACT B1801,C1203,C1203 B44,UNK,UNK GW362077 61-70 4 0 2.95 PD-1/ Gastrointestinal MSK- A0101,A0101,B0801, A01,A01,B08, 1 PDL-1 Stromal Tumor IMPACT B0801,C0701,C0701 B08,UNK,UNK QS331947 <30 0 0 5.9 PD-1/ Non-Small Cell MSK- A3002,A3002,B3801, A01,A01,B27, 1 PDL-1 Lung Cancer IMPACT B5801,C0302,C1203 B08,UNK,UNK AH761070 31-50 9 1 9.84 PD-1/ Bladder Cancer MSK- A1101,A0101,B0702, A03,A01,B07, 0 PDL-1 IMPACT B0801,C0701,C0702 B08,UNK,UNK FB523718 50-60 3 0 0 PD-1/ Melanoma MSK- A0201,A0201,B1501, A02,A02,B62, 1 PDL-1 IMPACT B5101,C0303,C0501 B07,UNK,UNK NJ637519 31-50 2 0 43.29 PD-1/ Colorectal MSK- A0101,A3201,B4901, A01,A01,UNK, 0 PDL-1 Cancer IMPACT B5201,C1202,C0701 B62,UNK,UNK TP649659 50-60 7 0 15.74 CTLA4 Soft Tissue MSK- A0301,A0201,B0702, A03,A02,B07, 0 Sarcoma IMPACT B5201,C1202,C0702 B62,UNK,UNK BF585566 31-50 3 0 8.85 PD-1/ Bladder Cancer MSK- A6802,A2601,B1402, A02,A01,B27, 0 PDL-1 IMPACT B3801,C0802,C1203 B27,UNK,UNK IK895715 31-50 22 0 7.87 PD-1/ Head and Neck MSK- A2601,A0201,B0705, A01,A02,B07, 0 PDL-1 Cancer IMPACT B6701,C1505,C1203 B07,UNK,UNK EI131873 50-60 15 1 9.84 PD-1/ Small Cell MSK- A1101,A0101,B1517, A03,A01,B58, 0 PDL-1 Lung Cancer IMPACT B5101,C1502,C0701 B07,UNK,UNK FW803759 50-60 54 0 19.68 CTLA4 Melanoma MSK- A0101,A2402,B0702, A01,A24,B07, 0 IMPACT B5501,C0303,C0702 B07,UNK,UNK GW946602 31-50 6 0 7.87 PD-1/ Melanoma MSK- A0101,A0201,B1517, A01,A02,B58, 0 PDL-1 IMPACT B1801,C0501,C0701 B44,UNK,UNK PZ923250 31-50 3 0 3.94 PD-1/ Glioma MSK- A0301,A3101,B0702, A03,A03,B07, 0 PDL-1 IMPACT B3508,C0401,C0702 B07,UNK,UNK ZJ847611 31-50 9 0 0 PD-1/ Non-Hodgkin MSK- A0101,A2601,B5701, A01,A01,B58, 0 PDL-1 Lymphoma IMPACT B3801,C1203,C0602 B27,UNK,UNK BW398128 31-50 2 1 9.84 PD-1/ Non-Small Cell MSK- A3201,A0201,B0702, A01,A02,B07, 0 PDL-1 Lung Cancer IMPACT B4002,C0202,C0702 B44,UNK,UNK FG408326 31-50 5 1 6.89 PD-1/ Hepatobiliary MSK- A3001,A0101,B0801, A01A03,A01,B08, 1 PDL-1 Cancer IMPACT B1801,C0701,C0701 B44,UNK,UNK PD448224 50-60 2 1 2.95 PD-1/ Adrenocortical MSK- A0301,A0301,B0702, A03,A03,B07, 1 PDL-1 Carcinoma IMPACT B1501,C0304,C0702 B62,UNK,UNK IS872618 50-60 7 0 4.92 PD-1/ Renal Cell MSK- A0101,A0101,B5501, A01,A01,B07, 1 PDL-1 Carcinoma IMPACT B1517,C0102,C0701 B68,UNK,UNK LR744370 50-60 19 0 8.85 Combo Melanoma MSK- A3002,A2402,B1402, A01,A24,B27, 0 IMPACT B1508,C0102,C0802 B07,UNK,UNK PW748829 61-70 54 0 4.92 CTLA4 Melanoma MSK- A6801,A0201,B5701, A03,A02,B58, 0 IMPACT B4402,C0501,C0602 B44,UNK,UNK JW229525 31-50 41 0 2.95 Combo Non-Small Cell MSK- A0301,A0201,B1501, A03,A02,B62, 0 Lung Cancer IMPACT B5802,C0303,C0602 B58,UNK,UNK NR471516 31-50 12 1 8.85 PD-1/ Melanoma MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 IMPACT B6701,C1203,C0702 B07,UNK,UNK XM766857 31-50 8 0 5.9 PD-1/ Renal Cell MSK- A0201,A0201,B2705, A02,A02,B27, 1 PDL-1 Carcinoma IMPACT B3801,C0102,C1203 B27,UNK,UNK YV996814 50-60 17 0 6.89 PD-1/ Colorectal MSK- A2402,A3301,B1402, A24,A03,B27, 0 PDL-1 Cancer IMPACT B0801,C0802,C0718 B08,UNK,UNK QR822407 50-60 17 0 18.69 Combo Melanoma MSK- A1101,A0201,B0702, A03,A02,B07, 0 IMPACT B1801,C0702,C0701 B44,UNK,UNK RF041334 50-60 30 0 2.95 PD-1/ Renal Cell MSK- A0201,A2601,B0801, A02,A01,B08, 1 PDL-1 Carcinoma IMPACT B1801,C0701,C0701 B44,UNK,UNK SP588250 31-50 6 0 6.89 PD-1/ Non-Small Cell MSK- A2402,A3303,B4001, A24,A03,B44, 0 PDL-1 Lung Cancer IMPACT B5801,C0302,C0702 B58,UNK,UNK SS128035 31-50 4 0 8.85 PD-1/ Head and Neck MSK- A2402,A2601,B1501, A24,A01,B62, 0 PDL-1 Cancer IMPACT B3801,C0303,C1203 B27,UNK,UNK WN367297 31-50 15 0 3.94 PD-1/ Non-Small Cell MSK- A3101,A3301,B1402, A03,A03,B27, 0 PDL-1 Lung Cancer IMPACT B3801,C0802,C1203 B27,UNK,UNK YG152378 50-60 3 0 11.81 PD-1/ Non-Hodgkin MSK- A0301,A2601,B0702, A03,A01,B07, 0 PDL-1 Lymphoma IMPACT B1801,C1203,C0702 B44,UNK,UNK NY093664 61-70 2 1 10.82 PD-1/ Non-Small Cell MSK- A0101,A0201,B1501, A01,A02,B62, 1 PDL-1 Lung Cancer IMPACT B3501,C0401,C0401 B07,UNK,UNK BC811776 61-70 2 0 22.63 PD-1/ Non-Small Cell MSK- A0101,A6801,B3701, A01,A03,B44, 0 PDL-1 Lung Cancer IMPACT B4402,C0602,C0704 B44,UNK,UNK CB764271 31-50 5 1 0 PD-1/ Hepatobiliary MSK- A0101,A2402,B3502, A01,A24,B07, 0 PDL-1 Cancer IMPACT B5501,C0303,C0401 B07,UNK,UNK DB559032 50-60 4 0 7.87 Combo Melanoma MSK- A0301,A2402,B0702, A03,A24,B07, 0 IMPACT B3508,C0401,C0702 B07,UNK,UNK HC203191 31-50 11 0 7.87 PD-1/ Non-Small Cell MSK- A0301,A3303,B4901, A03,A03,UNK, 0 PDL-1 Lung Cancer IMPACT B3501,C0802,C0701 B07,UNK,UNK OS427829 61-70 7 0 2.95 CTLA4 Prostate MSK- A0101,A0101,B0801, A01,A01,B08, 1 Cancer IMPACT B0801,C0701,C0701 B08,UNK,UNK VR485557 31-50 19 0 4.92 PD-1/ Bladder Cancer MSK- A0201,A0201,B0801, A02,A02,B08, 1 PDL-1 IMPACT B3508,C0401,C0701 B07,UNK,UNK XU013435 50-60 6 0 23.61 PD-1/ Non-Small Cell MSK- A3001,A2402,B1801, A01A03,A24,B44, 0 PDL-1 Lung Cancer IMPACT B1302,C0602,C0701 UNK,UNK,UNK YA270966 31-50 40 0 6.89 Combo Melanoma MSK- A0301,A0206,B0702, A03,A02,B07, 0 IMPACT B4801,C0803,C0702 B27,UNK,UNK KQ222690 50-60 15 0 4.92 PD-1/ Renal Cell MSK- A2402,A2301,B3801, A24,A24,B27, 0 PDL-1 Carcinoma IMPACT B4901,C1203,C0701 UNK,UNK,UNK RR191649 31-50 3 1 5.9 PD-1/ Cancer of MSK- A3001,A3201,B5501, A01A03,A01,B07, 0 PDL-1 Unknown IMPACT B1302,C0304,C0602 UNK,UNK,UNK Primary ZJ250921 50-60 1 1 10.82 PD-1/ Non-Small Cell MSK- A0301,A3001,B5601, A03,A01A03,B07, 0 PDL-1 Lung Cancer IMPACT B5101,C0102,C0401 B07,UNK,UNK DE029388 61-70 1 1 6.89 PD-1/ Bladder Cancer MSK- A0201,A0201,B4405, A02,A02,B44, 1 PDL-1 IMPACT B1302,C0202,C0602 UNK,UNK,UNK GS420214 31-50 36 0 3.94 Combo Non-Small Cell MSK- A0301,A0201,B2705, A03,A02,B27, 0 Lung Cancer IMPACT B3801,C0102,C1203 B27,UNK,UNK IL444062 31-50 0 1 2.95 PD-1/ Thyroid MSK- A0301,A2402,B0702, A03,A24,B07, 0 PDL-1 Cancer IMPACT B4001,C0304,C0702 B44,UNK,UNK RA263407 61-70 5 0 24.59 PD-1/ Adrenocortical MSK- A6801,A6601,B4001, A03,A03,B44, 0 PDL-1 Carcinoma IMPACT B4005,C0304,C0202 B44,UNK,UNK RP070224 >71 5 0 2.95 PD-1/ Colorectal MSK- A2902,A0201,B4402, A01A24,A02,B44, 0 PDL-1 Cancer IMPACT B4403,C1601,C0501 B44,UNK,UNK TF488143 50-60 3 1 2.95 PD-1/ Renal Cell MSK- A0301,A0201,B0702, A03,A02,B07, 1 PDL-1 Carcinoma IMPACT B0702,C0702,C0702 B07,UNK,UNK TF785669 31-50 42 0 5.9 PD-1/ Non-Small Cell MSK- A3001,A0201,B4403, A01A03,A02,B44, 0 PDL-1 Lung Cancer IMPACT B1302,C0602,C1602 UNK,UNK,UNK UK971155 31-50 2 0 20.66 PD-1/ Non-Small Cell MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 Lung Cancer IMPACT B5701,C0602,C0701 B58,UNK,UNK WQ120057 <30 26 0 48.21 CTLA4 Skin Cancer; MSK- A0201,A2601,B3701, A02,A01,B44, 0 Non-Melanoma IMPACT B1501,C0602,C0704 B62,UNK,UNK BR374139 50-60 0 1 19.68 PD-1/ Non-Hodgkin MSK- A0101,A6801,B4001, A01,A03,B44, 0 PDL-1 Lymphoma IMPACT B1801,C0304,C1203 B44,UNK,UNK DD361465 >71 2 0 1.97 Combo Cancer of MSK- A2902,A6802,B4901, A01A24,A02,UNK, 0 Unknown IMPACT B5802,C0602,C0701 B58,UNK,UNK Primary GZ425566 50-60 3 1 2.95 PD-1/ Non-Small Cell MSK- A0101,A2402,B0702, A01,A24,B07, 0 PDL-1 Lung Cancer IMPACT B1801,C0102,C0702 B44,UNK,UNK HO127075 31-50 1 1 14.76 Combo Small Cell MSK- A0101,A0201,B0801, A01,A02,B08, 0 Lung Cancer IMPACT B4402,C0501,C0701 B44,UNK,UNK OT254694 50-60 11 0 2.95 PD-1/ Renal Cell MSK- A2402,A6802,B3503, A24,A02,B07, 1 PDL-1 Carcinoma IMPACT B3501,C0401,C0401 B07,UNK,UNK QV527200 31-50 7 0 10.82 CTLA4 Melanoma MSK- A3002,A3301,B1402, A01,A03,B27, 0 IMPACT B3801,C0802,C1203 B27,UNK,UNK TH564442 >71 11 1 3.94 PD-1/ Bone Cancer MSK- A0101,A2402,B0801, A01,A24,B08, 1 PDL-1 IMPACT B0801,C0701,C0701 B08,UNK,UNK ZP620505 31-50 18 1 25.58 PD-1/ Non-Small Cell MSK- A0301,A2902,B5101, A03,A01A24,B07, 0 PDL-1 Lung Cancer IMPACT B4403,C1502,C1601 B44,UNK,UNK IN021880 <30 4 0 4.92 PD-1/ Cancer of MSK- A0301,A0201,B0702, A03,A02,B07, 1 PDL-1 Unknown IMPACT B3906,C0702,C0702 B27,UNK,UNK Primary JP245287 31-50 11 0 3.94 PD-1/ Renal Cell MSK- A0301,A0101,B0702, A03,A01,B07, 0 PDL-1 Carcinoma IMPACT B0801,C0702,C0701 B08,UNK,UNK JX534724 >71 8 1 6.89 PD-1/ Bone Cancer MSK- A0301,A0301,B0702, A03,A03,B07, 1 PDL-1 IMPACT B4901,C0701,C0702 UNK,UNK,UNK MF335699 31-50 6 0 8.85 PD-1/ Bladder Cancer MSK- A0201,A0201,B0801, A02,A02,B08, 1 PDL-1 IMPACT B3901,C0701,C0702 B27,UNK,UNK NK472415 31-50 18 0 10.82 Combo Melanoma MSK- A3001,A0206,B2705, A01A03,A02,B27, 0 IMPACT B3508,C0303,C0401 B07,UNK,UNK OE799834 50-60 5 1 1.97 PD-1/ Glioma MSK- A0301,A0301,B1501, A03,A03,B62, 1 PDL-1 IMPACT B3801,C1203,C0303 B27,UNK,UNK OM501087 31-50 2 1 7.87 PD-1/ Non-Small Cell MSK- A1101,A2402,B1402, A03,A24,B27, 0 PDL-1 Lung Cancer IMPACT B5801,C0802,C0706 B58,UNK,UNK XX353415 >71 3 0 5.9 PD-1/ Melanoma MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 IMPACT B1402,C0802,C0701 B27,UNK,UNK HK376614 50-60 4 0 13.77 PD-1/ Melanoma MSK- A0101,A2402,B3701, A01,A24,B44, 0 PDL-1 IMPACT B1501,C0304,C0602 B62,UNK,UNK IF324640 >71 21 1 4.92 Combo Renal Cell MSK- A0301,A3101,B0702, A03,A03,B07, 0 Carcinoma IMPACT B5101,C1402,C0702 B07,UNK,UNK KB724373 50-60 0 1 0.98 PD-1/ Skin Cancer; MSK- A1101,A3201,B5501, A03,A01,B07, 0 PDL-1 Non-Melanoma IMPACT B3501,C0303,C0202 B07,UNK,UNK OJ108820 61-70 3 1 65.42 Combo Non-Small Cell MSK- A1101,A2402,B5701, A03,A24,B58, 0 Lung Cancer IMPACT B5101,C0303,C0602 B07,UNK,UNK RT756250 <30 15 0 0.98 PD-1/ Non-Small Cell MSK- A3101,A3303,B4403, A03,A03,B44, 0 PDL-1 Lung Cancer IMPACT B4006,C0801,C0706 B44,UNK,UNK TX830700 61-70 2 1 0.98 PD-1/ Bladder Cancer MSK- A0302,A6801,B0801, A03,A03,B08, 0 PDL-1 IMPACT B3503,C0401,C0701 B07,UNK,UNK WI841389 50-60 12 0 44.27 Combo Melanoma MSK- A0301,A3101,B0702, A03,A03,B07, 0 IMPACT B4001,C0304,C0702 B44,UNK,UNK ZP418201 50-60 7 0 1.97 PD-1/ Renal Cell MSK- A3001,A1101,B1302, A01A03,A03,UNK, 0 PDL-1 Carcinoma IMPACT B5101,C0102,C0602 B07,UNK,UNK ZU021130 >71 2 1 4.92 Combo Small Cell MSK- A1101,A0201,B0705, A03,A02,B07, 0 Lung Cancer IMPACT B4402,C0401,C0501 B44,UNK,UNK DA179245 50-60 8 0 8.85 PD-1/ Renal Cell MSK- A0101,A0201,B4901, A01,A02,UNK, 0 PDL-1 Carcinoma IMPACT B5701,C0602,C0701 B58,UNK,UNK EZ592112 <30 1 1 1.97 PD-1/ Mesothelioma MSK- A0302,A0201,B1517, A03,A02,B58, 1 PDL-1 IMPACT B1801,C0701,C0701 B44,UNK,UNK KT781325 <30 1 1 3.94 PD-1/ Melanoma MSK- A0201,A0201,B5601, A02,A02,B07, 1 PDL-1 IMPACT B1801,C0102,C0501 B44,UNK,UNK NU094987 50-60 3 1 3.94 PD-1/ Glioma MSK- A0301,A3201,B5701, A03,A01,B58, 0 PDL-1 IMPACT B3501,C0401,C0602 B07,UNK,UNK RE682184 31-50 0 0 3.94 PD-1/ Hepatobiliary MSK- A0201,A0201,B0702, A02,A02,B07, 1 PDL-1 Cancer IMPACT B4002,C0202,C0702 B44,UNK,UNK TX092727 50-60 3 0 4.92 PD-1/ Colorectal MSK- A2402,A2301,B4001, A24,A24,B44, 0 PDL-1 Cancer IMPACT B4101,C0304,C1701 B44,UNK,UNK UB564651 31-50 11 0 6.89 PD-1/ Renal Cell MSK- A0101,A2402,B0801, A01,A24,B08, 0 PDL-1 Carcinoma IMPACT B1801,C0303,C0701 B44,UNK,UNK VW357743 61-70 1 1 4.92 PD-1/ Non-Small Cell MSK- A1104,A0207,B4601, A03,A02,B62, 0 PDL-1 Lung Cancer IMPACT B1502,C0102,C0801 B62,UNK,UNK YA688084 61-70 16 0 36.4 Combo Melanoma MSK- A3004,A2902,B0702, A01,A01A24,B07, 0 IMPACT B5001,C0602,C0702 B44,UNK,UNK CC632903 31-50 2 0 7.87 PD-1/ Bladder Cancer MSK- A0201,A6802,B1402, A02,A02,B27, 0 PDL-1 IMPACT B1302,C0802,C0602 UNK,UNK,UNK GV583013 >71 7 1 3.94 Combo Melanoma MSK- A0301,A2902,B0702, A03,A01A24,B07, 0 IMPACT B4403,C1601,C0702 B44,UNK,UNK HX366182 >71 2 1 2.95 PD-1/ Glioma MSK- A2402,A2601,B4901, A24,A01,UNK 0 PDL-1 IMPACT B5301,C0401,C0701 B07,UNK,UNK JJ949081 31-50 7 0 7.87 PD-1/ Renal Cell MSK- A0101,A2402,B0801, A01,A24,B08, 0 PDL-1 Carcinoma IMPACT B1501,C0303,C0701 B62,UNK,UNK OR856491 31-50 6 1 5.9 PD-1/ Non-Small Cell MSK- A0101,A7401,B0801, A01,A03,B08, 0 PDL-1 Lung Cancer IMPACT B5601,C0102,C0706 B07,UNK,UNK RV811068 >71 12 1 3.94 Combo Melanoma MSK- A0301,A0206,B1501, A03,A02,B62, 0 IMPACT B4402,C0303,C0501 B44,UNK,UNK TW125733 50-60 7 0 1.97 PD-1/ Glioma MSK- A0101,A2402,B3906, A01,A24,B27, 0 PDL-1 IMPACT B4403,C0602,C0702 B44,UNK,UNK AZ957907 50-60 6 0 47.22 PD-1/ Bladder Cancer MSK- A0301,A2601,B3801, A03,A01,B27, 0 PDL-1 IMPACT B4002,C0202,C1203 B44,UNK,UNK FF392752 61-70 3 0 4.92 CTLA4 Breast Cancer MSK- A1101,A0201,B3503, A03,A02,B07, 1 IMPACT B3501,C0401,C0401 B07,UNK,UNK FO996647 >71 9 0 13.77 Combo Melanoma MSK- A0301,A2402,B5101, A03,A24,B07, 1 IMPACT B5101,C0102,C0102 B07,UNK,UNK TS839271 61-70 55 0 15.74 CTLA4 Melanoma MSK- A0301,A0101,B0702, A03,A01,B07, 0 IMPACT B4402,C0501,C0702 B44,UNK,UNK UK533610 31-50 7 1 1.97 PD-1/ Cancer of MSK- A0301,A3301,B0702, A03,A03,B07, 0 PDL-1 Unknown IMPACT B1402,C0802,C0702 B27,UNK,UNK Primary UQ148407 31-50 1 0 0 PD-1/ Head and Neck MSK- A0101,A0101,B0801, A01,A01,B08, 1 PDL-1 Cancer IMPACT B0801,C0701,C0701 B08,UNK,UNK ZP246475 50-60 35 1 4.92 PD-1/ Renal Cell MSK- A1101,A2402,B3502, A03,A24,B07, 0 PDL-1 Carcinoma IMPACT B5201,C1202,C0401 B62,UNK,UNK KR586940 50-60 6 1 7.87 PD-1/ Non-Small Cell MSK- A0101,A2403,B0801, A01,A24,B08, 0 PDL-1 Lung Cancer IMPACT B3502,C0401,C0701 B07,UNK,UNK LS271625 50-60 7 0 6.89 PD-1/ Hepatobiliary MSK- A2402,A3303,B4001, A24,A03,B44, 0 PDL-1 Cancer IMPACT B5801,C0302,C0702 B58,UNK,UNK NI627069 61-70 5 0 1.97 PD-1/ Hodgkin MSK- A0207,A3303,B4002, A02,A03,B44, 0 PDL-1 Lymphoma IMPACT B5801,C0303,C0302 B58,UNK,UNK PD519263 31-50 4 0 48.21 Combo Melanoma MSK- A2902,A0201,B0702, A01A24,A02,B07, 0 IMPACT B5101,C1601,C0702 B07,UNK,UNK RK555724 31-50 2 1 22.63 PD-1/ Bladder Cancer MSK- A2402,A3101,B4001, A24,A03,B44, 0 PDL-1 IMPACT B1801,C0304,C0701 B44,UNK,UNK UQ753932 50-60 34 0 9.84 PD-1/ Non-Small Cell MSK- A0301,A3201,B0801, A03,A01,B08, 0 PDL-1 Lung Cancer IMPACT B5101,C1502,C0702 B07,UNK,UNK YI876909 31-50 3 1 0.98 PD-1/ Renal Cell MSK- A0301,A2902,B1402, A03,A01A24,B27, 0 PDL-1 Carcinoma IMPACT B5101,C1402,C0802 B07,UNK,UNK EH052498 61-70 5 0 34.43 PD-1/ Non-Small Cell MSK- A0101,A0101,B0801, A01,A01,B08, 1 PDL-1 Lung Cancer IMPACT B5701,C0602,C0701 B58,UNK,UNK HB171494 >71 58 1 12.79 CTLA4 Melanoma MSK- A0101,A2402,B3502, A01,A24,B07, 0 IMPACT B1302,C0502,C0401 UNK,UNK,UNK HY420730 31-50 1 1 1.97 PD-1/ Mesothelioma MSK- A0101,A1101,B2705, A01,A03,B27, 1 PDL-1 IMPACT B1508,C0102,C0102 B07,UNK,UNK SM106076 >71 18 0 5.9 Combo Melanoma MSK- A0201,A0201,B4403, A02,A02,B44, 1 IMPACT B1801,C0706,C0701 B44,UNK,UNK XJ302031 >71 4 1 0.98 PD-1/ Hepatobiliary MSK- A2902,A6802,B5201, A01A24,A02,B62, 0 PDL-1 Cancer IMPACT B1302,C1604,C1202 UNK,UNK,UNK XJ364453 61-70 10 0 1.97 Combo Non-Small Cell MSK- A2301,A0201,B3801, A24,A02,B27, 0 Lung Cancer IMPACT B5001,C0401,C1203 B44,UNK,UNK BL021996 31-50 1 1 29.51 Combo Melanoma MSK- A2902,A0201,B1801, A01A24,A02,B44, 0 IMPACT B5108,C1203,C1602 B07,UNK,UNK CN050789 61-70 22 0 5.9 Combo Renal Cell MSK- A0101,A0101,B0702, A01,A01,B07, 1 Carcinoma IMPACT B0801,C0701,C0702 B08,UNK,UNK EO236447 31-50 7 0 8.85 PD-1/ Small Cell MSK- A0101,A0201,B4201, A01,A02,B07, 0 PDL-1 Lung Cancer IMPACT B0702,C0701,C0702 B07,UNK,UNK ME175230 31-50 1 1 4.92 PD-1/ Prostate MSK- A0301,A0201,B1801, A03,A02,B44, 0 PDL-1 Cancer IMPACT B3503,C0401,C0701 B07,UNK,UNK MX600877 61-70 13 0 5.9 PD-1/ Non-Small Cell MSK- A2402,A2601,B4101, A24,A01,B44, 0 PDL-1 Lung Cancer IMPACT B3801,C1203,C1701 B27,UNK,UNK TO021548 >71 17 0 7.87 Combo Melanoma MSK- A1101,A0101,B0801, A03,A01,B08, 0 IMPACT B4403,C1601,C0701 B44,UNK,UNK VC243698 >71 8 0 2.95 CTLA4 Melanoma MSK- A1101,A1101,B5502, A03,A03,B07, 1 IMPACT B5101,C0102,C1402 B07,UNK,UNK YD777623 31-50 2 0 5.9 PD-1/ Renal Cell MSK- A0201,A0201,B4006, A02,A02,B44, 1 PDL-1 Carcinoma IMPACT B1501,C0102,C0304 B62,UNK,UNK YT816084 50-60 2 1 7.87 PD-1/ Head and Neck MSK- A0101,A0201,B1402, A01,A02,B27, 0 PDL-1 Cancer IMPACT B1501,C0304,C0802 B62,UNK,UNK ZK930604 31-50 11 0 3.94 PD-1/ Non-Small Cell MSK- A1101,A3101,B1401, A03,A03,B27, 0 PDL-1 Lung Cancer IMPACT B4901,C0802,C0701 UNK,UNK,UNK ZM436268 >71 4 0 0 PD-1/ Pancreatic MSK- A0201,A0201,B0801, A02,A02,B08, 1 PDL-1 Cancer IMPACT B5102,C0401,C0701 B07,UNK,UNK ZN659436 50-60 12 1 0 Combo Anal Cancer MSK- A0201,A0201,B4402, A02,A02,B44, 1 IMPACT B4402,C0501,C0501 B44,UNK,UNK AK398732 31-50 3 1 6.89 PD-1/ Non-Small Cell MSK- A0101,A2601,B3901, A01,A01,B27, 0 PDL-1 Lung Cancer IMPACT B3502,C1203,C0602 B07,UNK,UNK DM247664 >71 7 0 0.98 PD-1/ Melanoma MSK- A0301,A0101,B0702, A03,A01,B07, 0 PDL-1 IMPACT B0801,C0701,C0702 B08,UNK,UNK GB961648 61-70 1 0 0 PD-1/ Hepatobiliary MSK- A1101,A2402,B4006, A03,A24,B44, 0 PDL-1 Cancer IMPACT B3901,C0801,C0702 B27,UNK,UNK LH544200 >71 2 1 30.5 PD-1/ Glioma MSK- A0101,A3201,B5701, A01,A01,B58, 0 PDL-1 IMPACT B4402,C0501,C0602 B44,UNK,UNK LQ635575 31-50 10 0 1.97 Combo Melanoma MSK- A1101,A0101,B1501, A03,A01,B62, 0 IMPACT B5701,C0303,C0602 B58,UNK,UNK PV718637 >71 0 0 0 PD-1/ Hepatobiliary MSK- A0301,A0301,B4002, A03,A03,B44, 1 PDL-1 Cancer IMPACT B5101,C1502,C0401 B07,UNK,UNK QC207302 31-50 11 0 15.74 PD-1/ Non-Small Cell MSK- A3001,A0201,B4101, A01A03,A02,B44, 0 PDL-1 Lung Cancer IMPACT B1302,C0602,C1701 UNK,UNK,UNK SH764427 >71 4 1 5.9 PD-1/ Non-Small Cell MSK- A0101,A2402,B3906, A01,A24,B27, 0 PDL-1 Lung Cancer IMPACT B4402,C1604,C0702 B44,UNK,UNK ZG143121 >71 7 1 8.85 PD-1/ Non-Small Cell MSK- A2402,A3201,B0702, A24,A01,B07, 0 PDL-1 Lung Cancer IMPACT B1401,C0802,C0702 B27,UNK,UNK BZ683679 50-60 24 0 2.95 PD-1/ Renal Cell MSK- A0101,A3201,B0801, A01,A01,B08, 0 PDL-1 Carcinoma IMPACT B4101,C0701,C1701 B44,UNK,UNK DO813858 >71 3 0 3.94 PD-1/ Glioma MSK- A0101,A3201,B1501, A01,A01,B62, 0 PDL-1 IMPACT B5701,C0304,C0602 B58,UNK,UNK GJ373999 31-50 32 1 5.9 Combo Melanoma MSK- A1101,A1101,B5101, A03,A03,B07, 1 IMPACT B3501,C0401,C0401 B07,UNK,UNK GX055672 >71 67 0 47.22 CTLA4 Melanoma MSK- A1101,A0101,B0801, A03,A01,B08, 1 IMPACT B1801,C0701,C0701 B44,UNK,UNK IW603773 50-60 6 0 7.87 PD-1/ Non-Small Cell MSK- A0201,A2601,B2705, A02,A01,B27, 0 PDL-1 Lung Cancer IMPACT B5101,C0202,C1602 B07,UNK,UNK MW215777 61-70 1 1 5.9 PD-1/ Anal Cancer MSK- A3004,A3001,B8101, A01,A01A03,B07, 0 PDL-1 IMPACT B5801,C0302,C0401 B58,UNK,UNK SM334656 31-50 5 0 9.84 PD-1/ Melanoma MSK- A0301,A0101,B0801, A03,A01,B08, 0 PDL-1 IMPACT B4001,C0304,C0701 B44,UNK,UNK TP561311 50-60 8 1 3.94 PD-1/ Renal Cell MSK- A0201,A2601,B3801, A02,A01,B27, 0 PDL-1 Carcinoma IMPACT B4402,C1203,C0501 B44,UNK,UNK VX282680 61-70 1 0 0 PD-1/ Melanoma MSK- A0217,A3201,B5101, A02,A01,B07, 1 PDL-1 IMPACT B5101,C1502,C1502 B07,UNK,UNK VZ379970 >71 18 0 6.89 PD-1/ Glioma MSK- A3001,A0101,B3502, A01A03,A01,B07, 0 PDL-1 IMPACT B1302,C0401,C0602 UNK,UNK,UNK AQ234293 31-50 3 0 6.89 PD-1/ Non-Small Cell MSK- A1101,A3201,B4002, A03,A01,B44, 0 PDL-1 Lung Cancer IMPACT B3501,C0202,C0401 B07,UNK,UNK BR404154 50-60 0 0 9.84 PD-1/ Non-Small Cell MSK- A2902,A6802,B1510, A01A24,A02,B27, 0 PDL-1 Lung Cancer IMPACT B4403,C0304,C1601 B44,UNK,UNK DU521291 61-70 9 0 0.98 PD-1/ Renal Cell MSK- A0301,A3201,B6701, A03,A01,B07, 0 PDL-1 Carcinoma IMPACT B5601,C0102,C1203 B07,UNK,UNK EZ372884 >71 7 1 0 PD-1/ Renal Cell MSK- A0301,A3201,B3901, A03,A01,B27, 0 PDL-1 Carcinoma IMPACT B4002,C0202,C1203 B44,UNK,UNK HO314880 31-50 1 1 10.82 Combo Melanoma MSK- A1101,A0201,B1501, A03,A02,B62, 0 IMPACT B4001,C0303,C0304 B44,UNK,UNK JC025622 31-50 17 0 45.25 Combo Melanoma MSK- A0301,A1101,B0702, A03,A03,B07, 0 IMPACT B4403,C1601,C0702 B44,UNK,UNK NE722159 <30 0 0 163.31 PD-1/ Melanoma MSK- A2902,A2601,B4403, A01A24,A01,B44, 0 PDL-1 IMPACT B1801,C1601,C1203 B44,UNK,UNK OU097839 31-50 25 0 2.95 CTLA4 Prostate MSK- A0202,A0202,B1501, A02,A02,B62, 1 Cancer IMPACT B4001,C0304,C0401 B44,UNK,UNK TF774146 61-70 9 0 53.12 PD-1/ Melanoma MSK- A2402,A0201,B3508, A24,A02,B07, 0 PDL-1 IMPACT B1801,C0401,C1203 B44,UNK,UNK VE454857 50-60 2 0 40.34 PD-1/ Bladder Cancer MSK- A2301,A3101,B4402, A24,A03,B44, 0 PDL-1 IMPACT B4901,C0501,C0701 UNK,UNK,UNK XE884868 31-50 20 0 0 Combo Renal Cell MSK- A0101,A2601,B3801, A01,A01,B27, 0 Carcinoma IMPACT B5701,C1203,C0602 B58,UNK,UNK ZE129370 31-50 7 0 12.79 PD-1/ Pancreatic MSK- A0101,A0205,B3801, A01,A02,B27, 0 PDL-1 Cancer IMPACT B3502,C0401,C1203 B07,UNK,UNK ZE213131 >71 3 0 3.94 Combo Bone MSK- A1101,A0203,B1512, A03,A02,B62, 0 Cancer IMPACT B1301,C0304,C0403 UNK,UNK,UNK DB788312 61-70 11 0 60.01 PD-1/ Bladder Cancer MSK- A2402,A3201,B0702, A24,A01,B07, 0 PDL-1 IMPACT B4001,C0304,C0702 B44,UNK,UNK NL327469 50-60 3 0 4.92 PD-1/ Bladder Cancer MSK- A2301,A0201,B0702, A24,A02,B07, 0 PDL-1 IMPACT B5801,C0718,C0702 B58,UNK,UNK NW860530 50-60 13 0 1.97 CTLA4 Gastrointestinal MSK- A0301,A0201,B1501, A03,A02,B52, 0 Stromal Tumor IMPACT B1801,C0303,C0501 B44,UNK,UNK OW683720 50-60 8 0 3.94 PD-1/ Renal Cell MSK- A3001,A6801,B1302, A01A03,A03,UNK, 0 PDL-1 Carcinoma IMPACT B3501,C0401,C0602 B07,UNK,UNK PX347610 31-50 9 1 4.92 PD-1/ Head and Neck MSK- A0301,A3002,B0702, A03,A01,B07, 0 PDL-1 Cancer IMPACT B4403,C1601,C0702 B44,UNK,UNK QH692221 31-50 0 1 8.85 PD-1/ Renal Cell MSK- A2403,A0201,B5601, A24,A02,B07, 1 PDL-1 Carcinoma IMPACT B4601,C0102,C0102 B62,UNK,UNK UE728227 >71 20 0 6.89 Combo Renal Cell MSK- A3201,A2601,B1801, A01,A01,B44, 0 Carcinoma IMPACT B5101,C1502,C1203 B07,UNK,UNK UW595893 61-70 1 0 5.9 PD-1/ Glioma MSK- A2301,A2901,B4403, A24,A01A24,B44, 0 PDL-1 IMPACT B4901,C1601,C0701 UNK,UNK,UNK XK080812 50-60 5 0 0.98 CTLA4 Melanoma MSK- A0101,A6802,B1402, A01,A02,B27, 0 IMPACT B3701,C0802,C0602 B44,UNK,UNK CW049799 50-60 37 0 2.95 Combo Non-Small Cell MSK- A1101,A2402,B4001, A03,A24,B44, 0 Lung Cancer IMPACT B1501,C0401,C0702 B62,UNK,UNK DR673373 50-60 20 0 14.76 Combo Melanoma MSK- A2402,A2402,B3502, A24,A24,B07, 1 IMPACT B4901,C0401,C0701 UNK,UNK,UNK NI498165 31-50 6 0 0.98 PD-1/ Head and Neck MSK- A0101,A0201,B0802, A01,A02,B08, 1 PDL-1 Cancer IMPACT B0802,C0701,C0701 B08,UNK,UNK NU583295 61-70 5 0 53.12 PD-1/ Colorectal MSK- A1101,A2402,B1505, A03,A24,B62, 0 PDL-1 Cancer IMPACT B3501,C0303,C0401 B07,UNK,UNK PJ173593 >71 12 0 2.95 PD-1/ Melanoma MSK- A2402,A0201,B5201, A24,A02,B62, 0 PDL-1 IMPACT B1501,C0303,C1202 B62,UNK,UNK PV847859 50-60 0 0 17.71 PD-1/ Cancer of MSK- A0301,A2601,B3801, A03,A01,B27, 1 PDL-1 Unknown IMPACT B3801,C1203,C1203 B27,UNK,UNK Primary PX688045 50-60 6 0 1.97 PD-1/ Renal Cell MSK- A0301,A3001,B1302, A03,A01A03,UNK, 0 PDL-1 Carcinoma IMPACT B5101,C1402,C0602 B07,UNK,UNK RC915805 >71 17 0 3.94 PD-1/ Bone MSK- A0201,A0201,B4901, A02,A02,UNK, 1 PDL-1 Cancer IMPACT B1501,C0303,C0701 B62,UNK,UNK SG503340 31-50 4 1 11.81 PD-1/ Non-Small Cell MSK- A2403,A2402,B1801, A24,A24,B44, 1 PDL-1 Lung Cancer IMPACT B1801,C1203,C0701 B44,UNK,UNK TH039944 >71 2 0 0.98 PD-1/ Bone MSK- A3002,A0201,B8101, A01,A02,B07, 0 PDL-1 Cancer IMPACT B4501,C1601,C0804 B44,UNK,UNK TP130607 50-60 1 0 0.98 PD-1/ Adrenocortical MSK- A0101,A0101,B0801, A01,A01,B08, 1 PDL-1 Carcinoma IMPACT B3501,C0401,C0701 B07,UNK,UNK VO020126 31-50 12 1 21.64 Combo Melanoma MSK- A0301,A0101,B0702, A03,A01,B07, 0 IMPACT B0801,C0701,C0702 B08,UNK,UNK WK971939 >71 11 0 0.98 PD-1/ Hodgkin MSK- A0101,A0101,B0801, A01,A01,B08, 1 PDL-1 Lymphoma IMPACT B0801,C0701,C0701 B08,UNK,UNK YV503688 50-60 19 0 1.97 PD-1/ Glioma MSK- A0301,A0302,B2705, A03,A03,B27, 0 PDL-1 IMPACT B4402,C0102,C0704 B44,UNK,UNK BA636244 31-50 26 0 3.94 Combo Renal Cell MSK- A2402,A0201,B1517, A24,A02,B58, 0 Carcinoma IMPACT B3503,C0401,C0701 B07,UNK,UNK BM256386 31-50 13 1 6.89 PD-1/ Non-Small Cell MSK- A2301,A2301,B4101, A24,A24,B44, 1 PDL-1 Lung Cancer IMPACT B5001,C0602,C1701 B44,UNK,UNK BT364903 50-60 15 0 1.97 Combo Melanoma MSK- A3002,A0205,B3701, A01,A02,B44, 0 IMPACT B1801,C0501,C0602 B44,UNK,UNK CQ365110 61-70 5 0 1.97 PD-1/ Glioma MSK- A0201,A3201,B0702, A02,A01,B07, 0 PDL-1 IMPACT B5701,C0602,C0702 B58,UNK,UNK DU909576 50-60 1 1 10.82 PD-1/ Non-Small Cell MSK- A0101,A2601,B1517, A01,A01,B58, 0 PDL-1 Lung Cancer IMPACT B3502,C0401,C0701 B07,UNK,UNK EK320634 61-70 10 1 10.82 PD-1/ Non-Small Cell MSK- A2601,A0201,B0702, A01,A02,B07, 0 PDL-1 Lung Cancer IMPACT B4801,C0801,C0702 B27,UNK,UNK EV854604 61-70 5 1 3.94 PD-1/ Bladder Cancer MSK- A0301,A0101,B0702, A03,A01,B07, 0 PDL-1 IMPACT B0801,C0701,C0702 B08,UNK,UNK GX642946 31-50 5 0 7.87 PD-1/ Melanoma MSK- A0301,A2402,B1501, A03,A24,B62, 0 PDL-1 IMPACT B5101,C1502,C0304 B07,UNK,UNK KH191548 61-70 11 1 4.92 Combo Head and Neck MSK- A2402,A2902,B4403, A24,A01A24,B44, 0 Cancer IMPACT B5701,C1601,C0602 B58,UNK,UNK KX950195 31-50 0 0 11.8 PD-1/ Melanoma MSK- A1101,A0201,B0801, A03,A02,B08, 0 PDL-1 IMPACT B1402,C0802,C0701 B27,UNK,UNK OQ394665 61-70 56 0 18.69 CTLA4 Melanoma MSK- A0101,A2402,B0801, A01,A24,B08, 0 IMPACT B1801,C1203,C0701 B44,UNK,UNK PD027960 61-70 1 0 5.9 PD-1/ Glioma MSK- A0201,A0205,B5001, A02,A02,B44, 0 PDL-1 IMPACT B1801,C0602,C0501 B44,UNK,UNK PX578748 50-60 5 0 7.87 PD-1/ Renal Cell MSK- A2402,A3201,B0702, A24,A01,B07, 0 PDL-1 Carcinoma IMPACT B0801,C0701,C0702 B08,UNK,UNK RG945840 31-50 4 0 7.87 PD-1/ Non-Small Cell MSK- A0301,A3201,B3801, A03,A01,B27, 0 PDL-1 Lung Cancer IMPACT B4901,C1203,C0701 UNK,UNK,UNK SP021117 61-70 16 0 0.98 Combo Renal Cell MSK- A0301,A3002,B5701, A03,A01,B58, 0 Carcinoma IMPACT B1801,C0501,C0602 B44,UNK,UNK TE855191 50-60 10 0 10.82 PD-1/ Esophagogastric MSK- A0301,A2902,B0702, A03,A01A24,B07, 0 PDL-1 Cancer IMPACT B4403,C1601,C0702 B44,UNK,UNK VZ661197 50-60 26 0 3.94 PD-1/ Renal Cell MSK- A2402,A3201,B4001, A24,A01,B44, 0 PDL-1 Carcinoma IMPACT B3501,C0303,C0304 B07,UNK,UNK XV950799 31-50 6 0 6.89 PD-1/ Bladder Cancer MSK- A0201,A2601,B4402, A02,A01,B44, 0 PDL-1 IMPACT B3801,C0501,C1203 B27,UNK,UNK ZE182555 31-50 21 0 17.71 CTLA4 Melanoma MSK- A1101,A0201,B5101, A03,A02,B07, 0 IMPACT B4402,C1402,C1502 B44,UNK,UNK AR843502 31-50 2 1 5.9 PD-1/ Non-Small Cell MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 Lung Cancer IMPACT B1501,C0304,C0701 B62,UNK,UNK DY577205 50-60 4 0 57.06 PD-1/ Glioma MSK- A0201,A0201,B1302, A02,A02,UNK, 1 PDL-1 IMPACT B5101,C0401,C0602 B07,UNK,UNK FL158584 50-60 18 0 0.98 Combo Melanoma MSK- A2601,A2601,B3801, A01,A01,B27, 1 IMPACT B3801,C1203,C1203 B27,UNK,UNK GA026392 31-50 11 0 19.68 PD-1/ Melanoma MSK- A3001,A0201,B1302, A01A03,A02,UNK, 0 PDL-1 IMPACT B5102,C0401,C0602 B07,UNK,UNK HV618060 >71 0 1 2.95 PD-1/ Hepatobiliary MSK- A0301,A0201,B1402, A03,A02,B27, 0 PDL-1 Cancer IMPACT B1501,C0303,C0802 B62,UNK,UNK IG053882 31-50 6 0 95.43 PD-1/ Melanoma MSK- A0301,A2402,B0702, A03,A24,B07, 0 PDL-1 IMPACT B5101,C1502,C0702 B07,UNK,UNK KZ373856 31-50 6 0 1.97 PD-1/ Hepatobiliary MSK- A2402,A0206,B0705, A24,A02,B07, 1 PDL-1 Cancer IMPACT B6701,C0702,C0702 B07,UNK,UNK OF215282 61-70 2 0 2.95 PD-1/ Colorectal MSK- A1101,A2902,B2705, A03,A01A24,B27, 0 PDL-1 Cancer IMPACT B4501,C0202,C0602 B44,UNK,UNK OG884951 >71 15 0 18.69 Combo Melanoma MSK- A2402,A3201,B0702, A24,A01,B07, 0 IMPACT B2705,C0602,C0702 B27,UNK,UNK PN375315 31-50 11 0 2.95 PD-1/ Renal Cell MSK- A6801,A3101,B4001, A03,A03,B44, 0 PDL-1 Carcinoma IMPACT B4402,C0304,C0704 B44,UNK,UNK PV753450 50-60 0 0 4.92 PD-1/ Cancer of MSK- A3001,A0301,B4201, A01A03,A03,B07, 0 PDL-1 Unknown IMPACT B5802,C1701,C0602 B58,UNK,UNK Primary SC680835 31-50 11 0 2.95 PD-1/ Mesothelioma MSK- A1101,A0207,B4601, A03,A02,B62, 0 PDL-1 IMPACT B1502,C0102,C0801 B62,UNK,UNK SC857468 61-70 7 0 0 PD-1/ Cancer of MSK- A0301,A6801,B0702, A03,A03,B07, 0 PDL-1 Unknown IMPACT B4402,C0704,C0702 B44,UNK,UNK Primary TD169754 50-60 8 0 22.63 PD-1/ Non-Small Cell MSK- A0101,A0201,B3701, A01,A02,B44, 0 PDL-1 Lung Cancer IMPACT B1801,C1203,C0602 B44,UNK,UNK UR220432 >71 6 0 5.9 Combo Breast Cancer MSK- A0201,A0201,B0702, A02,A02,B07, 1 IMPACT B5101,C0303,C0701 B62,UNK,UNK VS987443 61-70 0 1 0.98 Combo Prostate MSK- A0301,A0301,B5801, A03,A03,B58, 1 Cancer IMPACT B3501,C0302,C0401 B07,UNK,UNK YZ765266 >71 6 0 2.95 PD-1/ Renal Cell MSK- A0101,A3101,B3901, A01,A03,B27, 0 PDL-1 Carcinoma IMPACT B5701,C1203,C0602 B58,UNK,UNK ZC277272 >71 4 1 8.85 CTLA4 Colorectal MSK- A1102,A2402,B4001, A03,A24,B44, 0 Cancer IMPACT B3505,C0401,C0702 B07,UNK,UNK AI419880 31-50 1 1 7.87 PD-1/ Non-Hodgkin MSK- A0301,A6801,B2705, A03,A03,B27, 0 PDL-1 Lymphoma IMPACT B5101,C0102,C0702 B07,UNK,UNK EQ427020 >71 3 1 1.97 Combo Melanoma MSK- A2402,A0201,B2705, A24,A02,B27, 0 IMPACT B1801,C1502,C0701 B44,UNK,UNK FE789562 31-50 2 0 9.84 PD-1/ Glioma MSK- A2301,A2601,B1501, A24,A01,B62, 0 PDL-1 IMPACT B4102,C0704,C1701 B44,UNK,UNK GY753639 61-70 7 0 14.76 PD-1/ Small Cell MSK- A2902,A3201,B4403, A01A24,A01,B44, 0 PDL-1 Lung Cancer IMPACT B5108,C1602,C1601 B07,UNK,UNK IK672558 >71 31 0 1.97 PD-1/ Thyroid MSK- A3001,A0101,B2702, A01A03,A01,B27, 0 PDL-1 Cancer IMPACT B5101,C1502,C0202 B07,UNK,UNK IV940855 61-70 11 0 0 PD-1/ Non-Small Cell MSK- A0301,A0101,B5501, A03,A01,B07, 0 PDL-1 Lung Cancer IMPACT B0702,C0303,C0702 B07,UNK,UNK KH410745 31-50 0 1 8.85 PD-1/ Non-Small Cell MSK- A3001,A0101,B5701, A01A03,A01,B58, 1 PDL-1 Lung Cancer IMPACT B1302,C0602,C0602 UNK,UNK,UNK MT645316 31-50 16 0 18.69 PD-1/ Melanoma MSK- A0101,A2601,B0702, A01,A01,B07, 0 PDL-1 IMPACT B0801,C0701,C0702 B08,UNK,UNK OS835316 31-50 15 0 27.55 PD-1/ Bladder Cancer MSK- A2601,A6601,B2705, A01,A03,B27, 0 PDL-1 IMPACT B4102,C0102,C1701 B44,UNK,UNK PH153703 31-50 5 0 5.9 PD-1/ Melanoma MSK- A2301,A0201,B1801, A24,A02,B44, 1 PDL-1 IMPACT B4901,C0701,C0701 UNK,UNK,UNK SU802799 50-60 8 0 38.37 PD-1/ Melanoma MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 IMPACT B1302,C0602,C0702 UNK,UNK,UNK TW199824 31-50 23 0 0 CTLA4 Prostate MSK- A1101,A2402,B5201, A03,A24,B62, 0 Cancer IMPACT B3508,C1202,C0401 B07,UNK,UNK UH905646 31-50 2 0 0.98 PD-1/ Soft Tissue MSK- A2402,A6801,B3906, A24,A03,B27, 0 PDL-1 Sarcoma IMPACT B1302,C0602,C0702 UNK,UNK,UNK WH068307 61-70 3 0 4.92 PD-1/ Glioma MSK- A0101,A3201,B0801, A01,A01,B08, 0 PDL-1 IMPACT B4001,C0304,C0701 B44,UNK,UNK XQ654957 31-50 1 0 3.94 PD-1/ Glioma MSK- A1101,A2402,B3802, A03,A24,UNK, 1 PDL-1 IMPACT B3802,C0702,C0702 UNK,UNK,UNK YC912629 31-50 13 0 3.94 CTLA4 Breast Cancer MSK- A2402,A0201,B4006, A24,A02,B44, 0 IMPACT B3503,C1502,C0401 B07,UNK,UNK ZI588054 31-50 0 0 5.9 PD-1/ Renal Cell MSK- A3001,A1101,B5501, A01A03,A03,B07, 0 PDL-1 Carcinoma IMPACT B1302,C0303,C0602 UNK,UNK,UNK ZX742344 31-50 1 1 4.92 PD-1/ Esophagogastric MSK- A0301,A2601,B3801, A03,A01,B27, 1 PDL-1 Cancer IMPACT B1801,C1203,C1203 B44,UNK,UNK BP367380 31-50 5 1 5.9 PD-1/ Non-Small Cell MSK- A6802,A6601,B1402, A02,A03,B27, 0 PDL-1 Lung Cancer IMPACT B1801,C0802,C1203 B44,UNK,UNK DZ958878 50-60 18 0 3.94 PD-1/ Glioma MSK- A1101,A3101,B0702, A03,A03,B07, 0 PDL-1 IMPACT B3901,C1203,C0702 B27,UNK,UNK GR856721 31-50 11 0 21.64 PD-1/ Bladder Cancer MSK- A0101,A0101,B5701, A01,A01,B58, 1 PDL-1 IMPACT B3508,C0401,C0602 B07,UNK,UNK HH642834 61-70 5 0 100.35 PD-1/ Glioma MSK- A2402,A3101,B1801, A24,A03,B44, 0 PDL-1 IMPACT B5701,C0602,C0701 B58,UNK,UNK JW331281 31-50 16 0 5.9 PD-1/ Melanoma MSK- A2601,A2601,B1501, A01,A01,B62, 1 PDL-1 IMPACT B3801,C0303,C1203 B27,UNK,UNK LD541574 31-50 15 0 2.95 PD-1/ Renal Cell MSK- A2402,A0201,B0801, A24,A02,B08, 0 PDL-1 Carcinoma IMPACT B5101,C0202,C0701 B07,UNK,UNK MD017290 61-70 5 1 6.89 PD-1/ Head and Neck MSK- A0101,A2402,B0801, A01,A24,B08, 0 PDL-1 Cancer IMPACT B5701,C0602,C0701 B58,UNK,UNK MW651937 50-60 0 1 16.72 PD-1/ Bladder Cancer MSK- A2402,A0201,B1501, A24,A02,B62, 0 PDL-1 IMPACT B4402,C0303,C0501 B44,UNK,UNK OZ442015 61-70 11 0 6.89 PD-1/ Glioma MSK- A0201,A2601,B3901, A02,A01,B27, 0 PDL-1 IMPACT B4002,C1502,C1203 B44,UNK,UNK RU189416 61-70 18 0 1.97 PD-1/ Glioma MSK- A1101,A1101,B1801, A03,A03,B44, 1 PDL-1 IMPACT B3501,C0401,C0701 B07,UNK,UNK TS854723 50-60 0 0 20.66 PD-1/ Non-Small Cell MSK- A6601,A3101,B0801, A03,A03,B08, 0 PDL-1 Lung Cancer IMPACT B1509,C0701,C0704 B27,UNK,UNK UJ633658 50-60 7 1 7.87 Combo Melanoma MSK- A0201,A0201,B1801, A02,A02,B44, 1 IMPACT B5101,C1502,C0701 B07,UNK,UNK UL388657 31-50 1 1 4.92 CTLA4 Pancreatic MSK- A3002,A0101,B1801, A01,A01,B44, 0 Cancer IMPACT B5001,C0602,C0501 B44,UNK,UNK WG479585 >71 20 0 4.92 PD-1/ Glioma MSK- A0201,A0201,B5702, A02,A02,B58, 1 PDL-1 IMPACT B5001,C0602,C1801 B44,UNK,UNK AH954476 61-70 11 0 3.94 PD-1/ Cancer of MSK- A0101,A2902,B0702, A01,A01A24,B07, 0 PDL-1 Unknown IMPACT B3503,C0401,C0702 B07,UNK,UNK Primary CW247724 31-50 15 0 19.68 Combo Non-Small Cell MSK- A2402,A3101,B2705, A24,A03,B27, 0 Lung Cancer IMPACT B0801,C0102,C0701 B08,UNK,UNK DT197689 31-50 0 0 0.98 PD-1/ Hepatobiliary MSK- A0301,A0301,B0702, A03,A03,B07, 1 PDL-1 Cancer IMPACT B1402,C0802,C0702 B27,UNK,UNK EO439129 31-50 5 0 0.98 Combo Melanoma MSK- A3002,A2301,B0702, A01,A24,B07, 0 IMPACT B1302,C0804,C0702 UNK,UNK,UNK GB346707 31-50 2 1 8.85 PD-1/ Non-Small Cell MSK- A2402,A2601,B3801, A24,A01,B27, 0 PDL-1 Lung Cancer IMPACT B3508,C1203,C0401 B07,UNK,UNK IN703823 50-60 6 0 3.94 Combo Melanoma MSK- A1101,A0217,B5501, A03,A02,B07, 0 IMPACT B4002,C0303,C0304 B44,UNK,UNK MV401545 50-60 2 0 3.94 PD-1/ Glioma MSK- A2402,A3201,B4001, A24,A01,B44, 0 PDL-1 IMPACT B1302,C0304,C0602 UNK,UNK,UNK PE291148 31-50 4 0 7.87 PD-1/ Non-Small Cell MSK- A3201,A2601,B3508, A01,A01,B07, 0 PDL-1 Lung Cancer IMPACT B1302,C0401,C0602 UNK,UNK,UNK PM383343 50-60 10 1 10.82 PD-1/ Non-Small Cell MSK- A1101,A2601,B0801, A03,A01,B08, 0 PDL-1 Lung Cancer IMPACT B4001,C0701,C0702 B44,UNK,UNK TR249275 50-60 11 0 6.89 PD-1/ Renal Cell MSK- A0101,A0201,B4001, A01,A02,B44, 0 PDL-1 Carcinoma IMPACT B5001,C0304,C0602 B44,UNK,UNK WC440856 31-50 6 1 3.94 PD-1/ Non-Small Cell MSK- A2902,A2901,B1402, A01A24,A01A24,B27, 0 PDL-1 Lung Cancer IMPACT B5701,C0602,C0802 B58,UNK,UNK WX598960 31-50 39 0 2.95 CTLA4 Melanoma MSK- A6801,A0201,B1402, A03,A02,B27, 0 IMPACT B2702,C0202,C0802 B27,UNK,UNK YE912753 50-60 3 0 2.95 PD-1/ Anal Cancer MSK- A3201,A0201,B2705, A01,A02,B27, 0 PDL-1 IMPACT B4402,C0202,C0501 B44,UNK,UNK YU883868 50-60 7 0 4.92 PD-1/ Non-Hodgkin MSK- A0101,A7401,B1402, A01,A03,B27, 0 PDL-1 Lymphoma IMPACT B5802,C0802,C0802 B58,UNK,UNK YY988865 31-50 3 0 96.41 PD-1/ Skin Cancer; MSK- A2301,A0201,B0702, A24,A02,B07, 0 PDL-1 Non-Melanoma IMPACT B1801,C0501,C0702 B44,UNK,UNK YZ113825 31-50 7 1 3.94 PD-1/ Non-Small Cell MSK- A0301,A2601,B0702, A03,A01,B07, 0 PDL-1 Lung Cancer IMPACT B3501,C0702,C0401 B07,UNK,UNK ZE100444 31-50 12 0 0 PD-1/ Soft Tissue MSK- A0201,A0201,B1501, A02,A02,B62, 1 PDL-1 Sarcoma IMPACT B5101,C0303,C1602 B07,UNK,UNK ZT370662 31-50 2 1 0 Combo Melanoma MSK- A0301,A0201,B4001, A03,A02,B44, 0 IMPACT B3501,C0304,C0401 B07,UNK,UNK CU577679 50-60 5 0 1.97 PD-1/ Soft Tissue MSK- A2301,A3201,B1801, A24,A01,B44, 1 PDL-1 Sarcoma IMPACT B4901,C0701,C0701 UNK,UNK,UNK JJ451223 >71 5 0 2.95 PD-1/ Pancreatic MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 Cancer IMPACT B0705,C1505,C0702 B07,UNK,UNK LL341780 31-50 5 0 36.4 PD-1/ Non-Small Cell MSK- A3201,A0201,B4701, A01,A02,UNK, 0 PDL-1 Lung Cancer IMPACT B1801,C0401,C0602 B44,UNK,UNK MM334107 31-50 13 1 3.94 PD-1/ Non-Small Cell MSK- A1101,A0203,B4001, A03,A02,B44, 0 PDL-1 Lung Cancer IMPACT B5102,C0102,C0304 B07,UNK,UNK MT926683 31-50 11 0 4.92 PD-1/ Renal Cell MSK- A0201,A0201,B4101, A02,A02,B44, 1 PDL-1 Carcinoma IMPACT B1801,C1701,C0701 B44,UNK,UNK PA328028 61-70 0 1 0 PD-1/ Non-Small Cell MSK- A0101,A3301,B1402, A01,A03,B27, 0 PDL-1 Lung Cancer IMPACT B3502,C0802,C0401 B07,UNK,UNK PW579192 31-50 1 0 2.95 PD-1/ Hepatobiliary MSK- A0101,A2402,B3801, A01,A24,B27, 0 PDL-1 Cancer IMPACT B5701,C1203,C0602 B58,UNK,UNK RF326353 61-70 4 0 4.92 PD-1/ Renal Cell MSK- A2902,A0206,B4403, A01A24,A02,B44, 0 PDL-1 Carcinoma IMPACT B3902,C1601,C0702 B27,UNK,UNK SL233608 31-50 10 0 0.98 PD-1/ Melanoma MSK- A3004,A2402,B0702, A01,A24,B07, 0 PDL-1 IMPACT B5001,C0602,C0702 B44,UNK,UNK SM717841 61-70 12 0 52.14 PD-1/ Melanoma MSK- A0101,A0201,B0702, A01,A02,B07, 0 PDL-1 IMPACT B5701,C0602,C0702 B58,UNK,UNK TA620796 50-60 4 0 1.97 PD-1/ Sex Cord MSK- A0101,A3101,B0801, A01,A03,B08, 0 PDL-1 Stromal Tumor IMPACT B4001,C0304,C0701 B44,UNK,UNK VY234263 50-60 41 0 7.87 PD-1/ Renal Cell MSK- A1101,A0101,B0801, A03,A01,B08, 0 PDL-1 Carcinoma IMPACT B3501,C0401,C0701 B07,UNK,UNK WG852822 50-60 0 1 2.95 PD-1/ Non-Small Cell MSK- A0301,A0201,B1402, A03,A02,B27, 0 PDL-1 Lung Cancer IMPACT B1801,C0802,C0701 B44,UNK,UNK YV942117 31-50 17 0 8.85 PD-1/ Melanoma MSK- A1101,A0101,B5701, A03,A01,B58, 0 PDL-1 IMPACT B5201,C1202,C0602 B62,UNK,UNK ZJ820780 31-50 4 1 14.76 PD-1/ Bladder Cancer MSK- A0101,A0201,B3901, A01,A02,B27, 1 PDL-1 IMPACT B3501,C0401,C0401 B07,UNK,UNK AI663614 31-50 8 0 10.82 PD-1/ Non-Small Cell MSK- A1101,A3201,B1501, A03,A01,B62, 0 PDL-1 Lung Cancer IMPACT B5801,C0303,C0302 B58,UNK,UNK CD455638 61-70 32 0 14.76 CTLA4 Melanoma MSK- A2402,A0201,B1501, A24,A02,B62, 0 IMPACT B4403,C0303,C1601 B44,UNK,UNK CG203297 31-50 1 0 5.9 PD-1/ Breast MSK- A2402,A0201,B1402, A24,A02,B27, 0 PDL-1 Cancer IMPACT B4405,C0802,C0202 B44,UNK,UNK DM486141 50-60 0 1 10.82 PD-1/ Non-Small Cell MSK- A2402,A3303,B0702, A24,A03,B07, 0 PDL-1 Lung Cancer IMPACT B4403,C0706,C0702 B44,UNK,UNK EK931793 31-50 10 1 2.95 PD-1/ Bladder Cancer MSK- A1101,A2402,B0801, A03,A24,B08, 0 PDL-1 IMPACT B1801,C1203,C0702 B44,UNK,UNK HC293273 50-60 31 0 1.97 Combo Renal Cell MSK- A3004,A0101,B4101, A01,A01,B44, 0 Carcinoma IMPACT B1517,C1701,C0701 B58,UNK,UNK IB756171 31-50 11 0 2.95 PD-1/ Head and Neck MSK- A2402,A0201,B4403, A24,A02,B44, 0 PDL-1 Cancer IMPACT B1501,C0303,C1601 B62,UNK,UNK KD258411 31-50 10 0 3.94 PD-1/ Pancreatic MSK- A1101,A2601,B5501, A03,A01,B07, 0 PDL-1 Cancer IMPACT B1402,C0102,C0802 B27,UNK,UNK OC866849 >71 13 0 8.85 Combo Non-Small Cell MSK- A0101,A2402,B5701, A01,A24,B58, 0 Lung Cancer IMPACT B3502,C0602,C0401 B07,UNK,UNK RL299291 31-50 13 0 6.89 PD-1/ Non-Small Cell MSK- A6801,A3201,B2705, A03,A01,B27, 0 PDL-1 Lung Cancer IMPACT B4001,C0102,C0304 B44,UNK,UNK YB400702 61-70 0 0 2.95 PD-1/ Glioma MSK- A2301,A6802,B4403, A24,A02,B44, 1 PDL-1 IMPACT B4402,C0401,C0401 B44,UNK,UNK YB599485 >71 3 1 4.92 PD-1/ Glioma MSK- A1102,A6802,B3802, A03,A02,UNK, 0 PDL-1 IMPACT B5301,C0401,C0702 B07,UNK,UNK YD008671 50-60 1 1 27.55 PD-1/ Bladder Cancer MSK- A3201,A2601,B0702, A01,A01,B07, 0 PDL-1 IMPACT B4402,C0501,C0702 B44,UNK,UNK YN251276 >71 0 0 6.89 PD-1/ Breast MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 Cancer IMPACT B1501,C0303,C0701 B62,UNK,UNK AD875088 50-60 0 1 24.59 PD-1/ Bladder Cancer MSK- A2301,A2402,B4403, A24,A24,B44, 1 PDL-1 IMPACT B3502,C0401,C0401 B07,UNK,UNK BG455363 61-70 5 0 18.69 PD-1/ Prostate MSK- A0101,A2301,B5701, A01,A24,B58, 0 PDL-1 Cancer IMPACT B4901,C0602,C0701 UNK,UNK,UNK BX707409 50-60 9 0 3.94 PD-1/ Non-Small Cell MSK- A0201,A3101,B1501, A02,A03,B62, 0 PDL-1 Lung Cancer IMPACT B5701,C0303,C0602 B58,UNK,UNK BY656262 50-60 28 1 4.92 PD-1/ Head and Neck MSK- A2301,A6801,B4901, A24,A03,UNK, 0 PDL-1 Cancer IMPACT B5101,C1502,C0701 B07,UNK,UNK CU241212 50-60 7 0 11.81 PD-1/ Cancer of MSK- A1101,A3301,B1402, A03,A03,B27, 0 PDL-1 Unknown IMPACT B4402,C0501,C0802 B44,UNK,UNK Primary DC116501 31-50 1 1 1.97 PD-1/ Renal Cell MSK- A2601,A2601,B0702, A01,A01,B07, 1 PDL-1 Carcinoma IMPACT B3501,C0401,C0702 B07,UNK,UNK FN036373 61-70 16 1 12.79 PD-1/ Bladder Cancer MSK- A0201,A0201,B4001, A02,A02,B44, 1 PDL-1 IMPACT B4001,C0304,C0304 B44,UNK,UNK FQ591029 31-50 12 0 0.98 PD-1/ Thyroid MSK- A0101,A2902,B0801, A01,A01A24,B08, 0 PDL-1 Cancer IMPACT B4403,C1601,C0701 B44,UNK,UNK GX642098 31-50 4 1 10.82 PD-1/ Non-Small Cell MSK- A0201,A2601,B1801, A02,A01,B44, 1 PDL-1 Lung Cancer IMPACT B1801,C1203,C0701 B44,UNK,UNK JQ503820 31-50 5 0 11.81 PD-1/ Non-Small Cell MSK- A0101,A2902,B4402, A01,A01A24,B44, 0 PDL-1 Lung Cancer IMPACT B5801,C0501,C0706 B58,UNK,UNK KT271657 31-50 7 0 11.81 PD-1/ Head and Neck MSK- A3004,A0201,B1801, A01,A02,B44, 0 PDL-1 Cancer IMPACT B4403,C0706,C0701 B44,UNK,UNK LE923094 >71 9 0 13.77 PD-1/ Adrenocortical MSK- A3002,A2301,B1402, A01,A24,B27, 0 PDL-1 Carcinoma IMPACT B4403,C0802,C0401 B44,UNK,UNK OZ370159 61-70 1 0 2.95 PD-1/ Non-Small Cell MSK- A0301,A0101,B3503, A03,A01,B07, 1 PDL-1 Lung Cancer IMPACT B3501,C0401,C0401 B07,UNK,UNK PW995997 31-50 7 1 1.97 PD-1/ Renal Cell MSK- A3001,A6901,B5501, A01A03,A02,B07, 0 PDL-1 Carcinoma IMPACT B5801,C0102,C0706 B58,UNK,UNK QK851300 50-60 3 0 6.89 PD-1/ Non-Small Cell MSK- A3002,A0201,B2702, A01,A02,B27, 0 PDL-1 Lung Cancer IMPACT B1801,C0202,C0501 B44,UNK,UNK ZK094596 >71 9 1 0.98 PD-1/ Glioma MSK- A0101,A0201,B1402, A01,A02,B27, 0 PDL-1 IMPACT B5701,C0802,C0602 B58,UNK,UNK CC702072 31-50 4 0 20.66 PD-1/ Cancer of MSK- A1101,A0201,B3501, A03,A02,B07, 1 PDL-1 Unknown IMPACT B3501,C0303,C0401 B07,UNK,UNK Primary CH796273 31-50 3 1 6.89 PD-1/ Pancreatic MSK- A0101,A0201,B1801, A01,A02,B44, 0 PDL-1 Cancer IMPACT B1302,C0602,C0701 UNK,UNK,UNK EL247113 31-50 4 0 5.9 PD-1/ Melanoma MSK- A0301,A0201,B4001, A03,A02,B44, 0 PDL-1 IMPACT B3501,C0304,C0401 B07,UNK,UNK EP440324 61-70 10 0 1.97 PD-1/ Adrenocortical MSK- A0201,A0201,B1501, A02,A02,B62, 1 PDL-1 Carcinoma IMPACT B5101,C1502,C0304 B07,UNK,UNK FU946944 31-50 0 1 12.79 PD-1/ Non-Small Cell MSK- A1101,A2402,B5701, A03,A24,B58, 0 PDL-1 Lung Cancer IMPACT B3508,C1203,C0602 B07,UNK,UNK FY552297 31-50 30 0 17.71 PD-1/ Renal Cell MSK- A1101,A0101,B1801, A03,A01,B44, 0 PDL-1 Carcinoma IMPACT B5801,C0701,C0706 B58,UNK,UNK HE368595 >71 3 0 4.92 PD-1/ Colorectal MSK- A0201,A0205,B4402, A02,A02,B44, 0 PDL-1 Cancer IMPACT B1517,C0501,C0701 B58,UNK,UNK HJ778699 >71 1 1 1.97 Combo Esophagogastric MSK- A0101,A0201,B0702, A01,A02,B07, 0 Cancer IMPACT B1501,C0304,C0702 B62,UNK,UNK HM524670 31-50 11 0 0 PD-1/ Skin Cancer; MSK- A0301,A2301,B3502, A03,A24,B07, 0 PDL-1 Non-Melanoma IMPACT B3503,C0602,C0401 B07,UNK,UNK IQ442756 31-50 7 0 20.66 PD-1/ Skin Cancer; MSK- A0201,A0205,B0702, A02,A02,B07, 0 PDL-1 Non-Melanoma IMPACT B2705,C1502,C0702 B27,UNK,UNK JD423803 31-50 4 0 15.74 PD-1/ Melanoma MSK- A1101,A2601,B3801, A03,A01,B27, 0 PDL-1 IMPACT B4001,C0304,C1203 B44,UNK,UNK JI639707 61-70 10 0 0 PD-1/ Renal Cell MSK- A3001,A0201,B1801, A01A03,A02,B44, 0 PDL-1 Carcinoma IMPACT B1302,C0602,C0701 UNK,UNK,UNK KG964615 50-60 26 1 0.98 Combo Melanoma MSK- A0101,A0201,B0801, A01,A02,B08, 1 IMPACT B1801,C0701,C0701 B44,UNK,UNK KT138482 31-50 1 0 3.94 Combo Soft Tissue MSK- A0101,A0201,B1402, A01,A02,B27, 0 Sarcoma IMPACT B1302,C0602,C0706 UNK,UNK,UNK KZ477043 31-50 19 0 9.84 Combo Renal Cell MSK- A2902,A2601,B1402, A01A24,A01,B27, 0 Carcinoma IMPACT B1802,C1203,C0802 B44,UNK,UNK NP845180 61-70 17 0 3.94 Combo Renal Cell MSK- A0301,A0101,B0702, A03,A01,B07, 0 Carcinoma IMPACT B3701,C0602,C0702 B44,UNK,UNK NS410554 50-60 33 0 5.9 PD-1/ Renal Cell MSK- A2601,A6801,B3701, A01,A03,B44, 0 PDL-1 Carcinoma IMPACT B3503,C0401,C0602 B07,UNK,UNK OW705404 50-60 30 0 13.77 CTLA4 Melanoma MSK- A0301,A2402,B3501, A03,A24,B07, 1 IMPACT B3508,C0401,C0401 B07,UNK,UNK PB770726 31-50 40 0 33.45 PD-1/ Melanoma MSK- A0301,A0201,B1501, A03,A02,B62, 0 PDL-1 IMPACT B3503,C0304,C0401 B07,UNK,UNK TV538691 >71 15 0 2.95 Combo Cancer of MSK- A2901,A0205,B0705, A01A24,A02,B07, 0 Unknown IMPACT B5001,C1505,C0602 B44,UNK,UNK Primary UZ818372 31-50 0 1 1.97 PD-1/ Non-Small Cell MSK- A0217,A0201,B4402, A02,A02,B44, 0 PDL-1 Lung Cancer IMPACT B5101,C0501,C1502 B07,UNK,UNK WX037861 31-50 25 0 0 PD-1/ Renal Cell MSK- A2402,A0201,B0801, A24,A02,B08, 0 PDL-1 Carcinoma IMPACT B1501,C0303,C0701 B62,UNK,UNK XS233951 31-50 0 0 5.9 PD-1/ Non-Small Cell MSK- A6801,A0201,B1503, A03,A02,B27, 0 PDL-1 Lung Cancer IMPACT B1518,C0210,C0704 B27,UNK,UNK YI335108 31-50 2 1 12.79 PD-1/ Non-Small Cell MSK- A0201,A2601,B0702, A02,A01,B07, 0 PDL-1 Lung Cancer IMPACT B3501,C1602,C0702 B07,UNK,UNK ZG039934 50-60 6 0 7.87 PD-1/ Non-Small Cell MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 Lung Cancer IMPACT B1801,C0501,C0702 B44,UNK,UNK DJ241021 61-70 7 1 3.94 PD-1/ Renal Cell MSK- A0301,A0301,B0702, A03,A03,B07, 1 PDL-1 Carcinoma IMPACT B3701,C0602,C0702 B44,UNK,UNK DL894556 61-70 2 0 13.77 PD-1/ Salivary Gland MSK- A2402,A0201,B0801, A24,A02,B08, 0 PDL-1 Cancer IMPACT B3906,C0702,C0701 B27,UNK,UNK EF262650 31-50 17 0 89.52 PD-1/ Colorectal MSK- A0302,A2402,B4601, A03,A24,B62, 0 PDL-1 Cancer IMPACT B3501,C0102,C0401 B07,UNK,UNK FJ315360 31-50 6 0 3.94 PD-1/ Head and Neck MSK- A0101,A3301,B1402, A01,A03,B27, 0 PDL-1 Cancer IMPACT B3502,C0401,C0802 B07,UNK,UNK FR397048 31-50 1 1 8.85 PD-1/ Non-Small Cell MSK- A3002,A1101,B5101, A01,A03,B07, 0 PDL-1 Lung Cancer IMPACT B3501,C0401,C1602 B07,UNK,UNK GK275052 50-60 39 1 6.89 CTLA4 Melanoma MSK- A0101,A0201,B2705, A01,A02,B27, 0 IMPACT B5701,C0102,C0602 B58,UNK,UNK HG173625 31-50 3 1 1.97 PD-1/ Pancreatic MSK- A0301,A2402,B5701, A03,A24,B58, 0 PDL-1 Cancer IMPACT B3501,C0602,C0401 B07,UNK,UNK HH607905 31-50 11 0 3.94 PD-1/ Non-Small Cell MSK- A0301,A0101,B3801, A03,A01,B27, 0 PDL-1 Lung Cancer IMPACT B3502,C1203,C0401 B07,UNK,UNK IB028541 31-50 20 1 3.94 PD-1/ Renal Cell MSK- A6801,A0201,B2705, A03,A02,B27, 0 PDL-1 Carcinoma IMPACT B3501,C0102,C0401 B07,UNK,UNK IK737288 61-70 1 0 4.92 PD-1/ Colorectal MSK- A0301,A0101,B0702, A03,A01,B07, 0 PDL-1 Cancer IMPACT B0801,C0701,C0702 B08,UNK,UNK IZ882356 31-50 20 1 3.94 PD-1/ Renal Cell MSK- A0301,A0101,B0702, A03,A01,B07, 1 PDL-1 Carcinoma IMPACT B0702,C0702,C0702 B07,UNK,UNK JM917596 50-60 5 0 3.94 Combo Melanoma MSK- A2601,A0205,B4101, A01,A02,B44, 0 IMPACT B3801,C1203,C0701 B27,UNK,UNK KC683122 61-70 6 0 6.89 PD-1/ Thyroid MSK- A2402,A2402,B1302, A24,A24,UNK, 1 PDL-1 Cancer IMPACT B5101,C0102,C0602 B07,UNK,UNK KG865106 31-50 37 0 2.95 CTLA4 Melanoma MSK- A3401,A0207,B4601, UNK,A02,B62, 0 IMPACT B4002,C0102,C1502 B44,UNK,UNK LI329268 31-50 3 0 5.9 PD-1/ Glioma MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 IMPACT B1501,C0303,C0701 B62,UNK,UNK MP310830 31-50 4 0 5.9 PD-1/ Glioma MSK- A1101,A0201,B5501, A03,A02,B07, 0 PDL-1 IMPACT B1801,C0303,C0701 B44,UNK,UNK MW707685 >71 0 1 0.98 PD-1/ Esophagogastric MSK- A1101,A2403,B0702, A03,A24,B07, 0 PDL-1 Cancer IMPACT B3502,C0401,C0702 B07,UNK,UNK MY935343 31-50 2 1 3.94 PD-1/ Small Cell MSK- A2601,A6901,B6701, A01,A02,B07, 0 PDL-1 Lung Cancer IMPACT B5501,C0303,C1203 B07,UNK,UNK RH600784 61-70 2 0 3.94 PD-1/ Non-Small Cell MSK- A3201,A6901,B4002, A01,A02,B44, 0 PDL-1 Lung Cancer IMPACT B3801,C0202,C1203 B27,UNK,UNK RK158581 31-50 9 1 8.85 Combo Melanoma MSK- A0301,A2402,B3508, A03,A24,B07, 0 IMPACT B5101,C0102,C0401 B07,UNK,UNK SI657615 50-60 4 1 19.68 PD-1/ Non-Small Cell MSK- A3001,A2402,B1801, A01A03,A24,B44, 0 PDL-1 Lung Cancer IMPACT B1302,C0602,C0718 UNK,UNK,UNK UJ858608 31-50 14 0 3.94 PD-1/ Non-Small Cell MSK- A2601,A0201,B1401, A01,A02,B27, 0 PDL-1 Lung Cancer IMPACT B0801,C1203,C0701 B08,UNK,UNK UT194883 61-70 25 0 2.95 PD-1/ Renal Cell MSK- A0201,A0201,B1801, A02,A02,B44, 1 PDL-1 Carcinoma IMPACT B1801,C0701,C0701 B44,UNK,UNK VU236547 31-50 6 0 1.97 PD-1/ Non-Small Cell MSK- A3601,A0201,B3901, A01,A02,B27, 0 PDL-1 Lung Cancer IMPACT B3501,C0401,C0304 B07,UNK,UNK YB335119 50-60 7 0 1.97 PD-1/ Renal Cell MSK- A0201,A0201,B0801, A02,A02,B08, 1 PDL-1 Carcinoma IMPACT B0801,C0701,C0701 B08,UNK,UNK ZT695305 >71 35 0 14.76 PD-1/ Esophagogastric MSK- A0201,A2601,B2702, A02,A01,B27, 0 PDL-1 Cancer IMPACT B3801,C0202,C1203 B27,UNK,UNK BG557112 61-70 9 0 3.94 PD-1/ Renal Cell MSK- A7401,A3303,B1503, A03,A03,B27, 1 PDL-1 Carcinoma IMPACT B1503,C0210,C0210 B27,UNK,UNK CB360697 31-50 9 0 2.95 PD-1/ Glioma MSK- A0101,A6901,B4402, A01,A02,B44, 0 PDL-1 IMPACT B5801,C0302,C0501 B58,UNK,UNK DY566456 31-50 11 1 1.97 PD-1/ Melanoma MSK- A0301,A7401,B3910, A03,A03,B07, 0 PDL-1 IMPACT B4403,C1505,C0401 B44,UNK,UNK FD268208 50-60 18 0 3.94 PD-1/ Head and Neck MSK- A0101,A0201,B3501, A01,A02,B07, 0 PDL-1 Cancer IMPACT B1302,C0401,C0602 UNK,UNK,UNK GD049509 61-70 3 1 3.94 PD-1/ Non-Small Cell MSK- A2402,A0201,B4402, A24,A02,B44, 0 PDL-1 Lung Cancer IMPACT B4405,C0501,C0202 B44,UNK,UNK IV980629 61-70 3 1 0.98 PD-1/ Bladder Cancer MSK- A6801,A0201,B4002, A03,A02,B44, 0 PDL-1 IMPACT B4402,C0304,C0501 B44,UNK,UNK KF271493 50-60 10 0 3.94 PD-1/ Renal Cell MSK- A2402,A2402,B5501, A24,A24,B07, 1 PDL-1 Carcinoma IMPACT B3502,C0102,C0401 B07,UNK,UNK LK714581 >71 13 0 1.97 PD-1/ Renal Cell MSK- A1101,A0101,B2705, A03,A01,B27, 0 PDL-1 Carcinoma IMPACT B1501,C0303,C0202 B62,UNK,UNK MT578443 31-50 2 0 0.98 PD-1/ Non-Small Cell MSK- A0101,A6801,B3701, A01,A03,B44, 0 PDL-1 Lung Cancer IMPACT B5101,C1402,C0602 B07,UNK,UNK MT610848 31-50 4 1 15.74 PD-1/ Non-Small Cell MSK- A0301,A0101,B0801, A03,A01,B08, 0 PDL-1 Lung Cancer IMPACT B3701,C0602,C0701 B44,UNK,UNK NP594656 61-70 8 0 17.71 PD-1/ Non-Small Cell MSK- A1101,A2601,B3801, A03,A01,B27, 0 PDL-1 Lung Cancer IMPACT B5201,C1203,C1202 B62,UNK,UNK NY608269 31-50 7 0 0.98 PD-1/ Melanoma MSK- A2402,A0201,B4403, A24,A02,B44, 0 PDL-1 IMPACT B4901,C1601,C0701 UNK,UNK,UNK OE704083 >71 8 0 0 PD-1/ Hepatobiliary MSK- A0101,A0201,B3902, A01,A02,B27, 0 PDL-1 Cancer IMPACT B0801,C0702,C0701 B08,UNK,UNK ON459466 31-50 22 0 5.9 PD-1/ Hepatobiliary MSK- A0201,A0201,B5701, A02,A02,B58, 1 PDL-1 Cancer IMPACT B1801,C0602,C0202 B44,UNK,UNK PL375255 50-60 4 0 3.94 PD-1/ Renal Cell MSK- A0101,A2402,B0702, A01,A24,B07, 0 PDL-1 Carcinoma IMPACT B5701,C0602,C0702 B58,UNK,UNK QF486379 61-70 3 1 3.94 PD-1/ Breast MSK- A2402,A0201,B2705, A24,A02,B27, 0 PDL-1 Cancer IMPACT B3501,C1601,C0202 B07,UNK,UNK QO131046 50-60 0 0 64.93 PD-1/ Melanoma MSK- A0101,A0201,B0801, A01,A02,B08, 1 PDL-1 IMPACT B4901,C0701,C0701 UNK,UNK,UNK QZ214610 31-50 6 1 19.68 PD-1/ Bladder Cancer MSK- A0301,A2301,B3701, A03,A24,B44, 0 PDL-1 IMPACT B4403,C0401,C0602 B44,UNK,UNK RS498156 50-60 7 0 1.97 PD-1/ Non-Small Cell MSK- A3101,A0201,B1301, A03,A02,UNK, 0 PDL-1 Lung Cancer IMPACT B5102,C1502,C0801 B07,UNK,UNK TY648092 31-50 0 0 8.85 PD-1/ Non-Small Cell MSK- A1101,A2601,B1801, A03,A01,B44, 0 PDL-1 Lung Cancer IMPACT B4403,C1601,C1203 B44,UNK,UNK UW635468 31-50 0 1 8.85 PD-1/ Bladder Cancer MSK- A0201,A0205,B4001, A02,A02,B44, 0 PDL-1 IMPACT B5001,C0304,C0602 B44,UNK,UNK VT365111 31-50 13 0 0.98 PD-1/ Esophagogastric MSK- A0201,A6802,B1402, A02,A02,B27, 0 PDL-1 Cancer IMPACT B4402,C0802,C0501 B44,UNK,UNK WB570014 50-60 6 0 4.92 PD-1/ Bladder Cancer MSK- A3002,A3201,B4101, A01,A01,B44, 0 PDL-1 IMPACT B1801,C0501,C1701 B44,UNK,UNK WM142326 31-50 7 0 4.92 PD-1/ Non-Small Cell MSK- A0301,A2403,B3801, A03,A24,B27, 0 PDL-1 Lung Cancer IMPACT B3501,C0401,C1203 B07,UNK,UNK XC744092 31-50 9 1 16.72 PD-1/ Non-Hodgkin MSK- A0301,A0201,B1402, A03,A02,B27, 0 PDL-1 Lymphoma IMPACT B4402,C0501,C0802 B44,UNK,UNK YA003885 31-50 15 1 5.9 PD-1/ Glioma MSK- A0301,A2601,B2705, A03,A01,B27, 0 PDL-1 IMPACT B4403,C0401,C0202 B44,UNK,UNK ZH374437 61-70 11 0 3.94 PD-1/ Renal Cell MSK- A0301,A2403,B3508, A03,A24,B07, 0 PDL-1 Carcinoma IMPACT B5101,C0102,C0401 B07,UNK,UNK AJ588466 61-70 11 0 1.97 Combo Melanoma MSK- A0101,A2402,B0801, A01,A24,B08, 0 IMPACT B1801,C0704,C0701 B44,UNK,UNK CJ942524 >71 7 0 26.56 Combo Melanoma MSK- A3201,A0201,B5501, A01,A02,B07, 1 IMPACT B5001,C0602,C0602 B44,UNK,UNK DR880178 31-50 8 1 3.94 PD-1/ Head and Neck MSK- A2301,A0201,B4403, A24,A02,B44, 1 PDL-1 Cancer IMPACT B3501,C0401,C0401 B07,UNK,UNK EI492052 61-70 11 0 1.97 PD-1/ Renal Cell MSK- A0205,A6802,B1801, A02,A02,B44, 0 PDL-1 Carcinoma IMPACT B5802,C0501,C0602 B58,UNK,UNK FA457711 61-70 6 1 0 PD-1/ Mesothelioma MSK- A0201,A2601,B1801, A02,A01,B44, 0 PDL-1 IMPACT B4402,C1203,C0501 B44,UNK,UNK FV068094 31-50 7 0 4.92 PD-1/ Melanoma MSK- A2402,A6801,B1402, A24,A03,B27, 0 PDL-1 IMPACT B4403,C0802,C0401 B44,UNK,UNK GY675187 50-60 6 0 1.97 PD-1/ Non-Small Cell MSK- A3001,A3303,B4201, A01A03,A03,B07, 0 PDL-1 Lung Cancer IMPACT B4403,C1701,C0706 B44,UNK,UNK HD432932 50-60 10 0 2.95 PD-1/ Melanoma MSK- A2402,A0201,B0702, A24,A02,B07, 0 PDL-1 IMPACT B4402,C0501,C0702 B44,UNK,UNK MR283895 50-60 15 0 5.9 PD-1/ Non-Small Cell MSK- A2402,A0201,B4402, A24,A02,B44, 0 PDL-1 Lung Cancer IMPACT B5101,C1402,C0501 B07,UNK,UNK NH936650 50-60 1 1 80.67 PD-1/ Colorectal MSK- A2402,A2301,B4403, A24,A24,B44, 0 PDL-1 Cancer IMPACT B1302,C0401,C0602 UNK,UNK,UNK PS172901 50-60 3 1 2.95 PD-1/ Renal Cell MSK- A0301,A0201,B4101, A03,A02,B44, 0 PDL-1 Carcinoma IMPACT B4002,C0202,C1701 B44,UNK,UNK QZ305528 >71 15 0 3.94 CTLA4 Breast MSK- A2301,A3402,B1503, A24,A03,B27, 0 Cancer IMPACT B1302,C0804,C0210 UNK,UNK,UNK RM606755 50-60 2 0 9.84 PD-1/ Head and Neck MSK- A3101,A0206,B5201, A03,A02,B62, 0 PDL-1 Cancer IMPACT B3503,C1202,C0401 B07,UNK,UNK SF663454 50-60 5 0 4.92 PD-1/ Glioma MSK- A0301,A0101,B3502, A03,A01,B07, 0 PDL-1 IMPACT B4402,C0401,C0704 B44,UNK,UNK SL376792 31-50 0 0 7.87 PD-1/ Non-Small Cell MSK- A0301,A0201,B4001, A03,A02,B44, 0 PDL-1 Lung Cancer IMPACT B4402,C0304,C0501 B44,UNK,UNK TP431425 61-70 2 0 3.94 PD-1/ Colorectal MSK- A0101,A0201,B0801, A01,A02,B08, 1 PDL-1 Cancer IMPACT B1801,C0701,C0701 B44,UNK,UNK TU246190 >71 2 1 4.92 PD-1/ Head and Neck MSK- A0205,A2402,B3701, A02,A24,B44, 1 PDL-1 Cancer IMPACT B5001,C0602,C0602 B44,UNK,UNK WL781475 50-60 9 0 12.79 PD-1/ Head and Neck MSK- A2402,A0201,B5501, A24,A02,B07, 0 PDL-1 Cancer IMPACT B4901,C0102,C0701 UNK,UNK,UNK WM370639 61-70 7 0 32.47 PD-1/ Non-Small Cell MSK- A0101,A2301,B0702, A01,A24,B07, 0 PDL-1 Lung Cancer IMPACT B5601,C0102,C0702 B07,UNK,UNK WQ553952 61-70 16 0 0.98 PD-1/ Renal Cell MSK- A0101,A0201,B0702, A01,A02,B07, 0 PDL-1 Carcinoma IMPACT B2705,C0202,C0702 B27,UNK,UNK XH115119 31-50 5 0 25.58 CTLA4 Melanoma MSK- A3301,A2601,B1402, A03,A01,B27, 0 IMPACT B3901,C0802,C1203 B07,UNK,UNK YO621057 31-50 6 0 0.98 Combo Melanoma MSK- A1101,A2301,B4403, A03,A24,B44, 0 IMPACT B4901,C1601,C0701 UNK,UNK,UNK AN056765 31-50 11 0 209.55 PD-1/ Bladder Cancer MSK- A2902,A0201,B4403, A01A24,A02,B44, 1 PDL-1 IMPACT B4501,C1601,C1601 B44,UNK,UNK AO895857 31-50 3 0 2.95 PD-1/ Bladder Cancer MSK- A3001,A0201,B4402, A01A03,A02,B44, 0 PDL-1 IMPACT B1302,C0602,C0501 UNK,UNK,UNK BA321062 50-60 9 0 0.98 PD-1/ Melanoma MSK- A0101,A3101,B3502, A01,A03,B07, 0 PDL-1 IMPACT B1801,C0401,C0701 B44,UNK,UNK BD574032 31-50 13 0 2.95 PD-1/ Non-Small Cell MSK- A0101,A2601,B0801, A01,A01,B08, 1 PDL-1 Lung Cancer IMPACT B1302,C0701,C0701 UNK,UNK,UNK BZ275325 50-60 7 0 5.9 PD-1/ Bladder Cancer MSK- A0201,A0201,B0702, A02,A02,B07, 1 PDL-1 IMPACT B1401,C0802,C0702 B27,UNK,UNK CR081968 61-70 0 0 4.92 PD-1/ Breast MSK- A0101,A0101,B3701, A01,A01,B44, 1 PDL-1 Cancer IMPACT B0801,C0602,C0701 B08,UNK,UNK EX155661 31-50 10 0 8.85 PD-1/ Non-Small Cell MSK- A0301,A0201,B5101, A03,A02,B07, 0 PDL-1 Lung Cancer IMPACT B3501,C0102,C0401 B07,UNK,UNK GP968505 31-50 4 1 1.97 CTLA4 Breast MSK- A0301,A0201,B1402, A03,A02,B27, 0 Cancer IMPACT B3501,C0401,C0802 B07,UNK,UNK IP840936 <30 13 0 16.72 PD-1/ Melanoma MSK- A2301,A6802,B1801, A24,A02,B44, 0 PDL-1 IMPACT B3501,C0401,C0701 B07,UNK,UNK NE560956 61-70 0 0 4.92 PD-1/ Glioma MSK- A0101,A0101,B1402, A01,A01,B27, 1 PDL-1 IMPACT B1801,C1203,C0802 B44,UNK,UNK NF005757 >71 5 1 1.97 CTLA4 Breast MSK- A0301,A0101,B0801, A03,A01,B08, 0 Cancer IMPACT B1501,C0704,C0701 B62,UNK,UNK OL416633 50-60 0 0 4.92 PD-1/ Non-Small Cell MSK- A0301,A6601,B1402, A03,A03,B27, 0 PDL-1 Lung Cancer IMPACT B1302,C0802,C0602 UNK,UNK,UNK OP518972 >71 3 0 6.89 PD-1/ Melanoma MSK- A2402,A3101,B2705, A24,A03,B27, 0 PDL-1 IMPACT B3502,C0102,C0401 B07,UNK,UNK OR099414 31-50 2 0 7.87 PD-1/ Non-Small Cell MSK- A0301,A0201,B3501, A03,A02,B07, 0 PDL-1 Lung Cancer IMPACT B5101,C0401,C0202 B07,UNK,UNK OS252841 50-60 10 1 6.89 Combo Melanoma MSK- A3004,A2301,B4403, A01,A24,B44, 1 IMPACT B5801,C0706,C0706 B58,UNK,UNK OW781235 31-50 15 0 1.97 PD-1/ Non-Small Cell MSK- A0301,A0101,B0702, A03,A01,B07, 0 PDL-1 Lung Cancer IMPACT B0801,C0701,C0702 B08,UNK,UNK PN231718 >71 7 0 2.95 PD-1/ NA MSK- A3001,A0207,B4601, A01A03,A02,B62, 0 PDL-1 IMPACT B1302,C0102,C0602 UNK,UNK,UNK SZ972064 50-60 2 0 11.81 PD-1/ Non-Small Cell MSK- A0301,A3101,B0702, A03,A03,B07, 1 PDL-1 Lung Cancer IMPACT B0702,C0702,C0702 B07,UNK,UNK TH038973 61-70 1 1 4.92 PD-1/ Gastrointestinal MSK- A0101,A2601,B4002, A01,A01,B44, 0 PDL-1 Neuroendocrine IMPACT B5101,C1502,C0202 B07,UNK,UNK Tumor VK243562 >71 14 0 11.71 PD-1/ Head and Neck MSK- A3201,A0201,B2705, A01,A02,B27, 0 PDL-1 Cancer IMPACT B3901,C1203,C0202 B27,UNK,UNK XM411141 31-50 4 0 17.71 PD-1/ Non-Small Cell MSK- A2601,A2501,B1801, A01,A01,B44, 1 PDL-1 Lung Cancer IMPACT B1801,C1203,C1203 B44,UNK,UNK XQ918599 61-70 3 0 6.89 PD-1/ Melanoma MSK- A2402,A2402,B3906, A24,A24,B27, 1 PDL-1 IMPACT B3502,C0401,C0702 B07,UNK,UNK XS919703 61-70 2 1 0 PD-1/ Mesothelioma MSK- A2402,A3401,B1502, A24,UNK,B62, 0 PDL-1 IMPACT B1501,C0801,C0702 B62,UNK,UNK XT149820 50-60 12 0 8.85 PD-1/ Renal Cell MSK- A0101,A0101,B1402, A01,A01,B27, 1 PDL-1 Carcinoma IMPACT B5701,C0802,C0602 B58,UNK,UNK XV738523 61-70 1 0 0 PD-1/ Hodgkin MSK- A0301,A0101,B0702, A03,A01,B07, 0 PDL-1 Lymphoma IMPACT B3701,C0602,C0702 B44,UNK,UNK YI008527 31-50 22 0 66.9 PD-1/ Colorectal MSK- A0101,A2608,B0702, A01,A01,B07, 0 PDL-1 Cancer IMPACT B1801,C0701,C0702 B44,UNK,UNK YM026555 31-50 2 1 17.71 PD-1/ Non-Small Cell MSK- A2901,A0201,B0702, A01A24,A02,B07, 0 PDL-1 Lung Cancer IMPACT B1517,C0701,C0702 B58,UNK,UNK YQ511961 31-50 2 1 13.77 PD-1/ Non-Small Cell MSK- A6801,A6601,B2702, A03,A03,B27, 0 PDL-1 Lung Cancer IMPACT B1801,C0202,C1203 B44,UNK,UNK ZY339428 50-60 32 0 7.87 CTLA4 Melanoma MSK- A1101,A2901,B0705, A01,A01A24,B07, 0 IMPACT B4001,C1505,C0702 B44,UNK,UNK EN312634 31-50 12 0 40.34 Combo Melanoma MSK- A3201,A0201,B4402, A01,A02,B44, 0 IMPACT B5801,C0501,C0706 B58,UNK,UNK FN198586 61-70 14 1 4.92 PD-1/ Colorectal MSK- A3201,A0201,B0702, A01,A02,B07, 0 PDL-1 Cancer IMPACT B1501,C0303,C0702 B62,UNK,UNK HH259934 50-60 0 0 6.89 PD-1/ Esophagogastric MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 Cancer IMPACT B4402,C0704,C0701 B44,UNK,UNK IC506084 31-50 10 0 3.94 PD-1/ Melanoma MSK- A0301,A0201,B1402, A03,A02,B27, 0 PDL-1 IMPACT B4101,C1701,C0802 B44,UNK,UNK LB442555 50-60 1 0 2.95 PD-1/ Anal MSK- A1101,A3301,B1402, A03,A03,B27, 0 PDL-1 Cancer IMPACT B3701,C0602,C0802 B44,UNK,UNK LF922776 50-60 5 0 2.95 PD-1/ Melanoma MSK- A0201,A3101,B1501, A02,A03,B62, 0 PDL-1 IMPACT B4402,C0102,C0501 B44,UNK,UNK LI730809 31-50 5 1 11.81 Combo Non-Small Cell MSK- A0101,A6801,B0801, A01,A03,B08, 0 Lung Cancer IMPACT B4402,C0704,C0701 B44,UNK,UNK MA289096 >71 4 1 9.84 PD-1/ Colorectal MSK- A0201,A0201,B5001, A02,A02,B44, 1 PDL-1 Cancer IMPACT B3501,C0401,C0602 B07,UNK,UNK ME718412 <30 10 0 35.42 PD-1/ Melanoma MSK- A0201,A0201,B1401, A02,A02,B27, 1 PDL-1 IMPACT B4402,C0802,C0501 B44,UNK,UNK MN756477 >71 6 0 7.87 PD-1/ Breast MSK- A6601,A0205,B4403, A03,A02,B44, 0 PDL-1 Cancer IMPACT B4102,C1601,C1701 B44,UNK,UNK NY665367 31-50 14 0 24.59 Combo Bladder Cancer MSK- A0101,A2402,B0801, A01,A24,B08, 0 IMPACT B4403,C1601,C0701 B44,UNK,UNK OP481847 61-70 6 0 3.94 PD-1/ Glioma MSK- A2402,A2902,B1501, A24,A01A24,B62, 1 PDL-1 IMPACT B3501,C0303,C0303 B07,UNK,UNK TQ390536 <30 10 0 61.98 PD-1/ Esophagogastric MSK- A2402,A6801,B4901, A24,A03,UNK, 0 PDL-1 Cancer IMPACT B3508,C0401,C0701 B07,UNK,UNK UG182832 31-50 6 0 6.89 PD-1/ Esophagogastric MSK- A3101,A2601,B3801, A03,A01,B27, 0 PDL-1 Cancer IMPACT B1302,C1203,C0602 UNK,UNK,UNK UU047700 >71 1 1 15.74 Combo Melanoma MSK- A0301,A0101,B4001, A03,A01,B44, 0 IMPACT B4402,C0304,C0501 B44,UNK,UNK UW067254 >71 9 1 3.94 PD-1/ Glioma MSK- A0101,A0205,B4403, A01,A02,B44, 0 PDL-1 IMPACT B5001,C0602,C0706 B44,UNK,UNK VF477197 31-50 16 0 8.85 PD-1/ Renal Cell MSK- A0101,A0206,B4801, A01,A02,B27, 0 PDL-1 Carcinoma IMPACT B3502,C0401,C0803 B07,UNK,UNK VL999909 50-60 1 1 1.97 PD-1/ Head and Neck MSK- A0101,A0101,B0801, A01,A01,B08, 1 PDL-1 Cancer IMPACT B2703,C0202,C0701 B27,UNK,UNK VP308482 31-50 2 1 7.87 PD-1/ Non-Small Cell MSK- A0101,A3201,B2705, A01,A01,B27, 0 PDL-1 Lung Cancer IMPACT B5701,C0102,C0602 B58,UNK,UNK WF233416 61-70 16 0 1.97 Combo Renal Cell MSK- A0201,A3402,B0801, A02,A03,B08, 0 Carcinoma IMPACT B5701,C0602,C0701 B58,UNK,UNK XB162513 31-50 4 1 9.84 PD-1/ Non-Small Cell MSK- A2601,A2601,B2705, A01,A01,B27, 1 PDL-1 Lung Cancer IMPACT B3801,C0102,C1203 B27,UNK,UNK XK727574 31-50 5 0 47.22 PD-1/ Melanoma MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 IMPACT B4402,C0501,C0701 B44,UNK,UNK XW686398 50-60 3 0 59.03 PD-1/ Melanoma MSK- A1101,A0202,B4101, A03,A02,B44, 0 PDL-1 IMPACT B3501,C0401,C1701 B07,UNK,UNK ZL119793 50-60 11 0 12.79 Combo Bladder Cancer MSK- A0101,A6601,B3801, A01,A03,B27, 0 IMPACT B5201,C1203,C1202 B62,UNK,UNK ZV563438 31-50 5 1 7.87 PD-1/ Pancreatic MSK- A6802,A0201,B3906, A02,A02,B27, 0 PDL-1 Cancer IMPACT B1402,C0802,C0702 B27,UNK,UNK BJ473490 31-50 4 1 13.77 PD-1/ Non-Small Cell MSK- A0301,A0301,B0702, A03,A03,B07, 1 PDL-1 Lung Cancer IMPACT B3801,C1203,C0702 B27,UNK,UNK BY950416 50-60 0 1 23.61 CTLA4 Esophagogastric MSK- A0101,A0101,B0801, A01,A01,B08, 1 Cancer IMPACT B3508,C0401,C0718 B07,UNK,UNK DW018325 31-50 18 0 17.71 Combo Melanoma MSK- A0201,A0201,B0702, A02,A02,B07, 1 IMPACT B5101,C1402,C0702 B07,UNK,UNK DW879977 <30 0 0 0 PD-1/ Non-Small Cell MSK- A0201,A0201,B0702, A02,A02,B07, 1 PDL-1 Lung Cancer IMPACT B4402,C0501,C0702 B44,UNK,UNK EH539523 50-60 3 0 0 PD-1/ Soft Tissue MSK- A2901,A3303,B4403, A01A24,A03,B44, 0 PDL-1 Sarcoma IMPACT B2705,C1502,C0706 B27,UNK,UNK FW831458 31-50 2 0 18.69 PD-1/ Non-Small Cell MSK- A1101,A6901,B4402, A03,A02,B44, 0 PDL-1 Lung Cancer IMPACT B3801,C0501,C1203 B27,UNK,UNK HA119880 61-70 7 1 5.9 PD-1/ Glioma MSK- A0301,A0201,B2702, A03,A02,B27, 0 PDL-1 IMPACT B1801,C0202,C1203 B44,UNK,UNK NG419064 50-60 5 0 11.81 PD-1/ Melanoma MSK- A0101,A0201,B3502, A01,A02,B07, 0 PDL-1 IMPACT B3805,C0401,C0602 B07,UNK,UNK NP589780 61-70 12 0 14.76 Combo Melanoma MSK- A0301,A3301,B1402, A03,A03,B27, 1 IMPACT B1402,C0802,C0802 B27,UNK,UNK OD510699 31-50 4 0 9.84 PD-1/ Non-Small Cell MSK- A0101,A0101,B0801, A01,A01,B08, 1 PDL-1 Lung Cancer IMPACT B3502,C0401,C0701 B07,UNK,UNK PG803905 50-60 28 1 2.95 PD-1/ Renal Cell MSK- A0101,A2902,B0702, A01,A01A24,B07, 0 PDL-1 Carcinoma IMPACT B1402,C0802,C0702 B27,UNK,UNK PS791389 31-50 6 0 4.92 PD-1/ Glioma MSK- A0301,A0201,B1402, A03,A02,B27, 0 PDL-1 IMPACT B4402,C0501,C0802 B44,UNK,UNK PT990489 50-60 13 0 34.43 PD-1/ Non-Small Cell MSK- A3301,A3301,B1402, A03,A03,B27, 1 PDL-1 Lung Cancer IMPACT B1402,C0802,C0802 B27,UNK,UNK QT113700 50-60 23 1 1.97 PD-1/ Renal Cell MSK- A0101,A2301,B0801, A01,A24,B08, 0 PDL-1 Carcinoma IMPACT B4403,C0401,C0701 B44,UNK,UNK QZ186262 31-50 39 0 92.48 PD-1/ Melanoma MSK- A0301,A2301,B0702, A03,A24,B07, 0 PDL-1 IMPACT B4901,C0702,C0701 UNK,UNK,UNK ST162140 50-60 6 0 7.87 PD-1/ Colorectal MSK- A0301,A0101,B0702, A03,A01,B07, 0 PDL-1 Cancer IMPACT B0801,C0701,C0702 B08,UNK,UNK TI731664 50-60 11 0 6.89 PD-1/ Non-Small Cell MSK- A0301,A0201,B4402, A03,A02,B44, 0 PDL-1 Lung Cancer IMPACT B5101,C0102,C0501 B07,UNK,UNK VB077802 61-70 42 0 3.94 CTLA4 Melanoma MSK- A0301,A0201,B0702, A03,A02,B07, 0 IMPACT B1801,C0702,C0701 B44,UNK,UNK VS997541 50-60 15 0 4.92 PD-1/ Melanoma MSK- A0101,A0206,B4801, A01,A02,B27, 0 PDL-1 IMPACT B0801,C0803,C0718 B08,UNK,UNK WJ196194 50-60 7 0 2.95 PD-1/ Glioma MSK- A1101,A6802,B1402, A03,A02,B27, 0 PDL-1 IMPACT B5101,C0802,C0501 B07,UNK,UNK WX378273 50-60 18 0 17.71 Combo Melanoma MSK- A2301,A3201,B4402, A24,A01,B44, 0 IMPACT B4901,C0501,C0701 UNK,UNK,UNK XK162854 31-50 0 0 3.94 PD-1/ Non-Small Cell MSK- A0301,A2902,B0702, A03,A01A24,B07, 0 PDL-1 Lung Cancer IMPACT B4403,C1601,C0702 B44,UNK,UNK XY160168 31-50 12 0 21.64 PD-1/ Non-Small Cell MSK- A3201,A6801,B2702, A01,A03,B27, 0 PDL-1 Lung Cancer IMPACT B4403,C0202,C0401 B44,UNK,UNK AJ891505 31-50 6 1 11.81 PD-1/ Non-Small Cell MSK- A0301,A0101,B0801, A03,A01,B08, 0 PDL-1 Lung Cancer IMPACT B1801,C0501,C0701 B44,UNK,UNK AK052983 61-70 4 0 6.89 PD-1/ Glioma MSK- A3201,A0205,B5001, A01,A02,B44, 0 PDL-1 IMPACT B3508,C0304,C0602 B07,UNK,UNK BY277443 61-70 13 0 0.98 PD-1/ Glioma MSK- A1101,A0203,B5201, A03,A02,B62, 0 PDL-1 IMPACT B1301,C0304,C1202 UNK,UNK,UNK CU714354 50-60 20 0 1.97 Combo Bladder Cancer MSK- A1101,A3303,B4403, A03,A03,B44, 0 IMPACT B5601,C0102,C0706 B07,UNK,UNK DC957706 31-50 1 1 1.97 Combo Soft Tissue MSK- A0201,A3101,B3901, A02,A03,B27, 0 Sarcoma IMPACT B3508,C0401,C0702 B07,UNK,UNK DR074297 61-70 10 0 3.94 PD-1/ Renal Cell MSK- A0101,A0201,B5201, A01,A02,B62, 0 PDL-1 Carcinoma IMPACT B3501,C1202,C0401 B07,UNK,UNK FG902387 31-50 12 1 5.9 PD-1/ Ampullary MSK- A0201,A2601,B3701, A02,A01,B44, 0 PDL-1 Carcinoma IMPACT B1801,C0602,C0701 B44,UNK,UNK HE548457 31-50 2 0 7.87 PD-1/ Glioma MSK- A2301,A2601,B3801, A24,A01,B27, 0 PDL-1 IMPACT B4901,C1203,C0701 UNK,UNK,UNK IE505811 31-50 0 0 6.89 PD-1/ Non-Small Cell MSK- A0101,A2601,B5701, A01,A01,B58, 0 PDL-1 Lung Cancer IMPACT B1801,C1203,C0602 B44,UNK,UNK KD996653 61-70 11 0 15.74 PD-1/ Non-Small Cell MSK- A2402,A6801,B1801, A24,A03,B44, 0 PDL-1 Lung Cancer IMPACT B5101,C1502,C0701 B07,UNK,UNK LU243185 31-50 1 0 2.95 PD-1/ Non-Small Cell MSK- A1101,A0201,B4402, A03,A02,B44, 0 PDL-1 Lung Cancer IMPACT B3501,C0401,C0501 B07,UNK,UNK LW347198 61-70 10 1 2.95 PD-1/ Melanoma MSK- A3002,A2402,B1503, A01,A24,B27, 0 PDL-1 IMPACT B4002,C0304,C0401 B44,UNK,UNK MG883401 50-60 20 0 12.79 Combo Melanoma MSK- A6801,A3301,B1402, A03,A03,B27, 0 IMPACT B4402,C0802,C0704 B44,UNK,UNK MQ099328 31-50 0 0 5.9 PD-1/ Breast MSK- A2902,A0201,B4403, A01A24,A02,B44, 0 PDL-1 Cancer IMPACT B1801,C1601,C0701 B44,UNK,UNK NR864503 >71 16 0 7.87 Combo Melanoma MSK- A2902,A2601,B4403, A01A24,A01,B44, 0 IMPACT B4402,C1601,C0501 B44,UNK,UNK OL048054 50-60 4 1 2.95 PD-1/ Melanoma MSK- A0301,A2301,B1402, A03,A24,B27, 0 PDL-1 IMPACT B1510,C0304,C0802 B27,UNK,UNK OO343430 50-60 0 0 3.94 PD-1/ Renal Cell MSK- A3201,A0201,B3701, A01,A02,B44, 0 PDL-1 Carcinoma IMPACT B1501,C0401,C0602 B62,UNK,UNK PX423160 50-60 1 1 19.68 PD-1/ Melanoma MSK- A3001,A0101,B2705, A01A03,A01,B27, 1 PDL-1 IMPACT B2705,C0202,C0602 B27,UNK,UNK RM264272 50-60 10 1 6.89 PD-1/ Renal Cell MSK- A0101,A0201,B4403, A01,A02,B44, 1 PDL-1 Carcinoma IMPACT B3503,C0401,C0401 B07,UNK,UNK SK499637 61-70 12 0 3.94 PD-1/ Glioma MSK- A0101,A0101,B5701, A01,A01,B58, 1 PDL-1 IMPACT B5701,C0602,C0602 B58,UNK,UNK SN378137 31-50 0 1 5.9 PD-1/ Non-Small Cell MSK- A0301,A2601,B0702, A03,A01,B07, 0 PDL-1 Lung Cancer IMPACT B6701,C1203,C0702 B07,UNK,UNK SQ358496 31-50 7 1 6.89 PD-1/ Bladder Cancer MSK- A6801,A0205,B0702, A03,A02,B07, 0 PDL-1 IMPACT B1509,C0702,C0704 B27,UNK,UNK TE370578 50-60 10 0 65.91 Combo Melanoma MSK- A0301,A0101,B0801, A03,A01,B08, 0 IMPACT B3501,C0401,C0701 B07,UNK,UNK TO340081 31-50 3 0 1.97 PD-1/ Head and Neck MSK- A0301,A0201,B4402, A03,A02,B44, 1 PDL-1 Cancer IMPACT B4402,C0501,C0704 B44,UNK,UNK TO569127 >71 5 0 2.95 Combo Melanoma MSK- A2601,A0201,B0702, A01,A02,B07, 0 IMPACT B3501,C0303,C0702 B07,UNK,UNK UB931860 31-50 2 1 0.98 PD-1/ Head and Neck MSK- A2402,A0201,B0702, A24,A02,B07, 0 PDL-1 Cancer IMPACT B1501,C0303,C0702 B62,UNK,UNK VR847789 61-70 13 0 22.63 PD-1/ Renal Cell MSK- A0201,A3303,B4006, A02,A03,B44, 0 PDL-1 Carcinoma IMPACT B5801,C0304,C0303 B58,UNK,UNK VX079278 61-70 6 1 2.95 PD-1/ Non-Small Cell MSK- A2402,A0207,B4601, A24,A02,B62, 0 PDL-1 Lung Cancer IMPACT B1302,C0102,C0602 UNK,UNK,UNK WG606901 50-60 6 0 25.58 PD-1/ Skin Cancer; MSK- A0201,A2601,B0702, A02,A01,B07, 0 PDL-1 Non-Melanoma IMPACT B3501,C0401,C0702 B07,UNK,UNK XE626384 50-60 11 0 11.81 PD-1/ Non-Small Cell MSK- A0101,A2601,B0801, A01,A01,B08, 0 PDL-1 Lung Cancer IMPACT B0702,C0701,C0702 B07,UNK,UNK YR566743 31-50 0 1 3.94 Combo Pancreatic MSK- A0301,A2402,B1402, A03,A24,B27, 1 Cancer IMPACT B1402,C0802,C0802 B27,UNK,UNK ZF792273 31-50 0 0 9.84 PD-1/ Pancreatic MSK- A2403,A0205,B5001, A24,A02,B44, 0 PDL-1 Cancer IMPACT B3501,C0401,C0602 B07,UNK,UNK AA919263 >71 3 0 0.98 PD-1/ Head and Neck MSK- A3001,A2402,B3503, A01A03,A24,B07, 0 PDL-1 Cancer IMPACT B1516,C1601,C1203 B58,UNK,UNK BB148083 61-70 2 0 1.97 PD-1/ Renal Cell MSK- A0301,A0101,B0801, A03,A01,B08, 0 PDL-1 Carcinoma IMPACT B4402,C0501,C0701 B44,UNK,UNK EI574944 31-50 3 1 0 PD-1/ Head and Neck MSK- A3201,A0201,B3801, A01,A02,B27, 0 PDL-1 Cancer IMPACT B5101,C1402,C1203 B07,UNK,UNK FM634739 50-60 17 0 6.89 PD-1/ Colorectal MSK- A2301,A0201,B4001, A24,A02,B44, 0 PDL-1 Cancer IMPACT B4901,C0304,C0701 UNK,UNK,UNK GH655330 50-60 28 1 1.97 CTLA4 Melanoma MSK- A0201,A3301,B4201, A02,A03,B07, 0 IMPACT B7801,C1701,C1601 B07,UNK,UNK JM757194 61-70 3 1 11.81 PD-1/ Melanoma MSK- A2403,A0201,B1801, A24,A02,B44, 0 PDL-1 IMPACT B5301,C0401,C1203 B07,UNK,UNK JN174072 31-50 12 0 35.42 Combo Melanoma MSK- A3002,A2601,B2705, A01,A01,B27, 0 IMPACT B1801,C0102,C0501 B44,UNK,UNK JR658183 50-60 1 1 1.97 PD-1/ Non-Small Cell MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 Lung Cancer IMPACT B4402,C0501,C0701 B44,UNK,UNK JS285396 31-50 15 0 5.9 PD-1/ Non-Small Cell MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 Lung Cancer IMPACT B3501,C0401,C0701 B07,UNK,UNK KI034546 50-60 0 0 48.21 PD-1/ Melanoma MSK- A2402,A0201,B4403, A24,A02,B44, 0 PDL-1 IMPACT B5101,C0102,C0501 B07,UNK,UNK KI279575 >71 17 0 44.27 PD-1/ Colorectal MSK- A0301,A2402,B0702, A03,A24,B07, 0 PDL-1 Cancer IMPACT B1801,C1203,C0702 B44,UNK,UNK LZ739624 50-60 12 1 1.97 CTLA4 Melanoma MSK- A0101,A2402,B5701, A01,A24,B58, 0 IMPACT B3502,C0401,C0602 B07,UNK,UNK MG245949 50-60 6 0 10.82 Combo Melanoma MSK- A3001,A0201,B1801, A01A03,A02,B44, 0 IMPACT B1302,C0602,C0701 UNK,UNK,UNK MY236910 31-50 4 1 7.87 Combo Melanoma MSK- A0101,A6802,B0801, A01,A02,B08, 0 IMPACT B1402,C0802,C0701 B27,UNK,UNK NP095956 31-50 5 0 31.48 Combo Melanoma MSK- A0101,A0101,B0801, A01,A01,B08, 1 IMPACT B5701,C0602,C0701 B58,UNK,UNK OR826293 31-50 1 0 9.84 Combo Small Cell MSK- A0301,A2402,B0702, A03,A24,B07, 0 Lung Cancer IMPACT B3508,C0401,C0702 B07,UNK,UNK OT894166 61-70 9 1 4.92 PD-1/ Glioma MSK- A1101,A1101,B1301, A03,A03,UNK, 1 PDL-1 IMPACT B5101,C0304,C1402 B07,UNK,UNK SF898078 31-50 37 0 3.94 PD-1/ Renal Cell MSK- A0301,A2601,B0702, A03,A01,B07, 0 Carcinoma IMPACT B3701,C0602,C0702 B44,UNK,UNK TS228316 31-50 39 0 48.21 CTLA4 Melanoma MSK- A0101,A2402,B0801, A01,A24,B08, 0 IMPACT B5701,C0602,C0701 B58,UNK,UNK TX032049 31-50 14 0 1.97 PD-1/ Glioma MSK- A1101,A3201,B5201, A03,A01,B62, 1 PDL-1 IMPACT B5201,C1202,C1202 B62,UNK,UNK UN859698 50-60 0 0 2.95 PD-1/ Non-Small Cell MSK- A3303,A0201,B0702, A03,A02,B07, 0 PDL-1 Lung Cancer IMPACT B1801,C1203,C0702 B44,UNK,UNK VV775396 >71 5 0 0 PD-1/ Soft Tissue MSK- A1101,A3101,B5201, A03,A03,B62, 0 PDL-1 Sarcoma IMPACT B5101,C1502,C1202 B07,UNK,UNK YH915303 31-50 5 0 5.9 PD-1/ Thyroid MSK- A2902,A6801,B1402, A01A24,A03,B27, 0 PDL-1 Cancer IMPACT B2702,C0802,C0202 B27,UNK,UNK ZZ383896 50-60 7 0 10.82 PD-1/ Bladder MSK- A3001,A3201,B3801, A01A03,A01,B27, 0 PDL-1 Cancer IMPACT B1302,C0602,C1203 UNK,UNK,UNK AI289139 61-70 29 1 2.95 PD-1/ Renal Cell MSK- A3001,A3101,B2705, A01A03,A03,B27, 0 PDL-1 Carcinoma IMPACT B1501,C0102,C0303 B62,UNK,UNK AZ436323 50-60 17 0 3.94 PD-1/ Glioma MSK- A2601,A3301,B0702, A01,A03,B07, 0 PDL-1 IMPACT B1402,C0802,C0702 B27,UNK,UNK CM374720 50-60 8 0 4.92 PD-1/ Renal Cell MSK- A0301,A0201,B0801, A03,A02,B08, 0 PDL-1 Carcinoma IMPACT B4001,C0304,C0701 B44,UNK,UNK CT849635 61-70 11 1 1.97 PD-1/ Head and Neck MSK- A0201,A0206,B2705, A02,A02,B27, 0 PDL-1 Cancer IMPACT B1302,C0303,C0602 UNK,UNK,UNK EN879707 31-50 7 0 10.82 CTLA4 Melanoma MSK- A0101,A2402,B2705, A01,A24,B27, 0 IMPACT B5101,C0102,C0202 B07,UNK,UNK EZ883373 31-50 29 0 3.94 PD-1/ Renal Cell MSK- A2602,A0207,B1501, A01,A02,B62, 1 PDL-1 Carcinoma IMPACT B1501,C0303,C0303 B62,UNK,UNK FQ072342 31-50 2 0 3.94 PD-1/ Bladder MSK- A0101,A0201,B4001, A01,A02,B44, 0 PDL-1 Cancer IMPACT B5701,C0304,C0602 B58,UNK,UNK HP035557 50-60 14 0 1.97 PD-1/ Bladder MSK- A0301,A3303,B0702, A03,A03,B07, 0 PDL-1 Cancer IMPACT B4901,C0701,C0702 UNK,UNK,UNK IG343955 >71 0 0 0.98 Combo Non-Small Cell MSK- A0101,A3303,B3701, A01,A03,B44, 0 Lung Cancer IMPACT B5101,C1602,C0602 B07,UNK,UNK KB328348 61-70 4 0 7.87 PD-1/ Head and Neck MSK- A0205,A3303,B0702, A02,A03,B07, 0 PDL-1 Cancer IMPACT B1516,C1402,C0702 B58,UNK,UNK KK881118 50-60 5 0 2.95 PD-1/ Glioma MSK- A0101,A6802,B1402, A01,A02,B27, 0 PDL-1 IMPACT B5801,C0802,C0706 B58,UNK,UNK MI360504 50-60 9 0 6.89 PD-1/ Non-Hodgkin MSK- A0201,A0201,B3503, A02,A02,B07, 1 PDL-1 Lymphoma IMPACT B3503,C0401,C0401 B07,UNK,UNK MJ017310 50-60 2 0 3.94 PD-1/ Glioma MSK- A2402,A2601,B4101, A24,A01,B44, 0 PDL-1 IMPACT B1801,C1701,C1203 B44,UNK,UNK ND912084 31-50 7 0 0.98 PD-1/ Skin Cancer; MSK- A3001,A6801,B4001, A01A03,A03,B44, 1 PDL-1 Non-Melanoma IMPACT B4001,C0304,C0304 B44,UNK,UNK NH243829 50-60 7 0 11.81 CTLA4 Melanoma MSK- A2601,A0201,B1402, A01,A02,B27, 0 IMPACT B3801,C0802,C1203 B27,UNK,UNK OW583283 31-50 4 0 36.4 PD-1/ Melanoma MSK- A3001,A6602,B4201, A01A03,A03,B07, 0 PDL-1 IMPACT B1801,C0501,C1701 B44,UNK,UNK QE052353 31-50 2 0 10.82 PD-1/ Non-Small Cell MSK- A0301,A2601,B0702, A03,A01,B07, 0 PDL-1 Lung Cancer IMPACT B6701,C1203,C0702 B07,UNK,UNK RT206143 31-50 6 0 7.87 PD-1/ Cancer of MSK- A0201,A0201,B4402, A02,A02,B44, 1 PDL-1 Unknown IMPACT B4402,C0501,C0704 B44,UNK,UNK Primary SB277970 50-60 10 0 13.77 Combo Melanoma MSK- A1101,A2601,B3801, A03,A01,B27, 0 IMPACT B3503,C0401,C1203 B07,UNK,UNK UE671470 61-70 65 0 1.97 PD-1/ Renal Cell MSK- A0101,A2402,B0702, A01,A24,B07, 0 PDL-1 Carcinoma IMPACT B4402,C0501,C0702 B44,UNK,UNK VB628966 31-50 13 0 9.84 Combo Renal Cell MSK- A1101,A2901,B0705, A03,A01A24,B07, 0 Carcinoma IMPACT B1402,C0802,C1505 B27,UNK,UNK VI875864 >71 1 1 4.92 PD-1/ Glioma MSK- A0301,A2601,B4402, A03,A01,B44, 0 PDL-1 IMPACT B4701,C1604,C0602 UNK,UNK,UNK VS684136 50-60 9 1 3.94 PD-1/ Bladder MSK- A1101,A2402,B4901, A03,A24,UNK, 0 PDL-1 Cancer IMPACT B5201,C1202,C0701 B62,UNK,UNK WB258446 31-50 11 1 3.94 PD-1/ Renal Cell MSK- A0101,A2301,B4403, A01,A24,B44, 1 PDL-1 Carcinoma IMPACT B3503,C0401,C0401 B07,UNK,UNK WX194323 50-60 4 1 2.95 PD-1/ Glioma MSK- A6801,A0201,B0702, A03,A02,B07, 0 PDL-1 IMPACT B3501,C0401,C0702 B07,UNK,UNK YU641238 50-60 3 1 4.92 PD-1/ Pancreatic MSK- A2402,A0201,B3801, A24,A02,B27, 0 PDL-1 Cancer IMPACT B4402,C1203,C0501 B44,UNK,UNK AU586996 50-60 3 1 0.98 PD-1/ Renal Cell MSK- A2402,A0205,B4402, A24,A02,B44, 0 PDL-1 Carcinoma IMPACT B3503,C0401,C0501 B07,UNK,UNK DQ804796 31-50 8 0 5.9 PD-1/ Non-Small Cell MSK- A0101,A2402,B0801, A01,A24,B08, 0 PDL-1 Lung Cancer IMPACT B3502,C0401,C0701 B07,UNK,UNK EE822574 61-70 13 1 2.95 CTLA4 Melanoma MSK- A0201,A0201,B3701, A02,A02,B44, 1 IMPACT B3801,C1203,C0602 B27,UNK,UNK EJ979278 61-70 9 0 1.97 Combo Melanoma MSK- A0301,A2402,B2702, A03,A24,B27, 0 IMPACT B1501,C0303,C0202 B62,UNK,UNK GC769217 31-50 0 0 17.71 PD-1/ Non-Small Cell MSK- A0101,A2902,B4403, A01,A01A24,B44, 0 PDL-1 Lung Cancer IMPACT B5601,C1601,C0701 B07,UNK,UNK JQ416542 >71 2 1 3.94 PD-1/ Pancreatic MSK- A1101,A0101,B0801, A03,A01,B08, 0 PDL-1 Cancer IMPACT B5101,C1502,C0701 B07,UNK,UNK KA699526 31-50 18 0 12.79 Combo Melanoma MSK- A0302,A0201,B4402, A03,A02,B44, 0 IMPACT B3502,C0501,C0401 B07,UNK,UNK MA647036 31-50 8 0 14.76 PD-1/ Non-Small Cell MSK- A3001,A0301,B1402, A01A03,A03,B27, 0 PDL-1 Lung Cancer IMPACT B1302,C0802,C0602 UNK,UNK,UNK MX495884 50-60 1 1 4.92 PD-1/ Esophagogastric MSK- A1101,A6802,B4403, A03,A02,B44, 1 PDL-1 Cancer IMPACT B5301,C0401,C0401 B07,UNK,UNK OM805229 31-50 9 0 15.74 PD-1/ Melanoma MSK- A2402,A2601,B1801, A24,A01,B44, 0 PDL-1 IMPACT B3508,C1203,C0401 B07,UNK,UNK OQ415968 >71 16 0 65.91 PD-1/ Colorectal MSK- A0101,A2902,B7301, A01,A01A24,B27, 0 PDL-1 Cancer IMPACT B4403,C1601,C1505 B44,UNK,UNK PF967643 31-50 2 0 12.79 PD-1/ Non-Small Cell MSK- A0101,A6601,B1501, A01,A03,B62, 0 PDL-1 Lung Cancer IMPACT B4102,C1701,C0701 B44,UNK,UNK RT169392 31-50 4 0 74.77 PD-1/ Melanoma MSK- A0101,A2601,B3701, A01,A01,B44, 0 PDL-1 IMPACT B3801,C1203,C0602 B27,UNK,UNK RX243136 50-60 13 0 11.81 PD-1/ Non-Small Cell MSK- A0301,A2601,B0801, A03,A01,B08, 0 PDL-1 Lung Cancer IMPACT B5301,C0304,C0210 B07,UNK,UNK SG417338 50-60 2 1 7.87 PD-1/ Non-Hodgkin MSK- A0301,A2402,B3501, A03,A24,B07, 1 PDL-1 Lymphoma IMPACT B3508,C0401,C0401 B07,UNK,UNK TJ094097 31-50 5 0 11.81 PD-1/ Melanoma MSK- A2402,A2601,B3801, A24,A01,B27, 1 PDL-1 IMPACT B3801,C1203,C1203 B27,UNK,UNK VM721100 31-50 7 0 20.66 PD-1/ Melanoma MSK- A0201,A0201,B0702, A02,A02,B07, 1 PDL-1 IMPACT B1801,C0702,C0701 B44,UNK,UNK WV623589 61-70 12 0 7.87 PD-1/ Colorectal MSK- A2902,A6801,B1518, A01A24,A03,B27, 0 PDL-1 Cancer IMPACT B4403,C1601,C0704 B44,UNK,UNK XC653229 31-50 2 1 13.77 PD-1/ Non-Small Cell MSK- A2301,A0201,B2705, A24,A02,B27, 0 PDL-1 Lung Cancer IMPACT B4901,C0102,C0701 UNK,UNK,UNK ZJ926402 61-70 9 0 4.92 PD-1/ Non-Small Cell MSK- A2902,A3301,B1402, A01A24,A03,B27, 0 PDL-1 Lung Cancer IMPACT B4403,C0802,C1601 B44,UNK,UNK AP548960 31-50 21 0 35.42 PD-1/ Melanoma MSK- A2402,A0201,B1501, A24,A02,B62, 0 PDL-1 IMPACT B4402,C0303,C0501 B44,UNK,UNK BD940228 50-60 14 0 7.87 Combo NA MSK- A2402,A0201,B0702, A24,A02,B07, 1 IMPACT B3901,C0702,C0702 B27,UNK,UNK CS024658 50-60 1 0 3.94 PD-1/ Glioma MSK- A0201,A0201,B3801, A02,A02,B27, 1 PDL-1 IMPACT B4402,C0501,C1203 B44,UNK,UNK DK756867 61-70 5 0 4.92 PD-1/ Breast Cancer MSK- A0301,A0101,B0801, A03,A01,B08, 0 PDL-1 IMPACT B3503,C0401,C0701 B07,UNK,UNK EQ981337 31-50 4 1 3.94 PD-1/ Renal Cell MSK- A0101,A2902,B0801, A01,A01A24,B08, 0 PDL-1 Carcinoma IMPACT B4403,C1601,C0701 B44,UNK,UNK GO662209 31-50 0 0 10.82 Combo Small Cell MSK- A0301,A2601,B1801, A03,A01,B44, 0 Lung Cancer IMPACT B3503,C1203,C0701 B07,UNK,UNK GU236132 50-60 1 1 3.94 PD-1/ Anal Cancer MSK- A0301,A6802,B3701, A03,A02,B44, 0 PDL-1 IMPACT B5301,C0401,C0602 B07,UNK,UNK KA118426 31-50 3 0 6.89 PD-1/ Renal Cell MSK- A2402,A0201,B1402, A24,A02,B27, 0 PDL-1 Carcinoma IMPACT B4001,C0102,C0802 B44,UNK,UNK MJ236116 31-50 22 1 5.9 CTLA4 Pancreatic MSK- A0201,A0201,B0801, A02,A02,B08, 1 Cancer IMPACT B1501,C0303,C0701 B62,UNK,UNK PC349900 31-50 3 0 3.94 PD-1/ Colorectal MSK- A3001,A1101,B0702, A01A03,A03,B07, 0 PDL-1 Cancer IMPACT B1302,C0602,C0702 UNK,UNK,UNK PW868809 50-60 8 0 16.72 PD-1/ Non-Small Cell MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 Lung Cancer IMPACT B4403,C0401,C0701 B44,UNK,UNK QZ994733 31-50 16 0 0 PD-1/ Skin Cancer; MSK- A0301,A2402,B6701, A03,A24,B07, 0 PDL-1 Non-Melanoma IMPACT B5501,C0102,C1203 B07,UNK,UNK SM492088 50-60 8 0 2.95 PD-1/ Adrenocortical MSK- A0101,A0201,B5701, A01,A02,B58, 0 PDL-1 Carcinoma IMPACT B4001,C0304,C0602 B44,UNK,UNK ST964388 31-50 12 1 150.52 PD-1/ Melanoma MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 IMPACT B1501,C0304,C0702 B62,UNK,UNK TD080094 61-70 4 0 8.85 PD-1/ Colorectal MSK- A2402,A0201,B0705, A24,A02,B07, 0 PDL-1 Cancer IMPACT B3701,C1505,C0802 B44,UNK,UNK VF708164 31-50 11 0 8.85 Combo Non-Small Cell MSK- A2402,A6901,B5501, A24,A02,B07, 0 Lung Cancer IMPACT B3502,C0303,C0401 B07,UNK,UNK XW509252 31-50 0 0 3.94 PD-1/ Non-Small Cell MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 Lung Cancer IMPACT B4101,C1701,C0701 B44,UNK,UNK BL451101 31-50 3 1 1.97 PD-1/ Esophagogastric MSK- A3001,A0301,B0702, A01A03,A03,B07, 0 PDL-1 Cancer IMPACT B5703,C0701,C0702 B58,UNK,UNK CP437800 61-70 2 0 0.98 PD-1/ Melanoma MSK- A3001,A0201,B0801, A01A03,A02,B08, 0 PDL-1 IMPACT B3801,C1203,C0701 B27,UNK,UNK DH083727 >71 1 1 12.79 PD-1/ Non-Hodgkin MSK- A0101,A0201,B5701, A01,A02,B58, 1 PDL-1 Lymphoma IMPACT B5701,C0602,C0602 B58,UNK,UNK EY617944 >71 3 0 65.91 PD-1/ NA MSK- A0207,A3303,B4601, A02,A03,B62, 0 PDL-1 IMPACT B5801,C0102,C0302 B58,UNK,UNK FO818879 >71 22 0 68.87 PD-1/ Colorectal MSK- A1101,A0201,B1302, A03,A02,UNK, 0 PDL-1 Cancer IMPACT B3501,C0401,C0602 B07,UNK,UNK FT888206 61-70 15 0 8.85 Combo Renal Cell MSK- A1101,A6801,B1402, A03,A03,B27, 0 Carcinoma IMPACT B3501,C0802,C0704 B07,UNK,UNK GC414305 50-60 10 0 5.9 PD-1/ Renal Cell MSK- A0301,A2402,B4101, A03,A24,B44, 0 PDL-1 Carcinoma IMPACT B4402,C1701,C1604 B44,UNK,UNK JL036420 50-60 5 1 5.9 PD-1/ Glioma MSK- A3001,A0101,B0801, A01A03,A01,B08, 0 PDL-1 IMPACT B5201,C1202,C0701 B62,UNK,UNK KJ592597 50-60 14 0 4.92 PD-1/ Melanoma MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 IMPACT B4402,C0501,C0701 B44,UNK,UNK LE083915 >71 12 1 23.61 Combo Bladder MSK- A2301,A2301,B4201, A24,A24,B07, 1 Cancer IMPACT B1516,C1402,C1701 B58,UNK,UNK MA086950 50-60 0 1 4.92 PD-1/ Melanoma MSK- A3001,A2402,B0801, A01A03,A24,B08, 0 PDL-1 IMPACT B3502,C0401,C0701 B07,UNK,UNK NL203214 >71 9 0 10.82 PD-1/ Head and Neck MSK- A2402,A0201,B5701, A24,A02,B58, 0 PDL-1 Cancer IMPACT B5101,C0102,C0605 B07,UNK,UNK RE754398 <30 11 0 22.63 PD-1/ Melanoma MSK- A0101,A3101,B0801, A01,A03,B08, 0 PDL-1 IMPACT B4701,C0602,C0701 UNK,UNK,UNK RY613181 50-60 12 0 5.9 PD-1/ Bladder MSK- A0201,A0201,B1401, A02,A02,B27, 1 PDL-1 Cancer IMPACT B5101,C0802,C0202 B07,UNK,UNK SD909203 31-50 0 1 2.95 PD-1/ Non-Small Cell MSK- A0101,A6801,B0801, A01,A03,B08, 0 PDL-1 Lung Cancer IMPACT B3503,C0401,C0701 B07,UNK,UNK SH271275 50-60 7 0 3.94 PD-1/ Renal Cell MSK- A1101,A6801,B0705, A03,A03,B07, 0 PDL-1 Carcinoma IMPACT B5101,C1402,C0702 B07,UNK,UNK TT770421 31-50 0 0 10.82 PD-1/ Head and Neck MSK- A2601,A0205,B0801, A01,A02,B08, 0 PDL-1 Cancer IMPACT B5001,C0602,C0702 B44,UNK,UNK TU904333 61-70 6 1 5.9 PD-1/ Non-Hodgkin MSK- A0101,A3301,B1402, A01,A03,B27, 0 PDL-1 Lymphoma IMPACT B5701,C0802,C0602 B58,UNK,UNK UP272365 31-50 6 1 16.72 PD-1/ Non-Small Cell MSK- A0101,A0101,B0801, A01,A01,B08, 1 PDL-1 Lung Cancer IMPACT B3502,C0401,C0701 B07,UNK,UNK WS993881 61-70 2 1 7.87 PD-1/ Non-Small Cell MSK- A2402,A2601,B3801, A24,A01,B27, 1 PDL-1 Lung Cancer IMPACT B1801,C1203,C1203 B44,UNK,UNK XK412876 61-70 11 0 3.94 PD-1/ Renal Cell MSK- A0101,A2902,B4403, A01,A01A24,B44, 0 PDL-1 Carcinoma IMPACT B4402,C1601,C0501 B44,UNK,UNK YT686462 50-60 23 0 3.94 PD-1/ Renal Cell MSK- A2901,A0201,B4002, A01A24,A02,B44, 0 PDL-1 Carcinoma IMPACT B5108,C0202,C1502 B07,UNK,UNK YX193539 <30 19 0 38.37 PD-1/ Melanoma MSK- A2402,A0205,B3801, A24,A02,B27, 0 PDL-1 IMPACT B5201,C1202,C1203 B62,UNK,UNK ZF254339 50-60 2 0 1.97 PD-1/ Anal MSK- A2402,A3303,B4402, A24,A03,B44, 0 PDL-1 Cancer IMPACT B3503,C0501,C1203 B07,UNK,UNK AN801016 50-60 26 1 4.92 Combo Renal Cell MSK- A0201,A0201,B1801, A02,A02,B44, 1 Carcinoma IMPACT B1801,C0701,C0701 B44,UNK,UNK AP783434 31-50 6 0 3.94 PD-1/ Colorectal MSK- A0301,A0302,B0702, A03,A03,B07, 0 PDL-1 Cancer IMPACT B5101,C1502,C0702 B07,UNK,UNK BE099274 31-50 1 1 4.92 PD-1/ Pancreatic MSK- A3301,A3301,B1402, A03,A03,B27, 1 PDL-1 Cancer IMPACT B1402,C0802,C0802 B27,UNK,UNK CR195193 50-60 2 1 2.95 PD-1/ Esophagogastric MSK- A3001,A2601,B1801, A01A03,A01,B44, 0 PDL-1 Cancer IMPACT B1302,C1203,C0602 UNK,UNK,UNK GM551205 50-60 6 0 7.87 PD-1/ Renal Cell MSK- A0301,A2902,B1510, A03,A01A24,B27, 0 PDL-1 Carcinoma IMPACT B1302,C0304,C0602 UNK,UNK,UNK HO216759 61-70 26 0 1.97 PD-1/ Renal Cell MSK- A2402,A0201,B4403, A24,A02,B44, 0 PDL-1 Carcinoma IMPACT B3503,C1203,C1601 B07,UNK,UNK IO169657 50-60 3 1 5.9 PD-1/ NA MSK- A2301,A0201,B1503, A24,A02,B27, 0 PDL-1 IMPACT B4403,C0210,C0706 B44,UNK,UNK MD570774 50-60 8 1 7.87 PD-1/ Non-Small Cell MSK- A2301,A0201,B1401, A24,A02,B27, 0 PDL-1 Lung Cancer IMPACT B4403,C0401,C0802 B44,UNK,UNK PJ729478 31-50 8 0 43.29 PD-1/ Esophagogastric MSK- A6802,A0205,B5001, A02,A02,B44, 0 PDL-1 Cancer IMPACT B5301,C0401,C0602 B07,UNK,UNK XP870786 61-70 13 0 2.95 Combo Renal Cell MSK- A0101,A6801,B3701, A01,A03,B44, 0 Carcinoma IMPACT B4001,C0304,C0602 B44,UNK,UNK YL892257 31-50 27 0 33.45 CTLA4 Melanoma MSK- A6801,A0201,B4001, A03,A02,B44, 0 IMPACT B4701,C0304,C0602 UNK,UNK,UNK ZH585728 31-50 12 1 1.97 PD-1/ Non-Small Cell MSK- A0301,A2601,B5101, A03,A01,B07, 0 PDL-1 Lung Cancer IMPACT B1302,C1402,C0602 UNK,UNK,UNK ZW725633 31-50 3 1 6.89 PD-1/ Non-Small Cell MSK- A3002,A3201,B1501, A01,A01,B62, 0 PDL-1 Lung Cancer IMPACT B1801,C0303,C0501 B44,UNK,UNK BN163408 31-50 2 1 5.9 PD-1/ Pancreatic MSK- A1101,A1101,B4403, A03,A03,B44, 1 PDL-1 Cancer IMPACT B5201,C1202,C1601 B62,UNK,UNK BV652107 31-50 4 0 7.87 PD-1/ Bladder MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 Cancer IMPACT B2705,C0202,C0701 B27,UNK,UNK EP826129 31-50 0 1 12.79 PD-1/ Bladder MSK- A3002,A3301,B1402, A01,A03,B27, 0 PDL-1 Cancer IMPACT B3901,C0802,C1203 B27,UNK,UNK HG877982 31-50 16 0 2.95 Combo Melanoma MSK- A2402,A0203,B5502, A24,A02,B07, 0 IMPACT B5601,C0102,C1203 B07,UNK,UNK HI763616 61-70 0 1 1.97 PD-1/ Head and Neck MSK- A0301,A1101,B0702, A03,A03,B07, 0 PDL-1 Cancer IMPACT B3502,C0401,C0702 B07,UNK,UNK IN074031 50-60 3 1 0.98 PD-1/ Melanoma MSK- A2403,A6801,B3801, A24,A03,B27, 0 PDL-1 IMPACT B4901,C1203,C0701 UNK,UNK,UNK IV487195 61-70 9 0 0 PD-1/ Melanoma MSK- A0201,A3201,B5501, A02,A01,B07, 0 PDL-1 IMPACT B4402,C0303,C0501 B44,UNK,UNK IY406522 50-60 12 0 0.98 PD-1/ Non-Small Cell MSK- A2301,A6601,B4102, A24,A03,B44, 0 PDL-1 Lung Cancer IMPACT B4901,C1701,C0701 UNK,UNK,UNK JP389116 31-50 42 0 5.9 PD-1/ Renal Cell MSK- A0101,A2301,B0702, A01,A24,B07, 0 PDL-1 Carcinoma IMPACT B5201,C0401,C1202 B62,UNK,UNK KJ238343 50-60 10 0 8.85 PD-1/ Melanoma MSK- A2301,A0201,B4101, A24,A02,B44, 0 PDL-1 IMPACT B5101,C1701,C1601 B07,UNK,UNK MB990307 50-60 0 0 2.95 PD-1/ Head and Neck MSK- A2902,A0201,B0702, A01A24,A02,B07, 0 PDL-1 Cancer IMPACT B4403,C0702,C1601 B44,UNK,UNK MI013541 61-70 18 0 8.85 Combo Renal Cell MSK- A0201,A0201,B0702, A02,A02,B07, 1 Carcinoma IMPACT B3901,C1203,C0702 B27,UNK,UNK QO539853 50-60 11 1 12.79 PD-1/ Head and Neck MSK- A0101,A0201,B4101, A01,A02,B44, 0 PDL-1 Cancer IMPACT B5101,C1502,C1701 B07,UNK,UNK RI645610 31-50 18 0 15.74 PD-1/ Melanoma MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 IMPACT B4001,C0304,C0701 B44,UNK,UNK TF132355 31-50 3 1 1.97 PD-1/ Esophagogastric MSK- A1101,A3101,B3901, A03,A03,B27, 0 PDL-1 Cancer IMPACT B4501,C1203,C0602 B44,UNK,UNK WF098442 31-50 1 1 3.94 PD-1/ Mesothelioma MSK- A3002,A0201,B0702, A01,A02,B07, 0 PDL-1 IMPACT B1801,C0501,C0702 B44,UNK,UNK WW621794 31-50 12 0 5.9 PD-1/ Melanoma MSK- A6802,A0201,B4403, A02,A02,B44, 0 PDL-1 IMPACT B1801,C0501,C0401 B44,UNK,UNK CA664206 31-50 0 1 6.89 PD-1/ Cancer of MSK- A6801,A0201,B4402, A03,A02,B44, 0 PDL-1 Unknown IMPACT B5701,C0602,C0704 B58,UNK,UNK Primary DB719328 31-50 0 0 2.95 PD-1/ Non-Small Cell MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 Lung Cancer IMPACT B1510,C0304,C0701 B27,UNK,UNK DT109230 31-50 0 1 10.82 PD-1/ Non-Small Cell MSK- A1101,A3301,B2705, A03,A03,B27, 0 PDL-1 Lung Cancer IMPACT B1402,C0202,C0802 B27,UNK,UNK FV129897 31-50 9 0 19.68 PD-1/ Non-Small Cell MSK- A3002,A0205,B3801, A01,A02,B27, 0 PDL-1 Lung Cancer IMPACT B1801,C0501,C1203 B44,UNK,UNK GL764741 31-50 4 1 4.92 PD-1/ Esophagogastric MSK- A0301,A0201,B0702, A03,A02,B07, 1 PDL-1 Cancer IMPACT B0702,C0702,C0702 B07,UNK,UNK HR150352 50-60 13 0 3.94 PD-1/ Non-Small Cell MSK- A0301,A2902,B1402, A03,A01A24,B27, 0 PDL-1 Lung Cancer IMPACT B4403,C0802,C1601 B44,UNK,UNK IY582475 61-70 1 1 0 PD-1/ Head and Neck MSK- A0201,A3101,B5601, A02,A03,B07, 0 PDL-1 Cancer IMPACT B5001,C0102,C0602 B44,UNK,UNK LR544436 31-50 5 0 13.77 PD-1/ Melanoma MSK- A3001,A1101,B5201, A01A03,A03,B62, 0 PDL-1 IMPACT B3501,C0401,C1202 B07,UNK,UNK LZ556947 61-70 4 0 6.89 PD-1/ Bladder MSK- A0101,A0201,B3502, A01,A02,B07, 1 PDL-1 Cancer IMPACT B5701,C0602,C0602 B58,UNK,UNK NI555118 61-70 1 1 25.58 PD-1/ Cancer of MSK- A0301,A0201,B1801, A03,A02,B44, 0 PDL-1 Unknown IMPACT B5701,C0602,C0701 B58,UNK,UNK Primary NO558430 50-60 2 1 4.92 PD-1/ Small Cell MSK- A0101,A0201,B4402, A01,A02,B44, 0 PDL-1 Lung Cancer IMPACT B4001,C0304,C1604 B44,UNK,UNK PO599962 >71 1 1 11.81 PD-1/ Head and Neck MSK- A0202,A0201,B3508, A02,A02,B07, 0 PDL-1 Cancer IMPACT B1801,C1601,C0401 B44,UNK,UNK QQ122966 31-50 2 1 1.97 PD-1/ Non-Small Cell MSK- A0101,A1101,B3501, A01,A03,B07, 0 PDL-1 Lung Cancer IMPACT B4901,C0401,C0701 UNK,UNK,UNK RA448371 31-50 7 1 24.59 PD-1/ Head and Neck MSK- A0201,A0201,B1507, A02,A02,B62, 1 PDL-1 Cancer IMPACT B4402,C0303,C0501 B44,UNK,UNK UR039273 31-50 14 0 6.89 Combo Head and Neck MSK- A1101,A0101,B4402, A03,A01,B44, 0 Cancer IMPACT B0801,C0501,C0701 B08,UNK,UNK UU457916 <30 24 1 7.87 PD-1/ Non-Small Cell MSK- A3201,A0201,B3501, A01,A02,B07, 0 PDL-1 Lung Cancer IMPACT B5801,C0401,C0706 B58,UNK,UNK VO447635 50-60 1 1 1.97 PD-1/ Non-Small Cell MSK- A0101,A6802,B3502, A01,A02,B07, 0 PDL-1 Lung Cancer IMPACT B1801,C0501,C0401 B44,UNK,UNK YI659458 31-50 9 0 5.9 PD-1/ Glioma MSK- A2402,A2601,B3801, A24,A01,B27, 0 PDL-1 IMPACT B3502,C0401,C1203 B07,UNK,UNK ZX303297 61-70 25 0 1.97 Combo Esophagogastric MSK- A0201,A0201,B5101, A02,A02,B07, 1 Cancer IMPACT B4501,C1502,C0602 B44,UNK,UNK AF406418 61-70 11 0 3.94 Combo Melanoma MSK- A2403,A0201,B0705, A24,A02,B07, 0 IMPACT B3501,C1505,C0401 B07,UNK,UNK AH216825 61-70 19 0 2.95 Combo Renal Cell MSK- A1101,A0205,B5001, A03,A02,B44, 0 Carcinoma IMPACT B3801,C0401,C0602 B07,UNK,UNK CB980147 50-60 3 1 5.9 CTLA4 Breast Cancer MSK- A1101,A2407,B3802, A03,UNK,UNK, 1 IMPACT B3802,C0702,C0702 UNK,UNK,UNK DB857913 31-50 8 0 3.94 PD-1/ Renal Cell MSK- A3401,A0201,B1502, UNK,A02,B62, 0 PDL-1 Carcinoma IMPACT B3505,C0401,C0801 B07,UNK,UNK FF987914 >71 6 1 3.94 PD-1/ Glioma MSK- A0201,A2601,B3906, A02,A01,B27, 1 PDL-1 IMPACT B3901,C1203,C1203 B27,UNK,UNK GZ870894 >71 11 0 9.84 PD-1/ Non-Hodgkin MSK- A1101,A3303,B0705, A03,A03,B07, 0 PDL-1 Lymphoma IMPACT B5801,C0302,C0702 B58,UNK,UNK IB207672 61-70 15 0 8.85 PD-1/ Non-Hodgkin MSK- A0101,A0201,B0704, A01,A02,B07, 0 PDL-1 Lymphoma IMPACT B3502,C0401,C0702 B07,UNK,UNK IK144116 >71 0 0 1.97 PD-1/ Pancreatic MSK- A0301,A3001,B0702, A03,A01A03,B07, 0 PDL-1 Cancer IMPACT B4201,C1701,C0702 B07,UNK,UNK IL112662 31-50 0 1 0 PD-1/ Non-Small Cell MSK- A0301,A3201,B5201, A03,A01,B62, 0 PDL-1 Lung Cancer IMPACT B5101,C0102,C1202 B07,UNK,UNK KN168588 >71 6 0 3.94 PD-1/ Embryonal MSK- A0201,A0205,B4101, A02,A02,B44, 0 PDL-1 Tumor IMPACT B4002,C0202,C0701 B44,UNK,UNK LD646751 >71 35 0 4.92 PD-1/ Renal Cell MSK- A3201,A0201,B1801, A01,A02,B44, 0 PDL-1 Carcinoma IMPACT B5101,C1402,C0701 B07,UNK,UNK LJ213345 61-70 17 0 5.9 PD-1/ Head and Neck MSK- A0301,A2601,B4001, A03,A01,B44, 0 PDL-1 Cancer IMPACT B4003,C1403,C0304 B44,UNK,UNK LJ413431 50-60 12 0 5.9 PD-1/ Non-Small Cell MSK- A1101,A0207,B6701, A03,A02,B07, 0 PDL-1 Lung Cancer IMPACT B5604,C0102,C0702 B07,UNK,UNK LQ937165 >71 9 0 47.22 Combo Colorectal MSK- A0101,A3101,B4101, A01,A03,B44, 0 Cancer IMPACT B4001,C0304,C1701 B44,UNK,UNK LZ664850 50-60 1 1 7.87 PD-1/ Esophagogastric MSK- A3001,A2301,B4403, A01A03,A24,B44, 0 PDL-1 Cancer IMPACT B1302,C0401,C0602 UNK,UNK,UNK OZ912616 61-70 1 0 1.97 PD-1/ Non-Small Cell MSK- A0207,A0207,B4601, A02,A02,B62, 1 PDL-1 Lung Cancer IMPACT B4601,C0102,C0102 B62,UNK,UNK PG408469 61-70 6 1 11.81 Combo Melanoma MSK- A2402,A3101,B4402, A24,A03,B44, 0 IMPACT B3801,C1604,C1203 B27,UNK,UNK PS726558 31-50 3 0 6.89 PD-1/ Colorectal MSK- A2301,A0201,B1801, A24,A02,B44, 1 PDL-1 Cancer IMPACT B4901,C0701,C0701 UNK,UNK,UNK RB741231 31-50 18 0 9.84 PD-1/ Non-Small Cell MSK- A6801,A2901,B1518, A03,A01A24,B27, 0 PDL-1 Lung Cancer IMPACT B5001,C0602,C0704 B44,UNK,UNK RD469703 >71 5 1 51.16 PD-1/ Glioma MSK- A0101,A0201,B0702, A01,A02,B07, 0 PDL-1 IMPACT B5801,C0702,C0706 B58,UNK,UNK RV981815 <30 11 1 24.59 PD-1/ Melanoma MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 IMPACT B5801,C0718,C0706 B58,UNK,UNK RX295147 31-50 2 0 4.92 CTLA4 Prostate MSK- A0301,A0201,B1501, A03,A02,B62, 0 Cancer IMPACT B3501,C0303,C0702 B07,UNK,UNK TW555037 31-50 7 1 1.97 PD-1/ Head and Neck MSK- A2901,A6801,B4101, A01A24,A03,B44, 0 PDL-1 Cancer IMPACT B4402,C1701,C0704 B44,UNK,UNK VR974691 50-60 3 0 4.92 PD-1/ Colorectal MSK- A2402,A2402,B1801, A24,A24,B44, 1 PDL-1 Cancer IMPACT B1801,C0701,C0701 B44,UNK,UNK VT439023 31-50 7 0 37.38 CTLA4 Melanoma MSK- A0101,A2601,B0801, A01,A01,B08, 0 IMPACT B3801,C1203,C0701 B27,UNK,UNK YH901261 61-70 5 1 4.92 Combo Head and Neck MSK- A3002,A1101,B4403, A01,A03,B44, 0 Cancer IMPACT B5301,C0401,C0706 B07,UNK,UNK ZK802313 31-50 3 1 2.95 PD-1/ Head and Neck MSK- A2402,A2902,B1801, A24,A01A24,B44, 0 PDL-1 Cancer IMPACT B5801,C1203,C0706 B58,UNK,UNK ZO158210 50-60 16 0 1.97 PD-1/ Non-Small Cell MSK- A0205,A0206,B1501, A02,A02,B62, 0 PDL-1 Lung Cancer IMPACT B5801,C0303,C0706 B58,UNK,UNK BF080539 31-50 15 0 19.68 CTLA4 Melanoma MSK- A6601,A6901,B5501, A03,A02,B07, 0 IMPACT B3502,C0303,C0401 B07,UNK,UNK DG100147 31-50 6 0 23.61 PD-1/ Non-Small Cell MSK- A3002,A2601,B4403, A01,A01,B44, 0 PDL-1 Lung Cancer IMPACT B5301,C1601,C0401 B07,UNK,UNK DR570890 31-50 11 0 1.97 PD-1/ Non-Hodgkin MSK- A3101,A3303,B0702, A03,A03,B07, 0 PDL-1 Lymphoma IMPACT B6701,C1203,C0702 B07,UNK,UNK EO910001 50-60 5 0 4.92 PD-1/ Non-Small Cell MSK- A2902,A0201,B4403, A01A24,A02,B44, 0 PDL-1 Lung Cancer IMPACT B4003,C0304,C1601 B44,UNK,UNK EQ924504 >71 0 1 8.85 PD-1/ Glioma MSK- A0101,A6801,B3701, A01,A03,B44, 0 PDL-1 IMPACT B4001,C0304,C0602 B44,UNK,UNK EY863064 61-70 1 1 1.97 Combo Melanoma MSK- A0301,A3201,B0702, A03,A01,B07, 0 IMPACT B4002,C0202,C0702 B44,UNK,UNK FC067855 50-60 6 1 2.95 Combo Pancreatic MSK- A0201,A0201,B1501, A02,A02,B62, 1 Cancer IMPACT B3501,C0102,C0401 B07,UNK,UNK GR143555 31-50 7 1 13.77 PD-1/ Non-Small Cell MSK- A3002,A2402,B3502, A01,A24,B07, 0 PDL-1 Lung Cancer IMPACT B1801,C0401,C0501 B44,UNK,UNK JD809822 50-60 0 1 6.89 PD-1/ Non-Small Cell MSK- A3001,A3001,B1801, A01A03,A01A03,B44, 1 PDL-1 Lung Cancer IMPACT B1801,C0210,C0210 B44,UNK,UNK JI866544 31-50 0 0 3.94 PD-1/ Esophagogastric MSK- A2301,A3303,B5301, A24,A03,B07, 1 PDL-1 Cancer IMPACT B5301,C0401,C0602 B07,UNK,UNK KM672291 61-70 32 0 8.85 CTLA4 Melanoma MSK- A0201,A0201,B3801, A02,A02,B27, 1 IMPACT B3503,C0401,C1203 B07,UNK,UNK MP430689 31-50 5 0 20.66 PD-1/ Non-Small Cell MSK- A0101,A0101,B4701, A01,A01,UNK, 1 PDL-1 Lung Cancer IMPACT B5201,C1202,C0602 B62,UNK,UNK NE455314 31-50 9 1 2.95 PD-1/ Esophagogastric MSK- A0301,A0301,B0702, A03,A03,B07, 1 PDL-1 Cancer IMPACT B0702,C0702,C0702 B07,UNK,UNK NG601396 >71 10 1 1.97 Combo Melanoma MSK- A2402,A2601,B0702, A24,A01,B07, 0 IMPACT B0702,C0202,C0702 B27,UNK,UNK NN070436 61-70 12 1 4.92 PD-1/ Glioma MSK- A1101,A0206,B4601, A03,A02,B62, 0 PDL-1 IMPACT B4001,C0102,C0304 B44,UNK,UNK NV234451 >71 0 1 6.89 Combo Melanoma MSK- A0201,A2601,B2705, A02,A01,B27, 0 IMPACT B4402,C0102,C0501 B44,UNK,UNK OD563707 31-50 2 1 0 PD-1/ Mesothelioma MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 IMPACT B5101,C1502,C0702 B07,UNK,UNK PQ019402 31-50 2 0 0.98 PD-1/ Hepatobiliary MSK- A0301,A0101,B1402, A03,A01,B27, 0 PDL-1 Cancer IMPACT B5701,C0802,C0602 B58,UNK,UNK QJ432676 50-60 15 0 2.95 PD-1/ Glioma MSK- A1101,A2402,B5501, A03,A24,B07, 0 PDL-1 IMPACT B3502,C0303,C0401 B07,UNK,UNK TE746331 >71 18 0 8.85 PD-1/ Esophagogastric MSK- A2402,A2601,B1402, A24,A01,B27, 0 PDL-1 Cancer IMPACT B5201,C0802,C1202 B62,UNK,UNK YT556349 31-50 22 0 3.94 Combo Melanoma MSK- A1101,A0101,B3801, A03,A01,B27, 0 IMPACT B5701,C1203,C0602 B58,UNK,UNK BF956201 31-50 13 0 5.9 PD-1/ Non-Small Cell MSK- A0201,A2601,B1801, A02,A01,B44, 0 PDL-1 Lung Cancer IMPACT B4501,C1601,C1203 B44,UNK,UNK BO691217 31-50 13 0 9.84 PD-1/ Non-Small Cell MSK- A0201,A3101,B0801, A02,A03,B08, 1 PDL-1 Lung Cancer IMPACT B1801,C0701,C0701 B44,UNK,UNK BW588321 50-60 11 0 4.92 Combo Melanoma MSK- A2301,A2601,B3801, A24,A01,B27, 0 IMPACT B4901,C1203,C0701 UNK,UNK,UNK CM345531 31-50 9 0 0 PD-1/ Non-Small Cell MSK- A0201,A3303,B4403, A02,A03,B44, 1 PDL-1 Lung Cancer IMPACT B3501,C0401,C0401 B07,UNK,UNK CZ908459 31-50 11 0 3.94 PD-1/ Glioma MSK- A2601,A6801,B3801, A01,A03,B27, 0 PDL-1 IMPACT B1302,C0602,C1203 UNK,UNK,UNK DH345617 >71 12 1 3.94 Combo Melanoma MSK- A0201,A0201,B4402, A02,A02,B44, 1 IMPACT B5101,C0102,C0501 B07,UNK,UNK DP953249 61-70 5 0 23.61 PD-1/ Non-Small Cell MSK- A2301,A3101,B4403, A24,A03,B44, 1 PDL-1 Lung Cancer IMPACT B3508,C0401,C0401 B07,UNK,UNK EJ708176 >71 3 1 0.98 CTLA4 Breast MSK- A0301,A0201,B2705, A03,A02,B27, 0 Cancer IMPACT B3503,C0102,C1203 B07,UNK,UNK ER096137 31-50 3 1 9.84 PD-1/ Esophagogastric MSK- A0302,A0201,B5201, A03,A02,B62, 0 PDL-1 Cancer IMPACT B1302,C0602,C1202 UNK,UNK,UNK HD143613 31-50 3 1 11.81 PD-1/ Bladder MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 Cancer IMPACT B3503,C0401,C0702 B07,UNK,UNK HV906622 >71 0 1 33.45 Combo Melanoma MSK- A0101,A3201,B1801, A01,A01,B44, 0 IMPACT B3502,C0401,C0701 B07,UNK,UNK IE795484 31-50 3 0 37.38 PD-1/ Melanoma MSK- A0301,A0101,B0801, A03,A01,B08, 0 PDL-1 IMPACT B2705,C0202,C0701 B27,UNK,UNK IJ433188 50-60 11 0 1.97 PD-1/ Soft Tissue MSK- A0201,A0201,B5501, A02,A02,B07, 1 PDL-1 Sarcoma IMPACT B1501,C0304,C0303 B62,UNK,UNK IM301482 50-60 6 0 5.9 PD-1/ Renal Cell MSK- A3002,A0201,B4402, A01,A02,B44, 0 PDL-1 Carcinoma IMPACT B3501,C0501,C0401 B07,UNK,UNK IM308572 61-70 1 1 9.84 Combo Melanoma MSK- A1101,A3101,B3508, A03,A03,B07, 0 IMPACT B5101,C0202,C0401 B07,UNK,UNK IY740960 31-50 15 0 2.95 Combo Renal Cell MSK- A2402,A6801,B2705, A24,A03,B27, 0 Carcinoma IMPACT B1801,C1502,C0701 B44,UNK,UNK LJ501075 61-70 11 0 3.94 PD-1/ Renal Cell MSK- A6801,A0201,B1402, A03,A02,B27, 0 PDL-1 Carcinoma IMPACT B4402,C0501,C0802 B44,UNK,UNK QA401796 31-50 15 0 2.95 PD-1/ Non-Small Cell MSK- A0201,A0201,B0702, A02,A02,B07, 1 PDL-1 Lung Cancer IMPACT B4405,C0202,C0702 B44,UNK,UNK SE569393 31-50 2 0 7.87 PD-1/ Non-Small Cell MSK- A0301,A2301,B1402, A03,A24,B27, 0 PDL-1 Lung Cancer IMPACT B4901,C0802,C0701 UNK,UNK,UNK TX408749 50-60 8 1 8.85 PD-1/ Melanoma MSK- A0301,A260,B1501, A03,A01,B62, 0 PDL-1 IMPACT B4001,C0304,C0303 B44,UNK,UNK UR037737 61-70 0 1 9.84 PD-1/ Non-Small Cell MSK- A0301,A3101,B0801, A03,A03,B08, 1 PDL-1 Lung Cancer IMPACT B5101,C0701,C0701 B07,UNK,UNK VU634626 31-50 10 0 1.97 PD-1/ Melanoma MSK- A0101,A0101,B0801, A01,A01,B08, 1 PDL-1 IMPACT B0801,C0701,C0701 B08,UNK,UNK WF523568 31-50 20 0 5.9 PD-1/ Head and Neck MSK- A2601,A2601,B3801, A01,A01,B27, 1 PDL-1 Cancer IMPACT B5101,C1502,C1203 B07,UNK,UNK XU469861 >71 17 0 0.98 PD-1/ Bone Cancer MSK- A6601,A0201,B4102, A03,A02,B44, 0 PDL-1 IMPACT B4402,C1701,C0704 B44,UNK,UNK BR857502 31-50 12 1 2.95 PD-1/ Non-Small Cell MSK- A1101,A2402,B4002, A03,A24,B44, 0 PDL-1 Lung Cancer IMPACT B3801,C0304,C1203 B27,UNK,UNK DE430582 31-50 5 1 3.94 PD-1/ Renal Cell MSK- A3001,A3001,B5001, A01A03,A01A03,B44, 1 PDL-1 Carcinoma IMPACT B4501,C1601,C0701 B44,UNK,UNK DK753827 50-60 15 0 2.95 Combo Renal Cell MSK- A1101,A2601,B2705, A03,A01,B27, 0 Carcinoma IMPACT B1402,C0102,C0802 B27,UNK,UNK EB388647 <30 4 1 36.4 PD-1/ Melanoma MSK- A0101,A6801,B0801, A01,A03,B08, 0 PDL-1 IMPACT B3701,C0602,C0701 B44,UNK,UNK EU139890 >71 4 0 1.97 PD-1/ Non-Small Cell MSK- A3101,A3101,B1508, A03,A03,B07, 1 PDL-1 Lung Cancer IMPACT B1508,C0102,C0102 B07,UNK,UNK HG213091 31-50 2 0 5.9 PD-1/ Small Cell MSK- A6601,A0201,B3502, A03,A02,B07, 0 PDL-1 Lung Cancer IMPACT B4402,C0401,C1502 B44,UNK,UNK HH230546 61-70 4 0 203.64 PD-1/ Colorectal MSK- A3001,A2402,B4002, A01A03,A24,B44, 0 PDL-1 Cancer IMPACT B3501,C0303,C0304 B07,UNK,UNK JF991036 31-50 1 0 50.17 Combo Non-Small Cell MSK- A2402,A0201,B4402, A24,A02,B44, 1 Lung Cancer IMPACT B4402,C0501,C1504 B44,UNK,UNK KF580579 31-50 3 0 5.9 CTLA4 Pancreatic MSK- A6801,A6802,B1402, A03,A02,B27, 0 Cancer IMPACT B2702,C0802,C0202 B27,UNK,UNK KO267493 61-70 7 0 14.76 CTLA4 Soft Tissue MSK- A2601,A2601,B3801, A01,A01,B27, 1 Sarcoma IMPACT B3801,C1203,C1203 B27,UNK,UNK MB313563 50-60 0 0 5.9 PD-1/ Cancer of MSK- A3004,A2301,B4901, A01,A24,UNK, 1 PDL-1 Unknown IMPACT B4901,C0701,C0701 UNK,UNK,UNK Primary PY916704 >71 0 0 7.87 PD-1/ Glioma MSK- A2301,A0201,B1402, A03,A02,B27, 0 PDL-1 IMPACT B4402,C0802,C0501 B44,UNK,UNK QM120917 31-50 2 1 0 PD-1/ Renal Cell MSK- A1101,A2402,B4402, A03,A24,B44, 0 PDL-1 Carcinoma IMPACT B1801,C1604,C0701 B44,UNK,UNK QP194424 <30 5 1 62.96 PD-1/ Skin Cancer; MSK- A0201,A0201,B0702, A02,A02,B07, 1 PDL-1 Non-Melanoma IMPACT B4402,C0501,C0702 B44,UNK,UNK RD412780 31-50 11 0 5.9 PD-1/ Renal Cell MSK- A3201,A3303,B2705, A01,A03,B27, 0 PDL-1 Carcinoma IMPACT B1801,C1203,C1502 B44,UNK,UNK RN967996 >71 15 0 1.97 PD-1/ Colorectal MSK- A1101,A2402,B3906, A03,A24,B27, 0 PDL-1 Cancer IMPACT B4006,C1502,C0702 B44,UNK,UNK TX586079 61-70 22 0 29.51 PD-1/ Esophagogastric MSK- A2301,A6802,B1510, A24,A02,B27, 0 PDL-1 Cancer IMPACT B4901,C0304,C0701 UNK,UNK,UNK UD586728 31-50 0 0 18.69 PD-1/ Non-Small Cell MSK- A2301,A0201,B3901, A24,A02,B27, 0 PDL-1 Lung Cancer IMPACT B4102,C1203,C1701 B44,UNK,UNK UW666903 50-60 18 1 7.87 PD-1/ Non-Small Cell MSK- A0301,A0201,B5501, A03,A02,B07, 1 PDL-1 Lung Cancer IMPACT B5501,C0102,C0701 B07,UNK,UNK VE077996 61-70 0 0 4.92 PD-1/ Non-Small Cell MSK- A1101,A0207,B0705, A03,A02,B07, 0 PDL-1 Lung Cancer IMPACT B4601,C0102,C1505 B62,UNK,UNK VO581533 31-50 0 0 33.45 PD-1/ Non-Small Cell MSK- A3004,A0102,B8101, A01,UNK,B07, 0 PDL-1 Lung Cancer IMPACT B4403,C0804,C0706 B44,UNK,UNK XA334516 50-60 23 0 1.97 Combo Non-Small Cell MSK- A2601,A3301,B1402, A01,A03,B27, 0 Lung Cancer IMPACT B3801,C0802,C1203 B27,UNK,UNK XF280080 >71 3 1 0 PD-1/ Adrenocortical MSK- A0301,A2601,B4403, A03,A01,B44, 0 PDL-1 Carcinoma IMPACT B5101,C0303,C1601 B07,UNK,UNK YI633805 31-50 8 0 1.97 PD-1/ Skin Cancer; MSK- A2402,A3303,B4901, A24,A03,UNK, 0 PDL-1 Non-Melanoma IMPACT B3502,C0401,C0701 B07,UNK,UNK YR519762 31-50 16 0 3.94 PD-1/ Non-Small Cell MSK- A0101,A3201,B0801, A01,A01,B08, 0 PDL-1 Lung Cancer IMPACT B2703,C0202,C0701 B27,UNK,UNK ZK526534 31-50 13 0 6.89 PD-1/ Bladder MSK- A1101,A3201,B0702, A03,A01,B07, 0 PDL-1 Cancer IMPACT B1801,C0501,C0702 B44,UNK,UNK DK273036 >71 8 0 2.95 PD-1/ Glioma MSK- A6801,A0201,B3901, A03,A02,B27, 0 PDL-1 IMPACT B5101,C1504,C0702 B07,UNK,UNK DM301970 >71 2 0 2.95 PD-1/ Colorectal MSK- A0301,A1101,B0702, A03,A03,B07, 0 PDL-1 Cancer IMPACT B3503,C0401,C0702 B07,UNK,UNK GC996651 31-50 5 1 8.85 Combo Head and Neck MSK- A0101,A2402,B0702, A01,A24,B07, 0 Cancer IMPACT B5101,C1502,C0702 B07,UNK,UNK IT581561 31-50 3 0 6.89 PD-1/ Glioma MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 IMPACT B4402,C0501,C0702 B44,UNK,UNK IV185293 31-50 6 0 2.95 PD-1/ Melanoma MSK- A2402,A2902,B1517, A24,A01A24,B58, 0 PDL-1 IMPACT B1402,C0802,C0701 B27,UNK,UNK LJ345209 31-50 2 1 3.94 PD-1/ Head and Neck MSK- A3201,A3201,B4002, A01,A01,B44, 1 PDL-1 Cancer IMPACT B4402,C0501,C0202 B44,UNK,UNK LQ921060 31-50 0 1 16.72 PD-1/ Non-Small Cell MSK- A0101,A2601,B0801, A01,A01,B08, 0 PDL-1 Lung Cancer IMPACT B1517,C0701,C0718 B58,UNK,UNK NE921221 31-50 4 0 6.89 PD-1/ Non-Small Cell MSK- A2402,A2402,B1801, A24,A24,B44, 1 PDL-1 Lung Cancer IMPACT B5101,C1402,C1203 B07,UNK,UNK PS842981 31-50 9 1 3.94 PD-1/ Bladder MSK- A0101,A0205,B5001, A01,A02,B44, 1 PDL-1 Cancer IMPACT B1801,C0602,C0602 B44,UNK,UNK RA926807 61-70 6 0 7.87 PD-1/ Non-Small Cell MSK- A1101,A2601,B0702, A03,A01,B07, 0 PDL-1 Lung Cancer IMPACT B5201,C1202,C0702 B62,UNK,UNK WC205663 31-50 2 0 3.94 Combo Non-Small Cell MSK- A2402,A0201,B2705, A24,A02,B27, 0 Lung Cancer IMPACT B4001,C0304,C0202 B44,UNK,UNK WL137245 61-70 47 0 11.81 PD-1/ Melanoma MSK- A0201,A0201,B4402, A02,A02,B44, 1 PDL-1 IMPACT B4001,C0304,C0701 B44,UNK,UNK WM306951 50-60 32 1 0 PD-1/ Renal Cell MSK- A2402,A3201,B3501, A24,A01,B07, 1 PDL-1 Carcinoma IMPACT B3501,C0102,C0401 B07,UNK,UNK WP072873 61-70 6 0 15.74 Combo Melanoma MSK- A0301,A2601,B0702, A03,A01,B07, 0 IMPACT B3501,C0401,C0702 B07,UNK,UNK YK675744 50-60 4 0 14.76 PD-1/ Bladder MSK- A0301,A1101,B0702, A03,A03,B07, 1 PDL-1 Cancer IMPACT B0702,C0702,C0702 B07,UNK,UNK YU626285 50-60 8 0 19.68 PD-1/ Melanoma MSK- A1101,A0201,B5501, A03,A02,B07, 0 PDL-1 IMPACT B1801,C0303,C0701 B44,UNK,UNK ZK342685 31-50 7 1 8.85 PD-1/ Melanoma MSK- A2402,A0201,B3906, A04,A02,B27, 0 PDL-1 IMPACT B3501,C0401,C0702 B07,UNK,UNK DS616046 50-60 20 0 0 PD-1/ Melanoma MSK- A2402,A0201,B1501, A24,A02,B62, 0 PDL-1 IMPACT B4001,C0303,C0304 B44,UNK,UNK FI164601 50-60 15 0 49.49 PD-1/ Non-Small Cell MSK- A0301,A1102,B2704, A03,A03,B27, 0 PDL-1 Lung Cancer IMPACT B4402,C1202,C0501 B44,UNK,UNK GG613373 31-50 7 1 0 PD-1/ Esophagogastric MSK- A1101,A2301,B3503, A03,A24,B07, 0 PDL-1 Cancer IMPACT B4901,C1203,C0718 UNK,UNK,UNK GK892986 >71 16 0 3.94 PD-1/ Bone Cancer MSK- A0101,A0201,B0801, A01,A02,B08, 0 PDL-1 IMPACT B1502,C0801,C0702 B62,UNK,UNK HA469182 31-50 25 0 46.24 CTLA4 Melanoma MSK- A0301,A0206,B0702, A03,A02,B07, 0 IMPACT B3501,C0303,C0702 B07,UNK,UNK KU939300 61-70 10 0 21.64 Combo Melanoma MSK- A3001,A3002,B1302, A01A03,A01,UNK, 0 IMPACT B3501,C0602,C0401 B07,UNK,UNK LM168179 50-60 1 0 3.94 PD-1/ Non-Small Cell MSK- A2902,A3301,B1402, A01A24,A03,B27, 0 PDL-1 Lung Cancer IMPACT B4403,C0802,C1801 B44,UNK,UNK OD052630 >71 32 1 4.92 PD-1/ Non-Small Cell MSK- A1101,A0201,B0702, A03,A02,B07, 1 PDL-1 Lung Cancer IMPACT B0702,C0702,C0702 B07,UNK,UNK OE955832 50-60 9 1 10.82 PD-1/ Non-Small Cell MSK- A3001,A3001,B1510, A01A03,A01A03,B27, 1 PDL-1 Lung Cancer IMPACT B1801,C0304,C0202 B44,UNK,UNK OP247065 31-50 14 0 68.87 PD-1/ Colorectal MSK- A2402,A2402,B0702, A24,A24,B07, 1 PDL-1 Cancer IMPACT B3503,C0401,C0702 B07,UNK,UNK OZ621986 50-60 12 0 1.97 Combo Melanoma MSK- A0301,A3002,B2705, A03,A01,B27, 0 IMPACT B1801,C0102,C0501 B44,UNK,UNK RW388101 50-60 2 1 5.9 PD-1/ Non-Small Cell MSK- A0201,A0201,B4402, A02,A02,B44, 1 PDL-1 Lung Cancer IMPACT B0501,C0102,C0202 B44,UNK,UNK SD891023 <30 17 0 3.94 PD-1/ Non-Small Cell MSK- A0101,A3101,B3801, A01,A03,B27, 0 PDL-1 Lung Cancer IMPACT B3503,C0401,C1203 B07,UNK,UNK WU141360 61-70 3 0 6.89 Combo Melanoma MSK- A0201,A0201,B0801, A02,A02,B08, 1 IMPACT B1501,C0303,C0701 B62,UNK,UNK WY430099 50-60 3 0 2.95 PD-1/ Non-Small Cell MSK- A0101,A2601,B1801, A01,A01,B44, 0 PDL-1 Lung Cancer IMPACT B3502,C1203,C0401 B07,UNK,UNK XI023833 31-50 2 0 4.92 PD-1/ Non-Small Cell MSK- A2402,A2402,B3502, A24,A24,B07, 1 PDL-1 Lung Cancer IMPACT B3501,C0401,C0401 B07,UNK,UNK XK805958 61-70 5 1 10.82 PD-1/ Non-Small Cell MSK- A1101,A2301,B1501, A03,A24,B62, 0 PDL-1 Lung Cancer IMPACT B1801,C0303,C0501 B44,UNK,UNK YR534379 >71 2 0 5.9 PD-1/ Colorectal MSK- A1101,A6801,B1801, A03,A03,B44, 0 PDL-1 Cancer IMPACT B5201,C1601,C0701 B62,UNK,UNK AY728758 >71 20 0 9.84 Combo Melanoma MSK- A0301,A3201,B4405, A03,A01,B44, 0 IMPACT B5101,C0102,C0202 B07,UNK,UNK CH836399 50-60 12 0 3.94 CTLA4 Breast Cancer MSK- A2301,A0201,B4403, A24,A02,B44, 0 IMPACT B4501,C0401,C1601 B44,UNK,UNK DF482553 31-50 1 0 11.81 PD-1/ Head and Neck MSK- A0101,A0101,B0801, A01,A01,B08, 1 PDL-1 Cancer IMPACT B0801,C0701,C0701 B08,UNK,UNK DS424270 31-50 1 1 9.84 PD-1/ Non-Small Cell MSK- A0301,A6601,B3801, A03,A03,B27, 0 PDL-1 Lung Cancer IMPACT B4102,C1203,C1701 B44,UNK,UNK GZ954783 61-70 17 0 19.68 PD-1/ Non-Small Cell MSK- A7401,A7401,B0702, A03,A03,B07, 1 PDL-1 Lung Cancer IMPACT B1503,C0210,C0702 B27,UNK,UNK JC504331 >71 7 0 4.92 CTLA4 Breast Cancer MSK- A0101,A0201,B0801, A01,A02,B08, 0 IMPACT B4402,C0704,C0701 B44,UNK,UNK JD755987 50-60 5 0 4.92 PD-1/ Renal Cell MSK- A0101,A0101,B0801, A01,A01,B08, 1 PDL-1 Carcinoma IMPACT B1302,C0602,C0701 UNK,UNK,UNK KI514356 50-60 0 0 5.9 PD-1/ Renal Cell MSK- A3001,A2902,B3701, A01A03,A01A24,B44, 1 PDL-1 Carcinoma IMPACT B1302,C0602,C0602 UNK,UNK,UNK KL738755 50-60 14 0 14.76 CTLA4 Breast Cancer MSK- A3601,A0201,B3501, A01,A02,B07, 0 IMPACT B5301,C1601,C0401 B07,UNK,UNK KN186707 31-50 2 0 3.94 CTLA4 Breast Cancer MSK- A0201,A0201,B0702, A02,A02,B07, 1 IMPACT B5101,C1502,C0702 B07,UNK,UNK MT269010 50-60 3 1 7.87 PD-1/ Non-Small Cell MSK- A0301,A1101,B1801, A03,A03,B44, 0 PDL-1 Lung Cancer IMPACT B5201,C1202,C0701 B62,UNK,UNK NJ492568 50-60 33 0 4.92 Combo Renal Cell MSK- A2402,A0201,B5501, A24,A02,B07, 0 Carcinoma IMPACT B3701,C0303,C0602 B44,UNK,UNK NL685509 61-70 8 1 1.97 Combo Esophagogastric MSK- A0301,A0201,B4403, A03,A02,B44, 0 Cancer IMPACT B4402,C0401,C0704 B44,UNK,UNK OW338232 50-60 3 0 17.71 PD-1/ Bladder MSK- A0301,A3101,B3801, A03,A03,B27, 1 PDL-1 Cancer IMPACT B3801,C1203,C1203 B27,UNK,UNK PM135012 31-50 13 1 6.89 PD-1/ Bladder MSK- A0301,A0301,B0702, A03,A03,B07, 1 PDL-1 Cancer IMPACT B0702,C0702,C0702 B07,UNK,UNK PS208416 50-60 6 0 4.92 PD-1/ Glioma MSK- A0301,A1101,B0702, A03,A03,B07, 1 PDL-1 IMPACT B1501,C0304,C0304 B62,UNK,UNK PY486092 31-50 3 1 2.95 PD-1/ Non-Small Cell MSK- A1101,A0201,B0801, A03,A02,B08, 0 PDL-1 Lung Cancer IMPACT B5701,C0602,C0701 B58,UNK,UNK QD664127 >71 58 0 11.81 CTLA4 Melanoma MSK- A0101,A0201,B4403, A01,A02,B44, 0 IMPACT B4402,C1601,C0501 B44,UNK,UNK RI100586 50-60 1 0 1.97 PD-1/ Glioma MSK- A1101,A2902,B5501, A03,A01A24,B07, 0 PDL-1 IMPACT B4403,C0303,C1601 B44,UNK,UNK RW567050 31-50 11 0 102.31 PD-1/ Melanoma MSK- A0201,A6901,B0705, A02,A02,B07, 0 PDL-1 IMPACT B5501,C1505,C0303 B07,UNK,UNK SQ789755 31-50 0 1 0.98 PD-1/ Non-Small Cell MSK- A0301,A0201,B3501, A03,A02,B07, 0 PDL-1 Lung Cancer IMPACT B5801,C0401,C076 B58,UNK,UNK UD810304 50-60 2 0 2.95 PD-1/ Non-Small Cell MSK- A1101,A0101,B2705, A03,A01,B27, 0 PDL-1 Lung Cancer IMPACT B3503,C0202,C0401 B07,UNK,UNK UP639709 50-60 4 0 7.87 PD-1/ Non-Small Cell MSK- A0201,A0201,B4402, A02,A02,B44, 1 PDL-1 Lung Cancer IMPACT B5101,C0501,C0202 B07,UNK,UNK WG937133 31-50 4 0 13.77 PD-1/ Colorectal MSK- A2601,A0201,B0801, A01,A02,B08, 0 PDL-1 Cancer IMPACT B1501,C0304,C0701 B62,UNK,UNK WZ633302 31-50 1 1 3.94 PD-1/ Cancer of MSK- A2402,A0201,B1501, A24,A02,B62, 0 PDL-1 Unknown IMPACT B5701,C0303,C0602 B58,UNK,UNK Primary YG749643 50-60 29 0 3.94 PD-1/ Renal Cell MSK- A1101,A3101,B4101, A03,A03,B44, 0 PDL-1 Carcinoma IMPACT B3503,C0401,C1701 B07,UNK,UNK YQ266016 61-70 14 0 5.9 PD-1/ Glioma MSK- A0201,A2601,B1401, A02,A01,B27, 0 PDL-1 IMPACT B1801,C0802,C1203 B44,UNK,UNK YQ653157 61-70 2 0 2.95 PD-1/ Non-Small Cell MSK- A1101,A0203,B1518, A03,A02,B27, 0 PDL-1 Lung Cancer IMPACT B1801,C0704,C0702 B44,UNK,UNK ZO253625 31-50 22 1 2.95 PD-1/ Bladder MSK- A0101,A0201,B5101, A01,A02,B07, 1 PDL-1 Cancer IMPACT B5101,C1402,C0202 B07,UNK,UNK ZQ021549 50-60 51 0 19.68 CTLA4 Melanoma MSK- A0301,A2601,B0702, A03,A01,B07, 0 IMPACT B5101,C1402,C0702 B07,UNK,UNK CE919172 31-50 10 0 8.85 PD-1/ Non-Small Cell MSK- A0301,A2402,B5801, A03,A24,B58, 0 PDL-1 Lung Cancer IMPACT B5101,C0202,C0706 B07,UNK,UNK DD869488 61-70 5 1 6.89 PD-1/ Head and Neck MSK- A0101,A2402,B0702, A01,A24,B07, 0 PDL-1 Cancer IMPACT B1517,C0701,C0702 B58,UNK,UNK DN709186 50-60 13 0 2.95 PD-1/ Non-Small Cell MSK- A0201,A0201,B4403, A02,A02,B44, 1 PDL-1 Lung Cancer IMPACT B4901,C1601,C0701 UNK,UNK,UNK EB405485 31-50 1 1 5.9 Combo Melanoma MSK- A0101,A0201,B3901, A01,A02,B27, 0 IMPACT B1517,C1203,C0701 B58,UNK,UNK HA424390 61-70 48 1 13.77 Combo Melanoma MSK- A0301,A6601,B0702, A03,A03,B07, 0 IMPACT B4201,C1701,C0702 B07,UNK,UNK HU860149 50-60 1 0 6.89 PD-1/ Colorectal MSK- A0101,A0201,B4403, A01,A02,B44, 0 PDL-1 Cancer IMPACT B5201,C0302,C1501 B62,UNK,UNK HY288210 31-50 1 1 8.85 PD-1/ Non-Small Cell MSK- A0201,A0201,B2705, A02,A02,B27, 1 PDL-1 Lung Cancer IMPACT B4402,C0202,C0704 B44,UNK,UNK IJ267060 31-50 7 0 4.92 PD-1/ Glioma MSK- A0301,A0101,B5701, A03,A01,B58, 0 PDL-1 IMPACT B3501,C0401,C0602 B07,UNK,UNK IJ938694 50-60 6 0 1.97 PD-1/ Melanoma MSK- A3002,A0201,B1801, A01,A02,B44, 0 PDL-1 IMPACT B5201,C0501,C1202 B62,UNK,UNK IU057564 31-50 31 0 3.94 Combo Renal Cell MSK- A0301,A0201,B0702, A03,A02,B07, 0 Carcinoma IMPACT B4405,C0202,C0702 B44,UNK,UNK KE694138 >71 13 0 3.94 PD-1/ Renal Cell MSK- A1101,A0201,B5401, A03,A02,B07, 0 PDL-1 Carcinoma IMPACT B4001,C0304,C1502 B44,UNK,UNK LR648308 31-50 38 0 2.95 Combo Non-Small Cell MSK- A2601,A6802,B4201, A01,A02,B07, 0 Lung Cancer IMPACT B3801,C1701,C1203 B27,UNK,UNK NN760931 61-70 1 1 5.9 Combo Head and Neck MSK- A2402,A0201,B1402, A24,A02,B27, 0 Cancer IMPACT B4001,C0304,C0802 B44,UNK,UNK NV186145 61-70 1 0 1.97 PD-1/ Breast Cancer MSK- A0101,A2402,B1501, A01,A24,B62, 0 PDL-1 IMPACT B3503,C0303,C0401 B07,UNK,UNK NW458476 <30 8 0 4.92 PD-1/ Non-Small Cell MSK- A0301,A0302,B0801, A03,A03,B08, 0 PDL-1 Lung Cancer IMPACT B5601,C0102,C0701 B07,UNK,UNK SQ342450 50-60 6 0 27.55 PD-1/ Breast Cancer MSK- A2301,A0201,B4402, A24,A02,B44, 1 PDL-1 IMPACT B1801,C0501,C0501 B44,UNK,UNK SY001440 <30 3 1 7.87 PD-1/ Non-Hodgkin MSK- A0302,A3303,B4402, A03,A03,B44, 0 PDL-1 Lymphoma IMPACT B5801,C1604,C0302 B58,UNK,UNK WC509975 31-50 2 1 4.92 PD-1/ Melanoma MSK- A0101,A2601,B1517, A01,A01,B58, 0 PDL-1 IMPACT B3801,C1203,C0701 B27,UNK,UNK XB540163 31-50 10 0 2.95 Combo Melanoma MSK- A3201,A0201,B4402, A01,A02,B44, 0 IMPACT B3501,C0501,C0401 B07,UNK,UNK ZK699203 61-70 14 0 2.95 PD-1/ Glioma MSK- A0101,A0201,B0702, A01,A02,B07, 0 PDL-1 IMPACT B1801,C0702,C0701 B44,UNK,UNK BU258265 50-60 9 1 14.76 PD-1/ Non-Small Cell MSK- A0101,A2601,B3801, A01,A01,B27, 1 PDL-1 Lung Cancer IMPACT B5701,C1203,C1203 B58,UNK,UNK CS636630 61-70 10 0 45.25 PD-1/ Non-Small Cell MSK- A0201,A2601,B3801, A02,A01,B27, 1 PDL-1 Lung Cancer IMPACT B1801,C1203,C1203 B44,UNK,UNK CY423132 31-50 7 0 0.98 PD-1/ Soft Tissue MSK- A2403,A0206,B1525, A24,A02,B62, 1 PDL-1 Sarcoma IMPACT B1525,C0403,C0702 B62,UNK,UNK FM860744 50-60 9 0 69.85 Combo Melanoma MSK- A0201,A3101,B6701, A02,A03,B07, 0 IMPACT B5601,C0102,C0702 B07,UNK,UNK IS891001 >71 0 0 0 PD-1/ Esophagogastric MSK- A0201,A2601,B4102, A02,A01,B44, 0 PDL-1 Cancer IMPACT B1801,C1203,C1701 B44,UNK,UNK JM263371 31-50 2 1 4.92 PD-1/ Bladder MSK- A3001,A3201,B1302, A01A03,A01,UNK, 0 PDL-1 Cancer IMPACT B1501,C0303,C0602 B62,UNK,UNK KM601311 61-70 11 0 50.17 PD-1/ Pancreatic MSK- A0301,A0101,B0801, A03,A01,B08, 0 PDL-1 Cancer IMPACT B5101,C1502,C0701 B07,UNK,UNK MM286349 <30 1 1 8.85 PD-1/ Non-Small Cell MSK- A0101,A6802,B1402, A01,A02,B27, 0 PDL-1 Lung Cancer IMPACT B3701,C0802,C0602 B44,UNK,UNK OD704763 31-50 0 0 6.89 PD-1/ Esophagogastric MSK- A3303,A0205,B4403, A03,A02,B44, 0 PDL-1 Cancer IMPACT B5201,C1202,C0706 B62,UNK,UNK OU070759 61-70 0 1 2.95 PD-1/ Thyroid MSK- A2301,A6601,B1503, A24,A03,B27, 1 PDL-1 Cancer IMPACT B1503,C0210,C0210 B27,UNK,UNK QP957710 >71 0 0 0 PD-1/ Head and Neck MSK- A0201,A2601,B3801, A02,A01,B27, 0 PDL-1 Cancer IMPACT B3501,C0401,C1203 B07,UNK,UNK RL045521 61-70 11 0 2.95 PD-1/ Soft Tissue MSK- A0302,A2601,B0801, A03,A01,B08, 0 PDL-1 Sarcoma IMPACT B3801,C1203,C0701 B27,UNK,UNK UX818012 50-60 22 0 2.95 Combo Melanoma MSK- A0301,A0101,B5101, A03,A01,B07, 0 IMPACT B5201,C1502,C1202 B62,UNK,UNK WI153171 >71 3 0 2.95 PD-1/ Non-Small Cell MSK- A2601,A0205,B3801, A01,A02,B27, 0 PDL-1 Lung Cancer IMPACT B5001,C1203,C0602 B44,UNK,UNK XD202834 50-60 8 0 1.97 PD-1/ Renal Cell MSK- A2402,A0201,B0702, A24,A02,B07, 0 PDL-1 Carcinoma IMPACT B4402,C0501,C0702 B44,UNK,UNK XJ239469 31-50 5 1 11.81 PD-1/ Melanoma MSK- A0301,A6901,B1402, A03,A02,B27, 0 PDL-1 IMPACT B5501,C0102,C0802 B07,UNK,UNK XP592070 61-70 0 0 1.97 PD-1/ Cancer of MSK- A1101,A2402,B0702, A03,A24,B07, 0 PDL-1 Unknown IMPACT B3501,C0401,C0702 B07,UNK,UNK Primary CI009821 31-50 46 0 0.98 PD-1/ Renal Cell MSK- A2402,A3303,B3801, A24,A03,B27, 1 PDL-1 Carcinoma IMPACT B1801,C1203,C1203 B44,UNK,UNK CW956274 50-60 15 0 7.87 PD-1/ Bladder MSK- A3201,A6801,B2705, A01,A03,B27, 0 PDL-1 Cancer IMPACT B1517,C0102,C0701 B58,UNK,UNK FL718778 31-50 10 0 51.16 PD-1/ Melanoma MSK- A0101,A3101,B5701, A01,A03,B58, 0 PDL-1 IMPACT B4001,C0304,C0602 B44,UNK,UNK HJ341308 61-70 2 0 6.89 PD-1/ Colorectal MSK- A0301,A1101,B0801, A03,A03,B08, 1 PDL-1 Cancer IMPACT B4901,C0701,C0701 UNK,UNK,UNK IL793595 50-60 2 0 8.85 PD-1/ Non-Small Cell MSK- A2301,A2301,B4901, A24,A24,UNK, 1 PDL-1 Lung Cancer IMPACT B4901,C0701,C0701 UNK,UNK,UNK IO180287 >71 6 1 0.98 CTLA4 Breast Cancer MSK- A1101,A0207,B4601, A03,A02,B62, 0 IMPACT B3801,C0102,C0702 UNK,UNK,UNK IQ553381 >71 8 0 2.95 PD-1/ Glioma MSK- A2902,A0201,B0801, A01A24,A02,B08, 0 PDL-1 IMPACT B4501,C0602,C0701 B44,UNK,UNK IT690202 31-50 24 0 25.58 CTLA4 Melanoma MSK- A0201,A0201,B2705, A02,A02,B27, 1 IMPACT B3501,C0102,C0401 B07,UNK,UNK JD896803 31-50 4 0 8.85 PD-1/ Head and Neck MSK- A0301,A6802,B1516, A03,A02,B58, 0 PDL-1 Cancer IMPACT B1402,C0802,C1601 B27,UNK,UNK JN789460 >71 5 0 3.94 PD-1/ Colorectal MSK- A0201,A0201,B4001, A02,A02,B44, 1 PDL-1 Cancer IMPACT B4001,C0304,C0304 B44,UNK,UNK ME751004 61-70 8 0 0.98 Combo Melanoma MSK- A1101,A2402,B4801, A03,A24,B27, 0 IMPACT B3802,C0801,C0702 UNK,UNK,UNK RS929970 50-60 0 1 13.77 PD-1/ Non-Small Cell MSK- A0301,A2402,B1402, A03,A24,B27, 0 PDL-1 Lung Cancer IMPACT B4901,C0802,C0701 UNK,UNK,UNK YQ690189 31-50 1 1 56.08 Combo Melanoma MSK- A0301,A2402,B0702, A03,A24,B07, 0 IMPACT B5101,C1602,C0702 B07,UNK,UNK ZM495295 50-60 21 0 49.19 Combo Melanoma MSK- A0101,A0201,B0801, A01,A02,B08, 0 IMPACT B2705,C0102,C0701 B27,UNK,UNK AJ060934 31-50 6 0 1.97 Combo Melanoma MSK- A0201,A0201,B4402, A02,A02,B44, 1 IMPACT B3501,C0303,C0501 B07,UNK,UNK DF384822 50-60 2 0 1.97 PD-1/ Adrenocortical MSK- A0301,A0101,B0801, A03,A01,B08, 0 PDL-1 Carcinoma IMPACT B3501,C0401,C0701 B07,UNK,UNK EG383799 50-60 3 1 17.71 PD-1/ Bladder MSK- A0301,A6601,B0702, A03,A03,B07, 0 PDL-1 Cancer IMPACT B4102,C1701,C0702 B44,UNK,UNK GF170625 31-50 0 0 11.81 Combo Melanoma MSK- A1101,A0101,B4403, A03,A01,B44, 1 IMPACT B3501,C0401,C0401 B07,UNK,UNK GQ117672 61-70 19 0 1.97 CTLA4 Prostate MSK- A0301,A3402,B4001, A03,A03,B44, 0 Cancer IMPACT B4901,C0304,C0701 UNK,UNK,UNK HM704600 50-60 5 0 2.95 Combo Renal Cell MSK- A1101,A2402,B3502, A03,A24,B07, 0 Carcinoma IMPACT B5201,C0401,C1202 B62,UNK,UNK LB607333 31-50 1 1 9.84 PD-1/ Non-Small Cell MSK- A0301,A3301,B4403, A03,A03,B44, 1 PDL-1 Lung Cancer IMPACT B1501,C0202,C0202 B62,UNK,UNK NM969273 61-70 4 1 3.94 PD-1/ Renal Cell MSK- A0201,A0201,B4402, A02,A02,B44, 1 PDL-1 Carcinoma IMPACT B1801,C0701,C0704 B44,UNK,UNK OR743518 50-60 1 1 153.47 PD-1/ Colorectal MSK- A0301,A0301,B3501, A03,A03,B07, 1 PDL-1 Cancer IMPACT B1801,C1203,C0401 B44,UNK,UNK QK745450 61-70 0 1 0 PD-1/ Prostate MSK- A0303,A3101,B1402, A03,A03,B27, 0 PDL-1 Cancer IMPACT B4001,C0304,C0802 B44,UNK,UNK QP994107 50-60 7 0 2.95 PD-1/ Bladder MSK- A0301,A2402,B2705, A03,A24,B27, 1 PDL-1 Cancer IMPACT B5601,C0102,C0102 B07,UNK,UNK SN968302 31-50 0 0 10.82 PD-1/ Non-Small Cell MSK- A3002,A2902,B1801, A01,A01A24,B44, 0 PDL-1 Lung Cancer IMPACT B3501,C0401,C0701 B07,UNK,UNK WM051316 31-50 0 1 16.72 PD-1/ Small Cell MSK- A1101,A3301,B1801, A03,A03,B44, 0 PDL-1 Lung Cancer IMPACT B3503,C0802,C1203 B07,UNK,UNK XY337478 31-50 1 1 8.85 PD-1/ Small Cell MSK- A2301,A0201,B0801, A24,A02,B08, 0 PDL-1 Lung Cancer IMPACT B5101,C1402,C0701 B07,UNK,UNK YK193564 31-50 46 0 1.97 CTLA4 Prostate MSK- A2402,A3101,B3502, A24,A03,B07, 1 Cancer IMPACT B3502,C0401,C0401 B07,UNK,UNK CG383415 31-50 1 0 9.84 PD-1/ Non-Small Cell MSK- A6601,A0201,B4403, A03,A02,B44, 0 PDL-1 Lung Cancer IMPACT B1801,C0602,C0704 B44,UNK,UNK CO637650 61-70 0 0 6.89 PD-1/ Anal Cancer MSK- A0301,A1101,B5501, A03,A03,B07, 0 PDL-1 IMPACT B3501,C0303,C0401 B07,UNK,UNK EB780441 31-50 3 0 5.9 PD-1/ Non-Small Cell MSK- A2902,A3101,B4403, A01A24,A03,B44, 0 PDL-1 Lung Cancer IMPACT B3502,C1601,C0401 B07,UNK,UNK ES720972 31-50 35 0 6.89 PD-1/ Renal Cell MSK- A2902,A0202,B4001, A01A24,A02,B44, 0 PDL-1 Carcinoma IMPACT B4501,C0304,C0602 B44,UNK,UNK FQ781658 >71 21 0 5.9 Combo Melanoma MSK- A2402,A3201,B4002, A24,A01,B44, 0 IMPACT B5701,C0202,C0602 B58,UNK,UNK JO533617 61-70 15 0 15.74 Combo Melanoma MSK- A1101,A3303,B4402, A03,A03,B44, 0 IMPACT B5801,C0302,C0501 B58,UNK,UNK KE061649 61-70 9 0 53.12 CTLA4 Melanoma MSK- A0301,A2902,B4403, A03,A01A24,B44, 0 IMPACT B1801,C1601,C0701 B44,UNK,UNK LL204901 50-60 25 0 2.95 Combo Renal Cell MSK- A2402,A6901,B5501, A24,A02,B07, 0 Carcinoma IMPACT B5101,C0303,C1602 B07,UNK,UNK MN398266 31-50 3 1 12.79 PD-1/ Bladder MSK- A6601,A6901,B5501, A03,A02,B07, 0 PDL-1 Cancer IMPACT B1801,C0102,C1203 B44,UNK,UNK MZ946567 31-50 22 0 15.74 Combo Melanoma MSK- A2601,A0205,B3801, A01,A02,B27, 0 IMPACT B5001,C1203,C0602 B44,UNK,UNK NF584722 31-50 7 0 3.94 PD-1/ Non-Small Cell MSK- A2402,A0201,B4101, A24,A02,B44, 0 PDL-1 Lung Cancer IMPACT B4006,C0304,C1701 B44,UNK,UNK OY229666 31-50 3 1 5.9 PD-1/ Bladder MSK- A2402,A2601,B1801, A24,A01,B44, 0 PDL-1 Cancer IMPACT B4402,C1604,C1203 B44,UNK,UNK PA236764 31-50 5 1 5.9 PD-1/ Non-Small Cell MSK- A0201,A2601,B4002, A02,A01,B44, 0 PDL-1 Lung Cancer IMPACT B4501,C1601,C0202 B44,UNK,UNK PP274205 31-50 3 0 59.03 PD-1/ Non-Small Cell MSK- A2402,A0201,B4402, A24,A02,B44, 0 PDL-1 Lung Cancer IMPACT B1501,C0303,C0501 B62,UNK,UNK RH563185 31-50 1 1 3.94 PD-1/ Non-Small Cell MSK- A3601,A3402,B5301, A01,A03,B07, 1 PDL-1 Lung Cancer IMPACT B5301,C0401,C0401 B07,UNK,UNK SH122153 50-60 0 0 10.82 PD-1/ Non-Small Cell MSK- A0301,A2402,B0801, A03,A24,B08, 0 PDL-1 Lung Cancer IMPACT B4403,C0602,C0702 B44,UNK,UNK SP276688 31-50 10 1 7.87 PD-1/ Glioma MSK- A2902,A0201,B1501, A01A24,A02,B62, 0 PDL-1 IMPACT B3501,C0304,C0401 B07,UNK,UNK TA931155 50-60 3 0 2.95 PD-1/ Non-Small Cell MSK- A0201,A2601,B1518, A02,A01,B27, 0 PDL-1 Lung Cancer IMPACT B2705,C0102,C0704 B27,UNK,UNK PG 416 AM575114 50-60 7 1 43.29 PD-1/ Melanoma MSK- A0301,A0301,B0702, A03,A03,B07, 1 PDL-1 IMPACT B3906,C0702,C0702 B27,UNK,UNK CC355649 50-60 7 1 3.94 PD-1/ Pancreatic MSK- A1101,A2402,B5401, A03,A24,B07, 0 PDL-1 Cancer IMPACT B1501,C0303,C0102 B62,UNK,UNK CF773926 31-50 0 1 7.87 PD-1/ Non-Small Cell MSK- A0301,A1101,B1517, A03,A03,B58, 0 PDL-1 Lung Cancer IMPACT B3801,C1203,C0701 B27,UNK,UNK IE285088 50-60 25 0 8.85 Combo Non-Small Cell MSK- A0101,A3101,B0801, A01,A03,B08, 0 Lung Cancer IMPACT B4001,C0304,C0701 B44,UNK,UNK JU006201 50-60 20 0 3.94 PD-1/ Renal Cell MSK- A0301,A2402,B5501, A03,A24,B07, 1 PDL-1 Carcinoma IMPACT B1501,C0303,C0303 B62,UNK,UNK NE982910 31-50 7 0 30.5 PD-1/ Non-Small Cell MSK- A0301,A0301,B0702, A03,A03,B07, 1 PDL-1 Lung Cancer IMPACT B0801,C0702,C0701 B08,UNK,UNK OJ264581 >71 23 1 0.98 Combo Non-Small Cell MSK- A0302,A1101,B4101, A03,A03,B44, 0 Lung Cancer IMPACT B3503,C0401,C1701 B07,UNK,UNK ON455477 50-60 13 0 4.92 PD-1/ Non-Small Cell MSK- A0101,A2301,B5701, A01,A24,B58, 0 PDL-1 Lung Cancer IMPACT B4901,C0602,C0701 UNK,UNK,UNK RT030006 61-70 9 1 3.94 PD-1/ Glioma MSK- A1101,A2402,B1402, A03,A24,B27, 0 PDL-1 IMPACT B5201,C0202,C1202 B62,UNK,UNK SD028427 50-60 0 0 12.79 Combo Small Cell MSK- A2402,A3303,B4001, A24,A03,B44, 0 Lung Cancer IMPACT B3503,C1203,C0702 B07,UNK,UNK SY259900 50-60 0 1 52.14 PD-1/ Colorectal MSK- A0205,A3301,B5101, A02,A03,B07, 1 PDL-1 Cancer IMPACT B5101,C1502,C1502 B07,UNK,UNK TA865919 50-60 3 0 2.95 PD-1/ Renal Cell MSK- A0301,A0101,B0801, A03,A01,B08, 1 PDL-1 Carcinoma IMPACT B1801,C0701,C0701 B44,UNK,UNK YW286579 31-50 5 0 25.58 PD-1/ Melanoma MSK- A0301,A0301,B0702, A03,A03,B07, 1 PDL-1 IMPACT B0702,C0702,C0702 B07,UNK,UNK ZU115700 31-50 11 0 66.9 Combo Melanoma MSK- A0101,A2902,B0801, A01,A01A24,B08, 0 IMPACT B4403,C0401,C0701 B44,UNK,UNK ZU944390 31-50 2 1 0 PD-1/ Bladder MSK- A0201,A3101,B0705, A02,A03,B07, 0 PDL-1 Cancer IMPACT B3502,C1505,C0401 B07,UNK,UNK BB892688 31-50 28 0 55.09 PD-1/ Non-Small Cell MSK- A0201,A0201,B0801, A02,A02,B08, 1 PDL-1 Lung Cancer IMPACT B1801,C0701,C0701 B44,UNK,UNK CN518405 61-70 11 1 3.94 PD-1/ Glioma MSK- A0301,A0201,B4402, A03,A02,B44, 0 PDL-1 IMPACT B5101,C0102,C0501 B07,UNK,UNK CP570210 61-70 19 0 24.59 Combo Melanoma MSK- A0101,A0101,B0801, A01,A01,B08, 1 IMPACT B0801,C0718,C0718 B08,UNK,UNK EA843645 >71 4 1 0.98 PD-1/ Glioma MSK- A0202,A0206,B2705, A02,A02,B27, 0 PDL-1 IMPACT B3501,C1601,C0202 B07,UNK,UNK FC638791 31-50 25 0 1.97 PD-1/ Renal Cell MSK- A3001,A2301,B4102, A01A03,A24,B44, 0 PDL-1 Carcinoma IMPACT B1302,C0602,C1701 UNK,UNK,UNK HM265065 50-60 10 1 4.92 PD-1/ Renal Cell MSK- A0101,A0201,B4403, A01,A02,B44, 0 PDL-1 Carcinoma IMPACT B1501,C0303,C1601 B62,UNK,UNK IO630165 31-50 0 1 5.9 PD-1/ Non-Small Cell MSK- A1101,A0101,B5701, A03,A01,B58, 0 PDL-1 Lung Cancer IMPACT B5101,C0401,C0602 B07,UNK,UNK JP019086 50-60 12 0 4.92 PD-1/ Non-Small Cell MSK- A3001,A0101,B0801, A01A03,A01,B08, 0 PDL-1 Lung Cancer IMPACT B4405,C0701,C0202 B44,UNK,UNK KA251902 31-50 20 0 23.61 CTLA4 Melanoma MSK- A0201,A0201,B5301, A02,A02,B07, 1 IMPACT B5101,C0102,C0401 B07,UNK,UNK LU597217 61-70 2 0 11.81 Combo Melanoma MSK- A0301,A2402,B3701, A03,A24,B44, 0 IMPACT B3501,C0401,C0602 B07,UNK,UNK NQ158708 31-50 13 0 43.29 PD-1/ Melanoma MSK- A2402,A2402,B3801, A24,A24,B27, 1 PDL-1 IMPACT B3502,C0401,C1203 B07,UNK,UNK TH671342 61-70 0 0 3.94 PD-1/ Glioma MSK- A0201,A0205,B0702, A02,A02,B07, 0 PDL-1 IMPACT B5001,C0602,C0702 B44,UNK,UNK VY563784 50-60 1 1 3.94 PD-1/ Glioma MSK- A0301,A0201,B0702, A03,A02,B07, 0 PDL-1 IMPACT B1517,C0701,C0702 B58,UNK,UNK XG294932 31-50 3 1 5.9 Combo Bladder MSK- A0301,A0201,B1801, A03,A02,B44, 0 Cancer IMPACT B3801,C1203,C0701 B27,UNK,UNK AG183498 50-60 8 0 3.94 PD-1/ Renal Cell MSK- A0301,A0201,B1501, A03,A02,B62, 0 PDL-1 Carcinoma IMPACT B3501,C0304,C0401 B07,UNK,UNK CF802090 50-60 35 0 10.82 PD-1/ Non-Small Cell MSK- A3002,A3101,B1801, A01,A03,B44, 0 PDL-1 Lung Cancer IMPACT B3502,C0401,C0501 B07,UNK,UNK DX937247 31-50 7 1 4.92 Combo Bladder MSK- A0301,A0301,B4701, A03,A03,UNK, 1 Cancer IMPACT B5101,C1502,C0602 B07,UNK,UNK EU725595 <30 8 0 0 PD-1/ Skin Cancer; MSK- A0201,A6901,B3501, A02,A02,B07, 0 PDL-1 Non-Melanoma IMPACT B4402,C0401,C0704 B44,UNK,UNK EY684077 >71 1 0 3.94 PD-1/ Soft Tissue MSK- A2402,A0201,B1402, A24,A02,B27, 0 PDL-1 Sarcoma IMPACT B5001,C0802,C0602 B44,UNK,UNK HR473373 31-50 0 1 7.87 PD-1/ Non-Small Cell MSK- A2402,A0201,B0702, A24,A02,B07, 0 PDL-1 Lung Cancer IMPACT B4001,C0304,C0702 B44,UNK,UNK KX293532 31-50 6 1 14.76 PD-1/ Bladder MSK- A2601,A0205,B5001, A01,A02,B44, 0 PDL-1 Cancer IMPACT B4901,C0602,C0701 UNK,UNK,UNK LJ970887 31-50 9 0 104.28 PD-1/ Skin Cancer; MSK- A0101,A2402,B0801, A01,A24,B08, 0 PDL-1 Non-Melanoma IMPACT B1801,C0501,C0701 B44,UNK,UNK NV509595 >71 10 0 1.97 PD-1/ Hepatobiliary MSK- A0301,A1101,B0702, A03,A03,B07, 0 PDL-1 Cancer IMPACT B4002,C0803,C0702 B44,UNK,UNK PE010787 50-60 4 1 12.79 PD-1/ Non-Small Cell MSK- A2402,A2402,B1508, A24,A24,B07, 1 PDL-1 Lung Cancer IMPACT B4601,C0102,C0102 B62,UNK,UNK QD162536 31-50 8 0 5.9 PD-1/ Non-Small Cell MSK- A0101,A3201,B0801, A01,A01,B08, 0 PDL-1 Lung Cancer IMPACT B5201,C1202,C0701 B62,UNK,UNK UA949121 >71 13 1 12.79 PD-1/ Non-Hodgkin MSK- A6801,A2601,B3502, A03,A01,B07, 0 PDL-1 Lymphoma IMPACT B5101,C1602,C0401 B07,UNK,UNK VV580731 61-70 26 0 3.94 PD-1/ Renal Cell MSK- A2402,A2601,B3801, A24,A01,B27, 0 PDL-1 Carcinoma IMPACT B3502,C0401,C1203 B07,UNK,UNK YO886748 50-60 6 1 10.82 PD-1/ Colorectal MSK- A0301,A2402,B5501, A03,A24,B07, 0 PDL-1 Cancer IMPACT B4701,C0102,C0602 UNK,UNK,UNK ZD030437 31-50 20 0 13.77 PD-1/ Non-Small Cell MSK- A3002,A6802,B1402, A01,A02,B27, 0 PDL-1 Lung Cancer IMPACT B1503,C0210,C0802 B27,UNK,UNK ZN003309 >71 7 0 0.98 PD-1/ Head and Neck MSK- A2402,A6801,B3801, A24,A03,B27, 0 PDL-1 Cancer IMPACT B5101,C0102,C1203 B07,UNK,UNK

APPENDIX 2 HLA PDB Position Position Position Dep. Rel. Rev. Exp. Allele ID Resolution Bridge A A B B C C Date Date Date Method Structure Title B0702 5EO0 1.70 Y R 62 I 66 E 163 Nov. 10, Feb. 24, * Mar. 30, 2016 X-RAY Crystal Structure of HLA-B0702-RFLS 2015 2015 * Apr. 20, 2016 DIFFRACTION B0702 5EO1 1.85 Y R 62 I 66 E 163 Nov. 10, Feb. 24, * Mar. 30, 2016 X-RAY Crystal Structure of HLA-B0702-RL0 2015 2015 * Apr. 20, 2016 DIFFRACTION B0801 1AGB 2.20 N R 62 I 66 T 163 Mar. 24, Jun. 16, * Apr. 1, 2003 X-RAY ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES 1997 1997 * Feb. 24, 2009 DIFFRACTION IN HLA B8-HIV-1 GAG PEPTIDE (GGRKKYKL-3R MUTATION) B0801 1AGC 2.10 N R 62 I 66 T 163 Mar. 24, Jun. 16, * Apr. 1, 2003 X-RAY ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES 1997 1997 * Feb. 24, 2009 DIFFRACTION IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYQL-7Q MUTATION) B0801 1AGD 2.05 N R 62 I 66 T 163 Mar. 24, Jun. 16, * Apr. 1, 2003 X-RAY ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES 1997 1997 * Feb. 24, 2009 DIFFRACTION IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYKL-INDEX PEPTIDE) B0801 1AGE 2.30 N R 62 I 66 T 163 Mar. 24, Jun. 16, * Apr. 1, 2003 X-RAY ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES 1997 1997 * Feb. 24, 2009 DIFFRACTION IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYRL-7R MUTATION) B0801 1AGF 2.20 N R 62 I 66 T 163 Mar. 24, Jun. 16, * Apr. 1, 2003 X-RAY ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES 1997 1997 * Feb. 24, 2009 DIFFRACTION IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYKL-5R MUTATION) B0801 1M05 1.00 N R 62 I 66 T 163 Jun. 11, Sep. 2, * Feb. 24, 2009 X-RAY HLA BS in complex with an Epstein Barr Virus determinant 2002 2003 DIFFRACTION B0801 3X13 1.80 N R 62 I 66 T 163 Oct. 24, Dec. 24, * Apr. 8, 2015 X-RAY Crystal Structure of HLA-B*0801.N90! 2014 2014 DIFFRACTION B0801 3X14 2.00 N R 62 I 66 T 163 Oct. 25, Dec. 24, * Apr. 8, 2015 X-RAY Crystal Structure of HLA-B*0801.N90!R82L.G83R 2014 2014 DIFFRACTION B0801 4QRP 2.90 N R 62 I 66 T 163 Jul. 2, Nov. 12, * Dec. 24, 2014 X-RAY Crystal Structure of HLA-B*0801 in complex with 2014 2014 DIFFRACTION HSKKKCOEL and DO31 TOR B0801 4QRQ 1.70 N R 62 I 66 T 163 Jul. 2, Nov. 12, * Dec. 24, 2014 X-RAY Crystal Structure of HLA-B*0801 in complex with 2014 2014 DIFFRACTION HSKKKCDEL B0801 4QRS 1.40 N R 62 I 66 T 163 Jul. 2, Dec. 10, X-RAY Crystal Structure of HLA-B*0801 in complex with 2014 2014 DIFFRACTION ELK_IYM ELKRKMYM B0801 4QRT 1.40 N R 62 I 66 T 163 Jul. 2, Jul. 16, X-RAY Crystal Structure of HLA-B*0801 in complex with 2014 2014 DIFFRACTION ELN_YYM ELNRKMYM B0801 4QRU 1.60 N R 62 I 66 T 163 Jul. 2, Feb. 4, X-RAY Crystal Structure of HLA-B*0801 in complex with 2014 2015 DIFFRACTION ELR_MYM ELRRKMMYM B1501 1XR8 2.30 Y R 62 I 66 L 163 Oct. 14, Apr. 14, * Mar. 18, 2008 X-RAY Crystal Structures of HLA-B*1501 in Complex with 2001 2005 * Jul. 13, 2011 DIFFRACTION Peptides from Human UbcH6 and Epstein-Barr Virus EBNA 3 B1501 1XR9 1.79 Y R 62 I 66 L 163 Oct. 14, Apr. 14, * Mar. 18, 2008 X-RAY Crystal Structures of HLA-B*1501 in Complex with 2001 2005 * Jul. 13, 2011 DIFFRACTION Peptides from Human UbcH6 and Epstein-Barr Virus EBNA 3 B1501 3G9N 1.87 Y R 62 I 66 L 163 Feb. 18, Feb. 26, * May 6, 2008 X-RAY Crystal Structures of a SARS Corona Virus Dariveo Peptide Bound to the 2008 2009 * Feb. 24, 2009 DIFFRACTION Human Major Histocompatibility Complex Class I molecule HLA-B*1501 B0801 4JOV 1.50 N R 62 I 66 T 163 Mar. 20, Jun. 26, * Jul. 17, 2013 X-RAY HLA-B*18:01 in complex with Epstein-Barr virus BZLF1-derived peptide 2013 2013 DIFFRACTION (residues 173-120) B0801 4XXO 1.43 N R 62 I 66 T 163 Jan. 30, Apr. 8, * Apr. 22, 2015 X-RAY HLA-B*1801 in complex with self-peptide, DELEIKAY 2015 2015 * May 13, 2015 DIFFRACTION B2705 1HSA 2.10 Y R 62 I 66 E 163 Jun. 11, Oct. 15, * Apr. 1, 2003 X-RAY THE THREE-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 1992 1992 * Feb. 24, 2009 DIFFRACTION ANGSTROMS RESOLUTION SUGGESTS A GENERAL MECHANISM FOR TIGHT PEPTIDE BINDING TO MHO B2705 1JGE 2.10 N R 62 I 66 E 163 Jun. 25, Oct. 30, * Dec. 23, 2002 X-RAY HLA-B*2705 bound to nona-peptide m9 2001 2002 * Aug. 12, 2009 DIFFRACTION * Feb. 24, 2009 B2705 IOGT 1.47 Y R 62 I 66 E 163 May 13, Jan. 29, * Feb. 24, 2009 X-RAY CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE 2003 2004 DIFFRACTION VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-400) B2705 1UXS 1.55 Y R 62 I 66 E 163 Mar. 1, Nov. 9, * Jan. 27, 2005 X-RAY CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE 2004 2004 * Feb. 15, 2005 DIFFRACTION LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2)OF * Feb. 24, 2009 EPSTEIN-BARR VIRUS B2705 1W0V 2.27 Y R 62 I 66 E 163 Jun. 14, Mar. 7, * Feb. 24, 2009 X-RAY CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE 2004 2005 * Jul. 13, 2013 DIFFRACTION SELF-PEPTIDE TIS FROM EGF-RESPONSE FACTOR 1 B2705 2A8B 1.40 N R 62 I 66 E 163 Jul. 7, Dec. 27, * Nov. 21, 2006 X-RAY Crystal Structure of hla-b*2705 complexed with the glucagon receptor 2005 2005 * Feb. 24, 2009 DIFFRACTION (gr) peptide (residues 412-420) * Jul. 13, 2013 B2705 2BSR 2.30 Y R 62 I 66 E 163 May 23, May 24, * Feb. 24, 2009 X-RAY CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE 2005 2005 DIFFRACTION IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705 B2705 2BSS 2.00 N R 62 I 66 E 163 May 23, May 24, * Feb. 24, 2009 X-RAY CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE 2005 2005 DIFFRACTION IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705 B2705 2BST 2.10 N R 62 I 66 E 163 May 23, May 24, * Feb. 24, 2009 X-RAY Crystal structures and KIR3DL1 recognition of three immunodominant viral 2005 2005 * Feb. 13, 2013 DIFFRACTION peptides complexed to HLA-B2705 * May 27, 2015 B2705 3B8S 1.80 Y R 62 I 66 E 163 Oct. 29, Jul. 22, * Oct. 14, 2006 X-RAY Crystal Structure of hla-b*2705 Complexed with the Citrultinated Vasoactive 2007 2008 * Feb. 24, 2009 DIFFRACTION Intestinal Peptide Type 1 Receptor (vipr) Peptide (residues 400-400) B2705 3BP4 1.85 Y R 62 I 66 E 163 Dec. 19, Dec. 23, * Aug. 18, 2009 X-RAY The high resolution crystal structure of HLA-B*2705 in complex 2007 2008 * Oct. 27, 2009 DIFFRACTION with a Cathepsin A signal sequence peptide pCatA * Jul. 13, 2011 B2705 3DTX 2.10 Y R 62 I 66 E 163 Jul. 18, May 5, * Oct. 12, 2011 X-RAY Crystal Structure of HLA-B*2705 complexed with the double citrulinated 2008 2009 DIFFRACTION vasoactive intestinal peptide type 1 receptor (VIPR) peptide (residues 400-408) B2705 3LV3 1.94 Y R 62 I 66 E 163 Feb. 19, Nov. 24, * Dec. 1, 2010 X-RAY Crystal structure of HLA-B*2705 complexed with a peptide derived 2010 2010 * Feb. 9, 2011 DIFFRACTION from the humal voltage-dependent calcium channel alpha1 subunit * Oct. 31, 2012 (residues 513-521) B2705 4G8G 2.40 Y R 62 I 66 E 163 Jul. 23, Mar. 20, * Apr. 10, 2013 X-RAY Crystal Structure of C12C TCR-HA B2705-KK10 2012 2013 DIFFRACTION B2705 4G8I 1.60 Y R 62 I 66 E 163 Jul. 23, Mar. 20, * Apr. 10, 2013 X-RAY Crystal Structure of HLA B2705-KK10-L6M 2012 2013 DIFFRACTION B2705 4G9D 1.60 N R 62 I 66 E 163 Jul. 23, Mar. 20, * Apr. 10, 2013 X-RAY Crystal Structure of HLA B2705-KK10 2012 2013 DIFFRACTION B2705 4G9F 1.90 Y R 62 I 66 E 163 Jul. 23, Mar. 20, * Apr. 10, 2013 X-RAY Crystal Structure of C12C TCR-HLAB2705 KK10-L6M 2012 2013 DIFFRACTION B3501 1A1N 2.00 N R 62 I 66 L 163 Dec. 11, Apr. 8, * Apr. 1, 2003 X-RAY MHC CLASS I MOLECULE B*3501 COMPLEXED WITH PEPTIDE 1997 1998 * Feb. 24, 2009 DIFFRACTION VPLRPMTY FROM THE NEF PROTEIN (75-82) OF HIV1 B3501 1A9B 3.20 N R 62 I 66 L 163 Apr. 3, Oct. 21, * Nov. 18, 1999 X-RAY DECAMER LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO 1998 1998 * Apr. 1, 2003 DIFFRACTION HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C * Feb. 24, 2009 TERMINUS B3501 1A9E 2.50 Y R 62 I 66 L 163 Apr. 5, Oct. 21, * Nov. 18, 1999 X-RAY DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO 1998 1998 * Apr. 1, 2003 DIFFRACTION HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C- * Feb. 24, 2009 TERMINUS B3501 1CG9 2.70 Y R 62 I 66 L 163 Mar. 25, Nov. 18, * Feb. 24, 2009 X-RAY COMPLEX RECOGNITION OF THE SUPERTYPIC BW6- 1999 2003 DIFFRACTION DETERMINANT ON HLA-B AND C MOLECULES BY THE MONOCLONAL ANTIBODY SFR8-B5 B3501 1XH3 1.48 N R 62 I 66 L 163 Sep. 17, Nov. 23, * Feb. 24, 2009 X-RAY Conformational Restraints and Flexibility of 14-Meric Peptides 2004 2004 * Jul. 13, 2011 DIFFRACTION in Complex with HLA-B*3501 B3501 1ZHK 1.60 Y R 62 I 66 L 163 Apr. 25, May 17, * Jun. 28, 2005 X-RAY Crystal structure of HLA-B*3501 presenting 13-mer EBV antigen 2005 2005 * Feb. 24, 2009 DIFFRACTION LPEPLPQGOLTAY * Apr. 16, 2014 B3501 1ZSD 1.70 N R 62 I 66 L 163 May 24, Jun. 7, * Sep. 27, 2005 X-RAY Crystal Structure Of HLA-B*3501 Presenting an 11-Mer EBV Antigen 2005 2005 * Feb. 24, 2009 DIFFRACTION EPLPQGOLTAY B3501 2AXG 2.00 Y R 62 I 66 L 163 Sep. 5, Nov. 29, * Feb. 24, 2009 X-RAY The Immunogenicity of a Viral Cytotoxic T Cell Epitope 2005 2005 DIFFRACTION is controlled by its MHC-bound Conformation B3501 2CIK 1.75 N R 62 I 66 L 163 Mar. 22, Oct. 25, * Nov. 22, 2006 X-RAY INSIGHTS INTO CROSSREACTIVITY IN HUMAN ALLORECOGNITION 2006 2006 * Dec. 20, 2006 DIFFRACTION THE STRUCTURE OF HLA-B35011 PRESENTING AN EPITOPE * Feb. 24, 2009 DERIVED GTOM CYTOCHROME P450. B3501 2FYY 1.50 N R 62 I 66 L 163 Feb. 8, Dec. 26, * Feb. 24, 2009 X-RAY The role of T cell receptor alpha genes in directing human MHC restriction 2006 2006 DIFFRACTION B3501 2FZ3 1.90 N R 62 I 66 L 163 Feb. 9, Dec. 26, * Feb. 24, 2009 X-RAY The role of T cell receptor alpha genes in directing human MHC restriction 2006 2006 DIFFRACTION B3501 2H8P 1.90 N R 62 I 66 L 163 May 31, Sep. 19, * Jun. 3, 2006 X-RAY Crystal structure of HLA-B*3501 presenting the human cytochrome P450 2006 2006 * Jul. 13, 2011 DIFFRACTION derived peptide, KPIVVLHGY B3501 2NX5 2.70 N R 62 I 66 L 163 Nov. 16, Feb. 27, * Feb. 24, 2009 X-RAY Crystal structure of ELSA TCR bound to HLA-B*3501 presenting 2006 2007 * Apr. 28, 2010 DIFFRACTION EBV peptide EPLPOGOLTAY at 1.7A B3501 3LKN 2.00 Y R 62 I 66 L 163 Jan. 27, Jul. 7, * Jul. 28, 2010 X-RAY Crystal Structure of HLA-B*3501 in complex with influenza NP418 epitope 2010 2010 DIFFRACTION from 1918 strain B3501 3LKO 1.80 N R 62 I 66 L 163 Jan. 27, Jul. 7, * Jul. 28, 2010 X-RAY Crystal Structure of HLA-B*3501 in complex with influenza NP418 epitope 2010 2010 DIFFRACTION from 1934 strain B3501 3LKP 1.80 N R 62 I 66 L 163 Jan. 27, Jul. 7, * Jul. 28, 2010 X-RAY Crystal Structure of HLA-B*3501 in complex with influenza NP418 epitope 2010 2010 DIFFRACTION from 1972 strain B3501 3LKQ 1.80 N R 62 I 66 L 163 Jan. 27, Jul. 7, * Jul. 28, 2010 X-RAY Crystal Structure of HLA-B*3501 in complex with influenza NP418 epitope 2010 2010 DIFFRACTION from 1977 strain B3501 3LKR 2.00 N R 62 I 66 L 163 Jan. 27, Jul. 7, * Jul. 28, 2010 X-RAY Crystal Structure of HLA-B*3501 in complex with influenza NP418 epitope 2010 2010 DIFFRACTION from 2009 H1N1 swine origin strain B3501 3LKS 1.90 Y R 62 I 66 L 163 Jan. 27, Jul. 7, * Jul. 28, 2010 X-RAY Crystal Structure of HLA-B*3501 in complex with influenza NP418 epitope 2010 2010 DIFFRACTION from 1980 strain B3501 3MV7 2.00 N R 62 I 66 L 163 May 3, Jun. 9, * Jul. 20, 2011 X-RAY Crystal Structure of the TK3 TCR in complex with HLA-B*3501/HPVG 2010 2010 DIFFRACTION B3501 3MV8 2.10 N R 62 I 66 L 163 May 3, Jun. 9, * Jul. 20, 2011 X-RAY Crystal Structure of the TK3-Gin55His TCR in complex with 2010 2010 DIFFRACTION HLA-B*3501/HPVG B3501 3MV9 2.70 N R 62 I 66 L 163 May 3, Jun. 9, * Jul. 20, 2011 X-RAY Crystal Structure of the TK3-Gin55Ala TCR in complex with 2010 2010 DIFFRACTION HLA-B*3501/HPVG B3501 4LNR 2.00 N R 62 I 66 L 163 Jul. 12, Jul. 23, X-RAY The structure of HLA-B*35:01 in complex with the peptide 2013 2014 DIFFRACTION (RPOVPLRPMTY) B3501 4PR5 1.80 N R 62 I 66 L 163 Mar. 5, Apr. 16, * Apr. 23, 2014 X-RAY Crystal Structure of a HLA-B*35:01-HPVG-05 2014 2014 * Jun. 18, 2014 DIFFRACTION * Jul. 2, 2014 B3501 4PRN 1.65 N R 62 I 66 L 163 Mar. 5, Apr. 16, * Apr. 23, 2014 X-RAY Crystal Structure of a HLA-B*35:01-HPVG-A4 2014 2014 * Jun. 18, 2014 DIFFRACTION * Jul. 2, 2014 B3501 4QRR 3.00 N R 62 I 66 L 163 Jul. 2, Dec. 10, * Dec. 17, 2014 X-RAY Crystal Structure of HLA-B*3501-IPS in complex with a Delta-Bera TCR, 2014 2014 * Dec. 31, 2014 DIFFRACTION clone 12 TCR B3508 1ZHL 1.50 Y R 62 I 66 L 163 Apr. 26, May 17, * Jun. 28, 2005 X-RAY Crystal Structure of HLA-B*3508 presenting 13-mer EBV antigen 2005 2005 * Feb. 24, 2009 DIFFRACTION LPEPLPQGOLTAY * Apr. 16, 2014 B3508 2AK4 2.50 Y R 62 I 66 L 163 Aug. 9, Oct. 11, * Jan. 31, 2005 X-RAY Crystal Structure of SB27 TCR in complex with HLA-B*3508-13mer peptide 2005 2005 * Feb. 24, 2009 DIFFRACTION B3508 2AXF 1.80 Y R 62 I 66 L 163 Aug. 5, Nov. 29, * Feb. 24, 2009 X-RAY The immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled 2005 2005 DIFFRACTION by its MHC-bound Conformation B3508 2NW3 1.70 N R 62 I 66 L 163 Nov. 14, Feb. 27, * Feb. 24, 2009 X-RAY Crystal structure of HLA-B*3508 presenting EOV peptide EPLPQGOLTAY 2006 2007 DIFFRACTION at 1.7A B3508 3BW9 1.75 Y R 62 I 66 L 163 Jan. 8, Apr. 22, * Feb. 24, 2009 X-RAY Crystal Structure of HLA-B*3508 in complex with a HCMV 12-mer peptide 2008 2008 DIFFRACTION from the pp55 protein B3508 3BWA 1.30 N R 62 I 66 L 163 Jan. 8, Apr. 22, * Feb. 24, 2009 X-RAY Crystal Structure of HLA-B*3508 in complex with a HCMV 8-mer peptide 2008 2008 DIFFRACTION from the pp55 protein B3508 3KWW 2.18 Y R 62 I 66 L 163 Dec. 1, Jun. 9, X-RAY Crystal Structure of the ‘restriction triad’ mutant of HLA B*3508, beta-2- 2009 2010 DIFFRACTION microglobulin and EBV peptide B3508 3KXF 3.10 Y R 62 I 66 L 163 Dec. 1, Jun. 9, * Apr. 27, 2011 X-RAY Crystal Structure of SB27 TCR in complex with the ‘restriction 2009 2010 * Feb. 26, 2014 DIFFRACTION triad’ mutant of HLA B*3508 18-mer B3508 3VFS 1.85 Y R 62 I 66 L 163 Jan. 10, Feb. 22, * Mar. 7, 2012 X-RAY crystal structure of HLA B*3508LPEP-P5Ala, peptide mutant 2012 2012 * Apr. 25, 2012 DIFFRACTION P5-ala * Aug. 8, 2012 B3508 3VFT 1.95 Y R 62 I 66 L 163 Jan. 10, Feb. 22, * Mar. 7, 2012 X-RAY crystal structure of HLA B*3508LPEP-P6Ala, peptide mutant 2012 2012 * Apr. 25, 2012 DIFFRACTION P6-ala * Aug. 8, 2012 B3508 3VFU 1.65 Y R 62 I 66 L 163 Jan. 10, Feb. 22, * Mar. 7, 2012 X-RAY crystal structure of HLA B*3508 LPEP-P7Ala, peptide mutant 2012 2012 * Apr. 25, 2012 DIFFRACTION P7-ala * Aug. 8, 2012 B3508 3VFV 1.55 Y R 62 I 66 L 163 Jan. 10, Feb. 22, * Mar. 7, 2012 X-RAY crystal structure of HLA B*3508 LPEP-P9Ala, peptide mutant 2012 2012 * Apr. 25, 2012 DIFFRACTION P8-ala * Aug. 8, 2012 B3508 3VFW 2.30 Y R 62 I 66 L 163 Jan. 10, Feb. 22, * Mar. 7, 2012 X-RAY crystal structure of HLA B*3508 LPEP-P10Ala, peptide mutant 2012 2012 * Apr. 25, 2012 DIFFRACTION P10-ala * Aug. 8, 2012 B3901 4O2C 1.80 N R 62 I 66 T 163 Dec. 17, Jul. 23, X-RAY An Nt-acetylated peptide complexed with HLA B*3901 2013 2014 DIFFRACTION B3901 4O2E 1.98 N R 62 I 66 T 163 Dec. 17, Jul. 23, X-RAY A peptide complexed with HLA-B*3901 2013 2014 DIFFRACTION B3901 4O2F 1.90 Y R 62 I 66 T 163 Dec. 17, Jul. 23, X-RAY A peptide complexed with HLA-B*3901 2013 2014 DIFFRACTION B4402 1M6O 1.60 N R 62 I 66 L 163 Jul. 17, Sep. 2, * Feb. 15, 2005 X-RAY Crystal Structure of HLA B*4402 in complex with HLA DPA*0201 2002 2003 * Feb. 24, 2009 DIFFRACTION peptide B4402 3DX6 1.70 N R 62 I 66 L 163 Jul. 23, Jan. 27, * Dec. 22, 2010 X-RAY Crystal Structure of 0*4402 presenting a 10mer EOV epitope 2008 2009 * Jul. 13, 2011 DIFFRACTION B4402 3KPL 1.96 N R 62 I 66 L 163 Nov. 15, Dec. 22, * Dec. 29, 2009 X-RAY Crystal Structure of HLA B*4403 in complex with 2009 2009 * Apr. 21, 2010 DIFFRACTION EEYLQAFTY a self peptide from the ABCD3 protein * Jul. 13, 2011 B4402 3KPM 1.60 N R 62 I 66 L 163 Nov. 16, Dec. 22, * Apr. 21, 2010 X-RAY Crystal Structure of HLA B*4402 in complex with 2009 2009 * Jul. 13, 2011 DIFFRACTION EEYLKAWTF, a mimotope B4402 3L3D 1.80 N R 62 I 66 L 163 Dec. 16, Mar. 16, * Feb. 26, 2014 X-RAY Crystal structure of HLA B*4402 in complex with 2009 2010 DIFFRACTION the F3A mutant of a self-peptide derived from DPA*0201 B4402 3D3G 2.10 N R 62 I 66 L 163 Dec. 16, Mar. 16, * Feb. 26, 2014 X-RAY Crystal structure of HLA B*4402 in complex with 2009 2010 DIFFRACTION the RSA mutant of a self-peptide derived from DPA*0201 B4402 3L3I 1.70 N R 62 I 66 L 163 Dec. 17, Mar. 16, * Feb. 26, 2014 X-RAY Crystal structure of HLA B*4402 in complex with 2009 2010 DIFFRACTION the F7A mutant of a self-peptide derived from DPA*0201 B4402 3L3J 2.40 N R 62 I 66 L 163 Dec. 17, Mar. 16, * Jul. 13, 2011 X-RAY Crystal structure of HLA B*4402 in complex with 2009 2010 * Feb. 26, 2014 DIFFRACTION the F3A/R5A double mutant of a self-peptide derived from DPA*0201 B4402 3L3K 2.60 Y R 62 I 66 L 163 Dec. 17, Mar. 16, * Jul. 13, 2011 X-RAY Crystal structure of HLA B*4402 in complex with 2009 2010 * Feb. 26, 2014 DIFFRACTION the R5A/F7A double mutant of a self-peptide derived from DPA*0201 B4403 1N2R 1.70 N R 62 I 66 L 163 Oct. 24, Mar. 16, * Feb. 24, 2009 X-RAY A natural selected dimorphism in HLA B*44 alters self peptide reportoire and 2002 2004 DIFFRACTION T cell recognition B4403 1SYS 2.40 N R 62 I 66 L 163 Apr. 1, Oct. 19, * Feb. 24, 2009 X-RAY Crystal structure of HLA B*4403, and peptide EEPTVSKKY 2004 2004 DIFFRACTION B4403 3DX7 1.60 N R 62 I 66 L 163 Jul. 23, Jan. 27, * Jul. 13, 2011 X-RAY Crystal Structure of HLA B*4403 presenting 10mer EOV antigen 2008 2009 DIFFRACTION B4403 3KPN 2.00 N R 62 I 66 L 163 Nov. 16, Dec. 22, * Dec. 29, 2009 X-RAY Crystal Structure of HLA B*4403 in complex with EEYLQAFTY a self 2009 2009 * Jan. 12, 2010 DIFFRACTION peptide from the the ABCD3 protein * Apr. 21, 2010 * Jul. 13, 2011 B4403 3KPD 2.30 N R 62 I 66 L 163 Nov. 16, Dec. 22, * Apr. 21, 2010 X-RAY Crystal Structure of HLA B*4403 in complex with EEYLKAWTF, 2009 2009 * Jul. 13, 2011 DIFFRACTION a mimotope B4403 4JQX 1.90 N R 62 I 66 L 163 Mar. 20, May 26, * Jul. 17, 2013 X-RAY HLA B*44:03 in complex with Epstein-Barr virus BZLF i-derived peptide 2013 2013 DIFFRACTION (residues 169-180) B4405 1SYV 1.70 N R 62 I 66 L 163 Apr. 2, Oct. 19, * Feb. 24, 2009 X-RAY HLA B*4405 complexed to the dominant self ligand EEFGRYGF 2004 2004 DIFFRACTION B4405 3DX8 2.10 Y R 62 I 66 L 163 Jul. 23, Jan. 27, * Jul. 13, 2011 X-RAY Crystal Structure of B*4405 presenting a 10mer EBV epitope 2008 2009 DIFFRACTION B4405 3DXA 3.50 N R 62 I 66 L 163 Jul. 23, Jan. 27, * Jul. 13, 2011 X-RAY Crystal Structure of the OM1 TCR in complex with HLA-B*4405 2008 2009 DIFFRACTION and decamer EBV antigen B4405 3KPP 1.90 N R 62 I 66 L 163 Nov. 15, Dec. 22, * Dec. 29, 2009 X-RAY Crystal Structure of HLA B*4405 in complex with EEYLQAFTY 2009 2009 * Apr. 21, 2010 DIFFRACTION a self peptide from the ABCD3 protein * Jul. 13, 2011 B4405 3KPO 1.84 N R 62 I 66 L 163 Nov. 16, Dec. 22, * Dec. 29, 2009 X-RAY Crystal Structure of HLA B*4405 in complex with EEYLKAWTF, 2009 2009 * Apr. 21, 2010 DIFFRACTION a mimotope * Nov. 17, 2010 * Jul. 13, 2011 B4405 3KPR 2.60 N R 62 I 66 L 163 Nov. 16, Dec. 22, * Dec. 29, 2009 X-RAY Crystal Structure of the LC13 TCR in complex with HLA B*4405 bound to 2009 2009 * Apr. 21, 2010 DIFFRACTION EEYLKAWTF a mimotope B4405 3KPS 2.70 N R 62 I 66 L 163 Nov. 16, Dec. 22, * Dec. 29, 2009 X-RAY Crystal Structure of the LC13 TCR in complex with HLA B*4405 bound to 2009 2009 * Apr. 21, 2010 DIFFRACTION EEYLQAFTY a self peptide from the ABCD3 protein B5101 1E27 2.20 N R 62 I 66 L 163 May 15, Sep. 12, * Feb. 24, 2009 X-RAY NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED 2000 2000 DIFFRACTION WITH HIV IMMUNODOMINANT EPITOPE KM1(LPPWAKEI) B5101 1E28 3.00 Y R 62 I 66 L 163 Jun. 18, Sep. 12, * Feb. 24, 2009 X-RAY NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED 2000 2000 DIFFRACTION WITH HIV IMMUNODOMINANT EPITOPE KM2(TAFTIPSI) B5101 4MJI 2.99 N R 62 I 66 L 163 Sep. 3, May 28, X-RAY T cell response to a HIV reverse transcriptase epitope 2013 2014 DIFFRACTION presented by the protective allele HLA-B*51:01 B5201 3W39 3.10 N R 63 I 67 L 164 Dec. 13, Feb. 13, X-RAY Crystal structure of HLA-B*5201 in complexed with HIV 2012 2013 DIFFRACTION immunodominant epitope (TAFTIPSI) B5301 1A1M 2.30 Y R 62 I 66 L 163 Dec. 11, Apr. 8, * Sep. 16, 2003 X-RAY MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE 1997 1998 * Feb. 24, 2009 DIFFRACTION TPYDINQML FROM GAG PROTEIN OF HIV2 B5301 1A1O 2.30 N R 62 I 66 L 163 Dec. 11, Apr. 8, * Apr. 1, 2003 X-RAY MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE 1997 1998 * Feb. 24, 2009 DIFFRACTION LS6 (KPIVQYDNF) FROM THE MALARIA PARASITE P. FALCIFARUM B5701 2RFX 2.50 N G 62 N 66 L 163 Oct. 2, Jul. 8, * Feb. 24, 2009 X-RAY Crystal structure of HLA-B*5701, presenting the self peptide, LSSPVTKSF 2007 2008 * Jul. 13, 2011 DIFFRACTION B5701 3UPR 2.00 N G 62 N 66 L 163 Nov. 18, Jun. 13, * Nov. 14. 2012 X-RAY HLA-B*57:01 complexed to pep-V and Abacavir 2011 2012 DIFFRACTION B5701 3VH8 1.80 N G 62 N 66 L 163 Aug. 24, Oct. 26, * Dec. 7, 2011 X-RAY KIR3DL1 in complex with HLA-B 5701 2011 2011 DIFFRACTION B5701 3VRI 1.60 N G 62 N 66 L 163 Apr. 11, May 30, * Jul. 4, 2012 X-RAY HLA-B*57:01-RVAQLENYI in complex with abacavir 2012 2012 DIFFRACTION B5701 3VRJ 1.00 N G 62 N 66 L 163 Apr. 11, May 30, * Jul. 4, 2012 X-RAY HLA-B*57:01-LTTKLTNTNI in complex with abacavir 2012 2012 DIFFRACTION B5701 3WUW 2.00 N G 62 N 66 L 163 May 8, May 28, X-RAY KIR3DL1 in complex with HLA-B 57:01.I80T 2014 2014 DIFFRACTION B5701 3X11 2.15 N G 62 N 66 L 163 Oct. 24, Dec. 24, * Apr. 8, 2015 X-RAY Crystal structure of HLA-B*5701.I80N.I_82R.R83G 2014 2014 DIFFRACTION B5701 3X12 1.80 N G 62 N 66 L 163 Oct. 24, Dec. 24, * Apr. 8, 2015 X-RAY Crystal structure of HLA-B*5701.I80N 2014 2014 DIFFRACTION B5701 5B38 2.30 N G 62 N 66 L 163 Feb. 12, Mar. 30, * Apr. 20, 2016 X-RAY KIR3DL1*005 in complex with HLA-B*57:01 2016 2016 * May 18, 2016 DIFFRACTION B5701 5B39 2.50 N G 62 N 66 L 163 Feb. 12, Mar. 30, * Apr. 20, 2016 X-RAY KIR3DL1*055 in complex with HLA-B*57:01 2016 2016 * May 18, 2016 DIFFRACTION B5801 5INC 2.88 N G 62 N 66 L 163 Mar. 7, Oct. 5, * Oct. 19, 2016 X-RAY Crystal structure of HLA-B*5801, a protective HLA allele for HIV-1 infection 2016 2016 DIFFRACTION B5801 5IND 2.13 N G 62 N 66 L 163 Mar. 7, Oct. 5, * Oct. 19, 2016 X-RAY Crystal structure of HLA-B*5801, a protective HLA allele for HIV-1 infection 2016 2016 DIFFRACTION

REFERENCES

-   1. Callahan M K, Postow M A, Wolchok J D. Targeting T Cell     Co-receptors for Cancer Therapy. Immunity. 2016; 44(5):1069-1078.     doi:10.1016/j.immuni.2016.04.023. -   2. Gibney G T, Weiner L M, Atkins M B. Predictive biomarkers for     checkpoint inhibitor-based immunotherapy. Lancet Oncol.     2016;17(12):e542-e551. doi:10.1016/S1470-2045(16)30406-5. -   3. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for     clinical response to CTLA-4 blockade in melanoma. N Engl J Med.     2014;371(23):2189-2199. doi:10.1056/NEJMoa1406498. -   4. Van Allen E M, Miao D, Schilling B, et al. Genomic correlates of     response to CTLA-4 blockade in metastatic melanoma. Science. 2015;     350(6257):207-211. doi:10.1126/science.aad0095. -   5. Rizvi N A, Hellmann M D, Snyder A, et al. Cancer immunology.     Mutational landscape determines sensitivity to PD-1 blockade in     non-small cell lung cancer. Science. 2015; 348(6230):124-128.     doi:10.1126/science.aaa1348. -   6. Rosenberg J E, Hoffman-Censits J, Powles T, et al. Atezolizumab     in patients with locally advanced and metastatic urothelial     carcinoma who have progressed following treatment with     platinum-based chemotherapy: a single-arm, multicentre, phase 2     trial. Lancet. 2016; 387(10031):1909-1920.     doi:10.1016/S0140-6736(16)00561-4. -   7. Hugo W, Zaretsky J M, Sun L, et al. Genomic and Transcriptomic     Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.     Cell. 2016; 165(1):35-44. doi:10.1016/j.cell.2016.02.065. -   8. Cheng D T, Mitchell T N, Zehir A, et al. Memorial Sloan     Kettering-Integrated Mutation Profiling of Actionable Cancer Targets     (MSK-IMPACT): A Hybridization Capture-Based Next-Generation     Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol     Diagn. 2015;17(3):251-264. doi:10.1016/j.jmoldx.2014.12.006. -   9. Frampton G M, Fabrizio D, Chalmers Z R, et al. Assessment of     tumor mutation burden from >60,000 clinical cancer patients using     comprehensive genomic profiling. In: J Clin Oncol, Vol 34. 2016.     11558 -   10. Johnson D B, Frampton G M, Rioth M J, et al. Targeted Next     Generation Sequencing Identifies Markers of Response to PD-1     Blockade. Cancer Immunol Res. 2016; 4(11):959-967.     doi:10.1158/2326-6066.CIR-16-0143. -   11. Zehir A, Benayed R, Shah R H, et al. Mutational Landscape of     Metastatic Cancer Revealed from Prospective Clinical Sequencing of     10,000 Patients. Nat Med. Submitted. -   12. Alexandrov L B, Nik-Zainal S, Wedge D C, et al. Signatures of     mutational processes in human cancer. Nature. 2013;     500(7463):415-421. doi:10.1038/nature12477. -   13. Schumacher T N, Schreiber R D. Neoantigens in cancer     immunotherapy. Science. 2015;348(6230):69-74.     doi:10.1126/science.aaa4971. -   14. Bouffet E, Larouche V, Campbell B B, et al. Immune Checkpoint     Inhibition for Hypermutant Glioblastoma Multiforme Resulting From     Germline Biallelic Mismatch Repair Deficiency. J Clin Oncol. 2016;     34(19):2206-2211. doi:10.1200/JCO.2016.66.6552. -   15. McGranahan N, Furness A J S, Rosenthal R, et al. Clonal     neoantigens elicit T cell immunoreactivity and sensitivity to immune     checkpoint blockade. Science. 2016; 351(6280):1463-1469.     doi:10.1126/science.aaf1490. -   16. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus     Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl     J Med. 2015; 373(17):1627-1639. doi:10.1056/NEJMoa1507643. -   17. Ross D S, Zehir A, Cheng D T, et al. Next-Generation Assessment     of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification     Status: Clinical Validation in the Context of a Hybrid     Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. J     Mol Diagn. 2017; 19(2):244-254. doi:10.1016/j.jmoldx.2016.09.010 -   18. Dyck L, Mills, K H G. Immune Checkpoints and their Inhibition in     Cancer and Infectious Diseases. Eur J Immunol. 2017; 47(5):765-779.     doi: 10.1002/eji.201646875. -   19. Riley J L. PD-1 Signaling in Primary T Cells. Immunol Rev. 2009;     229(1):114-125. doi: 10.1111/j.1600-065X.2009.00767.x. -   20. Larkin A, Chiarion-Sileni V, Gonzalez E, et al. Combined     Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N     Engl J Med 2015; 373(1):23-34. doi: 10.1056/NEJMoa1504030. -   21. H. I. V. C. S. International et al., The major genetic     determinants of HIV-1 control affect HLA class I peptide     presentation. Science 330, 1551-1557 (2010). -   22. M. Carrington et al., HLA and HIV-1: heterozygote advantage and     B*35-Cw*04 disadvantage. Science 283, 1748-1752 (1999). -   23. J. Fellay et al., A whole-genome association study of major     determinants for host control of HIV-1. Science 317, 944-947 (2007). -   24. X. J. Gao et al., Effect of a single amino acid change in MHC     class I molecules on the rate of progression to AIDS. New England     Journal of Medicine 344, 1668-1675 (2001). -   25. E. Trachtenberg et al., Advantage of rare HLA supertype in HIV     disease progression. Nat Med 9, 928-935 (2003). -   26. P. J. R. Goulder, B. D. Walker, HIV and HLA Class I: An Evolving     Relationship. Immunity 37, 426-440 (2012). -   27. A. V. S. Hill et al., Common West African Hla Antigens Are     Associated with Protection from Severe Malaria. Nature 352, 595-600     (1991). -   28. P. Kiepiela et al., Dominant influence of HLA-B in mediating the     potential co-evolution of HIV and HLA. Nature 432, 769-774 (2004). -   29. T. J. T. PI., HLA and disease associations. (Springer Science &     Business Media, 2012). -   30. P. Parham, T. Ohta, Population biology of antigen presentation     by MHC class I molecules. Science 272, 67-74 (1996). -   31. D. Chowell et al., TCR contact residue hydrophobicity is a     hallmark of immunogenic CD8(+) T cell epitopes. Proceedings of the     National Academy of Sciences of the United States of America 112,     E1754-E1762 (2015). -   32. P. C. Doherty, R. M. Zinkernagel, A biological role for the     major histocompatibility antigens. Lancet 1, 1406-1409 (1975). -   33. M. M. Gubin et al., Checkpoint blockade cancer immunotherapy     targets tumour-specific mutant antigens. Nature 515, 577-581 (2014). -   34. E. Tran et al., Immunogenicity of somatic mutations in human     gastrointestinal cancers. Science 350, 1387-1390 (2015). -   35. E. Tran et al., T-Cell Transfer Therapy Targeting Mutant KRAS in     Cancer. N Engl J Med 375, 2255-2262 (2016). -   36. N. Riaz, J. J. Havel, V. Makarov, e. al., T. A. Chan,     Immunogenomic Dissection of

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. In Review, (2017).

-   37. K. Kiyotani, T. H. Mai, Y. Nakamura, Comparison of exome-based     HLA class I genotyping tools: identification of platform-specific     genotyping errors. J Hum Genet, (2016). -   38. S. A. Shukla et al., Comprehensive analysis of cancer-associated     somatic mutations in class I HLA genes. Nat Biotechnol 33, 1152-1158     (2015). -   39. H. Cao et al., An integrated tool to study MHC region: accurate     SNV detection and HLA genes typing in human MHC region using     targeted high-throughput sequencing. PLoS One 8, e69388 (2013). -   40. A. Szolek et al., OptiType: precision HLA typing from     next-generation sequencing data. Bioinformatics 30, 3310-3316     (2014). -   41. D. M. Hyman et al., Precision medicine at Memorial Sloan     Kettering Cancer Center:

clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today 20, 1422-1428 (2015).

-   42. N. Riaz et al., Recurrent SERPINB3 and SERPINB4 mutations in     patients who respond to anti-CTLA4 immunotherapy. Nature Genetics     48, 1327-1329 (2016). -   43. M. A. DePristo et al., A framework for variation discovery and     genotyping using next-generation DNA sequencing data. Nature     Genetics 43, 491-+ (2011). -   44. H. Li, R. Durbin, Fast and accurate short read alignment with     Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009). -   45. A. McKenna et al., The Genome Analysis Toolkit: a MapReduce     framework for analyzing next-generation DNA sequencing data. Genome     Res 20, 1297-1303 (2010). -   46. K. Cibulskis et al., Sensitive detection of somatic point     mutations in impure and heterogeneous cancer samples. Nature     Biotechnology 31, 213-219 (2013). -   47. D. C. Koboldt et al., VarScan 2: Somatic mutation and copy     number alteration discovery in cancer by exome sequencing. Genome     Research 22, 568-576 (2012). -   48. D. E. Larson et al., SomaticSniper: identification of somatic     point mutations in whole genome sequencing data. Bioinformatics 28,     311-317 (2012). -   49. C. T. Saunders et al., Strelka: accurate somatic small-variant     calling from sequenced tumor-normal sample pairs. Bioinformatics 28,     1811-1817 (2012). -   50. Z. R. Chalmers et al., Analysis of 100,000 human cancer genomes     reveals the landscape of tumor mutational burden. Genome Med 9, 34     (2017). -   51. R. L. Shen, V. E. Seshan, FACETS: allele-specific copy number     and clonal heterogeneity analysis tool for high-throughput DNA     sequencing. Nucleic Acids Research 44, (2016). -   52. W. Humphrey, A. Dalke, K. Schulten, VMD: Visual molecular     dynamics. J Mol Graph Model 14, 33-38 (1996). -   53. P. Liu, X. H. Huang, R. H. Zhou, B. J. Berne, Observation of a     dewetting transition in the collapse of the melittin tetramer.     Nature 437, 159-162 (2005). -   54. Y. Tu et al., Destructive extraction of phospholipids from     Escherichia coli membranes by graphene nanosheets. Nat Nanotechnol     8, 594-601 (2013). -   55. R. H. Zhou, X. H. Huang, C. J. Margulis, B. J. Berne,     Hydrophobic collapse in multidomain protein folding. Science 305,     1605-1609 (2004). -   56. J. C. Phillips et al., Scalable molecular dynamics with NAMD. J     Comput Chem 26, 1781-1802 (2005). -   57. M. J. Abraham, Performance enhancements for GROMACS nonbonded     interactions on BlueGene. J Comput Chem 32, 2041-2046 (2011). -   58. M. R. Thursz, H. C. Thomas, B. M. Greenwood, A. V. Hill,     Heterozygote advantage for HLA class-II type in hepatitis B virus     infection. Nat Genet 17, 11-12 (1997). -   59. D. Snary, C. J. Barnstable, W. F. Bodmer, M. J. Crumpton,     Molecular structure of human histocompatibility antigens: the HLA-C     series. Eur J Immunol 7, 580-585 (1977). -   60. S. G. Marsh, Parham, P. and Barber, L. D., The HLA factsbook.     (Academic Press, 1999). -   61. M. R. Schaefer et al., A novel trafficking signal within the     HLA-C cytoplasmic tail allows regulated expression upon     differentiation of macrophages. J Immunol 180, 7804-7817 (2008). -   62. N. Anfossi et al., Coordinated expression of Ig-like inhibitory     MEW class I receptors and acquisition of cytotoxic function in human     CD8+ T cells. J Immunol 173, 7223-7229 (2004). -   63. D. S. Chen, I. Mellman, Elements of cancer immunity and the     cancer-immune set point. Nature 541, 321-330 (2017). -   64. T. N. Schumacher, R. D. Schreiber, Neoantigens in cancer     immunotherapy. Science 348, 69-74 (2015). -   65. D. T. Le et al., PD-1 Blockade in Tumors with Mismatch-Repair     Deficiency. N Engl J Med 372, 2509-2520 (2015). -   66. N. Aptsiauri et al., MHC class I antigens and immune     surveillance in transformed cells. Int Rev Cytol 256, 139-189     (2007). -   67. A. Sette, J. Sidney, Nine major HLA class I supertypes account     for the vast preponderance of HLA-A and -B polymorphism.     Immunogenetics 50, 201-212 (1999). -   68. J. Sidney, B. Peters, N. Frahm, C. Brander, A. Sette, HLA class     I supertypes: a revised and updated classification. BMC Immunol 9, 1     (2008). -   69. M. Dibrino et al., Identification of the Peptide Binding Motif     for Hla-B44, One of the Most Common Hla-B Alleles in the Caucasian     Population. Biochemistry-Us 34, 10130-10138 (1995). -   70. J. B. Szender et al., HLA superfamily assignment is a predictor     of immune response to cancer testis antigens and survival in ovarian     cancer. Gynecol Oncol 142, 158-162 (2016). -   71. H. Pearson et al., MHC class I-associated peptides derive from     selective regions of the human genome. Journal of Clinical     Investigation 126, 4690-4701 (2016). -   72. Jordan, E. J. et al. Prospective Comprehensive Molecular     Characterization of Lung Adenocarcinomas for Efficient Patient     Matching to Approved and Emerging Therapies. Cancer Discov 7,     596-609 (2017). -   73. Janjigian, Y. Y. et al. Genetic Predictors of Response to     Systemic Therapy in

Esophagogastric Cancer. Cancer Discov (2017). doi:10.1158/2159-8290.CD-17-0787

-   74. Hellmann, M. D. et al. Molecular determinants of response and     resistance to anti-PD-(L)1 blockade in patients with NSCLC profiled     with targeted next-generation sequencing (NGS). J. Clin. Oncol. 35,     9015-9015 (2017). -   75. Chowell, D. et al. Patient HLA class I genotype influences     cancer response to checkpoint blockade immunotherapy. Science 62,     eaao4572 (2017). -   76. Balachandran, V. P. et al. Identification of unique neoantigen     qualities in long-term survivors of pancreatic cancer. Nature 551,     512-516 (2017). -   77. Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N.     Molecular and genetic properties of tumors associated with local     immune cytolytic activity. Cell 160, 48-61 (2015). -   78. Topalian, S. L. et al. Safety, activity, and immune correlates     of anti-PD-1 antibody in cancer. N Engl J Med 366, 2443-2454 (2012). -   79. Segal, N. H. et al. Epitope landscape in breast and colorectal     cancer. Cancer Res. 68, 889-892 (2008). -   80. Verdegaal, E. M. E. et al. Neoantigen landscape dynamics during     human melanoma-T cell interactions. Nature 536, 91-95 (2016).

EQUIVALENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims 

1. A method comprising: administering immunotherapy to a subject with a tumor that displays a tumor mutational load above a threshold that has been correlated with a statistically significant probability of responding to immunotherapy.
 2. The method of claim 1, wherein the tumor is a solid type tumor selected from the group consisting of bladder cancer, breast cancer, esophagogastric cancer, glioma, head and neck cancer, melanoma, non-small cell lung cancer, renal cell carcinoma. 3.-4. (canceled)
 5. The method of claim 1, wherein the immunotherapy is an-antibody. 6.-8. (canceled)
 9. The method of claim 1, wherein the immunotherapy is a combination of one or more of PD-1 or PD-L1 blockade therapy and CTLA-4 blockade therapy.
 10. The method of claim 1, wherein the immunotherapy is selected from the group comprising of atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab, or tremelimumab, and combinations therein.
 11. The method of claim 1, wherein the displayed tumor mutational load is or was determined by use of a targeted sequence panel.
 12. (canceled)
 13. The method of claim 1, wherein the tumor mutational load is measured by next-generation sequencing.
 14. The method of claim 1, wherein the tumor mutational load is measured by Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT).
 15. The method of claim 1, wherein the subject has a tumor included below and the tumor mutational load threshold after immune checkpoint modulator treatment is as set forth below: Cancer Type Threshold Bladder Cancer About 7 to about 27 Breast Cancer About 1 to about 14 Esophagogastric Cancer About 1 to about 21 Glioma About 1 to about 15 Head and Neck Cancer About 1 to about 18 Melanoma About 1 to about 31 Non-Small Cell Lung Cancer About 1 to about 29 Renal Cell Carcinoma About 1 to about 12


16. (canceled)
 17. The method of claim 1, wherein the immunotherapy is demonstrated to have a statistically significant probability of improving overall survival when administered to a population displaying a tumor mutational load above the threshold. 18.-20. (canceled)
 21. A method comprising: administering immunotherapy to a subject who displays HLA class I heterozygosity in a tumor.
 22. The method of claim 21, wherein the subject displays heterozygosity at one or more HLA class I loci.
 23. (canceled)
 24. The method of claim 21, wherein the HLA class I heterozygosity is determined by sequencing. 25.-28. (canceled)
 29. The method of claim 21, wherein the immunotherapy is one or more of PD-1 or PD-L1 blockade therapies or CTLA-4 blockade therapies. 30.-32. (canceled)
 33. A method comprising steps of: administering immunotherapy to a subject with a tumor that displays a tumor mutational load above a threshold that has been correlated with a statistically significant probability of responding to immunotherapy and displays HLA class I heterozygosity. 34.-35. (canceled)
 36. The method of claim 33, wherein the HLA class I heterozygosity is determined by sequencing. 37.-39. (canceled)
 40. The method of claim 33, wherein the immunotherapy is administration of an immune checkpoint modulator. 41-44. (canceled)
 45. The method of claim 33, wherein the immunotherapy is a combination of one or more of PD-1 blockade therapy and CTLA-4 blockade therapy. 46.-49. (canceled)
 50. The method of claim 33, wherein the tumor mutational load is measured by Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT).
 51. The method of claim 33, wherein the subject has a tumor included below and the tumor mutational load threshold after immune checkpoint modulator treatment is as set forth below: Cancer Type Threshold Bladder Cancer About 7 to about 27 Breast Cancer About 1 to about 14 Esophagogastric Cancer About 1 to about 21 Glioma About 1 to about 15 Head and Neck Cancer About 1 to about 18 Melanoma About 1 to about 31 Non-Small Cell Lung Cancer About 1 to about 29 Renal Cell Carcinoma About 1 to about 12

52.-54. (canceled) 